Rank;BriefTitle;PrimaryOutcomeMeasure;PrimaryOutcomeTimeFrame;SecondaryOutcomeMeasure;OverallStatus;Phase
1;Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program;To conduct and evaluate a study that incorporates patient navigation programs to recruit and screen participants for Multiple Myeloma and its disease precursors, MGUS or smoldering MM;12 months;Not yet recruiting;Not Applicable
1;Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program;To conduct and evaluate a study that incorporates patient navigation programs to recruit and screen participants for Multiple Myeloma and its disease precursors, MGUS or smoldering MM;12 months;Not yet recruiting;Not Applicable
1;Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program;To study participant knowledge of Multiple Myeloma;12 months,;Not yet recruiting;Not Applicable
2;Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis;Number of Multiple Myeloma (MM) Participants Categorized by Clinical Characteristics;From initial diagnosis up to end of follow up treatment or to the retrospective cut-off date within the time of interest (between January 1, 2008, and December 31, 2016) [approximately 11.7 years];Overall Survival (OS);Completed,
2;Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis;Number of Multiple Myeloma (MM) Participants Categorized by Treatment Patterns;From initial diagnosis up to end of follow up treatment or to the retrospective cut-off date within the time of interest (between January 1, 2008, and December 31, 2016) [approximately 11.7 years];Duration of Treatment;Completed,
3;CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma;Adverse events that Are related to treatment;2 years;Estimate 2 year overall survival(OS) after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment;Terminated;Not Applicable
3;CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma;Adverse events that Are related to treatment;2 years;Estimate 2 year relapse rate after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment;Terminated;Not Applicable
3;CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma;Adverse events that Are related to treatment;2 years;Estimate 2 year progression free survival after infusion of BCMA/CD138/CD38/CD56-CART and sequential treatment;Terminated;Not Applicable
4;The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma;DNA mutations associated with the existence of multiple myeloma;baseline, pre-intervention/procedure/surgery;Not yet recruiting,
4;The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma;DNA mutations associated with the existence of multiple myeloma;during the intervention/procedure/surgery;Not yet recruiting,
4;The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma;DNA mutations associated with the existence of multiple myeloma;immediately after the intervention/procedure/surgery;Not yet recruiting,
4;The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma;DNA mutations associated with the existence of multiple myeloma;at 1 year;Not yet recruiting,
4;The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma;DNA mutations associated with the existence of multiple myeloma;up to 24 weeks;Not yet recruiting,
4;The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma;DNA mutations associated with the existence of multiple myeloma;through study completion, an average of 1 year,;Not yet recruiting,
5;Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile;Molecular profiles and clinical characteristics that define subsets of myeloma patients at initial diagnosis and at relapse of disease.;Baseline to 8 years.;Response rates;Active, not recruiting,
5;Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile;Molecular profiles and clinical characteristics that define subsets of myeloma patients at initial diagnosis and at relapse of disease.;Baseline to 8 years.;Survival rates;Active, not recruiting,
5;Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile;Molecular profiles and clinical characteristics that define subsets of myeloma patients at initial diagnosis and at relapse of disease.;Baseline to 8 years.;Bone disease assessed radiographically;Active, not recruiting,
5;Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile;Molecular profiles and clinical characteristics that define subsets of myeloma patients at initial diagnosis and at relapse of disease.;Baseline to 8 years.;Health-related quality of life;Active, not recruiting,
5;Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile;Molecular profiles and clinical characteristics that define subsets of myeloma patients at initial diagnosis and at relapse of disease.;Baseline to 8 years.;Resource utilization;Active, not recruiting,
5;Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile;Molecular profiles and clinical characteristics that define subsets of myeloma patients at initial diagnosis and at relapse of disease.;Baseline to 8 years.;Severe adverse events;Active, not recruiting,
6;Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma;The sensitivity and specificity of a cfDNA methylation-based early detection modelfor multiple myeloma.;12 months;The sensitivity and specificity of a cfDNA methylation-based early detection model for multiple myeloma at different clinical stages.;Recruiting,
6;Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma;The sensitivity and specificity of a cfDNA methylation-based early detection modelfor multiple myeloma.;12 months;The performance of a cfDNA methylation-based prognostic model for multiple myeloma.;Recruiting,
6;Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma;The sensitivity and specificity of a cfDNA methylation-based early detection modelfor multiple myeloma.;12 months;The specific cfDNA methylation landscape of multiple myeloma in China;Recruiting,
7;Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma;Comparison of quality of life evolution in outpatients with multiple myeloma between the two groups;6 months;Qualitative evaluation of quality of life;Recruiting;Not Applicable
7;Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma;Comparison of quality of life evolution in outpatients with multiple myeloma between the two groups;6 months;Comparison of quality of life in outpatients with multiple myeloma between the two groups;Recruiting;Not Applicable
7;Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma;Comparison of quality of life evolution in outpatients with multiple myeloma between the two groups;6 months;Comparison of quality of life in outpatients with multiple myeloma between the two groups;Recruiting;Not Applicable
7;Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma;Comparison of quality of life evolution in outpatients with multiple myeloma between the two groups;6 months;Comparison of autonomy evolution in outpatients with multiple myeloma between the two groups;Recruiting;Not Applicable
8;Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma;Detection of plasmocytes by imaging flow cytometry techniques in plasmocytes cell line.;during the first six months of the study;Withdrawn,
8;Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple Myeloma;Detection of plasmocytes by imaging flow cytometry techniques in multiple myeloma bone marrow (MM BM).;from 6 months after the beginning of the study to two years after the beginning of the study,;Withdrawn,
9;Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma;Mean Multiple Myeloma Lesions Detected;Day 1, Day 2;Visual Image Analysis of Detected Multiple Myeloma Lesions;Completed;Phase 2
10;Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma;Effect of Drug Combination on Multiple Myeloma;The best response for all patients at any point were assessed for patients that were treated on study, from start of treatment up to 20 weeks,;Terminated;Phase 2
11;A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma;One-Year Progression-Free Survival (PFS) Rate;Up to 1 Year;Progressive Disease Indicator Rate (PDIR) at 6 Months;Completed;Phase 2
11;A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma;One-Year Progression-Free Survival (PFS) Rate;Up to 1 Year;Progression-Free Survival;Completed;Phase 2
11;A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma;One-Year Progression-Free Survival (PFS) Rate;Up to 1 Year;Percentage of Participants With Serum M-protein Response;Completed;Phase 2
11;A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma;One-Year Progression-Free Survival (PFS) Rate;Up to 1 Year;Time to Worsening in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30) Scale Score;Completed;Phase 2
11;A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma;One-Year Progression-Free Survival (PFS) Rate;Up to 1 Year;Time to Worsening in the Brief Pain Inventory (BPI) Worst Item Scores;Completed;Phase 2
11;A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma;One-Year Progression-Free Survival (PFS) Rate;Up to 1 Year;Number of Participants With Symptomatic Multiple Myeloma With Adverse Prognostic Features;Completed;Phase 2
11;A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma;One-Year Progression-Free Survival (PFS) Rate;Up to 1 Year;Number of Participants With Best Response to First Subsequent Multiple Myeloma Treatment;Completed;Phase 2
11;A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma;One-Year Progression-Free Survival (PFS) Rate;Up to 1 Year;Overall Survival (OS);Completed;Phase 2
12;Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma;Measure the expression levels of CXCR4, CD47, and pS6 by flow cytometry in myeloma patient's marrow aspirate;3 years;Determine if Pim kinase inhibitors or sphingosine kinase 2 inhibitors will inhibit patients' myeloma cells;Completed,
13;Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma;Effect of Drug Combination on Multiple Myeloma;This was collected from patients for their duration on study treatment. Only the best response was recorded. Best responses were reported at any point of the study, from start of treatment up until removal of study, which occurred up to 57.4 cycles;Median Time to Maximum Response;Completed;Phase 2
13;Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma;Effect of Drug Combination on Multiple Myeloma;This was collected from patients for their duration on study treatment. Only the best response was recorded. Best responses were reported at any point of the study, from start of treatment up until removal of study, which occurred up to 57.4 cycles;Event Free Survival;Completed;Phase 2
13;Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma;Effect of Drug Combination on Multiple Myeloma;This was collected from patients for their duration on study treatment. Only the best response was recorded. Best responses were reported at any point of the study, from start of treatment up until removal of study, which occurred up to 57.4 cycles;Progression Free Survival;Completed;Phase 2
14;High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma;To evaluate the progression free survival at one year in multiple myeloma patients who receive sequentially administered high dose cyclophosphamide and VP-16 followed by high-dose BCNU (Carmustine) plus Melphalan;4 years;To evaluate the response rates of multiple myeloma patients to this sequentially administered high dose chemotherapy.;Completed;Phase 2
14;High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma;To evaluate the progression free survival at one year in multiple myeloma patients who receive sequentially administered high dose cyclophosphamide and VP-16 followed by high-dose BCNU (Carmustine) plus Melphalan;4 years;To evaluate the safety and toxicity of this sequential high dose chemotherapy program in multiple myeloma patients.;Completed;Phase 2
15;Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma;progression-free disease and overall toxicity in myeloma multiple;3 years;skeletal event;Completed,
16;A Study of WVT078 in Patients With Multiple Myeloma (MM);Incidence of dose limiting toxicity (DLTs) in Cycle 1;28 days (first cycle);Best Overall Response (BOR);Active, not recruiting;Phase 1
16;A Study of WVT078 in Patients With Multiple Myeloma (MM);Frequency of dose interruptions;Up to 28 months;Duration of Response (DOR);Active, not recruiting;Phase 1
16;A Study of WVT078 in Patients With Multiple Myeloma (MM);Frequency of discontinuations;up to 28 months;Progresson Free Survival (PFS);Active, not recruiting;Phase 1
16;A Study of WVT078 in Patients With Multiple Myeloma (MM);Frequency of dose reductions;up to 28 months;AUC of WVT078 derived from serum concentrations;Active, not recruiting;Phase 1
16;A Study of WVT078 in Patients With Multiple Myeloma (MM);Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, ECGs, and CRS/immune-mediated reactions;Up to 31 months;Cmax of WVT078 derived from serum concentrations;Active, not recruiting;Phase 1
17;A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma;Determine antitumor activity of ultrahigh dose dexamethasone (UHDD) as monotherapy in relapsed multiple myeloma.;1 year;Characterize the safety and tolerability by assessing the number of related adverse events of UHDD as monotherapy in patients with relapsed multiple myeloma.;Withdrawn;Phase 2
17;A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma;Determine antitumor activity of ultrahigh dose dexamethasone (UHDD) as monotherapy in relapsed multiple myeloma.;1 year;Determine the progression free survival amongst responders.;Withdrawn;Phase 2
17;A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma;Determine antitumor activity of ultrahigh dose dexamethasone (UHDD) as monotherapy in relapsed multiple myeloma.;1 year;Determine the subset of patients in whom UHDD can be used as monotherapy for treatment of relapsed multiple myeloma;Withdrawn;Phase 2
18;Efficacy Study of CYT997 in Multiple Myeloma;Overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma;Baseline to study completion;Number of cycles required to achieve maximum response;Terminated;Phase 2
18;Efficacy Study of CYT997 in Multiple Myeloma;Overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma;Baseline to study completion;Overall survival;Terminated;Phase 2
18;Efficacy Study of CYT997 in Multiple Myeloma;Overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma;Baseline to study completion;Safety and tolerability;Terminated;Phase 2
18;Efficacy Study of CYT997 in Multiple Myeloma;Overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma;Baseline to study completion;Time to disease progression;Terminated;Phase 2
19;Thrombosis in Patients With Multiple Myeloma in an University Medical Center;Venous thromboembolism incidence;1 year;Arterial thromboembolism;Completed,
20;Etiology of Multiple Myeloma: A Case-Control Study;The goal of this epidemiological research study is to identify biological and lifestyle factors that may be associated with the development of Multiple Myeloma (MM).;2 Years,;Unknown status,
21;A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM;Monthly eligibility and recruitment rates per month of patients with multiple myeloma;Up to 12 months;Proportion of respondents scoring 4 or 5 on the Patient Platform Usability Survey or Healthcare Provider Platform Survey;Terminated;Phase 1
21;A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM;User average weekly log-in rates over the duration of follow-up from patients with MM and HCPs;Up to 6 months;Quality of life measured by Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) total score;Terminated;Phase 1
22;89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma;Focal lesion of 89Zr-bevacizumab PET scanning in patients with relapsing multiple myeloma;during scanning,;Unknown status;Not Applicable
23;Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma;Response rate (the combined CR + PR + MR) with treatment perifosine;Every 3 weeks;Response rate (CR + PR + MR) with combination therapy;Completed;Phase 2
23;Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma;Response rate (the combined CR + PR + MR) with treatment perifosine;Every 3 weeks;Assess the safety and tolerability of perifosine alone and in combination;Completed;Phase 2
23;Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma;Response rate (the combined CR + PR + MR) with treatment perifosine;Every 3 weeks;Obtain correlative data in patients with multiple myeloma treated with perifosine and in combination;Completed;Phase 2
24;Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions;Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS);2 years;Proportion of Participants With Relapsed Multiple Myeloma Alive at 2 Years;Completed;Phase 2
24;Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions;Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS);2 years;Number of Participants Who Relapse That Are Restored to Remission (CR);Completed;Phase 2
25;Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation;Feasibility of comprehensive chemical gustometry in participants with multiple myeloma undergoing autologous HCT;Change from baseline assessment up to 100 days,;Active, not recruiting,
26;Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM);Trajectories of cognitive functions NIHTB-CB;Up to 6 months;Predictors of changes in cognitive function;Recruiting,
26;Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM);Trajectories of cognitive functions PROMIS;Up to 6 months;Predictors of changes in physical function;Recruiting,
26;Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM);Trajectories of HRQoL cognitive functions;Up to 6 months;Predictors of changes in quality of life;Recruiting,
26;Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM);Trajectories of physical function measured by ADLs;Up to 6 months;Gain a complete understanding of the challenges patients and care partners living with multiple myeloma face;Recruiting,
27;Denosumab for Smoldering Multiple Myeloma;Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases.;1 year;Proportion of Subjects With Skeletal Related Events;Active, not recruiting;Phase 2
27;Denosumab for Smoldering Multiple Myeloma;Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases.;1 year;Proportion of Subjects With Disease Progression to Multiple Myeloma;Active, not recruiting;Phase 2
27;Denosumab for Smoldering Multiple Myeloma;Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases.;1 year;Proportion of Subjects With Progression Free Survival;Active, not recruiting;Phase 2
27;Denosumab for Smoldering Multiple Myeloma;Proportion of Subjects With a Downgraded Risk of Progression of Smoldering Multiple Myeloma if the Risk Category Decreases.;1 year;Proportion of Subjects With Change in Bone Mineral Density;Active, not recruiting;Phase 2
28;"Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)";"Percentage of Participants With t(11;14) Status by Fluorescence In Situ Hybridization (FISH) Analysis of Bone Marrow Plasma Cells";Up to approximately 2.5 months following last subject last visit;"Percentage of Participants Achieving Stability of t(11;14) Status";Recruiting,
28;"Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)";Percentage of Participants With BCL2 Status by Quantitative Polymerase Chain Reaction (qPCR) Analysis of Bone Marrow Plasma Cells;Up to approximately 2.5 months following last subject last visit;Percentage of Participants Achieving Stability of BCL2 Status;Recruiting,
29;A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.;Determine incidence of risks as outlined in the Risk Management Plan;Up to 3 years;Pregnancy Prevention Programme Effectiveness;Completed,
29;A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.;Determine incidence of risks as outlined in the Risk Management Plan;Up to 3 years;Previous Treatments;Completed,
30;Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America;Number of Participants with Previous Comorbidities;1 year;Incidence Percentage of Participants with Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and non-Hodgkin lymphoma (NHL);Completed,
30;Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America;Number of Participants as per treatment therapy received;1 year;Prevalence Percentage of Participants with CLL, MM and NHL;Completed,
31;Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma;Recommended phase II dose (RPTD);9 Months;Disease control rate;Terminated;Phase 1
31;Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma;Recommended phase II dose (RPTD);9 Months;Progression free survival (PFS);Terminated;Phase 2
32;Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma;Rate of progression to Multiple Myeloma;2 years after end of treament;Change in monoclonal protein (M-spike) or serum free light chains (sFLC);Not yet recruiting;Phase 2
32;Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma;Rate of progression to Multiple Myeloma;2 years after end of treament;Progression free survival;Not yet recruiting;Phase 2
32;Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma;Rate of progression to Multiple Myeloma;2 years after end of treament;Rate of skeletal related events;Not yet recruiting;Phase 2
32;Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma;Rate of progression to Multiple Myeloma;2 years after end of treament;rate of adverse events;Not yet recruiting;Phase 2
33;Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma;zinc-finger protein gene 217 in myeloma patients;2 years,;Unknown status;Not Applicable
34;Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma;Number of Adverse events of special interest during Len/Dex therapy;Up to approximately 72 months;Incidence (number) of thromboembolism;Completed,
34;Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma;Number of Adverse events of special interest during Len/Dex therapy;Up to approximately 72 months;Duration of Len/Dex treatment over the course of the study;Completed,
34;Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma;Number of Adverse events of special interest during Len/Dex therapy;Up to approximately 72 months;Number of patients with good and poor compliance to lenalidomide and dexamethasone;Completed,
34;Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma;Number of Adverse events of special interest during Len/Dex therapy;Up to approximately 72 months;Type and frequency of prophylaxis treatment for prevention of thromboembolism;Completed,
35;Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma;To determine tumor response, overall and progression free survival following thalidomide therapy in patients with multiple myeloma,;To determine toxicities associated with thalidomide in patients with multiple myeloma;Completed;Phase 2
36;Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy;Progression Free Survival;2 years;Time to Response;Completed;Phase 2
36;Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy;Progression Free Survival;2 years;Overall Survival;Completed;Phase 2
36;Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy;Progression Free Survival;2 years;Time to Progression;Completed;Phase 2
36;Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy;Progression Free Survival;2 years;Duration of Response;Completed;Phase 2
37;A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma;To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in multiple myeloma patients.;End of cycle 1 (DLT) and approximately 16 months after start of treatment (MTD);Determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with thymoglobulin;Completed;Phase 1
37;A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma;To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in multiple myeloma patients.;End of cycle 1 (DLT) and approximately 16 months after start of treatment (MTD);To determine the time to response, duration of response, and time to progression and overall survival;Completed;Phase 1
37;A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma;To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in multiple myeloma patients.;End of cycle 1 (DLT) and approximately 16 months after start of treatment (MTD);To determine the safety and tolerability of thymoglobulin;Completed;Phase 1
37;A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma;To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in multiple myeloma patients.;End of cycle 1 (DLT) and approximately 16 months after start of treatment (MTD);Assess the changes in lymphocyte apoptosis signaling in treated patients;Completed;Phase 1
38;A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma;number of myeloma lesions;through study completion, an average of 1 year;standardized uptake value (SUV) of myeloma lesions;Recruiting;Not Applicable
39;Multiple Myeloma Patient Registry;Overall Response Rate;Up to 3 years;Terminated,
39;Multiple Myeloma Patient Registry;Time to Next Treatment (TTNT);Up to 3 years;Terminated,
39;Multiple Myeloma Patient Registry;Overall Survival (OS);Up to 3 years;Terminated,
39;Multiple Myeloma Patient Registry;Survival Time;Up to 3 years;Terminated,
39;Multiple Myeloma Patient Registry;European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score;Up to 3 years;Terminated,
39;Multiple Myeloma Patient Registry;Katz Index of Independence for Activities of Daily Living;Up to 3 years;Terminated,
39;Multiple Myeloma Patient Registry;Lawton Instrumental Activities of Daily Living;Up to 3 years,;Terminated,
40;"A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma";Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma;Day 1 of Cycles 2, 3, and 4 and then every 3 months thereafter (up to 25 months).;Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma;Completed;Phase 2
41;Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma;To determine the progression-free survival of patients with multiple myeloma treated with tandem cycles of high-dose melphalan followed by high-dose melphalan in combination with bortezomib with autologous HSC transplantation.;3 years;To determine the response rate, overall survival, and regimen-related toxicities of patients with multiple myeloma treated with high-dose melphalan or high-dose melphalan in combination with bortezomib given in tandem transplants.;Active, not recruiting;Phase 3
42;Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma;Rate of Response in Participants Receiving Fenofibrate Therapy;After two cycles, about 2 months;Number of Subjects Experiencing Adverse Events;Terminated;Phase 2
42;Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma;Rate of Response in Participants Receiving Fenofibrate Therapy;After two cycles, about 2 months;Proportion of Participants Achieving Progression-Free Survival;Terminated;Phase 2
43;Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma;Sensitivity vs resistance to new immunotherapies;5 years;Recruiting,
43;Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma;Cell extrinsic mechanisms of response;5 years;Recruiting,
43;Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma;Biomarkers of response;5 years;Recruiting,
43;Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma;Biomarkers of response;5 years,;Recruiting,
44;A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma;Overall response rate by International Myeloma Working Group criteria.;2 years;Progression Free Survival;Active, not recruiting;Phase 2
44;A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by CTCAE v4.0;2 years;Progression Free Survival;Active, not recruiting;Phase 2
45;Optical Genome Mapping in Characterization of Multiple Myeloma;Validate the use of Optical Genome Mapping in Multiple Myeloma characterization;At MM diagnosis;Evaluate Optical Genome Mapping for identification of genetic abnormalities that are not detected with FISH in Multiple Myeloma;Not yet recruiting,
46;Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE);Time to progression (TTP) from MGUS/SMM to overt multiple myeloma.;15 years,;Recruiting,
47;A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2);Proportion of Minimal Residual Disease (MRD)-negative subjects;Up to 2 years after CT103A infusion;Best overall response (BOR);Not yet recruiting;Phase 1
47;A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2);Median progression-free survival (mPFS);Up to 2 years after CT103A infusion;Median survival (mOS);Not yet recruiting;Phase 1
48;Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma;Number of Patients Who Develop Immunologic Response to Nivolumab and the DC/MM Fusion Vaccine;2 years;Number of Patients Who Achieve a Clinical Response (SD, PR, VGPR, CR);Terminated;Phase 2
48;Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma;Number of Patients Who Develop Immunologic Response to Nivolumab and the DC/MM Fusion Vaccine;2 years;Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0;Terminated;Phase 2
48;Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma;Number of Patients Who Develop Immunologic Response to Nivolumab and the DC/MM Fusion Vaccine;2 years;Number of Patients Who Are Alive Without Progression at 2 Years;Terminated;Phase 2
49;A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets;Overall Response Rate (ORR) per Adapted International Myeloma Working Group (IMWG) criteria;Up to Approximately 12 Months;Duration of Response (DOR);Recruiting;Phase 1
49;A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets;Overall Response Rate (ORR) per Adapted International Myeloma Working Group (IMWG) criteria;Up to Approximately 12 Months;Depth of Response Minimal Residual Disease (MRD);Recruiting;Phase 1
49;A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets;Overall Response Rate (ORR) per Adapted International Myeloma Working Group (IMWG) criteria;Up to Approximately 12 Months;Progression Free Survival (PFS);Recruiting;Phase 1
49;A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets;Overall Response Rate (ORR) per Adapted International Myeloma Working Group (IMWG) criteria;Up to Approximately 12 Months;Overall Survival (OS);Recruiting;Phase 1
50;Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma;To determine the maximum tolerated dose of P276-00 in subjects with relapsed and/or relapsed/refractory Multiple Myeloma;18 months,;Completed;Phase 1
50;Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma;To determine the maximum tolerated dose of P276-00 in subjects with relapsed and/or relapsed/refractory Multiple Myeloma;18 months,;Completed;Phase 2
51;Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138;Occurrence of study related adverse events;Until week 24;Anti-myeloma responses to CART-138 cell infusions;Unknown status;Phase 1
51;Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138;Occurrence of study related adverse events;Until week 24;Anti-myeloma responses to CART-138 cell infusions;Unknown status;Phase 2
52;UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma;Antithrombotic Effect of VELCADE in a Malignancy Associated With a Hypercoagulable State in Patients With Relapsed/Refractory Multiple Myeloma.;60 days,;Completed;Not Applicable
53;Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects;This study is to see if MRI techniques can be used for early evaluation of cardiac amyloidosis which is sometimes seen in individuals with multiple myeloma.;The time frame is five additional minutes & three additional images during and MRI.,;Terminated,
54;Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients;Efficacy of Velcade;48 hours,;Terminated;Phase 2
55;Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone;Time to progression (TTP);maximum 3 years per Patient;Overall Response Rate;Completed,
55;Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone;Time to progression (TTP);maximum 3 years per Patient;Time to Treatment Discontinuation (TTD);Completed,
55;Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone;Time to progression (TTP);maximum 3 years per Patient;Overall Survival (OS);Completed,
55;Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone;Time to progression (TTP);maximum 3 years per Patient;Safety Profile;Completed,
55;Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone;Time to progression (TTP);maximum 3 years per Patient;Dosage of Lenalidomide and Dexamethasone;Completed,
55;Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone;Time to progression (TTP);maximum 3 years per Patient;Kidney Function;Completed,
55;Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone;Time to progression (TTP);maximum 3 years per Patient;Neutropenia / Infection (Concomitant Medication);Completed,
55;Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and Dexamethasone;Time to progression (TTP);maximum 3 years per Patient;Thrombosis Prophylaxis;Completed,
56;PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma;Response rate of PAD induction Therapy,;Response rate of PAD followed by Thal/Dex maintenance;Unknown status;Phase 2
56;PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma;Response rate of PAD induction Therapy,;Progression free survival and Overall survival of PAD/Thal-Dex.;Unknown status;Phase 2
56;PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma;Response rate of PAD induction Therapy,;To evaluate toxicities of PAD/Thal-Dex;Unknown status;Phase 2
57;LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma;Occurrence of treatment related adverse events as assessed by CTCAE v4.0;Day 1-30 days after injection;Anti-myeloma responses to LCAR-B38M cell treatment;Unknown status;Phase 1
57;LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma;Occurrence of treatment related adverse events as assessed by CTCAE v4.0;Day 1-30 days after injection;Anti-myeloma responses to LCAR-B38M cell treatment;Unknown status;Phase 2
58;Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma;Incidence of Treatment-related Adverse Events;3 years;Overall Remission Rate(ORR) of BCMA-PD1-CART cells in Lymphoma;Unknown status;Phase 2
58;Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma;Incidence of Treatment-related Adverse Events;3 years;Overall survival(OS) of BCMA-PD1-CART cells in Lymphoma;Unknown status;Phase 2
58;Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma;Incidence of Treatment-related Adverse Events;3 years;Progress-free survival(PFS) of BCMA-PD1-CART cells in Lymphoma;Unknown status;Phase 2
58;Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma;Incidence of Treatment-related Adverse Events;3 years;Rate of BCMA-PD1-CARTcells in peripheral blood cells;Unknown status;Phase 2
58;Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma;Incidence of Treatment-related Adverse Events;3 years;Quantity of BCMA-PD1-CART cells copies in peripheral blood cells.;Unknown status;Phase 2
59;Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06);To evaluate the stringent Complete Response (sCR) rate of the combination of MLN9708, Lenalidomide and Dexamethasone in newly diagnosed multiple myeloma (MM) patients after extended consolidation therapy;sixteen months;To evaluate the overall response rate after induction therapy;Unknown status;Phase 2
59;Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06);To evaluate the stringent Complete Response (sCR) rate of the combination of MLN9708, Lenalidomide and Dexamethasone in newly diagnosed multiple myeloma (MM) patients after extended consolidation therapy;sixteen months;To evaluate the safety Evaluate the safety;Unknown status;Phase 2
59;Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06);To evaluate the stringent Complete Response (sCR) rate of the combination of MLN9708, Lenalidomide and Dexamethasone in newly diagnosed multiple myeloma (MM) patients after extended consolidation therapy;sixteen months;To evaluate the quality of stem cell harvest;Unknown status;Phase 2
59;Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06);To evaluate the stringent Complete Response (sCR) rate of the combination of MLN9708, Lenalidomide and Dexamethasone in newly diagnosed multiple myeloma (MM) patients after extended consolidation therapy;sixteen months;To evaluate the overall response rate after high-dose therapy (prior to consolidation);Unknown status;Phase 2
59;Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06);To evaluate the stringent Complete Response (sCR) rate of the combination of MLN9708, Lenalidomide and Dexamethasone in newly diagnosed multiple myeloma (MM) patients after extended consolidation therapy;sixteen months;To evaluate the overall response rate after consolidation therapy;Unknown status;Phase 2
59;Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06);To evaluate the stringent Complete Response (sCR) rate of the combination of MLN9708, Lenalidomide and Dexamethasone in newly diagnosed multiple myeloma (MM) patients after extended consolidation therapy;sixteen months;To evaluate the feasibility of maintenance with MLN9708;Unknown status;Phase 2
59;Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06);To evaluate the stringent Complete Response (sCR) rate of the combination of MLN9708, Lenalidomide and Dexamethasone in newly diagnosed multiple myeloma (MM) patients after extended consolidation therapy;sixteen months;To evaluate duration of response, progression-free and overall survival;Unknown status;Phase 2
60;A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004);PHASE I: Maximum tolerated dose (MTD) of vorinostat in patients with advanced multiple myeloma.;"1) Anti-tumor activity in patients with advanced multiple myeloma; 2) Biological effects of SAHA in peripheral mononuclear cells and bone marrow plasma cells; 3) Correlation of biological effects of SAHA with serum drug concentration.";Terminated;Phase 1
60;A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004);PHASE II: Safety and overall response rate to SAHA in patients with advanced multiple myeloma.,;"1) Anti-tumor activity in patients with advanced multiple myeloma; 2) Biological effects of SAHA in peripheral mononuclear cells and bone marrow plasma cells; 3) Correlation of biological effects of SAHA with serum drug concentration.";Terminated;Phase 1
61;Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma;Number of Patients with Adverse events;8 weeks;Expansion of the CTLs;Recruiting;Phase 1
61;Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma;Number of Patients with Adverse events;8 weeks;Persistence of the CTLs;Recruiting;Phase 1
61;Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma;Number of Patients with Adverse events;8 weeks;Reduction of the Multiple Myeloma;Recruiting;Phase 1
62;Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma;Very Good Partial Response (VGPR) + Complete Response (CR) Rate using the IMWG response criteria;12 months,;Recruiting;Phase 2
63;Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma;change from baseline in Thrombin generation measure;day 21;image-confirmed venous thromboembolic events;Completed,
63;Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma;change from baseline in Thrombin generation measure;day 42;change from baseline in TFPI resistance measure;Completed,
63;Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma;change from baseline in Thrombin generation measure;day 63;change from baseline in acquired protein S deficiency measure;Completed,
63;Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma;change from baseline in Thrombin generation measure;day 0;change from baseline in TFPI resistance measure;Completed,
64;Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma;Response of relapsed refractory multiple myeloma (RRMM) patient to elotuzumab, selinexor, and dexamethasone (ESd).;18-24 months.;Incidence of adverse events in RRMM patients treated with ESd.;Withdrawn;Phase 2
64;Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma;Response of relapsed refractory multiple myeloma (RRMM) patient to elotuzumab, selinexor, and dexamethasone (ESd).;18-24 months.;Duration of Response (DOR) of RRMM patients to ESd.;Withdrawn;Phase 2
64;Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma;Response of relapsed refractory multiple myeloma (RRMM) patient to elotuzumab, selinexor, and dexamethasone (ESd).;18-24 months.;Overall Survival (OS) of RRMM patients treated with ESd.;Withdrawn;Phase 2
65;Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma;Number of Participants at Each Response Category (Stable Disease, Minimal Response, Partial Response, Very Good Partial Response, Near Complete Response/Complete Resonse);Data was collected for each subject for the duration of the participation in the study, which was an average of 4.8 cycles.;Number of Participants With Dose Reductions in Bortezomib, Dexamethasone or Both;Completed;Phase 2
66;Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma;To evaluate the safety of bortezomib when given in combination with CC-5013 in subjects with relapsed and relapsed/refractory multiple myeloma, to identify the MTD as well as a RP2D.;2 years;To evaluate the response of the combination of bortezomib and CC-5013;Completed;Phase 1
66;Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma;To evaluate the safety of bortezomib when given in combination with CC-5013 in subjects with relapsed and relapsed/refractory multiple myeloma, to identify the MTD as well as a RP2D.;2 years;To determine the pharmacokinetics of bortezomib and CC5013 in patients with multiple myeloma.;Completed;Phase 1
67;Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma;Contrast-to-noise ratio;3 months after the CT scan,;Recruiting,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Very Good Partial Response (VGPR) Rate;Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Complete Response (CR) Rate;Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Stringent Complete Response (sCR) Rate;Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Minimal Residual Disease (MRD) Negative Rate;Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Clinical Benefit Rate (CBR);Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Duration of Response;Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Time to Response;Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Time to Next Treatment [TTNT];Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Progression-free Survival (PFS);Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Time to Progression on the Next Line of Subsequent Antimyeloma Therapy or Death (PFS2);Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Overall Survival (OS);Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Change from Baseline in Health-related Quality of Life (HRQoL) using European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Scale Score;Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Change from Baseline in Health-related Quality of Life (HRQoL) using European Organization for Research and Treatment of Cancer (EORTC) QLQ-MY20 Scale Score;Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Change from Baseline in Health-related Quality of Life (HRQoL) using EQ-5D-5L Questionnaire Score;Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Number of Patients with Adverse Events (AEs);Completed,
68;A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment;Overall Response Rate (ORR);Up to 24 months;Severity of Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE);Completed,
69;Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease,,,;Approved for marketing,
70;Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy;Number of Participants With Overall Induced Mucinous Glycoprotein-1 (MUC-1)-Specific Immune Response;From the date of randomization up to Week 104;Number of Participants With Baseline Immune Response and Initial Increase of MUC1 Specific Immune Response;Completed;Phase 2
70;Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy;Number of Participants With Overall Induced Mucinous Glycoprotein-1 (MUC-1)-Specific Immune Response;From the date of randomization up to Week 104;Number of Participants With Overall Induced Immune Response by Human Leukocyte-associated Antigen (HLA) Type;Completed;Phase 2
70;Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy;Number of Participants With Overall Induced Mucinous Glycoprotein-1 (MUC-1)-Specific Immune Response;From the date of randomization up to Week 104;Percentage of Participants With Objective Clinical Response (Complete Response [CR], or Partial Response [PR], or Minimal Response [MR];Completed;Phase 2
70;Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy;Number of Participants With Overall Induced Mucinous Glycoprotein-1 (MUC-1)-Specific Immune Response;From the date of randomization up to Week 104;Time to Progression (TTP);Completed;Phase 2
70;Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy;Number of Participants With Overall Induced Mucinous Glycoprotein-1 (MUC-1)-Specific Immune Response;From the date of randomization up to Week 104;Time to Anti-tumor Therapy;Completed;Phase 2
70;Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy;Number of Participants With Overall Induced Mucinous Glycoprotein-1 (MUC-1)-Specific Immune Response;From the date of randomization up to Week 104;Number of Participants With Treatment Emergent Adverse Events (TEAEs),Serious TEAEs, TEAEs of Grade 3 or 4 According to NCI-CTCAE v3.0, TEAEs Leading to Discontinuation and Injection Site Reactions (ISRs);Completed;Phase 2
71;Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma;Phase 1 (a & b): To determine the maximum tolerated dose of ACY-1215 as monotherapy or in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.;Upon completion of 21-day treatment cycle;Characterize the safety of ACY-1215 alone or in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma;Completed;Phase 1
71;Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma;Phase 2a: To determine the objective response rate to ACY-1215 in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.;Assessed every other treatment cycle (cycles 2, 4 and 6);Determine the single- and multiple-dose PK of ACY-1215 alone and in combination with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma;Completed;Phase 2
72;Quality of Life the Danish Multiple Myeloma Patients;A longitudinal description of quality of life (QoL) using patient-reported outcomes measurement (PROM) for the general population of multiple myeloma patients.;24 months;Description of changes in QoL over time, based on PROM for the general population of multiple myeloma patients.;Active, not recruiting,
72;Quality of Life the Danish Multiple Myeloma Patients;A longitudinal description of quality of life (QoL) using patient-reported outcomes measurement (PROM) for the general population of multiple myeloma patients.;24 months;Description of the impact of peripheral neuropathy on QoL in the general population of multiple myeloma patients over time, based on PROM.;Active, not recruiting,
72;Quality of Life the Danish Multiple Myeloma Patients;A longitudinal description of quality of life (QoL) using patient-reported outcomes measurement (PROM) for the general population of multiple myeloma patients.;24 months;Description of the impact of recalibration response shift for interpretation of data from longitudinal QoL studies using PROM for QoL measurement in the general population of previously untreated multiple myeloma patients.;Active, not recruiting,
73;Study of Natalizumab in Relapsed/Refractory Multiple Myeloma;Number of Participants With Dose Limiting Toxicities (DLTs);Day 1 up to Day 28;Number Of Participants Who Achieve A Complete Response;Terminated;Phase 1
73;Study of Natalizumab in Relapsed/Refractory Multiple Myeloma;Objective Response Rate (ORR);Day 1 up to Month 6;Kaplan-Meier Estimates for Duration Of Response For Participants With A Response;Terminated;Phase 2
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Time to Next Treatment (TTNT);Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Percentage of Participants Achieving Very Good Partial Response (VGPR);Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Percentage of Participants Achieving Complete Response (CR);Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Percentage of Participants Achieving Stringent Complete Response (sCR);Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Duration of Ixazomib Therapy (DOT);Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Duration of CR;Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Overall Survival (OS);Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Health-related Quality of Life (HRQOL) Based on European Organization for Research and Treatment of Cancer Multiple Myeloma Module (EORTC QLQ-MY20);Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);HRQOL Based on EORTC QLQ-C30;Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);HRQOL Based on EuroQoL Group 5-Dimension 5-Level (EQ-5D-5L);Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Treatment Satisfaction Questionnaire for Medication (TSQM-9);Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Number of Participants Categorized Based on Healthcare Resource Utilization;Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Number of Participants Categorized Based on Reason for Dose Reduction of Ixazomib Therapy;Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Number of Participants Categorized Based on Reason for Interruption of Ixazomib Therapy;Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Number of Participants Categorized Based on Reason for Discontinuation of Ixazomib Therapy;Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Relative Dose Intensity (RDI);Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Number of Participants who Experience at Least one Adverse Event (AE);Recruiting,
74;A Study of NINLARO® in Chinese Adults With Multiple Myeloma;Progression Free Survival (PFS);From the date of first administration of ixazomib therapy to the date of first documentation of progressive disease (PD) or death, lost to follow-up, whichever occurs first (up to 24 months);Number of Participants Categorized Based on Occurrence of Second Primary Malignancies (SPM);Recruiting,
75;Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement;Progression free survival;From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.;Overall survival;Recruiting;Phase 2
75;Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement;Progression free survival;From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.;Overall response rate;Recruiting;Phase 2
75;Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement;Progression free survival;From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.;Adverse Events;Recruiting;Phase 2
76;A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma;To determine tumor response of 2ME2 administered orally by evaluation of objective responses in patients with plateau phase or relapsed multiple myeloma;At least yearly;To assess the safety and tolerability of 2ME2 administered orally by evaluation of the frequency, severity, and duration of treatment-emergent adverse events in patients with plateau phase or relapsed multiple myeloma;Completed;Phase 2
76;A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma;To determine tumor response of 2ME2 administered orally by evaluation of objective responses in patients with plateau phase or relapsed multiple myeloma;At least yearly;To determine the minimum 2ME2 levels achieved in plasma following daily oral administration in patients with plateau phase or relapsed multiple myeloma;Completed;Phase 2
77;An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma;Overall response rate (ORR)- Cohort 1;Up to approximately 5 years;Complete response (CR) rate - Cohort 1;Recruiting;Phase 2
77;An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma;Complete response (CR) rate - Cohort 2a , b, c and Cohort 3;Up to approximately 5 years;Overall response rate (ORR) - Cohort 2a, b, c and Cohort 3;Recruiting;Phase 2
78;Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM);Level of compliance at PETHEMA centres in Spain with the clinical practice guidelines proposed by the Spanish Myeloma Group for the treatment of relapsed and refractory MM with POMCIDEX.;3 months,;Completed,
79;VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma;PFS (progression-free survival);18 Month after VMP therapy administration;ORR (Overall Response Rate);Unknown status,
79;VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma;PFS (progression-free survival);18 Month after VMP therapy administration;CR (Complete Response);Unknown status,
79;VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma;PFS (progression-free survival);18 Month after VMP therapy administration;Time to Response (TTR);Unknown status,
79;VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma;PFS (progression-free survival);18 Month after VMP therapy administration;Time to Progression (TTP);Unknown status,
79;VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma;PFS (progression-free survival);18 Month after VMP therapy administration;Time to Next Treatment (TTNT);Unknown status,
79;VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma;PFS (progression-free survival);18 Month after VMP therapy administration;OS (Overall Survival);Unknown status,
79;VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma;PFS (progression-free survival);18 Month after VMP therapy administration;Percentage of IMWG frailty scores at Cycle 5 and Cycle 9;Unknown status,
79;VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma;PFS (progression-free survival);18 Month after VMP therapy administration;Prognosis prediction factors;Unknown status,
80;Vaccines and COVID-19 in Multiple Myeloma;Feasibility of obtaining baseline clinical and PRO data capture from 200 consented patients.;At Baseline;COVID Vaccine Prevalence;Not yet recruiting,
80;Vaccines and COVID-19 in Multiple Myeloma;Feasibility of obtaining 30-day clinical and PRO data capture from 200 consented patients.;30 days after enrollment;COVID Booster Incidence;Not yet recruiting,
80;Vaccines and COVID-19 in Multiple Myeloma;Feasibility of obtaining 6-month clinical and PRO data capture from 200 consented patients.;6 months after enrollment;PRO Review;Not yet recruiting,
81;Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients;Overall response rate;142 days;Progression-free survival (PFS);Completed;Phase 2
81;Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients;Overall response rate;142 days;Time to progression (TTP);Completed;Phase 2
81;Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients;Overall response rate;142 days;Time to Next Therapy (TtNT);Completed;Phase 2
81;Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients;Overall response rate;142 days;Number and severity of Adverse events as a measure of safety and toxicity profile;Completed;Phase 2
82;Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients;Determine the PFS (progression free survival) in patients with multiple myeloma, treated with perifosine, bortezomib and dexamethasone compared to patients treated with placebo, bortezomib and dexamethasone;6 - 24 months;Overall survival (OS);Terminated;Phase 3
82;Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients;Determine the PFS (progression free survival) in patients with multiple myeloma, treated with perifosine, bortezomib and dexamethasone compared to patients treated with placebo, bortezomib and dexamethasone;6 - 24 months;Overall response rate (ORR);Terminated;Phase 3
82;Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients;Determine the PFS (progression free survival) in patients with multiple myeloma, treated with perifosine, bortezomib and dexamethasone compared to patients treated with placebo, bortezomib and dexamethasone;6 - 24 months;Adverse Events;Terminated;Phase 3
83;Bortezomib With Melphalan and Prednisone for Multiple Myeloma;Response;6 weeks following completion of treatment;Number of Patients With Any Grade or Severe Adverse Event;Completed;Phase 2
83;Bortezomib With Melphalan and Prednisone for Multiple Myeloma;Response;6 weeks following completion of treatment;Median Duration of Response;Completed;Phase 2
84;A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM);Near Complete Response (nCR)/CR Rate of the Combination of Panobinostat With Bortezomib, Lenalidomide and Dexamethasone (P-RVD) vs RVD in Newly Diagnosed Multiple Myeloma Patients;84 days;Minimal Residual Disease (MRD) Negativity (mCR) After 4 Cycles of Induction by Next Gen Sequencing;Terminated;Phase 2
84;A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM);Near Complete Response (nCR)/CR Rate of the Combination of Panobinostat With Bortezomib, Lenalidomide and Dexamethasone (P-RVD) vs RVD in Newly Diagnosed Multiple Myeloma Patients;84 days;Best Overall Response Rate (ORR) and MRD Negativity After ASCT and Maintenance;Terminated;Phase 2
84;A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM);Near Complete Response (nCR)/CR Rate of the Combination of Panobinostat With Bortezomib, Lenalidomide and Dexamethasone (P-RVD) vs RVD in Newly Diagnosed Multiple Myeloma Patients;84 days;Depth of Response by International Myeloma Working Group (IMWG) Criteria;Terminated;Phase 2
84;A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM);Near Complete Response (nCR)/CR Rate of the Combination of Panobinostat With Bortezomib, Lenalidomide and Dexamethasone (P-RVD) vs RVD in Newly Diagnosed Multiple Myeloma Patients;84 days;Duration of Response;Terminated;Phase 2
84;A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM);Near Complete Response (nCR)/CR Rate of the Combination of Panobinostat With Bortezomib, Lenalidomide and Dexamethasone (P-RVD) vs RVD in Newly Diagnosed Multiple Myeloma Patients;84 days;Overall Survival;Terminated;Phase 2
84;A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM);Near Complete Response (nCR)/CR Rate of the Combination of Panobinostat With Bortezomib, Lenalidomide and Dexamethasone (P-RVD) vs RVD in Newly Diagnosed Multiple Myeloma Patients;84 days;Progression Free Survival;Terminated;Phase 2
85;Antineoplaston Therapy in Treating Patients With Multiple Myeloma;Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable;36 months,;Terminated;Phase 2
86;Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma;Compare five-year survival;5 years post transplant;Progression-free survival (PFS);Recruiting,
86;Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma;Compare five-year survival;5 years post transplant;Relapse or progression;Recruiting,
86;Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma;Compare five-year survival;5 years post transplant;Transplant related mortality;Recruiting,
86;Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma;Compare five-year survival;5 years post transplant;Incidence of acute GVHD;Recruiting,
86;Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma;Compare five-year survival;5 years post transplant;Incidence of chronic GVHD;Recruiting,
87;Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma;Number of whole-body bone lesions;Day 0;Diagnostic performance for the detection of focal bone lesions;Recruiting;Phase 3
87;Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma;Number of whole-body bone lesions;Day 7;Diagnostic performance for the detection of focal bone lesions;Recruiting;Phase 3
87;Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma;Number of bone lesions within defined skeletal areas;Day 0;Diagnostic performances for the detection of diffuse infiltrative disease of the spine;Recruiting;Phase 3
87;Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma;Number of bone lesions within defined skeletal areas;Day 7;Diagnostic performances for the detection of diffuse infiltrative disease of the spine;Recruiting;Phase 3
88;Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive;Overall Responde Rate (ORR);every 6 months;Progression free survival (PFS);Unknown status;Phase 2
88;Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive;Overall Responde Rate (ORR);every 6 months;Complete Remission Rate (CR);Unknown status;Phase 2
88;Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive;Overall Responde Rate (ORR);every 6 months;Duration of Response (DoR);Unknown status;Phase 2
89;Survival Outcomes of Multiple Myeloma Patients Admitted on Assiut Clinical Hematology Unit;Determine the survival outcomes of multiple myeloma patients admitted on Assiut clinical Hematology unit;2 years,;Not yet recruiting,
90;Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma;The number of subjects in each status category of the International Myeloma Working Group (stringent complete response, complete response, very good partial response, partial response, minimal response, stable disease, progressive disease).;Year 1;Recruiting;Phase 2
90;Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma;The number of subjects in each status category of the International Myeloma Working Group (stringent complete response, complete response, very good partial response, partial response, minimal response, stable disease, progressive disease).;Year 2;Recruiting;Phase 2
90;Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma;The number of subjects in each status category of the International Myeloma Working Group (stringent complete response, complete response, very good partial response, partial response, minimal response, stable disease, progressive disease).;Year 3,;Recruiting;Phase 2
91;Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma;Serum Macrophage-Colony Stimulating Factor (M-CSF) levels;Day 1;Tumour osteolysis;Completed;Not Applicable
92;Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma;Phase 1: Frequency and Severity Of Treatment-Emergent Adverse Events (TEAEs);Up to 18 months;Maximum Concentration (Cmax) of ISB 1442 in Serum;Recruiting;Phase 1
92;Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma;Phase 1: Number of Dose-Limiting Toxicities (DLTS) During the First 28 Days After the First Administration of ISB 1442 (Cycle 1);Up to 28 days;Time to Reach Maximum Concentration (Tmax) of ISB 1442 in Serum;Recruiting;Phase 2
93;A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma;MTD (Maximum Tolerated Dose) of panobinostat in combination with RVD;2 Years;Response to pan-RVD (minimal response or better;Completed;Phase 1
93;A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma;Recommended dose of the combination for Phase 2 studies in participants with relapsed and relapsed/refractory multiple myeloma (MM) with SC bortezomib.;2 Years;Progression-free survival (PFS);Completed;Phase 1
94;Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma;Combined Therapy - Median Progression Free Survival;up to 36 months;Response Rate;Completed;Phase 2
94;Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma;Combined Therapy - Median Progression Free Survival;up to 36 months;Number of Participants With Serious Adverse Events;Completed;Phase 2
94;Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma;Combined Therapy - Median Progression Free Survival;up to 36 months;Single Agent - Median Progressive Free Survival (PFS);Completed;Phase 2
94;Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma;Combined Therapy - Median Progression Free Survival;up to 36 months;Number of Participants With 1 Year Overall Survival (OS);Completed;Phase 2
95;Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma;Dose Limiting Toxicities (DLT) - Number of Participants With at Least 1 DLT;Starting with first study drug administration until 30-day follow-up visit (average 4.99 months);Qualitative and Quantitative Toxicities of BT062;Completed;Phase 1
95;Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma;Maximum Tolerated Dose (MTD);First 28-day cycle;Multi-dose Pharmacokinetics Properties of BT062 - Cmax;Completed;Phase 2
96;Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD);Remission status of multiple myeloma;3 years;Graft versus host disease (GVHD);Completed;Phase 1
96;Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD);Renal allograft acceptance and ability to discontinue immunosuppressive therapy;3 years;Opportunistic infections;Completed;Phase 1
97;Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma;Overall Response Rate (ORR) of BPV;2 years;Number and percentage of patients achieving a complete response;Completed;Phase 2
97;Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma;Overall Response Rate (ORR) of BPV;2 years;Progression-free survival (PFS);Completed;Phase 2
97;Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma;Overall Response Rate (ORR) of BPV;2 years;Overall survival (OS);Completed;Phase 2
97;Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma;Overall Response Rate (ORR) of BPV;2 years;Time-to-progression (TTP);Completed;Phase 2
97;Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma;Overall Response Rate (ORR) of BPV;2 years;Disease-free survival (DFS);Completed;Phase 2
97;Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma;Overall Response Rate (ORR) of BPV;2 years;Duration of response (DOR);Completed;Phase 2
97;Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma;Overall Response Rate (ORR) of BPV;2 years;Renal response according to IMWG (CRrenal, PRrenal, MRrenal);Completed;Phase 2
97;Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma;Overall Response Rate (ORR) of BPV;2 years;Toxicity (with respect to adverse events of CTCAE grade ≧3 and SAEs);Completed;Phase 2
97;Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma;Overall Response Rate (ORR) of BPV;2 years;Time to objective Response (TOR);Completed;Phase 2
97;Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma;Overall Response Rate (ORR) of BPV;2 years;Time to treatment failure (TTF);Completed;Phase 2
98;Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.;The occurrence of the events;6 MONTHS;Type of Vulnerability;Unknown status;Not Applicable
98;Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.;The occurrence of the events;6 MONTHS;Therapeutic changes;Unknown status;Not Applicable
98;Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.;The occurrence of the events;6 MONTHS;Toxicity during treatment;Unknown status;Not Applicable
98;Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.;The occurrence of the events;6 MONTHS;Progression to 1 and 2 years;Unknown status;Not Applicable
98;Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.;The occurrence of the events;6 MONTHS;Complete response at 1 and 2 years;Unknown status;Not Applicable
99;High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma;To estimate the response at day 100 following transplant (rate of CR);Day 100;Number of patients with overall survival post-transplant;Completed;Phase 2
99;High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma;To estimate the response at day 100 following transplant (rate of CR);Day 100;Number of patients with event-free survival;Completed;Phase 2
99;High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma;To estimate the response at day 100 following transplant (rate of CR);Day 100;Number of patients with non-relapse mortality;Completed;Phase 2
100;Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma;Maximum tolerated dose.;1 Cycle (28-Days);Overall response rate.;Withdrawn;Phase 1
100;Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma;Maximum tolerated dose.;1 Cycle (28-Days);Progression free survival.;Withdrawn;Phase 1
100;Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma;Maximum tolerated dose.;1 Cycle (28-Days);Treatment-emergent adverse events.;Withdrawn;Phase 1
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Overall Survival (OS);Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Event-free Survival (EFS);Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Overall Response Rate (ORR);Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Minimal Residual Disease (MRD);Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Complete Response (CR) Rate;Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Duration of Response (DOR);Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Time to Response (TTR);Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Adverse Events (AEs);Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Pharmacokinetics- Cmax;Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Pharmacokinetics- tmax;Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Pharmacokinetics- AUC;Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Pharmacokinetics- t-last;Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Pharmacokinetics- AUC0-28days;Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30);Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Subject-reported outcomes as measured by EuroQoL Group European Quality of Life-5 Dimensions health state classifier to 5 Levels (EQ-5D-5L) Health Questionnaire;Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Subject-reported outcomes as measured by European Quality of Life Multiple Myeloma Module (EORTC-QLQ-MY20);Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Time to next antimyeloma treatment;Active, not recruiting;Phase 3
101;Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Minimum of 5 years from randomization;Progression-free survival after next line therapy (PFS2);Active, not recruiting;Phase 3
102;VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT);Primary endpoints are to study the safety of four cycles of VELCADE in patients with multiple myeloma following high-dose chemotherapy and autologous PBSCT.,;The secondary objectives of this study are to assess the efficacy of four cycles of VELCADE at two different dose levels as maintenance treatment in patients with multiple myeloma;Unknown status;Phase 2
102;VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT);Primary endpoints are to study the safety of four cycles of VELCADE in patients with multiple myeloma following high-dose chemotherapy and autologous PBSCT.,;and detectable residual disease following high-dose chemotherapy and autologous PBSCT;Unknown status;Phase 2
102;VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT);Primary endpoints are to study the safety of four cycles of VELCADE in patients with multiple myeloma following high-dose chemotherapy and autologous PBSCT.,;to assess the 2 year progression-free survival;Unknown status;Phase 2
102;VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT);Primary endpoints are to study the safety of four cycles of VELCADE in patients with multiple myeloma following high-dose chemotherapy and autologous PBSCT.,;and to assess the 2 year overall survival.;Unknown status;Phase 2
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Very Good Partial Response (VGPR) Rate;Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Complete Response (CR) Rate;Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Stringent Complete Response (sCR) Rate;Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Minimal Residual Disease (MRD) Negative Rate;Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Clinical Benefit Rate (CBR);Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Duration of Response (DOR);Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Time to Response (TTR);Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Time to Best Response;Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Time to Next Treatment (TTNT);Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Progression-free Survival (PFS);Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Time to Progression on the Next Line of Subsequent Antimyeloma Therapy or Death, Whichever Occurs First (PFS2);Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Overall Survival (OS);Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score;Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L);Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Change from Baseline in Health-related Quality of Life (HRQoL) (Symptoms, Functioning, and Well-being) Assessed by EORTC QLQ-IL39;Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Number of Participants with Adverse Events (AEs);Active, not recruiting,
103;A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 35 months;Severity of Adverse Events as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE);Active, not recruiting,
104;A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma;Maximum tolerated dose of HG146;Up to 3 months;Peak Plasma Concentration (Cmax);Recruiting;Phase 1
104;A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma;Maximum tolerated dose of HG146;Up to 3 months;Area under the plasma concentration versus time curve (AUC);Recruiting;Phase 1
104;A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma;Maximum tolerated dose of HG146;Up to 3 months;Time of Peak Concentration (Tmax);Recruiting;Phase 1
104;A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma;Maximum tolerated dose of HG146;Up to 3 months;Half life (T1/2);Recruiting;Phase 1
104;A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma;Maximum tolerated dose of HG146;Up to 3 months;Incidence of adverse events related to treatments;Recruiting;Phase 1
104;A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma;Maximum tolerated dose of HG146;Up to 3 months;Incidence of laboratory abnormalities related to treatments;Recruiting;Phase 1
105;Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma;Incidence of venous thromboembolic (VTE) and/or arterial thromboembolic (ATE) events in patients with Multiple Myeloma placed on the Rivaroxaban vs Aspirin after starting with Len-Dex therapy;6 months;External validation of the IMWG criteria for risk assessment of thromboembolic events in multiple myeloma patients;Recruiting;Phase 2
105;Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by CTCAE v6.0;6 months;Assessment of correlation of between levels of biomarkers of myeloma and thrombosis with the risk of ATE or VTE;Recruiting;Phase 3
106;Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma;Rate of Patients Achieving an Objective Response;from start to end of study (14 months);Safety Assessment;Completed;Phase 2
106;Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma;Rate of Patients Achieving an Objective Response;from start to end of study (14 months);Pharmacodynamics of IPH2101;Completed;Phase 2
106;Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma;Rate of Patients Achieving an Objective Response;from start to end of study (14 months);Secondary Anti-tumor Activity;Completed;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;CR Rate [Based on the International Myeloma Working Group (IMWG) Criteria];Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Response Rate (Based on the IMWG Criteria);Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;CR Rate Based on the (Bladé) Criteria;Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Response Rate (Based on the Bladé Criteria);Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Response Rate (Based on the Modified SWOG Criteria);Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Progression-Free Survival (PFS);Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Time to Treatment Failure (TTF);Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Duration of Response (DOR);Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Overall Survival (OS);Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Number of Subjects With Adverse Event, Related Adverse Event, Serious Adverse Event, and Related Serious Adverse Event;Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Number of Adverse Events, Related Adverse Events, Serious Adverse Events, and Related Serious Adverse Events;Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values;Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Number of Abnormalities (Grade ≥3) in Laboratory Test Values;Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Pharmacokinetic Parameters (Cmax);Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Pharmacokinetic Parameters (Tmax);Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Pharmacokinetic Parameters (AUC);Terminated;Phase 2
107;Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma;Complete Response (CR) Rate [Based on the Modified Southwest Oncology Group (SWOG) Criteria];Up to 36 weeks;Pharmacokinetic Parameters (t1/2);Terminated;Phase 2
108;Role of Osteocytes in Myeloma Bone Disease;Molecular interactions between multiple myeloma and osteocytes;Up to 4 years;Multiple Myeloma osteocytes and tumor staging;Recruiting,
108;Role of Osteocytes in Myeloma Bone Disease;Molecular interactions between multiple myeloma and osteocytes;Up to 4 years;Multiple Myeloma osteocytes and Type I collagen fragments on bone resorption;Recruiting,
109;Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma;Response Rate (RR) After 6 Cycles of Therapy Using the Proposed International Myeloma Working Group Uniform Response Criteria;After 6 cycles;Treatment Related Adverse Events Grade 3 or Higher;Completed;Phase 2
109;Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma;Response Rate (RR) After 6 Cycles of Therapy Using the Proposed International Myeloma Working Group Uniform Response Criteria;After 6 cycles;Quality of Life Using the FACT-G Data;Completed;Phase 2
110;A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma;Maximum-Tolerated Dose (MTD);Up to 28 days from the last dose of study drug in Cycle 1 (each cycle is 28 days);Safety and Tolerability as Measured by the Incidence of TEAEs;Recruiting;Phase 1
110;A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma;Recommended Phase 2 Dose (PR2D);Up to 28 days from the last dose of study drug;Incidence of Abnormal Laboratory Values and Vital Signs;Recruiting;Phase 1
111;A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma;Achievement of a target of ≥ 2*10^6 CD34+ cells/kg collected during apheresis period in patients with multiple myeloma.;Day 5, 6, 7;Achievement of a target of ≥ 2*10^6 CD34+ cells/kg collected during apheresis period in patients with malignant lymphoma.;Completed;Phase 2
112;An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function;Percentage of Participants With Renal Compromised Multiple Myeloma by International Myeloma Working Group (IMWG) Uniform Response Criteria;Week 24 or Early termination visit (30-45 days after last dose);Best Response to Treatment;Terminated;Phase 2
112;An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function;Percentage of Participants With Renal Compromised Multiple Myeloma by International Myeloma Working Group (IMWG) Uniform Response Criteria;Week 24 or Early termination visit (30-45 days after last dose);Time to Progression (TTP) of Disease;Terminated;Phase 2
112;An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function;Percentage of Participants With Renal Compromised Multiple Myeloma by International Myeloma Working Group (IMWG) Uniform Response Criteria;Week 24 or Early termination visit (30-45 days after last dose);Duration of Response;Terminated;Phase 2
112;An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function;Percentage of Participants With Renal Compromised Multiple Myeloma by International Myeloma Working Group (IMWG) Uniform Response Criteria;Week 24 or Early termination visit (30-45 days after last dose);Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score;Terminated;Phase 2
112;An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function;Percentage of Participants With Renal Compromised Multiple Myeloma by International Myeloma Working Group (IMWG) Uniform Response Criteria;Week 24 or Early termination visit (30-45 days after last dose);Karnofsky Performance Status (KPS) Score;Terminated;Phase 2
112;An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function;Percentage of Participants With Renal Compromised Multiple Myeloma by International Myeloma Working Group (IMWG) Uniform Response Criteria;Week 24 or Early termination visit (30-45 days after last dose);Quality of Life Assessment by QLQ C-30;Terminated;Phase 2
112;An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function;Percentage of Participants With Renal Compromised Multiple Myeloma by International Myeloma Working Group (IMWG) Uniform Response Criteria;Week 24 or Early termination visit (30-45 days after last dose);Quality of Life Assessed by Euro Quality of Life (EQ-5D);Terminated;Phase 2
112;An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function;Percentage of Participants With Renal Compromised Multiple Myeloma by International Myeloma Working Group (IMWG) Uniform Response Criteria;Week 24 or Early termination visit (30-45 days after last dose);Renal Function;Terminated;Phase 2
113;Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma;Percent enrichment of 13-Carbon in the tricarboxylic acid (TCA) cycle intermediates within bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma;Up to 1 day;Percent enrichment of 13-Carbon in the TCA cycle intermediates within bone marrow plasma from patients with MGUS and multiple myeloma;Recruiting;Not Applicable
113;Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma;Percent enrichment of 13-Carbon in the tricarboxylic acid (TCA) cycle intermediates within bone marrow plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma;Up to 1 day;Percent enrichment of 13-Carbon in the TCA cycle intermediates within the peripheral blood plasma from patients with MGUS and multiple myeloma;Recruiting;Not Applicable
114;Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR);2 year;Safety (incidence of adverse events defined as dose-limited toxicity);Unknown status;Phase 1
114;Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma;minimal residual disease（MRD）;2 year;Expression of CD19 CART cells;Unknown status;Phase 1
115;Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions;Rate of progression to active Multiple Myeloma (MM);Up to 5 years;Frequency of participant conversion from MGUS/SMM to Myeloma defining genomic events;Recruiting,
115;Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions;Rate of progression to active Multiple Myeloma (MM);Up to 5 years;Frequency of participant conversion from MGUS/SMM to associated progressive phenotype;Recruiting,
115;Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions;Rate of progression to active Multiple Myeloma (MM);Up to 5 years;Rate of participant conversion from MGUS/SMM to Myeloma defining genomic events;Recruiting,
115;Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions;Rate of progression to active Multiple Myeloma (MM);Up to 5 years;Rate of participant conversion from MGUS/SMM to associated progressive phenotype;Recruiting,
116;Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple Myeloma;Multiple myeloma identified as bone disease, myeloma or plasmacytoma;baseline;Disease heterogeneity;Unknown status,
116;Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple Myeloma;Multiple myeloma identified as bone disease, myeloma or plasmacytoma;baseline;Early signs of bone remodeling;Unknown status,
117;Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma;Safety and Efficacy;Through day +104 following immunotherapy;Time to Engraftment in Patients Who Proceed to Myeloablative Chemotherapy After Receiving 90Y Zevalin® (Ibritumomab Tiuxetan).;Terminated;Phase 2
117;Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma;Safety and Efficacy;Through day +104 following immunotherapy;Degree of CD20 Expression on Plasma Cells and/or Targeting of Post-germinal Center B Cells Correlation With Toxicity, Response and Biodistribution;Terminated;Phase 2
118;Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy;Proportion of Patients Experiencing a Serious Bacterial Infection;First three months of chemotherapy,;Completed;Phase 3
119;Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma;Progression Free Survival (PFS);End of 2 year, post transplant follow-up;Overall Survival (OS) Rate;Completed;Phase 2
119;Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma;Progression Free Survival (PFS);End of 2 year, post transplant follow-up;Molecular Complete Response (CR) Rates in Patients With Multiple Myeloma;Completed;Phase 2
120;A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance;Creatinine levels to determinates Renal function response;Up to 12 months;Race of participants at Baseline;Completed,
120;A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance;Age of participants at baseline to determinates Renal function response;Baseline visit;Clinical Outcome of participants with Multiple Myeloma (MM) clinical description;Completed,
120;A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance;Weight of participants at baseline to determinates Renal function response;Baseline visit;Renal response rate assessment in clinical practice.;Completed,
120;A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance;Gender of participants at baseline to determinates Renal function response;Baseline visit;Time dependent Renal response rate assessment in clinical practice.;Completed,
121;RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma;To evaluate the safety of RAD001 when given in combination with lenalidomide and to identify the maximum tolerated dose (MTD) as well as a recommended Phase 2 dose for the combination in this patient population.;2 years;To evaluate the response to the combination of RAD001 and lenalidomide in subjects with multiple myeloma.;Completed;Phase 1
121;RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma;To evaluate the safety of RAD001 when given in combination with lenalidomide and to identify the maximum tolerated dose (MTD) as well as a recommended Phase 2 dose for the combination in this patient population.;2 years;To determine the pharmacokinetics of RAD001 and lenalidomide.;Completed;Phase 1
121;RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma;To evaluate the safety of RAD001 when given in combination with lenalidomide and to identify the maximum tolerated dose (MTD) as well as a recommended Phase 2 dose for the combination in this patient population.;2 years;To identify possible surrogate markers to better define mechanisms of action for the combination of the two drugs.;Completed;Phase 1
122;Busulfan and Melphalan Conditioning in Multiple Myeloma;Treatment response up to 2 months after ASCT;2 months later after last patent received ASCT;Progression free survival(PFS);Unknown status;Phase 2
122;Busulfan and Melphalan Conditioning in Multiple Myeloma;Safety and toxicity (frequency of grade 3 or worse toxicities) of the conditioning regimen;2 months later after last patent received ASCT;Overall survival (OS);Unknown status;Phase 2
123;Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI);Percentage of bone marrow fat in vertebral bone marrow;At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty;Sex;Unknown status,
123;Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI);Vertebral fracture severity score;At the moment of the diagnosis of the vertebral fracture before treatment by vertebroplasty;Age at the diagnosis of multiple myeloma;Unknown status,
124;RMPT for Relapsed/Refractory Multiple Myeloma;Myeloma response rate in terms of partial remission (PR) and very good partial remission (VGPR);4 years;progression free survival and overall survival;Completed;Phase 2
125;RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma;Overall response rate;One (1) year after last dose of RAPA-201 cells.;Effect of therapy on disease control;Recruiting;Phase 2
125;RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma;Overall response rate;One (1) year after last dose of RAPA-201 cells.;Effect in Quality of Life;Recruiting;Phase 2
126;Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma;Maximum Tolerated Dose of Bendamustine;Six months for each dosing cohort;Overall Survival (OS);Completed;Phase 1
126;Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma;Objective Response Rate;18 months;Progression Free Survival (PFS);Completed;Phase 2
127;Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma;Overall Response Rate (PR+nCR+CR);after eight cycyles of treatment (24 weeks);Responders to Treatment;Completed;Phase 2
127;Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma;Overall Response Rate (PR+nCR+CR);after eight cycyles of treatment (24 weeks);Time to Response (Greater Than or Equal to PR) Based on Investigator Assessment;Completed;Phase 2
127;Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma;Overall Response Rate (PR+nCR+CR);after eight cycyles of treatment (24 weeks);Progression-free Survival;Completed;Phase 2
127;Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma;Overall Response Rate (PR+nCR+CR);after eight cycyles of treatment (24 weeks);Time to Progression;Completed;Phase 2
127;Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma;Overall Response Rate (PR+nCR+CR);after eight cycyles of treatment (24 weeks);Over All Survival;Completed;Phase 2
128;To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma;the effect of sham procedure & conservative management alone (arm 1) versus balloon kyphoplasty (arm 2) on patient reported pain scores as assessed by VAS (at week 4);At week 4;the effect of conservative management alone versus balloon kyphoplasty on patient reported pain scores as assessed by VAS (at weeks 1, 8, 12, 16, 26, year 1 and year 2);Terminated;Not Applicable
128;To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma;the effect of sham procedure & conservative management alone (arm 1) versus balloon kyphoplasty (arm 2) on patient reported pain scores as assessed by VAS (at week 4);At week 4;the pain relief requirements of conservative management alone versus balloon kyphoplasty using a daily pain diary (capturing usage of pain relief by type);Terminated;Not Applicable
128;To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma;the effect of sham procedure & conservative management alone (arm 1) versus balloon kyphoplasty (arm 2) on patient reported pain scores as assessed by VAS (at week 4);At week 4;the effect of conservative management alone versus balloon kyphoplasty on patient reported Quality Of Life outcomes;Terminated;Not Applicable
128;To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma;the effect of sham procedure & conservative management alone (arm 1) versus balloon kyphoplasty (arm 2) on patient reported pain scores as assessed by VAS (at week 4);At week 4;procedure related complications of conservative management alone versus balloon kyphoplasty;Terminated;Not Applicable
128;To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma;the effect of sham procedure & conservative management alone (arm 1) versus balloon kyphoplasty (arm 2) on patient reported pain scores as assessed by VAS (at week 4);At week 4;the cost utility of the conservative management alone versus the balloon kyphoplasty;Terminated;Not Applicable
129;Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib;Endothelial Function and Dyspnea Associations in Multiple Myeloma Patients;2 months;Cardiovascular Toxicities Associated with Changes in Carfilzomib-Induced Endothelial Function;Recruiting,
129;Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib;Endothelial Function and Dyspnea Associations in Multiple Myeloma Patients;2 months;The Affects of Carfilzomib Dose/Dosing Schedule on the Incidence of Dyspnea;Recruiting,
129;Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib;Endothelial Function and Dyspnea Associations in Multiple Myeloma Patients;2 months;Changes in Cardiovascular Physiology and Risk Factors Associated with Endothelial Function;Recruiting,
130;Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation;Changes in neurocognitive functions in older participants with Multiple Myeloma following high-dose (HD) chemotherapy and autologous stem cell transplantation (ASCT) assessed by initial and follow-up neurocognitive evaluation;up to 4 months following chemotherapy and ASCT;Active, not recruiting;Not Applicable
130;Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation;Changes in regional brain volume and functional connectivity when baseline and follow-up MRIs are compared.;up to 4 months following chemotherapy and ASCT,;Active, not recruiting;Not Applicable
131;Inflammatory Cytokines in Symptom Production in Multiple Myeloma;Multiple myeloma module of MDASI (MDASI-MM) Questionnaire;Baseline with 12 Month Longitudinal Assessment,;Completed,
132;Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma;Event-free Survival;1 year;Safety and Toxicity;Completed;Phase 2
132;Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma;Safety of Maintenance Rituximab Following High Dose Cyclophosphamide;2, 3, 6, 9, and 12 months;Complete Response (CR) Rate and Partial Response (PR) Rate;Completed;Phase 2
133;Protocol to Obtain Blood and Bone Marrow Samples for Myeloma Research;Cancer cell response to molecular testing of killing cell parts.;2 Years,;Terminated,
134;A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate;100 weeks;Number of Participants with Severe Adverse Events;Unknown status;Phase 1
135;Biomarkers in Multiple Myeloma;Level of thrombin generation in newly diagnosed and untreated MM;24 months;Association between biomarkers (thrombin, factor VIII, D-Dimers, pro-coagulant phospholipids) and VTE onset;Recruiting;Not Applicable
135;Biomarkers in Multiple Myeloma;Level of factor VIII in newly diagnosed and untreated MM;24 months;Association between biomarkers (thrombin, factor VIII, D-Dimers, pro-coagulant phospholipids) and MM outcome;Recruiting;Not Applicable
135;Biomarkers in Multiple Myeloma;Level of D-Dimers in newly diagnosed and untreated MM;24 months;Evolution of biomarkers (thrombin, factor VIII, D-Dimers, pro-coagulant phospholipids) at 3 months post-treatment;Recruiting;Not Applicable
135;Biomarkers in Multiple Myeloma;Level of pro-coagulant phospholipids in newly diagnosed and untreated MM;24 months;Evaluation of the exposition of Apixaban (Eliquis®);Recruiting;Not Applicable
136;A Registry Study of Participants With Multiple Myeloma in Latin America;Demographic Characteristics of Multiple Myeloma (MM) Participants;Baseline;Overall Survival (OS);Completed,
136;A Registry Study of Participants With Multiple Myeloma in Latin America;Number of Participants with Comorbid Conditions;Baseline;Progression-Free Survival (PFS);Completed,
136;A Registry Study of Participants With Multiple Myeloma in Latin America;General Health Status Based on Frailty Score;Approximately up to 2.7 years;Percentage of Participants with Complete Response (CR);Completed,
136;A Registry Study of Participants With Multiple Myeloma in Latin America;Eastern Cooperative Oncology Group (ECOG) Performance Status Score;Approximately up to 2.7 years;Percentage of Participants with Stringent Complete Response (sCR);Completed,
136;A Registry Study of Participants With Multiple Myeloma in Latin America;Sequence of Treatments in Participants with Multiple Myeloma (MM);Approximately up to 2.7 years;Duration of Response;Completed,
136;A Registry Study of Participants With Multiple Myeloma in Latin America;Number of Participants in Each Stage of Multiple Myeloma (MM) Disease;Approximately up to 2.7 years;Time to Next Treatment;Completed,
137;Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma;Feasibility, usability, and acceptability of a tablet-based modified geriatric assessment using online questionnaires.;Years 1-2;Description of treatment decision making patterns chosen by hematologists managing older patients with multiple myeloma;Completed;Not Applicable
137;Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma;Physician use and perceived utility of the modified geriatric assessment;Years 1-2;Description of rates of CTCAE Grade 3-5 toxicities in older adults with MM who receive treatment following a treatment decision making visit at which an mCGA is completed;Completed;Not Applicable
138;A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma;Response Rate;1 year;Count of Participants With Serious and Non-Serious Adverse Events;Terminated;Phase 2
139;Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma;Progression-free Survival (PFS);From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.;Overall Survival;Completed;Phase 3
139;Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma;Progression-free Survival (PFS);From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.;Overall Response Rate;Completed;Phase 3
139;Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma;Progression-free Survival (PFS);From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.;Disease Control Rate;Completed;Phase 3
139;Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma;Progression-free Survival (PFS);From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.;Duration of Response;Completed;Phase 3
139;Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma;Progression-free Survival (PFS);From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.;Duration of Disease Control;Completed;Phase 3
139;Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma;Progression-free Survival (PFS);From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.;Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores;Completed;Phase 3
140;Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study);Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis;Day 1;Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode;Completed,
140;Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study);Percentage of MM Participants Categorized by Clinical Variables at Diagnosis;Day 1;Number of New Relevant Variables That Are Not Currently Collected in Clinical Records and That Could Influence in the Disease Management at Relapse;Completed,
140;Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study);Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode;Day 1;Health-Related Quality of Life (HRQOL) Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30;Completed,
141;Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat;Phase I: Maximum Tolerated Dose (MTD);Up to 8 months;Stringent Complete Remission (sCR) Rate after 4 and 8 Cycles of Treatment;Withdrawn;Phase 1
141;Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat;Phase I: Maximum Tolerated Dose (MTD);Up to 8 months;Phase II: Overall Response Rate (ORR);Withdrawn;Phase 2
142;Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma;Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment;6 months;Complete Response Rate at 6 Months;Completed;Not Applicable
142;Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma;Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment;6 months;Toxicity as Assessed by NCI CTCAE v3.0;Completed;Not Applicable
142;Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma;Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment;6 months;Time to Progression Post Transplant;Completed;Not Applicable
142;Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma;Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment;6 months;Progression-free and Overall Survival;Completed;Not Applicable
142;Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma;Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment;6 months;Pre- and Post-ALI Immune Response to Cancer Testis Antigens (CTA);Completed;Not Applicable
142;Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma;Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment;6 months;CTA Expression Before and After Azacitidine Therapy;Completed;Not Applicable
143;O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma;Evaluate the efficacy of O6-benzylguanine combined with carmustine in patients with previously untreated or refractory multiple myeloma.;Every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response. Patients are followed every 2 months.,;Completed;Phase 2
144;Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients;Number of Patients Without Symptomatic Myeloma;up to 1 year;Overall Response Rate;Terminated;Phase 2
144;Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients;Number of Patients Without Symptomatic Myeloma;up to 1 year;Bone Density Changes;Terminated;Phase 2
144;Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients;Number of Patients Without Symptomatic Myeloma;up to 1 year;PET-MRI Changes;Terminated;Phase 2
144;Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients;Number of Patients Without Symptomatic Myeloma;up to 1 year;Change in Serum Interleukin-6 (IL-6);Terminated;Phase 2
144;Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients;Number of Patients Without Symptomatic Myeloma;up to 1 year;Change in Serum Stromal Cell-derived Factor-1 (SDF-1);Terminated;Phase 2
144;Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients;Number of Patients Without Symptomatic Myeloma;up to 1 year;Change in Serum Receptor Activator of Nuclear-factor Kappa B Ligand (RANKL);Terminated;Phase 2
144;Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients;Number of Patients Without Symptomatic Myeloma;up to 1 year;Change in Serum Macrophage Inflammatory Protein-1α (MIP-1α);Terminated;Phase 2
144;Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients;Number of Patients Without Symptomatic Myeloma;up to 1 year;Change in Serum Dickkopf-1 (DKK-1);Terminated;Phase 2
144;Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients;Number of Patients Without Symptomatic Myeloma;up to 1 year;Change in Serum C-terminal Telopeptide (CTX);Terminated;Phase 2
144;Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients;Number of Patients Without Symptomatic Myeloma;up to 1 year;Change in Urine N-terminal Telopeptide (NTx);Terminated;Phase 2
145;Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM]);Adverse Events (AEs);Up to approximately 6 months,;Completed,
146;Connect® MM- The Multiple Myeloma Disease Registry;Identify and summarize patterns in therapeutic regimens;Minimum 8 years;Summarize Effectiveness of Treatment Regimens;Active, not recruiting,
146;Connect® MM- The Multiple Myeloma Disease Registry;Identify and summarize patterns in therapeutic regimens and patient outcomes;Minimum 8 years;Summarize health-related quality of life (HRQoL) relation to treatment regimens/sequence and clinical outcomes;Active, not recruiting,
147;CART-19 for Multiple Myeloma;Number of Adverse Events;2 years,;Completed;Phase 1
148;Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma;Response Rate (RR);From the date of randomization to the date of the first major documented response (CR, PR or MR) that occurs, evaluated up to 35 days after the completion of 6th treatment cycles or if the response occurs earlier.;Time to progression (TTP) during treatment with metformin and HDdexa according to criteria for defining response of the International Myeloma Working Group (IMWG);Unknown status;Phase 2
148;Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma;Response Rate (RR);From the date of randomization to the date of the first major documented response (CR, PR or MR) that occurs, evaluated up to 35 days after the completion of 6th treatment cycles or if the response occurs earlier.;Duration of response (DOR) during treatment with metformin and HDdexa according to criteria for defining response of the International Myeloma Working Group (IMWG);Unknown status;Phase 2
148;Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma;Response Rate (RR);From the date of randomization to the date of the first major documented response (CR, PR or MR) that occurs, evaluated up to 35 days after the completion of 6th treatment cycles or if the response occurs earlier.;Event free survival (EFS) during treatment with metformin and HDdexa according to criteria for defining response of the International Myeloma Working Group (IMWG);Unknown status;Phase 2
149;A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma;The percentage of participants who achieve a complete response (CR);Up to 7 years;The percentage of participants who are minimal residual disease (MRD) negative;Active, not recruiting;Phase 2
149;A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma;The percentage of participants that have an event (disease progression or death) per patient-year;Up to 7 years;Time to next treatment (TNT);Active, not recruiting;Phase 2
150;Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment;Observance of treatment by patients following Revlimid - Velcade - Dexamethasone protocol who had the benefit of a Guided Clinical Pharmacy Consultation;End of treatment. Day 21 +/- 5 days;Results of the self-questionnaire for patients following the Revlimid - Velcade - Dexamethasone protocol who benefitted from the guided clinical pharmacy consultation.;Recruiting;Not Applicable
150;Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment;Observance of treatment by patients following Revlimid - Dexamethazone protocol who had the benefit of the Guided Clinical Pharmacy Consultation;End of treatment. Day 28 +/- 5 days;Results of the self-questionnaire for patients following the Revlimid - Velcade - Dexamethasone protocol who did not have the benefit of the guided clinical pharmacy consultation;Recruiting;Not Applicable
150;Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment;Observance of treatment by patients following Revlimid - Velcade - Dexamethasone protocol who did not not have the benefit of a Guided Clinical Pharmacy Consultation;End of treatment. Day 21 +/- 5 days;Results of the self-questionnaire for patients following the Revlimid - Dexamethazone protocol who benefitted from the guided clinical pharmacy consultation;Recruiting;Not Applicable
150;Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment;Observance of treatment by patients following Revlimid - Dexamethazone protocol who did not have the benefit of the Guided Clinical Pharmacy Consultation;End of treatment. Day 28 +/- 5 days;Results of the self-questionnaire for patients following the Revlimid - Dexamethazone protocol who did not have the benefit of the guided clinical pharmacy consultation;Recruiting;Not Applicable
151;Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma;Rate of Very Good Partial Response (No Prior CAR T-Cell Therapy Cohort);6-24 months;Overall Response Rate;Not yet recruiting;Phase 2
151;Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma;Rate of Overall Response (Prior CAR T-Cell Therapy Cohort);6-24 months;Minimal Residual Disease Negativity Rate;Not yet recruiting;Phase 2
152;Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients;Progression-free Survival;"From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively";Overall Survival;Completed;Phase 3
152;Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients;Progression-free Survival;"From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively";Overall Response;Completed;Phase 3
152;Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients;Progression-free Survival;"From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively";Duration of Response;Completed;Phase 3
152;Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients;Progression-free Survival;"From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively";Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy;Completed;Phase 3
152;Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients;Progression-free Survival;"From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively";Percentage of Participants With a Significant Reduction in Left Ventricular Ejection Fraction (LVEF);Completed;Phase 3
152;Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients;Progression-free Survival;"From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively";Change From Baseline in Right Ventricular Fractional Area Change (FAC);Completed;Phase 3
152;Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients;Progression-free Survival;"From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively";Change From Baseline in Pulmonary Artery Systolic Pressure (PASP);Completed;Phase 3
153;Multiple Myeloma and Environmental Exposure to Pesticides in the French West Indies: A Population Based Case-control Study.;Measure of association between exposure to chlordecone and risk of multiple myeloma.;Pesticide samples will be sent to the Reference Laboratory of Animal Ecology and Ecotoxicology in Liège once or twice a year. For a given patient, the time frame (questionnaire + and blood analyses) will be 12 months after inclusion.;proportion of MM cases attributable to pesticide exposure;Unknown status,
154;Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine;Number of patients with dose limiting toxicity (DLT) by CTCAE, v5.0;8 weeks;Overall response rate according to the modified International Myeloma Working Group (IMWG) Uniform Response criteria.;Active, not recruiting;Phase 1
155;Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency;effect of BHQ880 compared with placebo on time to first Skeletal Related Event (SRE) in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone;18-month median time to first SRE assumed for the placebo arm;safety and tolerability of BHQ880 in combination with bortezomib and dexamethasone;Completed;Phase 2
155;Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency;effect of BHQ880 compared with placebo on time to first Skeletal Related Event (SRE) in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone;18-month median time to first SRE assumed for the placebo arm;Characterize the PharmacoKinetics (PK) profiles of BHQ880 and bortezomib;Completed;Phase 2
155;Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency;effect of BHQ880 compared with placebo on time to first Skeletal Related Event (SRE) in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone;18-month median time to first SRE assumed for the placebo arm;Evaluate the effect of BHQ880 on bone metabolism;Completed;Phase 2
155;Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency;effect of BHQ880 compared with placebo on time to first Skeletal Related Event (SRE) in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone;18-month median time to first SRE assumed for the placebo arm;Determine the antimyeloma effect of BHQ880 compared to placebo when used in combination with bortezomib and dexamethasone.;Completed;Phase 2
156;Feasibility Study of an ePRO Monitoring for Patients With Multiple Myeloma and Development of Item Lists;Patient rated feasibility and adequacy of the item lists and symptom monitoring program;6 weeks after inclusion of the patient or after the patient used the portal 3 times, whichever came first;Completeness of questionnaires;Completed,
156;Feasibility Study of an ePRO Monitoring for Patients With Multiple Myeloma and Development of Item Lists;Assessment completion rate;From the inclusion of the patient until the end of the study (ie, at maximum 12 months) or until the patient withdraws, whichever came first;Frequency of clinical alerts in the system;Completed,
157;Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma;Establish a maximum-tolerated dose of Palbociclib, lenalidomide, and dexamethasone for patients with relapsed or refractory multiple myeloma;3 years;Number of subjects who demonstrate a response to Palbociclib, Lenalidomide, and dexamethasone;Terminated;Phase 1
157;Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma;Establish a maximum-tolerated dose of Palbociclib, lenalidomide, and dexamethasone for patients with relapsed or refractory multiple myeloma;3 years;Survival duration without disease progression of relapsed/refractory study subjects treated with palbociclib, lenalidomide, and dexamethasone;Terminated;Phase 1
157;Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma;Establish a maximum-tolerated dose of Palbociclib, lenalidomide, and dexamethasone for patients with relapsed or refractory multiple myeloma;3 years;Toxicity profile associated with the study regimen (palbociclib, lenalidomide, and dexamethasone);Terminated;Phase 1
158;CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with Severe/Adverse Events as a Measure of Safety;28 days;Objective response rate of complete remission and partial remission;Unknown status;Early Phase 1
158;CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma;CAR-T Cell expansion level;24 months;Overall survival time;Unknown status;Early Phase 1
159;Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE);Overall Survival (OS) for participants with relapsed/refractory multiple myeloma (RRMM);Up to 5 years;Treatment patterns of approved MM therapies as measured by the Response Rate for participants with RRMM;Recruiting,
159;Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE);Overall Survival (OS) for participants with newly-diagnosed multiple myeloma (NDMM);Up to 8 years;Treatment patterns of approved MM therapies as measured by the Response Rate for participants with NDMM;Recruiting,
159;Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE);Progression-Free Survival (PFS) for participants with RRMM;Up to 5 years;Healthcare resource utilization (HCRU) for participants with RRMM;Recruiting,
159;Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE);Progression-Free Survival (PFS) for participants with NDMM;Up to 8 years;Healthcare resource utilization (HCRU) for participants with NDMM;Recruiting,
160;A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma;Time to tumor progression (TTP);Up to 3 years;Number of patients who survived;Completed;Phase 3
160;A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma;Time to tumor progression (TTP);Up to 3 years;Time to first symptomatic skeletal-related event (SRE)(clinical need for radiation therapy or surgery to bone);Completed;Phase 3
160;A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma;Time to tumor progression (TTP);Up to 3 years;Myeloma response rate;Completed;Phase 3
160;A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma;Time to tumor progression (TTP);Up to 3 years;Number of participants with adverse events;Completed;Phase 3
161;Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma;Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len;At the end of 4 th cycle (each cycle is 28 days), an average 4 months;Treatment-emergent adverse events according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 5.0).;Not yet recruiting;Phase 2
161;Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma;Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len;At the end of 4 th cycle (each cycle is 28 days), an average 4 months;overall response rate(PR or better) as defined by the IMWG response criteria;Not yet recruiting;Phase 2
161;Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma;Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len;At the end of 4 th cycle (each cycle is 28 days), an average 4 months;Very good partial response or better, defined as VGPR or CR according to the IMWG criteria at the time of data cutoff;Not yet recruiting;Phase 2
161;Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma;Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len;At the end of 4 th cycle (each cycle is 28 days), an average 4 months;Compleat response or better, defined as negative immunofixation of serum and urine, and disappearance of any soft tissue plasmacytomas, and <5% plasma cells in bone marrow*;Not yet recruiting;Phase 2
161;Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma;Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len;At the end of 4 th cycle (each cycle is 28 days), an average 4 months;Time to response;Not yet recruiting;Phase 2
161;Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma;Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len;At the end of 4 th cycle (each cycle is 28 days), an average 4 months;Duration of response;Not yet recruiting;Phase 2
161;Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma;Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len;At the end of 4 th cycle (each cycle is 28 days), an average 4 months;Time from randomization to discontinuation of therapy for any reason including death, progression or toxicity;Not yet recruiting;Phase 2
161;Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma;Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len;At the end of 4 th cycle (each cycle is 28 days), an average 4 months;Overall survival time;Not yet recruiting;Phase 2
161;Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma;Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len;At the end of 4 th cycle (each cycle is 28 days), an average 4 months;TTTF, defined as the time from the date of the first dose of study treatment to discontinuation of therapy for any reason including death, progression, toxicity;Not yet recruiting;Phase 2
161;Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma;Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len;At the end of 4 th cycle (each cycle is 28 days), an average 4 months;TTNT, defined as the time from date of the first dose of study treatment to the start of the next-line treatmentTime-to-next treatment;Not yet recruiting;Phase 2
161;Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma;Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len;At the end of 4 th cycle (each cycle is 28 days), an average 4 months;Rate of minimal residual disease (MRD)-negativity (at level of 10-5 and 10-6 by NGS) at 6 months;Not yet recruiting;Phase 2
161;Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma;Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len;At the end of 4 th cycle (each cycle is 28 days), an average 4 months;Rate of Sustained MRD-negativity-(at level of 10-5 and 10-6 by NGS);Not yet recruiting;Phase 2
162;Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma;Objective Tumor Response Rate;1 year;Maximum Tolerated Dose of brostallicin;Completed;Phase 1
162;Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma;Objective Tumor Response Rate;1 year;Time to response;Completed;Phase 2
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Adverse event reporting;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Clinical outcomes after each CAR T cell regimen;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Duration of Response;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Progression-free Survival (PFS);Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Overall Survival (OS);Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Evaluate effects of huCART19 on correlative parameters of CART BCMA resistance and clonogenic multiple myeloma cells, such as the following:;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Composition of investigative products;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Maintenance therapy effects on persistence;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;In vivo CAR T cell expansion as measured by flow cytometry;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;In vivo CAR T cell expansion as measured by qPCR;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Duration of in vivo persistence of CAR T cells.;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Effects of maintenance therapy on CAR T cell pharmacokinetic parameters.;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Bioactivity by multiplex cytokine analysis;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Cellular composition of CAR T cell products;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Immune cell phenotyping;Active, not recruiting;Phase 1
163;Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma;Adverse event reporting;90 Days;Impact of T Cells on systemic soluble immune factors in patients;Active, not recruiting;Phase 1
164;Stage I Multiple Myeloma Treatment;Survival without progress;every month during 6 years;predictive factors of a fast evolution of multiple myeloma;Unknown status;Phase 4
164;Stage I Multiple Myeloma Treatment;Survival without progress;every month during 6 years;Secondary effects of zolédronate;Unknown status;Phase 4
165;Study of Combination PS-341 and Thalidomide in Multiple Myeloma;Assess the toxicity of PS-341 combined with one of four doses of thalidomide in patients with refractory multiple myeloma;until pt progresses or unexceptible toxicity,;Completed;Phase 1
166;LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma;Occurrence of treatment related adverse events;Day 1-30 days after injection;Anti-myeloma responses to LCAR-B4822M cell treatment;Unknown status;Phase 1
166;LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma;Occurrence of treatment related adverse events;Day 1-30 days after injection;Anti-myeloma responses to LCAR-B38M cell treatment;Unknown status;Phase 1
167;Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma;Maximum tolerated dose (MTD) of the combination of panobinostat and carfilzomib;28 day cycle,;Completed;Phase 1
168;Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma;Safety of STI-6129;Baseline through study completion at up to approximately 24 months;Measuring Pharmacokinetic [PK] Profile;Active, not recruiting;Phase 1
168;Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma;Safety of STI-6129;Baseline through study completion at up to approximately 24 months;Overall response and duration;Active, not recruiting;Phase 2
169;Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM);36 participants evaluated for safety with treatment-related adverse events and grading by using CTCAE v4.0.;3 years;36 participants evaluated for response to treatment by testing blood for multiple myeloma levels.;Recruiting;Phase 1
169;Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM);36 participants evaluated for tolerability with treatment-related adverse events and grading by using CTCAE v4.0.;3 years;36 participants evaluated for progression by testing blood for multiple myeloma levels.;Recruiting;Phase 2
170;BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma;Adverse events that related to treatment;2 years;Rate of BCMA CAR-T cells in bone marrow and peripheral blood;Recruiting;Phase 1
170;BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma;The response rate of BCMA CAR-T treatment in patients with relapse/refractory Multiple Myeloma that treatment by BCMA CAR-T cells therapy;2 years;Quantity of BCMA CAR copies in bone marrow and peripheral blood;Recruiting;Phase 2
171;A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma;89Zr-daratumumab PET/CT for pre-treatment multiple myeloma imaging;up to 3 years;Recruiting;Phase 2
171;A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma;89Zr-daratumumab PET/CT for post-treatment multiple myeloma imaging;up to 3 years;Recruiting;Phase 2
171;A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma;Prediction of response to therapy;up to 3 years,;Recruiting;Phase 2
172;Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma;Dose Limiting Toxicities (DLTs) of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-myeloma Regimens in Participants With Relapsed/Refractory (R/R) Multiple Myeloma (MM);Up to 28 days after study drug administration;Percentage of Participants Achieving Best Overall Response of Documented Partial Response (PR) or Better;Terminated;Phase 1
172;Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma;Dose Limiting Toxicities (DLTs) of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-myeloma Regimens in Participants With Relapsed/Refractory (R/R) Multiple Myeloma (MM);Up to 28 days after study drug administration;Progression Free Survival (PFS);Terminated;Phase 1
172;Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma;Dose Limiting Toxicities (DLTs) of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-myeloma Regimens in Participants With Relapsed/Refractory (R/R) Multiple Myeloma (MM);Up to 28 days after study drug administration;Duration of Response (DOR);Terminated;Phase 1
172;Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma;Dose Limiting Toxicities (DLTs) of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-myeloma Regimens in Participants With Relapsed/Refractory (R/R) Multiple Myeloma (MM);Up to 28 days after study drug administration;Time to Progression (TTP);Terminated;Phase 1
173;Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide);Progression Free Survival (PFS);2 years after enrollment of last patient;Overall Survival (OS);Terminated,
173;Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide);Response Rates;2 years after enrollment of last patient;Time to Response (TTR) and Duration of Response (DOR);Terminated,
174;VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates;Response rate of VTD induction Therapy;2008-02-01;Response rate of VTD/MPT maintenance therapy;Completed;Phase 2
174;VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates;Response rate of VTD induction Therapy;2008-02-01;Progression free survival Overall survival of VTD/MPT;Completed;Phase 2
174;VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates;Response rate of VTD induction Therapy;2008-02-01;To evaluate toxicities of VTD/MPT;Completed;Phase 2
175;A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects;Number of Participants With Dose-limiting Toxicities (DLTs);First cycle treatment over 28-days;Overall Response Rate (ORR);Completed;Phase 1
175;A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects;Number of Participants With Dose-limiting Toxicities (DLTs);First cycle treatment over 28-days;Time To Response (TTR);Completed;Phase 1
175;A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects;Number of Participants With Dose-limiting Toxicities (DLTs);First cycle treatment over 28-days;Number of Participants With Adverse Events;Completed;Phase 1
176;Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse;Time to next need treatment;6 months;Time to symptom relapse;Completed;Phase 4
176;Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse;Time to next need treatment;6 months;disease progression;Completed;Phase 4
176;Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse;Time to next need treatment;6 months;prognostic factors;Completed;Phase 4
176;Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse;Time to next need treatment;6 months;antitumour effect of ZOL;Completed;Phase 4
176;Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse;Time to next need treatment;6 months;Overall survival;Completed;Phase 4
177;Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma;Adverse events that related to treatment;2 years;Rate of BCMA CAR-T cells in bone marrow and peripheral blood;Recruiting;Phase 1
177;Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma;The response rate of BCMA CAR-T treatment in patients with relapse/refractory Multiple Myeloma that treatment by BCMA CAR-T cells therapy;6 months;Quantity of BCMA CAR copies in bone marrow and peripheral blood;Recruiting;Phase 2
178;A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma;Number of Participants With Adverse Events (AE) During the Treatment Phase;"Until data cut-off of 22 Oct 2009; AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit. Maximum exposure to Lenalidomide treatment was 1260 days.";Time to Progression;Completed;Phase 3
178;A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma;Number of Participants With Adverse Events (AE) During the Extension Phase;"From 22 Oct 2009 to November 2013; AEs/SAEs were recorded from informed consent to 30 days post treatment discontinuation visit.";Myeloma Response Rate;Completed;Phase 3
179;Study of bb2121 in Multiple Myeloma;Incidence of adverse events (AEs) and abnormal laboratory test results, including dose limiting toxicities (DLTs);Day 1 through Month 60;Disease-specific response criteria including: overall response rate (ORR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM.;Completed;Phase 1
180;PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy);Change From Baseline to Progression of the Cell Surface Expression of CS1 From Bone Marrow-Derived Multiple Myeloma (MM) Cells;From baseline (screening) to time of progression (up to approximately 54 months);Percent of Bone Marrow-Derived Multiple Myeloma (MM) Cells Expressing Cell Surface CS1 at Time of Progression;Terminated;Phase 3
180;PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy);Change From Baseline to Progression of the Cell Surface Expression of CS1 From Bone Marrow-Derived Multiple Myeloma (MM) Cells;From baseline (screening) to time of progression (up to approximately 54 months);Levels of CS1 Soluble Form (sCS1) in Serum;Terminated;Phase 3
180;PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy);Change From Baseline to Progression of the Cell Surface Expression of CS1 From Bone Marrow-Derived Multiple Myeloma (MM) Cells;From baseline (screening) to time of progression (up to approximately 54 months);Change From Baseline in the Levels of CS1 Soluble Form (sCS1) in Serum During Therapy and At Progression;Terminated;Phase 3
180;PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy);Change From Baseline to Progression of the Cell Surface Expression of CS1 From Bone Marrow-Derived Multiple Myeloma (MM) Cells;From baseline (screening) to time of progression (up to approximately 54 months);Change From Baseline in the Number of Circulating Multiple Myeloma (MM) Cells;Terminated;Phase 3
180;PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy);Change From Baseline to Progression of the Cell Surface Expression of CS1 From Bone Marrow-Derived Multiple Myeloma (MM) Cells;From baseline (screening) to time of progression (up to approximately 54 months);Change From Baseline in Cell Surface CS1 Expression Levels in Circulating Multiple Myeloma (MM) Cells;Terminated;Phase 3
180;PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy);Change From Baseline to Progression of the Cell Surface Expression of CS1 From Bone Marrow-Derived Multiple Myeloma (MM) Cells;From baseline (screening) to time of progression (up to approximately 54 months);CS1 Expression Levels in Matched Samples of Bone Marrow-Derived Multiple Myeloma (MM) Cells and Circulating MM Cells;Terminated;Phase 3
181;S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate Complete Remission (CR), Remission (R), and Partial Remission (PR).;1 year;Toxicity Evaluation;Terminated;Phase 2
181;S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate Complete Remission (CR), Remission (R), and Partial Remission (PR).;1 year;Progression-Free Survival;Terminated;Phase 2
182;Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma;Number of Patients With an Adverse Event Attributable to the Investigational Therapy;2 months;Immune Reconstitution in Recipients of Th1.(T Helper Cell) Rapa Cells.;Terminated;Phase 1
182;Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma;Number of Participants With Progression Free Survival in Cohort A Th1 (Type 1 T Helper Cells)/Tc1 (T Cytotoxic Cells, Type 1) Rapa Prevention of Relapse;Study completion at 22 months;Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0);Terminated;Phase 2
183;Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma;Complete Response Rate;3 years;Overall Survival Rate (OS);Completed;Phase 4
183;Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma;Complete Response Rate;3 years;Overall Survival Rate (OS);Completed;Phase 4
183;Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma;Complete Response Rate;3 years;Progression Free Survival (PFS);Completed;Phase 4
183;Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma;Complete Response Rate;3 years;Progression Free Survival (PFS);Completed;Phase 4
184;A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Patients were followed until documented progression, unacceptable toxicity, patient/physician decision to withdraw or date of death, whichever came first. Longest time to response in study recorded as 15.3 months. Longest time on treatment 35 months.;Progression Free Survival (PFS);Completed;Phase 2
184;A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Patients were followed until documented progression, unacceptable toxicity, patient/physician decision to withdraw or date of death, whichever came first. Longest time to response in study recorded as 15.3 months. Longest time on treatment 35 months.;Duration of Response;Completed;Phase 2
184;A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Patients were followed until documented progression, unacceptable toxicity, patient/physician decision to withdraw or date of death, whichever came first. Longest time to response in study recorded as 15.3 months. Longest time on treatment 35 months.;Overall Survival;Completed;Phase 2
184;A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Patients were followed until documented progression, unacceptable toxicity, patient/physician decision to withdraw or date of death, whichever came first. Longest time to response in study recorded as 15.3 months. Longest time on treatment 35 months.;Functional Status and Well-being: EORTC QLQ-C30;Completed;Phase 2
184;A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Patients were followed until documented progression, unacceptable toxicity, patient/physician decision to withdraw or date of death, whichever came first. Longest time to response in study recorded as 15.3 months. Longest time on treatment 35 months.;Functional Status and Well-being: EQ-5D-3L;Completed;Phase 2
184;A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Patients were followed until documented progression, unacceptable toxicity, patient/physician decision to withdraw or date of death, whichever came first. Longest time to response in study recorded as 15.3 months. Longest time on treatment 35 months.;Clinical Benefit Rate;Completed;Phase 2
184;A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Patients were followed until documented progression, unacceptable toxicity, patient/physician decision to withdraw or date of death, whichever came first. Longest time to response in study recorded as 15.3 months. Longest time on treatment 35 months.;Time to Response;Completed;Phase 2
184;A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Patients were followed until documented progression, unacceptable toxicity, patient/physician decision to withdraw or date of death, whichever came first. Longest time to response in study recorded as 15.3 months. Longest time on treatment 35 months.;Time to Progression;Completed;Phase 2
185;Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma;Clinical Response to Treatment;1-6 months;Peripheral Motor and Sensory Neuropathy (Grade 2 and Higher);Completed;Phase 2
185;Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma;Clinical Response to Treatment;1-6 months;Mobilization of Stem Cells in Patients Proceeding to Autologous Peripheral Stem Transplantation;Completed;Phase 2
185;Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma;Clinical Response to Treatment;1-6 months;The Time to Response;Completed;Phase 2
185;Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma;Clinical Response to Treatment;1-6 months;Quality of Life;Completed;Phase 2
186;The Molecular Characterization of Multiple Myeloma at Relapse;Molecular characteristics (by FISH, SNP, GEP, miRNA);0-3 years;Event free survival (EFS);Completed,
186;The Molecular Characterization of Multiple Myeloma at Relapse;Molecular characteristics (by FISH, SNP, GEP, miRNA);0-3 years;Overall survival (OS);Completed,
187;Serum NGAL IN Patients With Multiple Myeloma;serum Neutrophil Gelatinase-associated Lipocalin in patients with multiple myeloma;baseline to 3 months,;Not yet recruiting,
188;Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI;Detection of lesions;Up to 4 years;Recruiting;Not Applicable
188;Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI;Assessment of therapy response;Up to 4 years;Recruiting;Not Applicable
188;Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI;Progression Free Survival (PFS);Up to 4 years;Recruiting;Not Applicable
188;Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI;Overall Survival (OS);Up to 4 years,;Recruiting;Not Applicable
189;Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma;Percentage of Participants With Very Good Partial Remission (VGPR) or Better;up to 4 months;Median Progression Free Survival (PFS) in months;Unknown status;Phase 3
189;Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma;Percentage of Participants With Very Good Partial Remission (VGPR) or Better;up to 4 months;2 Year Overall Survival (OS) Rate;Unknown status;Phase 3
189;Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma;Percentage of Participants With Very Good Partial Remission (VGPR) or Better;up to 4 months;Number of participants with adverse events;Unknown status;Phase 3
190;a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma;Adverse events that related to treatment;2 years;Rate of BCMA targeted prime CAR-T cells in bone marrow and peripheral blood;Recruiting;Phase 1
190;a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma;The response rate of BCMA targeted prime CAR-T treatment in patients with relapse/refractory Multiple Myeloma that treatment by BCMA targeted prime CAR-T cells therapy;2 years;Quantity of BCMA targeted prime CAR copies in bone marrow and peripheral blood;Recruiting;Phase 2
191;Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use;Duration of carfilzomib treatment;31 august 2021;Time to next treatment;Completed,
191;Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use;Duration of carfilzomib treatment;31 august 2021;Progression Free survival (PFS);Completed,
192;Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma;Maximum Tolerated Dose (MTD) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma;28 days;Rate of Response of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma;Withdrawn;Phase 1
192;Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma;Adverse Events (AE) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma;Start of study drug combination up to 30 days after the last dose of drug;Progression Free Survival (PFS) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma;Withdrawn;Phase 1
193;A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma;Overall response rate (CR+PR);Every 3 months;Time to response;Terminated;Phase 2
193;A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma;Overall response rate (CR+PR);Every 3 months;Safety and tolerability of clofarabine;Terminated;Phase 2
193;A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma;Overall response rate (CR+PR);Every 3 months;Duration of response;Terminated;Phase 2
193;A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma;Overall response rate (CR+PR);Every 3 months;Time to progression;Terminated;Phase 2
194;Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older;To compare the progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib.;Participants will be followed post transplant for a minimum of 2 years, and after that may be monitored as part of the study indefinitely;To compare the response rate, overall survival and toxicity of high-dose melphalan versus high-dose melphalan and bortezomib;Active, not recruiting;Phase 2
195;Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma;Number of Phase I Patients Receiving 2.3mg, 3mg, or 4mg MLN9708 Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Maximum Tolerated Dose;Collected from day of first dose to the end of the first treatment cycle, up to 28 days;Median Progression-Free Survival (PFS) at 2 Years Post-maintenance Therapy;Completed;Phase 2
195;Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma;Number of Participants With Grade 3/4/5 Serious Adverse Events and Adverse Events as a Measure of Safety of MLN9708 When Used as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma Multiple Myeloma;Defined as the time from Day 1 of study drug administration until 30 days after treatment completion for up to 2 years.;Median Overall Survival (OS) at 2 Years Post-allogeneic Stem Cell Transplant (ASCT);Completed;Phase 2
196;A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma;Phase I: Determine the safety and feasibility of administering BI-505 in conjunction with HDM+ASCT in multiple myeloma patients;Adverse events will be assessed within 30 days of ASCT in the safety part of the study.;Determine the effect of BI-505 on rate of stringent complete response (sCR) at day 100 in subgroups stratified according to response to initial therapy (+/- VGPR).;Terminated;Phase 1
196;A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma;Phase II: Determine the effect of BI-505 on rate of stringent complete response for multiple myeloma patients with measurable disease pre-ASCT.;At Day 100 after ASCT;Determine the effect of BI-505 administered in conjunction with HDM + ASCT on IMWG response category (PR, VGPR, CR, sCR) at one year post-ASCT and progression-free survival.;Terminated;Phase 2
197;A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma;morbidity of psychological distress in patients with multiple myeloma.;Baseline (the time when the patient is enrolled to the study);morbidity of anxiety in patients with multiple myeloma.;Recruiting,
197;A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma;morbidity of psychological distress in patients with multiple myeloma.;Baseline (the time when the patient is enrolled to the study);morbidity of insomnia in patients with multiple myeloma.;Recruiting,
198;Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma;Safety, pharmacokinetics and pharmacodynamics at multiple doses;At the completion of each dose escalation cohort;Clinical response after various doses;Completed;Phase 1
199;Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma;Combined Response Rate During the Induction Phase in Newly Diagnosed Multiple Myeloma (NDMM) Participants;Day 1 of Cycles 1-13, 28-day cycles (Up to 1 year);Number of Participants With Adverse Events (AEs), Grade 3 or Higher AEs, AEs Resulting in Treatment Discontinuation, AEs Resulting in Dose Reduction and Serious Adverse Events (SAEs) in NDMM Participants;Completed;Phase 2
199;Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma;Overall Response Rate (ORR) in Relapsed and/or Refractory Multiple Myeloma (RRMM) Participants;Day 1 of each 28 day cycle (Up to 45 months);Percentage of Participants With CR + VGPR + PR (ORR), CR, VGPR, PR and Stable Disease (SD), Progressive Disease (PD) During the Induction Phase;Completed;Phase 2
200;A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma;The Incidence of adverse events (TEAEs) within 30 days after intravenous infusion of C-CAR088;30 days;Overall response rate (ORR);Unknown status;Phase 1
200;A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma;The Incidence of adverse events (TEAEs) within 30 days after intravenous infusion of C-CAR088;30 days;Progression free survival (PFS);Unknown status;Phase 1
201;D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma;1.1 To evaluate, in a randomized phase III clinical trial in previously treated multiple myeloma patients whether angio-chemotherapy with D.T. PACE may be equivalent or superior to tandem transplant.,,;Completed;Phase 3
202;Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma;The primary objective of this study is to identify the maximum tolerated dose;1 year;The secondary objective of this study is to measure the pharmacokinetics of;Completed;Phase 1
202;Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma;The primary objective of this study is to identify the maximum tolerated dose;1 year;The secondary objective of this study is to measure the pharmacokinetics of;Completed;Phase 2
203;A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma;Safety: The incidence of treatment-emergent adverse events (TEAEs);30 days;Overall response rate (ORR);Unknown status;Phase 1
203;A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma;Safety: The incidence of treatment-emergent adverse events (TEAEs);30 days;Progression free survival (PFS);Unknown status;Phase 1
203;A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma;Safety: The incidence of treatment-emergent adverse events (TEAEs);30 days;The CART cell duration in vivo;Unknown status;Phase 1
203;A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma;Safety: The incidence of treatment-emergent adverse events (TEAEs);30 days;The soluble BCMA changes in peripheral blood;Unknown status;Phase 1
204;BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma;Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 5.0;6 months;Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm;Recruiting;Early Phase 1
204;BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma;Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 5.0;6 months;Duration of CAR-positive T cells in circulation;Recruiting;Early Phase 1
205;Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma;Multiple myeloma,,;Completed;Phase 1
205;Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma;Multiple myeloma,,;Completed;Phase 2
206;Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma;Adverse events based on the NCI Common Terminology Criteria (CTC) version 3.0;Ongoing from start of treatment until 30 days post;Laboratory tests to include: serum protein electrophoresis, quantitative immunoglobulins assay and immunofixation, 24 hour urine collection for Bence Jones protein, total proteins, and creatinine, bone marrow aspiration and analysis for plasma cells;Completed;Phase 1
207;Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma;Event Free Survival;3 years;Disease Response;Terminated;Phase 2
207;Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma;Event Free Survival;3 years;Overall survival;Terminated;Phase 2
207;Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma;Event Free Survival;3 years;Grade > 2 toxicities;Terminated;Phase 2
207;Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma;Event Free Survival;3 years;Incidence of infections;Terminated;Phase 2
207;Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma;Event Free Survival;3 years;Treatment related Mortality;Terminated;Phase 2
208;A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma;Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT);Day 1 to Day 28;Maximum Observed Concentration (Cmax) of AMG 224;Completed;Phase 1
208;A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma;Number of Participants With a Treatment-emergent Adverse Event (TEAE);"Day 1 of Cycle 1 to up to the end of Cycle 4, where each cycle is 3 weeks; up to 12 weeks.";Minimum Observed Concentration (Cmin) of AMG 224;Completed;Phase 1
209;Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma;Response Rates by Blade Criteria;Up to 1 year;Progression-free Survival;Completed;Phase 2
209;Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma;Response Rates by Blade Criteria;Up to 1 year;Overall Survival;Completed;Phase 2
209;Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma;Response Rates by Blade Criteria;Up to 1 year;Feasibility as Measured by Participant Withdrawal or Removal;Completed;Phase 2
209;Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma;Response Rates by Blade Criteria;Up to 1 year;Safety as Measured by Grade 3-5 Adverse Events;Completed;Phase 2
209;Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma;Response Rates by Blade Criteria;Up to 1 year;Anti-tumor Immune Response;Completed;Phase 2
209;Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma;Response Rates by Blade Criteria;Up to 1 year;The Effect of aMILs on Osteoclastogenesis as Measured by Bone Turnover (RANKL/OPG Ratio);Completed;Phase 2
209;Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma;Response Rates by Blade Criteria;Up to 1 year;The Effect of aMILs on Osteoclastogenesis as Measured by Bone Turnover (Serum C Telopeptide Levels);Completed;Phase 2
209;Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma;Response Rates by Blade Criteria;Up to 1 year;The Effect of aMILs on Osteoclastogenesis as Measured by Bone Turnover (bAlkaline Phosphatase Levels);Completed;Phase 2
209;Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma;Response Rates by Blade Criteria;Up to 1 year;The Effect of aMILs on Osteoclastogenesis as Measured by Bone Turnover (Osteocalcin Levels);Completed;Phase 2
209;Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma;Response Rates by Blade Criteria;Up to 1 year;Effect of aMILs on Clonogenic Myeloma Precursors;Completed;Phase 2
210;Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics;Treatment toxicities:neuritis;From registration to December,2022;Progression-free survival;Enrolling by invitation,
210;Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics;Confirmed responses: Strictly Complete response, sCR;From registration to December,2022;Overall survival;Enrolling by invitation,
211;A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma;"To Establish the Safety, Tolerability, and RP2D (Phase 1); To Assess the Overall Response Rate in Subjects With Advanced Multiple Myeloma (Phase 2).";21 day cycle, up to 52 weeks;Phase 1: PK Absorption Tmax hr Day 11;Completed;Phase 1
211;A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma;"To Establish the Safety, Tolerability, and RP2D (Phase 1); To Assess the Overall Response Rate in Subjects With Advanced Multiple Myeloma (Phase 2).";21 day cycle, up to 52 weeks;Phase 1: PK Exposure Cmax ng/mL Day 11;Completed;Phase 2
212;ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma;Response rate;4 weeks after completion of 8 treatment cycles;Complete response rate;Completed;Phase 2
212;ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma;Response rate;4 weeks after completion of 8 treatment cycles;Very good partial response rate;Completed;Phase 2
212;ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma;Response rate;4 weeks after completion of 8 treatment cycles;Time to progression;Completed;Phase 2
212;ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma;Response rate;4 weeks after completion of 8 treatment cycles;Progression free survival;Completed;Phase 2
213;Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma;Incidence of adverse events (AEs);Up to 28 days after CAR-T cell infusion;Objective response rate (ORR);Recruiting;Early Phase 1
213;Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma;Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood and bone marrow );Up to 24 weeks after CAR-T cell infusion;Overall survival (OS);Recruiting;Early Phase 1
214;Safety and Efficacy Assessments of Osalmid in Multiple Myeloma;overall response rate;at week16;time to progression;Unknown status;Phase 1
214;Safety and Efficacy Assessments of Osalmid in Multiple Myeloma;overall response rate;at week16;duration of response;Unknown status;Phase 2
215;Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma;Maximum Tolerated Dose of ACE-011;2 years;Efficacy of ACE-011;Active, not recruiting;Phase 1
215;Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma;Maximum Tolerated Dose of ACE-011;2 years;Safety of ACE-011;Active, not recruiting;Phase 1
215;Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma;Maximum Tolerated Dose of ACE-011;2 years;Pharmacodynamic measures;Active, not recruiting;Phase 1
215;Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma;Maximum Tolerated Dose of ACE-011;2 years;Pharmacodynamic markers;Active, not recruiting;Phase 1
216;Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma;Tolerability of fluphenazine.;21 day treatment cycle(s);Changes in serum and urine M-protein or free light chain concentrations determined using protein electrophoresis.;Unknown status;Phase 1
217;Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer,,,;Completed;Phase 2
218;Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma;Safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with refractory multiple myeloma.;Up to 30 days after last treatment;Effects of G-CSF on bone marrow and bone marrow cytokine and chemokine levels. Including: Quantification of marrow osteoblasts and CAR cells, measurement of SDF-1 (CXCL12), IL-6, BAFF, assessment of myeloma cell proliferation and survival in bone marrow;Terminated;Early Phase 1
218;Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma;Safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with refractory multiple myeloma.;Up to 30 days after last treatment;Response rate as defined by the International Myeloma Working Group (IMWG) criteria;Terminated;Early Phase 1
218;Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma;Safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with refractory multiple myeloma.;Up to 30 days after last treatment;Overall survival duration of patients treated on study;Terminated;Early Phase 1
218;Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma;Safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with refractory multiple myeloma.;Up to 30 days after last treatment;Progression-free survival of patients treated on study;Terminated;Early Phase 1
218;Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma;Safety of the combination of G-CSF and bortezomib-, carfilzomib-, or IMID-based treatment regimens in patients with refractory multiple myeloma.;Up to 30 days after last treatment;Duration of response of patients treated on study;Terminated;Early Phase 1
219;Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma;MTD of pidilizumab combined with lenalidomide defined as the dose level at which no more than one of 6 patients experiences a dose-limiting toxicity (Phase I);28 days;Time to progression;Terminated;Phase 1
219;Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma;Overall response rate in responding patients according to the IMWG response criteria (Phase II);Up to 30 days;Overall survival (Phase II);Terminated;Phase 1
220;Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma;Incidence of adverse events within 1 month after CAR-T cell infusion;30days;Objective Response Rate(ORR) at 90 days;Unknown status;Phase 1
221;Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM);Phase I - Maximum Planned Dose (MPD) Level;9 months;Phase II: Progression-Free Survival (PFS);Completed;Phase 1
221;Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM);Phase II: Overall Response Rate (ORR);Up to 6 months;Phase II: Two Year Overall Survival (OS);Completed;Phase 2
222;Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT);Complete response (CR) rate;6 months,;Recruiting;Phase 2
223;Multiple Myeloma Minimal Residual Disease;Quantification of residual disease;Residual disease is assessed up to 18 months after inclusion;kinetic of variation of the residual tumor cells detected by flow cytometry method;Completed,
223;Multiple Myeloma Minimal Residual Disease;Quantification of residual disease;Residual disease is assessed up to 18 months after inclusion;kinetic of variation of the residual tumor cells detected by new generation sequencing method;Completed,
223;Multiple Myeloma Minimal Residual Disease;Quantification of residual disease;Residual disease is assessed up to 18 months after inclusion;kinetic of variation of the circulating tumor cells;Completed,
224;Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma;Overall Response Rate;12 Weeks;Time to Progression;Active, not recruiting;Phase 2
224;Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma;Rate and Severity of Peripheral Neuropathy;12 Weeks;Progression Free Survival;Active, not recruiting;Phase 2
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Single Dose End-of-infusion Concentration (Cinf) for CP-751,871;Completed;Phase 1
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Single Dose Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CP-751,871;Completed;Phase 1
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Single Dose Volume of Distribution (Vz) for CP-751,871;Completed;Phase 1
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Single Dose Plasma Decay Half-life (t1/2) for CP-751,871;Completed;Phase 1
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Single Dose Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] for CP-751,871;Completed;Phase 1
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Single Dose Volume of Distribution at Steady State (Vss) for CP-751,871;Completed;Phase 1
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Single Dose Systemic Clearance (CL) for CP-751,871;Completed;Phase 1
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Multiple Dose Cinf for CP-751,871;Completed;Phase 1
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Multiple Dose Minimum Observed Plasma Trough Concentration (Cmin) for CP-751,871;Completed;Phase 1
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Pharmacodynamic-based Dose;Completed;Phase 1
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Human Anti-human Antibody (HAHA) Response to CP-751,871;Completed;Phase 1
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Percentage of Participants With Objective Response (OR);Completed;Phase 1
225;CP-751,871 Treatment For Patients With Multiple Myeloma;Maximum Tolerated Dose (MTD);Baseline up to Cycle 1 (Week 4 or Week 8);Time to Disease Progression;Completed;Phase 1
226;Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography;sensitivity and specificity per patient analysis;Up to 6 months after [18F]Florbetaben PET/CT scanning;sensitivity and specificity per organ analysis;Completed;Not Applicable
226;Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography;sensitivity and specificity per patient analysis;Up to 6 months after [18F]Florbetaben PET/CT scanning;Correlation with severity;Completed;Not Applicable
226;Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography;sensitivity and specificity per patient analysis;Up to 6 months after [18F]Florbetaben PET/CT scanning;Adverse events;Completed;Not Applicable
227;Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid;Change in Paraprotein Level and Free Light Chain (FLC) Ratio From Baseline Measurement;4 weeks after treatment begins;Overall Survival;Terminated;Not Applicable
227;Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid;Change in Paraprotein Level and Free Light Chain (FLC) Ratio From Baseline Measurement;4 weeks after treatment begins;Duration of Response;Terminated;Not Applicable
227;Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid;Change in Paraprotein Level and Free Light Chain (FLC) Ratio From Baseline Measurement;4 weeks after treatment begins;Progression Free Survival (PFS);Terminated;Not Applicable
227;Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid;Change in Paraprotein Level and Free Light Chain (FLC) Ratio From Baseline Measurement;4 weeks after treatment begins;Duration of Response;Terminated;Not Applicable
227;Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid;Change in Paraprotein Level and Free Light Chain (FLC) Ratio From Baseline Measurement;4 weeks after treatment begins;Duration of Response;Terminated;Not Applicable
227;Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid;Change in Paraprotein Level and Free Light Chain (FLC) Ratio From Baseline Measurement;4 weeks after treatment begins;Incidence Rate of Toxicity;Terminated;Not Applicable
227;Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid;Change in Paraprotein Level and Free Light Chain (FLC) Ratio From Baseline Measurement;4 weeks after treatment begins;Comparison of Quality of Life Scores;Terminated;Not Applicable
228;Institut Paoli Calmettes Multiple Myeloma Database;Survival of patients;10 years;Collection of patients characteristics;Recruiting,
229;A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency;Percent Change Of sCTX Levels;2 years;Percent Change In Bone Mineral Density;Unknown status;Phase 2
229;A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency;Percent Change Of sCTX Levels;2 years;Percent Change In uNTX Levels;Unknown status;Phase 2
229;A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency;Percent Change Of sCTX Levels;2 years;Subject Incidence Of Hypocalcemia;Unknown status;Phase 2
229;A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency;Percent Change Of sCTX Levels;2 years;Subject Incidence Of Occurrence Of Documented SRE At 12 Months;Unknown status;Phase 2
229;A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency;Percent Change Of sCTX Levels;2 years;Subject Incidence Of Adverse Events;Unknown status;Phase 2
229;A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency;Percent Change Of sCTX Levels;2 years;Percent Change In Bone Turnover Markers;Unknown status;Phase 2
230;TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma;Maximum tolerated dose;Evaluation of pharmacokinetics and pharmacodynamics;Terminated;Phase 1
230;TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma;Dose limiting toxicity;Evaluation of pharmacokinetics and pharmacodynamics;Terminated;Phase 1
230;TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma;Safety profile,;Evaluation of pharmacokinetics and pharmacodynamics;Terminated;Phase 1
231;Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma;Recommended Dose of Plitidepsin in Combination With Bortezomib and Dexamethasone;After 28-day cycle;Response According to International Myeloma Working Group Criteria;Completed;Phase 1
231;Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma;Recommended Dose of Bortezomib in Combination With Plitidepsin and Dexamethasone;After 28-day cycle;Overall Response Rate;Completed;Phase 1
231;Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma;Recommended Dose of Dexamethasone in Combination With Plitidepsin and Bortezomib;After 28-day cycle;Duration of Response;Completed;Phase 1
231;Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma;Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs);After 28-day cycle;Time to Progression;Completed;Phase 1
232;Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma;The Maximum Tolerated Dose (MTD) of Carfilzomib;6 Months;The Percentage of Patients Alive Without Progression;Completed;Phase 1
232;Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma;The Percentage of Patients That Achieve a Response to Treatment;4 Months After Treatment Start;The Percentage of Patients Alive Without Progression;Completed;Phase 2
233;Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM);Number of participants with Adverse Events, with abnormal vital signs, abnormal physical examination findings, abnormal laboratory test results, abnormal ECGs and abnormal echocardiograms.;12 months;overall response rate (ORR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM;Recruiting;Phase 2
233;Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM);Number of participants with Adverse Events, with abnormal vital signs, abnormal physical examination findings, abnormal laboratory test results, abnormal ECGs and abnormal echocardiograms.;12 months;complete response (CR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM;Recruiting;Phase 2
233;Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM);Number of participants with Adverse Events, with abnormal vital signs, abnormal physical examination findings, abnormal laboratory test results, abnormal ECGs and abnormal echocardiograms.;12 months;very good partial response (VGPR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM;Recruiting;Phase 2
233;Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM);Number of participants with Adverse Events, with abnormal vital signs, abnormal physical examination findings, abnormal laboratory test results, abnormal ECGs and abnormal echocardiograms.;12 months;partial response (PR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM;Recruiting;Phase 2
234;Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma;Number of participants with dose limiting toxicities (DLT);up to 85 days;Identification of recommended phase 2 dose of I-131-CLR1404 with concurrent weekly dexamethasone;Completed;Phase 1
234;Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma;Number of participants with dose limiting toxicities (DLT);up to 85 days;Identification of recommended phase 2 dose of I-131-CLR1404 without dexamethasone;Completed;Phase 1
234;Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma;Number of participants with dose limiting toxicities (DLT);up to 85 days;Identify the recommended dosing schedule of I-131-CLR1404, in relapsed or refractory MM;Completed;Phase 1
235;Phase I/II Study of hLL1 in Multiple Myeloma;safety and tolerability of hLL1 administered twice weekly for 4 consecutive weeks;first 12 weeks, then over 2 years;The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.;Completed;Phase 1
235;Phase I/II Study of hLL1 in Multiple Myeloma;safety and tolerability of hLL1 administered twice weekly for 4 consecutive weeks;first 12 weeks, then over 2 years;The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.;Completed;Phase 2
236;Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma;Safety and tolerability of ciforadenant in combination with daratumumab relapsed / refractory multiple myeloma.;From start of treatment to end of treatment, up to 24 months;Overall response rate.;Completed;Phase 1
236;Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma;Safety and tolerability of ciforadenant in combination with daratumumab relapsed / refractory multiple myeloma.;28 days following first administration of ciforadnenat in combination with daratumumab;Duration of response.;Completed;Phase 1
237;Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03);Maximum tolerated dose of TMI;Up to 60 days post-transplant.;Progression Free Survival;Completed;Phase 1
238;Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma;Response to Car-BiRD Treatment.;From baseline to best response, up to 116 weeks.;Event Free Survival;Active, not recruiting;Phase 2
238;Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma;Response to Car-BiRD Treatment.;From baseline to best response, up to 116 weeks.;MRD Negativity Following CarBiRD Regimen;Active, not recruiting;Phase 2
238;Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma;Response to Car-BiRD Treatment.;From baseline to best response, up to 116 weeks.;Progression Free Survival;Active, not recruiting;Phase 2
238;Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma;Response to Car-BiRD Treatment.;From baseline to best response, up to 116 weeks.;Stem Cells Collection;Active, not recruiting;Phase 2
239;Lenalidomide Maintenance Therapy for Multiple Myeloma;Longitudinal Assessment of T Cell (Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8), Natural Killer T-cell (NKT) and Natural Killer (NK) Cell Counts;participants were followed for the duration of their treatment, an average of 2 years;Number of Participants With Serious and Non-serious Adverse Events;Terminated;Phase 2
239;Lenalidomide Maintenance Therapy for Multiple Myeloma;Longitudinal Assessment of T Cell (Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8), Natural Killer T-cell (NKT) and Natural Killer (NK) Cell Counts;participants were followed for the duration of their treatment, an average of 2 years;Duration of Response;Terminated;Phase 2
239;Lenalidomide Maintenance Therapy for Multiple Myeloma;Longitudinal Assessment of T Cell (Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8), Natural Killer T-cell (NKT) and Natural Killer (NK) Cell Counts;participants were followed for the duration of their treatment, an average of 2 years;Progression Free Survival (PFS);Terminated;Phase 2
239;Lenalidomide Maintenance Therapy for Multiple Myeloma;Longitudinal Assessment of T Cell (Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8), Natural Killer T-cell (NKT) and Natural Killer (NK) Cell Counts;participants were followed for the duration of their treatment, an average of 2 years;Natural Killer (NK) Cell Function and Activity;Terminated;Phase 2
239;Lenalidomide Maintenance Therapy for Multiple Myeloma;Longitudinal Assessment of T Cell (Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8), Natural Killer T-cell (NKT) and Natural Killer (NK) Cell Counts;participants were followed for the duration of their treatment, an average of 2 years;Changes in B Cell Subsets, Myeloid Derived Suppressor Cells and T Regulatory Cells by Phenotypic Analysis During the Course of Therapy;Terminated;Phase 2
239;Lenalidomide Maintenance Therapy for Multiple Myeloma;Longitudinal Assessment of T Cell (Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8), Natural Killer T-cell (NKT) and Natural Killer (NK) Cell Counts;participants were followed for the duration of their treatment, an average of 2 years;Expression of Cereblon (CRBN) and How it Relates to Natural Killer (NK) Cell Number and Activity;Terminated;Phase 2
240;A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma;Safety and dose of carfilzomib, lenalidomide, vorinostat and dexamethasone for MM;12 months;Overall response rate (ORR) Time to next treatment (TTNT) Time to progression (TTP) Duration of response (DOR;Active, not recruiting;Phase 1
240;A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma;Safety and dose of carfilzomib, lenalidomide, vorinostat and dexamethasone for MM;12 months;Overall response rate (ORR) Time to next treatment (TTNT) Time to progression (TTP) Duration of response (DOR;Active, not recruiting;Phase 2
241;Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens;Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous Lenalidomide Containing Regimen;On treatment portion of study is completed after 12 cycles (each cycle is 28 days in duration) and one month of follow up. Patients may be followed for up to two years after last dose of lenalidomide and vorinostat for disease status and survival.,;Completed;Phase 1
241;Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens;Overall Response Rate (PR or Better) of Vorinostat in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory MM Refractory to a Previous Lenalidomide Containing Regimen;On treatment portion of study is completed after 12 cycles (each cycle is 28 days in duration) and one month of follow up. Patients may be followed for up to two years after last dose of lenalidomide and vorinostat for disease status and survival.,;Completed;Phase 2
242;Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma;Number of Participants With a Positive Response to Bortezomib Measured by the Bone Marker Parathyroid Hormone;6 months;Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Osteocalcin;Terminated;Phase 2
242;Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma;Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Calcium;6 months;Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Osteocalcin;Terminated;Phase 2
242;Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma;Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Alkaline Phosphatase;6 months;Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Osteocalcin;Terminated;Phase 2
242;Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma;Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Magnesium;6 months;Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Osteocalcin;Terminated;Phase 2
242;Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma;Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Phosphate.;6 months;Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Osteocalcin;Terminated;Phase 2
243;Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma;Event-free survival 4 years after auto-allo/ auto-auto Tandem-SCT. Any of the following will be considered an endpoint event: recurrence or progression of primary disease, disease related mortality, or treatment related mortality.;four years after Tandem stem cell transplantation;Incidence of acute GvHD;Unknown status;Phase 2
243;Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma;Event-free survival 4 years after auto-allo/ auto-auto Tandem-SCT. Any of the following will be considered an endpoint event: recurrence or progression of primary disease, disease related mortality, or treatment related mortality.;four years after Tandem stem cell transplantation;Incidence of chronic GvHD;Unknown status;Phase 2
243;Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma;Event-free survival 4 years after auto-allo/ auto-auto Tandem-SCT. Any of the following will be considered an endpoint event: recurrence or progression of primary disease, disease related mortality, or treatment related mortality.;four years after Tandem stem cell transplantation;Toxicity of conditioning regimen and of maintenance therapy;Unknown status;Phase 2
243;Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma;Event-free survival 4 years after auto-allo/ auto-auto Tandem-SCT. Any of the following will be considered an endpoint event: recurrence or progression of primary disease, disease related mortality, or treatment related mortality.;four years after Tandem stem cell transplantation;cumulative incidence of relapse;Unknown status;Phase 2
243;Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma;Event-free survival 4 years after auto-allo/ auto-auto Tandem-SCT. Any of the following will be considered an endpoint event: recurrence or progression of primary disease, disease related mortality, or treatment related mortality.;four years after Tandem stem cell transplantation;Disease related mortality;Unknown status;Phase 2
243;Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma;Event-free survival 4 years after auto-allo/ auto-auto Tandem-SCT. Any of the following will be considered an endpoint event: recurrence or progression of primary disease, disease related mortality, or treatment related mortality.;four years after Tandem stem cell transplantation;Treatment related mortality;Unknown status;Phase 2
243;Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma;Event-free survival 4 years after auto-allo/ auto-auto Tandem-SCT. Any of the following will be considered an endpoint event: recurrence or progression of primary disease, disease related mortality, or treatment related mortality.;four years after Tandem stem cell transplantation;overall survival;Unknown status;Phase 2
244;Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma;To evaluate the clinical efficacy of AT7519M alone or in combination with bortezomib;Subjects with be followed until disease progression (an average of 4 cycles per subject. i.e an average of 84 days);Assess the type, incidence and severity of clinically significant treatment emergent adverse events as assessed by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) V 4.03;Completed;Phase 1
244;Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma;To evaluate the clinical efficacy of AT7519M alone or in combination with bortezomib;Subjects with be followed until disease progression (an average of 4 cycles per subject. i.e an average of 84 days);To define the pharmacokinetic profile of AT7519M and bortezomib when administered alone or in combination with bortezomib;Completed;Phase 2
245;Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging;Validation;2 years;Therapy assessment;Unknown status,
246;Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma;Number of patients with relapsing/refractory multiple myeloma with TEAE, included serious AE;30 weeks;Decrease in M protein and clinical response rate (PR plus CR according to the European Group for Blood & Marrow Transplantation - EBMT- criteria).;Terminated;Phase 2
247;Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma;number of patients developing Engraftment syndrome following stem cell transplant;6 months post-transplant,;Completed,
248;An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma;Response Rate;2 years;The Rate of Clinical Benefit Response (CBR);Withdrawn;Phase 2
248;An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by CTCAE v4.0;6 months;Time to Response;Withdrawn;Phase 2
249;PHA-739358 for the Treatment of Multiple Myeloma;Response Rate according to International Myeloma Working Group uniform response criteria for multiple myeloma.;At end of each cycle;Overall safety profile;Terminated;Phase 2
250;Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma;Safety;One year (assessed at Cycle 1).;Pharmacokinetic and pharmacodynamic assessments.;Unknown status;Phase 1
250;Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma;Safety;One year (assessed at Cycle 1).;Assess for efficacy response;Unknown status;Phase 1
250;Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma;Safety;One year (assessed at Cycle 1).;Establish the recommended Phase 2 dose;Unknown status;Phase 1
251;Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma;Estimate the overall response rate.;18 months;Evaluate the quality of life measures in patients.;Withdrawn;Phase 2
251;Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma;Estimate the overall response rate.;18 months;Assess the safety and tolerability.;Withdrawn;Phase 2
251;Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma;Estimate the overall response rate.;18 months;Estimate the overall survival.;Withdrawn;Phase 2
251;Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma;Estimate the overall response rate.;18 months;Estimate Progression-free survival;Withdrawn;Phase 2
252;Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma;The patient's best response to treatment with CEP-18770 in combination with lenalidomide and dexamethasone;Baseline to endpoint (defined as a maximum of 1 year after first administration of CEP-18770 or until disease progression);Time interval from the date of first response to the date of disease progression;Terminated;Phase 1
252;Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma;Determination of the maximum tolerated dose (MTD) of CEP-18770 in combination with lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma;Days 1 to 28 of cycle 1;Time interval from the date of first dose to the date of disease progression;Terminated;Phase 2
253;Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma;Disease Response;2 years,;Completed;Phase 2
254;Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma;Dose-limiting toxicities (DLTs);From time of informed consent through one week following 8th FPBMC infusion;Overall response rate (ORR);Recruiting;Phase 1
254;Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma;Adverse event profile;From time of informed consent through 30 days following last FPBMC infusion;Minimal Residual Disease (MRD) status;Recruiting;Phase 2
255;Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma;To assess the toxicity associated with vaccination of multiple myeloma patients with dendritic cell/myeloma fusions and GM-CSF prior to stem cell mobilization and following high dose chemotherapy with stem cell rescue.;5 years;To determine whether tumor specific cellular and humoral immunity can be induced by serial vaccination with DC/tumor cell fusions in conjunction with high dose chemotherapy with stem cell rescue;Completed;Phase 1
255;Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma;To assess the toxicity associated with vaccination of multiple myeloma patients with dendritic cell/myeloma fusions and GM-CSF prior to stem cell mobilization and following high dose chemotherapy with stem cell rescue.;5 years;To determine if vaccination with DC/tumor cell fusions results in clinical disease response in patients with evidence of residual disease post-transplant;Completed;Phase 1
255;Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma;To assess the toxicity associated with vaccination of multiple myeloma patients with dendritic cell/myeloma fusions and GM-CSF prior to stem cell mobilization and following high dose chemotherapy with stem cell rescue.;5 years;To determine the time to disease progression in this participant population.;Completed;Phase 1
256;Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients;Maximum tolerated dose of Bisthianostat;Up to 24 months;Peak Plasma Concentration (Cmax);Unknown status;Phase 1
256;Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients;Treatment-related adverse events considered as dose-limiting toxicity;During the first cycle (4 weeks);Area under the plasma concentration versus time curve (AUC);Unknown status;Phase 1
257;Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04);Response assessment according to the criteria IMWG;15-17 month;Response assessment according to the criteria IMWG;Completed;Phase 3
257;Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04);Response assessment according to the criteria IMWG;15-17 month;Number of Adverse Events;Completed;Phase 3
257;Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04);Response assessment according to the criteria IMWG;15-17 month;Number of collected stem cell;Completed;Phase 3
257;Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04);Response assessment according to the criteria IMWG;15-17 month;Number of death;Completed;Phase 3
257;Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04);Response assessment according to the criteria IMWG;15-17 month;Response assessment according to the criteria IMWG;Completed;Phase 3
257;Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04);Response assessment according to the criteria IMWG;15-17 month;Number of relapse according to the criteria IMWG;Completed;Phase 3
258;A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma;Estimate the MTD and/or RDE;12 months;Number of participants with adverse events and serious adverse events.;Completed;Phase 1
258;A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma;Estimate the MTD and/or RDE;12 months;Pharmacokinetic (PK) effects of LGH447;Completed;Phase 1
258;A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma;Estimate the MTD and/or RDE;12 months;Pharmacodynamic (PD) effects of LGH447;Completed;Phase 1
258;A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma;Estimate the MTD and/or RDE;12 months;Anti-Myeloma activity associated with LGH447;Completed;Phase 1
258;A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma;Estimate the MTD and/or RDE;12 months;Effect of multiple-doses of LGH447 on the PK of midazolam;Completed;Phase 1
259;A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate;3 years;Adverse effects of AT9283;Completed;Phase 2
259;A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate;3 years;Evaluation of potential predictive and prognostic biomarkers (marrow, blood);Completed;Phase 2
259;A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate;3 years;Evaluation of disease-related symptoms including pain, fatigue, mucositis;Completed;Phase 2
260;Level of Physical Activity and Its Associations With Fatigue and Quality of Life in Multiple Myeloma Survivors;Change in the level of physical activity, occurrence of fatigue and quality of life amongst multiple myeloma survivors in the local setting;1 year,;Unknown status,
261;Myeloma-Developing Regimens Using Genomics (MyDRUG);Overall Response Rate - Actionable Genetic Alteration;Patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 2 years;Recruiting;Phase 1
261;Myeloma-Developing Regimens Using Genomics (MyDRUG);Overall Response Rate - Non-Actionable Genetic Alteration;Patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 2 years,;Recruiting;Phase 2
262;Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft;Maximal response rate Assesment of the International Myeloma Working Group uniform response criteria;1 month after the last consolidation cure;survival and progression-free survival;Withdrawn;Phase 2
262;Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft;Maximal response rate Assesment of the International Myeloma Working Group uniform response criteria;1 month after the last consolidation cure;evaluation of the answer to the treatment to improve or maintain the response;Withdrawn;Phase 2
262;Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft;Maximal response rate Assesment of the International Myeloma Working Group uniform response criteria;1 month after the last consolidation cure;Role of the consolidation phase in the improvement or maintenance of the response to the treatment Time before progression;Withdrawn;Phase 2
262;Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft;Maximal response rate Assesment of the International Myeloma Working Group uniform response criteria;1 month after the last consolidation cure;Conversion from negative residual disease to positive residual disease or maintenance of a negative residual disease during all therapeutical phases;Withdrawn;Phase 2
262;Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft;Maximal response rate Assesment of the International Myeloma Working Group uniform response criteria;1 month after the last consolidation cure;correlation between residual disease and duration of the response to the treatment;Withdrawn;Phase 2
262;Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft;Maximal response rate Assesment of the International Myeloma Working Group uniform response criteria;1 month after the last consolidation cure;Tolerance to each phase of treatment (the induction phase, the intensive treatment, the consolidation phase);Withdrawn;Phase 2
263;Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma;For all registered patients: progression free survival (PFS) as defined by time from registration to progression or death from any cause (whichever occurs first).;end of trial (last patient last visit);Overall survival measured from the time of registration /randomization R1/ randomization R2. Patients still alive or lost to follow up are censored at the date they were last known to be alive.;Unknown status;Phase 3
263;Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma;"For all patients included in R1; PFS as defined by time from randomization R1 to progression or death from any cause whichever comes first";end of trial (last patient last visit);Toxicity;Unknown status;Phase 3
263;Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma;"For all patients included in R2; PFS as defined by time from randomization R2 to progression or death from any cause whichever comes first";end of trial (last patient last visit);Response (PR, VGPR, CR and stringent CR), and improvement of response during the various stages of the treatment.;Unknown status;Phase 3
264;The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy;Overall survival of patients with multiple myeloma treated with Huang-Lian-Jie-Du-Tang（HLJDT) in maintain therapy;6 months,;Unknown status;Phase 1
265;Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma;Maximum Tolerated Dose (MTD) of Combination Therapy With VELCADE, Dexamethasone, and Doxil, (RVDD);1 month post treatment;The Percentage of Patients That Achieved Partial or Complete Response to Treatment.;Completed;Phase 1
265;Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma;Maximum Tolerated Dose (MTD) of Combination Therapy With VELCADE, Dexamethasone, and Doxil, (RVDD);1 month post treatment;The Percentage of Patients That Achieved Partial or Complete Response to Treatment.;Completed;Phase 2
266;Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma;The evaluation of Independent Review Committee-documented time to progression (TTP).;>160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms;Response rate (CR + PR), according to the EBMT criteria;Completed;Phase 3
266;Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma;The evaluation of Independent Review Committee-documented time to progression (TTP).;>160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms;Response duration;Completed;Phase 3
266;Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma;The evaluation of Independent Review Committee-documented time to progression (TTP).;>160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms;Clinical benefit as measured by ECOG performance status, transfusion requirement and Grade ≥3 infections (assessed by the National Cancer Institute Common Toxicity Criteria);Completed;Phase 3
266;Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma;The evaluation of Independent Review Committee-documented time to progression (TTP).;>160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms;Progression-free survival (PFS);Completed;Phase 3
266;Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma;The evaluation of Independent Review Committee-documented time to progression (TTP).;>160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms;Overall survival (OS);Completed;Phase 3
266;Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma;The evaluation of Independent Review Committee-documented time to progression (TTP).;>160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms;Composite of disease progression and death (recurrent time(s) from randomisation to disease progression and/or death);Completed;Phase 3
266;Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma;The evaluation of Independent Review Committee-documented time to progression (TTP).;>160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms;Quality of life as determined by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30);Completed;Phase 3
266;Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma;The evaluation of Independent Review Committee-documented time to progression (TTP).;>160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms;Adverse events (AEs);Completed;Phase 3
266;Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma;The evaluation of Independent Review Committee-documented time to progression (TTP).;>160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms;Assessment of peripheral neuropathy;Completed;Phase 3
266;Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma;The evaluation of Independent Review Committee-documented time to progression (TTP).;>160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms;Vital signs and physical examination;Completed;Phase 3
266;Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma;The evaluation of Independent Review Committee-documented time to progression (TTP).;>160 IRC confirmed disease progression in the Dexamethasone or Thalidomide 400 mg/day arms;Clinical laboratory tests;Completed;Phase 3
267;Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma;Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy;2 years;Progression Free Survival;Active, not recruiting;Phase 2
267;Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma;Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy;2 years;Time To Progression;Active, not recruiting;Phase 2
267;Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma;Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy;2 years;Duration of Response;Active, not recruiting;Phase 2
267;Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma;Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy;2 years;Objective Response Rate;Active, not recruiting;Phase 2
267;Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma;Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy;2 years;Overall Survival;Active, not recruiting;Phase 2
268;Non-interventional Study on Time to Response and Quality of Life in Relapsed/Refractory Multiple Myeloma When Treated With Lenalidomide in Second Line,,,;Completed,
269;Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma;The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months;6 months after therapy;Objective Response Rate;Completed;Phase 2
269;Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma;The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months;6 months after therapy;Duration of Response;Completed;Phase 2
269;Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma;The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months;6 months after therapy;Progression Free Survival;Completed;Phase 2
269;Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma;The Proportion of Patients Alive and Without Progressive Disease (PD) for ≥6 Months;6 months after therapy;Overall Survival;Completed;Phase 2
270;Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma;Percentage of patients with treatment related adverse effect;1 month;Anti-tumor activity of fourth generation multiple CAR-T cells after infusion;Unknown status;Phase 1
270;Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma;Percentage of patients with treatment related adverse effect;1 month;Anti-tumor activity of fourth generation multiple CAR-T cells in patients with relapsed or refractory MM;Unknown status;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Percentage of Participants With Acute GVHD (Grades III-IV);Completed;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Percentage of Participants With Chronic GVHD;Completed;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Percentage of Participants With Best Response to Treatment After Randomization;Completed;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Percentage of Participants With Response to Treatment;Completed;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Percentage of Participants With Disease Progression;Completed;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Percentage of Participants With Overall Survival (OS);Completed;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Percentage of Participants With Treatment-Related Mortality (TRM);Completed;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Percentage of Participants With Toxicities Post-randomization by Toxicity Type;Completed;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Percentage of Participants With Toxicities Post-randomization by Time Point;Completed;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Percentage of Participants With Infections Post-randomization by Infection Type;Completed;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Percentage of Participants With Infections Post-randomization by Time Point;Completed;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Functional Assessment of Cancer Therapy (FACT) - Bone Marrow Transplant (BMT) Total Score;Completed;Phase 2
271;Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302);Percentage of Participants With Progression-Free Survival;12 months and 21 months post-randomization;Medical Outcomes Study (MOS) - Short Form 36 (SF-36) Score;Completed;Phase 2
272;Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting;Overall response rate (ORR);Approximately 2 years;Overall survival (OS);Active, not recruiting;Phase 2
272;Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting;Overall response rate (ORR);Approximately 2 years;Progression-free survival (PFS);Active, not recruiting;Phase 2
272;Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting;Overall response rate (ORR);Approximately 2 years;Duration of Response (DoR);Active, not recruiting;Phase 2
272;Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting;Overall response rate (ORR);Approximately 2 years;Time to Response (TTR);Active, not recruiting;Phase 2
272;Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting;Overall response rate (ORR);Approximately 2 years;Time to progression (TTP);Active, not recruiting;Phase 2
272;Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting;Overall response rate (ORR);Approximately 2 years;Adverse Events;Active, not recruiting;Phase 2
273;Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma;Number of Participants With Dose Limiting Toxicities;After the start of treatment and up to 60 days;Number of Participants With Best Response;Completed;Phase 1
273;Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma;Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0);Date treatment consent signed to date off study, approx. 3 mos and 7 days for DL 0.3 x 10^6 CAR + T cells, 4 mos and 4 days for 1.0 x 10^6 CAR + T cells, 9 mos and 13 days for 3.0 x 10^6 CAR + T cells, and 48 mos and 12 days for 9.0 x 10^6 CAR + T cells.;Number of Participants With Best Response;Completed;Phase 1
274;A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma;Recommended dose (RD) of PT-112 for further studies in patients with relapsed or refractory multiple myeloma (MM);18 months;Peak Plasma Concentration (Cmax);Completed;Phase 1
274;A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma;Recommended dose (RD) of PT-112 for further studies in patients with relapsed or refractory multiple myeloma (MM);18 months;Area under the plasma concentration versus time curve (AUC);Completed;Phase 1
274;A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma;Recommended dose (RD) of PT-112 for further studies in patients with relapsed or refractory multiple myeloma (MM);18 months;Dose-limiting toxicities (DLTs);Completed;Phase 1
274;A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma;Recommended dose (RD) of PT-112 for further studies in patients with relapsed or refractory multiple myeloma (MM);18 months;Number of patients with Adverse Events (AEs);Completed;Phase 1
274;A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma;Recommended dose (RD) of PT-112 for further studies in patients with relapsed or refractory multiple myeloma (MM);18 months;Tumor response, including assessment of minimal residual disease, according to the International Myeloma Working Group (IMWG) response criteria;Completed;Phase 1
274;A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma;Recommended dose (RD) of PT-112 for further studies in patients with relapsed or refractory multiple myeloma (MM);18 months;Duration of response;Completed;Phase 1
274;A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma;Recommended dose (RD) of PT-112 for further studies in patients with relapsed or refractory multiple myeloma (MM);18 months;Progression free survival;Completed;Phase 1
274;A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma;Recommended dose (RD) of PT-112 for further studies in patients with relapsed or refractory multiple myeloma (MM);18 months;Relationship between sensitivity/response to treatment and disease status including cytogenetic biomarkers;Completed;Phase 1
275;ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma;Phase 1b: MTD and dosing schedule of ACY-1215 administered in combination with pomalidomide and low-dose dexamethasone in patients with MM;28 days;Phase 1b & 2: Safety assessed by type, frequency and severity of AEs and relationship of AEs to study drug;Active, not recruiting;Phase 1
275;ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma;Phase 2: Overall response rate of ACY-1215 in combination with pomalidomide and dexamethasone in patients with relapsed-and-refractory multiple myeloma;Every 56 days for the duration on treatment, an estimated average of 4 months;Phase 1b and 2: Efficacy assessed by time to response, duration of response, time to progression, progression free survival, and objective response as assessed by a central adjudication committee;Active, not recruiting;Phase 2
276;A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments;Part 1, 2 and 3: Number of Participants with any Adverse Event;Up to 52 months;Part 1, 2 and 3: Observed Plasma Concentration of Bela;Not yet recruiting;Phase 1
276;A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments;Part 1: Number of Participants with Dose Limiting Toxicities (DLTs);Cycle 1 (Each cycle is of 28 days);Part 1, 2 and 3: Area Under the Curve (AUC) of Bela;Not yet recruiting;Phase 2
277;Bone Pain in Multiple Myeloma- a Translational Study;Change in bone innervation by immunohistological assessment (presence);"Change from baseline to completion of first line treatment (expected to be measured at 8 months after baseline; expected to be reported within 2 years from baseline) for patients with a positive myeloma diagnosis.";Change in serum bone biomarkers (CTX1, P1NP) measured by ELISA;Active, not recruiting,
277;Bone Pain in Multiple Myeloma- a Translational Study;Change in bone innervation by immunohistological assessment (location);"Change from baseline to completion of first line treatment (expected to be measured at 8 months after baseline; expected to be reported within 2 years from baseline) for patients with a positive myeloma diagnosis.";Change in inflammatory serum biomarkers measured by multiplex array.;Active, not recruiting,
278;Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma,,,;Completed;Phase 2
279;sdAb-based TRNT of Multiple Myeloma: a Feasibility Study;Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein.;Within 2 years after study completion;Completed;Not Applicable
279;sdAb-based TRNT of Multiple Myeloma: a Feasibility Study;Amount of Paraprotein-targeting sdAbs Generated Per Patient;Within 2 years after study completion,;Completed;Not Applicable
280;68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma;Metabolic parameter;through study completion, an average of 2 years;Adverse effects;Recruiting;Early Phase 1
280;68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma;PET-positive diffuse bone marrow involvement;through study completion, an average of 2 years;Tumor burden assessment;Recruiting;Early Phase 1
280;68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma;PET-positive focal bone marrow lesions;through study completion, an average of 2 years;Follow-up assessment;Recruiting;Early Phase 1
280;68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma;PET-positive extramedullary lesions;through study completion, an average of 2 years;CXCR4 expression in biopsies and metabolic parameters in PET;Recruiting;Early Phase 1
281;Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma;Maximum plasma concentration (Cmax) of ABBV-838;"Cycle 1 Day 1 (C1D1) and C3D1 pre- and post-dose; C1D4, C1D8, C1D15, C2D1, C2D15, C3D4, C3D8, C3D15, C4D1, and all subsequent ABBV-838 pre-dose dosing cycles";Preliminary activity of ABBV-838 monotherapy;Terminated;Phase 1
281;Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma;Maximum tolerated dose of ABBV-838;Up to 2 years from first dose of study;Preliminary activity of ABBV-838 monotherapy;Terminated;Phase 1
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Race of participants at Baseline;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Age of participants at Baseline;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Gender of participants at Baseline;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Stage of Multiple Myeloma (MM) before study entry based on the international staging system (ISS);Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Time from first pathologic diagnosis;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;The number of Comorbidities;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Concomitant treatments related to MM;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;ECOG performance status;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Define the abnormal finding in complete blood count at base line;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Define the abnormal findings within the Biochemistry panel;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;The time from biological progression until clinical relapse;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Overall Response rate;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Event-free survival (EFS);Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Progression-free survival (PFS);Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Overall survival (OS);Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;EORTC QLQ-C30 Questionnaire;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;QLQ-MY24 Questionnaire;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Cost associated with participants visit to hospital/primary health care associated with anti-myeloma therapy;Terminated,
282;Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma;Time to progression (TTP);Up to 38 months;Adverse Events (AEs);Terminated,
283;PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma;Dose Escalation: Number of participants with Dose-limiting toxicities (DLT);At the end of Cycle 1 (each Cycle is 21 or 28 days);To evaluate incidence of treatment emergent adverse events and laboratory abnormalities;Active, not recruiting;Phase 1
283;PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma;To evaluate anti-myeloma activity by objective response rate (ORR) in dose expansion;From baseline through disease progression, patient refusal, unacceptable toxicity or study completion (approximately 2 years);To evaluate anti-myeloma activity by objective response rate (ORR) in dose escalation;Active, not recruiting;Phase 1
283;PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma;To evaluate anti-myeloma activity by duration of response (DOR) in dose expansion;From baseline through disease progression, patient refusal, unacceptable toxicity or study completion (approximately 2 years);To evaluate anti-myeloma activity by time to event endpoints;Active, not recruiting;Phase 1
284;Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants With Adverse Events;From first dose of study drug until 30 days following last dose of study drug (up to 2482 days);Phase 1: Overall Response Rate;Completed;Phase 1
284;Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma;Phase 1: Maximum Observed Plasma Concentration (Cmax) of Venetoclax;Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose;Time to Response (TTR);Completed;Phase 2
285;A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma;To determine the maximum tolerated dose;During the first 28 day treatment cycle;To determine the safety and tolerability in the study population;Terminated;Phase 1
285;A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma;To determine the maximum tolerated dose;During the first 28 day treatment cycle;To evaluate the pharmacokinetics of study drug;Terminated;Phase 1
285;A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma;To determine the maximum tolerated dose;During the first 28 day treatment cycle;To assess anti-tumor effects as classified by International Uniform Response Criteria for Multiple Myeloma;Terminated;Phase 1
286;MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma;Occurrence of adverse events (AEs);From time of informed consent through 90 days post end of treatment;MEDI2228 maximum observed concentration for PK;Completed;Phase 1
286;MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma;Occurrence of SAE (serious adverse events);From time of informed consent through 90 days post end of treatment;MEDI2228 area under the concentration-time curve for PK;Completed;Phase 1
286;MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma;Occurrence of DLTs (dose limiting toxicities);From time of informed consent through 90 days post end of treatment;MEDI2228 clearance for PK;Completed;Phase 1
286;MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma;Number of patients with changes in laboratory parameters from baseline;From time of informed consent and up to 21 days post end of treatment;MEDI2228 terminal half-life for PK;Completed;Phase 1
286;MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma;Number of patients with changes in vital signs from baseline;From time of informed consent and up to 21 days post end of treatment;Number of subjects who develop anti-drug antibodies (ADAs);Completed;Phase 1
286;MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma;Number of patients with changes in elctrocardiogram (ECG) results from baseline;From time of informed consent and up to 21 days post end of treatment;Objective response rate (ORR);Completed;Phase 1
287;Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma;Progression Free Survival No Results Due to 1 Subject Came Off Treatment Within 7 Days and 1 Subject Came Off Treatment Within 5 Days. Not Enough Data to Analyze;Up to 1 year post-transplant.,;Terminated;Phase 1
288;BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma;Incidence and severity of adverse events after GC012F infusion;up to 24 weeks after GC012F infusion;Percentage of MRD negative patients after GC012F treatment;Recruiting;Early Phase 1
288;BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma;Incidence and severity of adverse events after GC012F infusion;up to 24 weeks after GC012F infusion;ORR (PR, VGPR, CR and sCR) of patients receive GC012F treatment;Recruiting;Early Phase 1
288;BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma;Incidence and severity of adverse events after GC012F infusion;up to 24 weeks after GC012F infusion;Progression free survival after GC012F treatment;Recruiting;Early Phase 1
288;BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma;Incidence and severity of adverse events after GC012F infusion;up to 24 weeks after GC012F infusion;Copies and cell counts of CAR in blood and bone marrow (if available) after GC012F treatment;Recruiting;Early Phase 1
288;BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma;Incidence and severity of adverse events after GC012F infusion;up to 24 weeks after GC012F infusion;Cytokines in serum after GC012F treatment;Recruiting;Early Phase 1
288;BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma;Incidence and severity of adverse events after GC012F infusion;up to 24 weeks after GC012F infusion;Subset of lymphocytes and ADA in blood after GC012F treatment;Recruiting;Early Phase 1
288;BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma;Incidence and severity of adverse events after GC012F infusion;up to 24 weeks after GC012F infusion;Replication competent lentivirus (RCL) in blood after GC012F treatment;Recruiting;Early Phase 1
288;BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma;Incidence and severity of adverse events after GC012F infusion;up to 24 weeks after GC012F infusion;Duration of response after GC012F treatment;Recruiting;Early Phase 1
288;BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma;Incidence and severity of adverse events after GC012F infusion;up to 24 weeks after GC012F infusion;Overall survival after GC012F treatment;Recruiting;Early Phase 1
289;Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma;Objective Response Rate of the Drug Combination in This Patient Populations.;Full response assessment was conducted at the end of cycle 8 (average of168 days) and after cycle 4 (84 days) for patients proceeding to transplant.;Estimated 18-month Progression Free Survival (PFS) Rate;Active, not recruiting;Phase 1
289;Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma;Objective Response Rate of the Drug Combination in This Patient Populations.;Full response assessment was conducted at the end of cycle 8 (average of168 days) and after cycle 4 (84 days) for patients proceeding to transplant.;Percentage of Patients Who Remained in Response for More Than 18 Months;Active, not recruiting;Phase 2
290;Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM);Efficacy in terms of response and survival;2 years;Safety in terms of hematological and non-hematological adverse events;Completed;Phase 2
290;Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM);Efficacy in terms of response and survival;2 years;The progression free survival (PFS);Completed;Phase 2
290;Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM);Efficacy in terms of response and survival;2 years;The overall survival (OS);Completed;Phase 2
290;Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM);Efficacy in terms of response and survival;2 years;Duration of time to progression (TTP);Completed;Phase 2
290;Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM);Efficacy in terms of response and survival;2 years;Time to next therapy (TNT);Completed;Phase 2
290;Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM);Efficacy in terms of response and survival;2 years;Identification of patient's subgroups according to specific prognostic factors;Completed;Phase 2
291;BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma;Incidence of Dose limiting toxicities (DLT);28 days;Manufacture success rate (defined as number of subjects treated with planned target dose divided by total number of subjects treated);Recruiting;Phase 1
291;BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma;Nature of Dose limiting toxicities (DLT);28 days;Overall Response Rate (ORR);Recruiting;Phase 1
291;BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma;Incidence and severity of adverse events (AEs) and serious adverse events (SAEs);24 months;Response rate at 3 and 6 months in Part A;Recruiting;Phase 1
292;Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma;The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC QLQ-C30 fatigue scale ratings, independently from other prognostic factors for OS in MM, including the clinically-based prognostic frailty score.;30 months from study entry;To devise a patient-centered frailty score for RRMM patients.;Recruiting,
292;Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma;The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC QLQ-C30 fatigue scale ratings, independently from other prognostic factors for OS in MM, including the clinically-based prognostic frailty score.;30 months from study entry;To investigate the prognostic value of the frailty score in the setting of RRMM.;Recruiting,
292;Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma;The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC QLQ-C30 fatigue scale ratings, independently from other prognostic factors for OS in MM, including the clinically-based prognostic frailty score.;30 months from study entry;To investigate QoL over time (outcome measures: EORTC QLQ-C30 and QLQ-MY20) by type of treatment and examine factors that contribute the most in maintaining baseline QoL levels.;Recruiting,
292;Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma;The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC QLQ-C30 fatigue scale ratings, independently from other prognostic factors for OS in MM, including the clinically-based prognostic frailty score.;30 months from study entry;To investigate relationship between satisfaction with information provision (outcome measure: EORTC INFO-25) and QoL outcomes (outcome measures: EORTC QLQ-C30 and QLQ-MY20).;Recruiting,
292;Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma;The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC QLQ-C30 fatigue scale ratings, independently from other prognostic factors for OS in MM, including the clinically-based prognostic frailty score.;30 months from study entry;To assess patients' preferences for involvement in treatment decision-making and the relationships between preferences and patient characteristics.;Recruiting,
292;Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma;The primary objective is overall survival (OS) as predicted by baseline self-reported EORTC QLQ-C30 fatigue scale ratings, independently from other prognostic factors for OS in MM, including the clinically-based prognostic frailty score.;30 months from study entry;To assess and compare the baseline self-reported EORTC QLQ-C30 fatigue scale ratings, between those RRMM patients who had received only one line of treatment (1 line) versus more than one line of treatment (>1 line) at study entry;Recruiting,
293;A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma;Progression-Free Survival (PFS);Up to approximately 43 months from first randomization;Overall Response Rate (ORR);Recruiting;Phase 3
293;A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma;US Specific: Overall Response Rate (ORR) per the Independent Review Committee (IRC);Up to approximately 43 months;Very Good Partial Response or Better Response Rate (VGPR);Recruiting;Phase 3
294;Protein Tyrosine Kinases (PTK) in Multiple Myeloma;To determine the effectiveness of PTK in treating patients with relapsed or refractory myeloma,;To evaluate the progression free survival of patients treated with PTK;Completed;Phase 2
294;Protein Tyrosine Kinases (PTK) in Multiple Myeloma;To determine the effectiveness of PTK in treating patients with relapsed or refractory myeloma,;to investigate the safety of PTK in patients with relapsed/refractory multiple myeloma;Completed;Phase 2
295;Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma;To determine tolerability and safety profile of a maximum of 12 cycles or 12 months from first dose (which ever comes first) of lenalidomide maintenance therapy post allogeneic hematopoietic cell transplantation for high risk multiple myeloma.;12 months;To estimate the incidences of ≥ grade 3 adverse events, graft failure, infections, treatment-related mortality (TRM) and incidence and severity of acute and chronic GVHD after initiation of lenalidomide.;Completed;Phase 2
295;Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma;To determine tolerability and safety profile of a maximum of 12 cycles or 12 months from first dose (which ever comes first) of lenalidomide maintenance therapy post allogeneic hematopoietic cell transplantation for high risk multiple myeloma.;12 months;To measure the overall response and best response rates to lenalidomide maintenance therapy following allogeneic HCT.;Completed;Phase 2
295;Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma;To determine tolerability and safety profile of a maximum of 12 cycles or 12 months from first dose (which ever comes first) of lenalidomide maintenance therapy post allogeneic hematopoietic cell transplantation for high risk multiple myeloma.;12 months;To determine time to disease progression and overall survival after lenalidomide.;Completed;Phase 2
296;A Multiple Myeloma Trial in Patients With Bone Metastases;The Number of Participants With a Significant Increase in Serum Creatinine at 12 Months;Baseline and 12 Months;The Number of Participants With a Significant Increase in Serum Creatinine at 24 Months;Completed;Phase 4
296;A Multiple Myeloma Trial in Patients With Bone Metastases;The Number of Participants With Disease Progression;24 Months;Time to First Significant Increase in Serum Creatinine;Completed;Phase 4
297;Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma;Progression-free Survival (PFS) After Initiation of Pomalidomide Therapy;1 year following initiation of pomalidomide therapy,;Completed;Phase 2
298;Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma;Response Rate (Complete Response(CR) / Partial Response (PR));From Start of the Study up to 57 Weeks approximately.;Overall Response Rate;Terminated;Phase 2
298;Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma;Response Rate (Complete Response(CR) / Partial Response (PR));From Start of the Study up to 57 Weeks approximately.;Clinical Benefit Rate;Terminated;Phase 2
298;Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma;Response Rate (Complete Response(CR) / Partial Response (PR));From Start of the Study up to 57 Weeks approximately.;Duration of Response;Terminated;Phase 2
298;Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma;Response Rate (Complete Response(CR) / Partial Response (PR));From Start of the Study up to 57 Weeks approximately.;Time to Response;Terminated;Phase 2
298;Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma;Response Rate (Complete Response(CR) / Partial Response (PR));From Start of the Study up to 57 Weeks approximately.;Progression Free Survival (PFS);Terminated;Phase 2
298;Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma;Response Rate (Complete Response(CR) / Partial Response (PR));From Start of the Study up to 57 Weeks approximately.;Safety and Tolerability;Terminated;Phase 2
298;Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma;Response Rate (Complete Response(CR) / Partial Response (PR));From Start of the Study up to 57 Weeks approximately.;Time to Peak Concentration (Tmax) of Panobinostat;Terminated;Phase 2
298;Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma;Response Rate (Complete Response(CR) / Partial Response (PR));From Start of the Study up to 57 Weeks approximately.;Maximum Plasma Concentration (Cmax) of Panobinostat;Terminated;Phase 2
298;Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma;Response Rate (Complete Response(CR) / Partial Response (PR));From Start of the Study up to 57 Weeks approximately.;Area Under the Plasma Concentration (AUC0-24) of Panobinostat;Terminated;Phase 2
298;Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma;Response Rate (Complete Response(CR) / Partial Response (PR));From Start of the Study up to 57 Weeks approximately.;Last Observed Plasma Concentration (Clast) of Panobinostat;Terminated;Phase 2
298;Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma;Response Rate (Complete Response(CR) / Partial Response (PR));From Start of the Study up to 57 Weeks approximately.;Time of Clast (Tlast) of Panobinostat;Terminated;Phase 2
299;A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure;Health-Related Quality of Life (HRQoL) in specific domains: Fatigue, as measured by EORTC QLQ-C30;Up to 1 year;HRQoL in specific domains: Functional Scale as measured by the EORTC QLQ-C30;Active, not recruiting,
299;A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure;HRQoL in specific domains: Pain, as measured by the EORTC QLQ-C30;Up to 1 year;HRQoL in specific domains: Symptoms Scale as measured by the EORTC QLQ-C30;Active, not recruiting,
299;A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure;HRQoL in specific domains: Physical Functioning as measured by the EORTC QLQ-C30;Up to 1 year;HRQoL in specific domains: Global Health Status as measured by the EORTC QLQ-C30;Active, not recruiting,
299;A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure;HRQoL in specific domains: Cognitive Functioning, as measured by the EORTC QLQ-C30;Up to 1 year;HRQoL in specific domains: Future Perspective as measured by the EORTC QLQ-MY20;Active, not recruiting,
299;A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure;HRQoL in specific domains: Global health, as measured by the EORTC QLQ-C30;Up to 1 year;HRQoL in specific domains: Body Image as measured by the EORTC QLQ-MY20;Active, not recruiting,
299;A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure;HRQoL in specific domains: Disease Symptoms as measured by the EORTC QLQ-MY20;Up to 1 year;HRQoL in specific domains: Generic HRQoL as measured by the EQ-5D-5L;Active, not recruiting,
300;Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma;overall response rate;2 years;overall response rate;Active, not recruiting;Phase 2
300;Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma;overall response rate;2 years;response;Active, not recruiting;Phase 2
300;Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma;overall response rate;2 years;toxicity;Active, not recruiting;Phase 2
300;Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma;overall response rate;2 years;quality of life (QOL);Active, not recruiting;Phase 2
300;Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma;overall response rate;2 years;progression-free survival (PFS);Active, not recruiting;Phase 2
300;Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma;overall response rate;2 years;Characterization of genomic mutations of targetable genes;Active, not recruiting;Phase 2
300;Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma;overall response rate;2 years;Characterization of immunomodulatory checkpoint pathways in multiple myeloma;Active, not recruiting;Phase 2
301;A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma;Objective response rate of belinostat administered in combination with bortezomib in multiple myeloma subjects who are refractory to or have relapsed from at least one prior bortezomib-containing regimen.;Duration of response, time to response (TTR), and time to progression (TTP).;Terminated;Phase 2
301;A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma;Safety of belinostat plus bortezomib.,;Effect on biomarkers of bone metabolism. Effect on disease-related bone pain.;Terminated;Phase 2
302;SST0001 (Roneparstat) in Advanced Multiple Myeloma;Maximum tolerated dose (MTD).;28 days of first cycle of therapy.;Adverse events, physical examination and laboratory tests.;Completed;Phase 1
302;SST0001 (Roneparstat) in Advanced Multiple Myeloma;Maximum tolerated dose (MTD).;28 days of first cycle of therapy.;Maximum plasma concentration (Cmax);Completed;Phase 1
302;SST0001 (Roneparstat) in Advanced Multiple Myeloma;Maximum tolerated dose (MTD).;28 days of first cycle of therapy.;Time to achieve Cmax (Tmax);Completed;Phase 1
302;SST0001 (Roneparstat) in Advanced Multiple Myeloma;Maximum tolerated dose (MTD).;28 days of first cycle of therapy.;Area under the concentration curve from administration to the last observed concentration time (AUClast);Completed;Phase 1
302;SST0001 (Roneparstat) in Advanced Multiple Myeloma;Maximum tolerated dose (MTD).;28 days of first cycle of therapy.;Half-life (T1/2);Completed;Phase 1
302;SST0001 (Roneparstat) in Advanced Multiple Myeloma;Maximum tolerated dose (MTD).;28 days of first cycle of therapy.;aPTT (Activated Partial Thromboplastin Time);Completed;Phase 1
302;SST0001 (Roneparstat) in Advanced Multiple Myeloma;Maximum tolerated dose (MTD).;28 days of first cycle of therapy.;TT (Thrombin Time);Completed;Phase 1
302;SST0001 (Roneparstat) in Advanced Multiple Myeloma;Maximum tolerated dose (MTD).;28 days of first cycle of therapy.;INR (International Normalized Ratio);Completed;Phase 1
302;SST0001 (Roneparstat) in Advanced Multiple Myeloma;Maximum tolerated dose (MTD).;28 days of first cycle of therapy.;Tumor response.;Completed;Phase 1
303;Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma;Determine the maximum tolerated dose for each formulation of oprozomib in combination with pomalidomide and dexamethasone;The primary analysis will be based on subject data collected up to 2 months from the date of last subject enrollment;Maximum observed concentration (Cmax);Completed;Phase 1
303;Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma;Incidence of treatment-related adverse events for all subjects on continued oprozomib treatment;Data collected up to 2 months from the date of last subject enrollment.;Time to Cmax (tmax);Completed;Phase 1
303;Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma;Incidence of treatment-emergent adverse events;Data collected up to 2 months from the date of last subject enrollment.;Area under the concentration-time curve;Completed;Phase 1
303;Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma;Number of patients with changes in laboratory test results;The primary analysis will be based on subject data collected up to 2 months from the date of last subject enrollment;Overall response;Completed;Phase 1
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Participants Response to Treatment;Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Percentage of Participants With Myeloma Progression of Vaccine and Non-vaccine Arms;Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Percentage of Participants With Myeloma Progression in Pairwise Analysis;Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Percentage of Participants With Treatment-related Mortality (TRM);Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Percentage of Participants With Progression-Free Survival;Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Percentage of Participants With Progression-Free Survival in Pairwise Analysis;Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Percentage of Participants With Overall Survival;Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Percentage of Participants With Overall Survival in Pairwise Analysis;Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Number of Grade ≥ 3 Toxicities;Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Participants With Grade ≥ 3 Toxicities;Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Number of Grade 2 and 3 Infections;Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Percentage of Participants With Grade 2 and 3 Infections;Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Percentage of Participants With Grade 2 and 3 Infections in Pairwise Analysis;Completed;Phase 2
304;Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401);Percentage of Participants With 1-year Response Rate of CR/sCR;1 year;Number of Participants With Minimal Residual Disease (MRD);Completed;Phase 2
305;APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma;Phase I - Number of Subjects With Grade 3 to 5 Toxicity During the Dose Limiting Toxicity (DLT) Period;Up to 28 days post-infusion;Proportion of Patients for Whom an AUTO2 Product Can be Generated;Terminated;Phase 1
305;APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma;Phase I - Number of Subjects With a Dose Limiting Toxicity (DLT);Up to 28 days post-infusion;Clinical Benefit Rate;Terminated;Phase 2
306;Prevalence of Ocular Disorders in Multiple Myeloma (MM-OO-16);To assess prevalence of reduced visual acuity (>/= 20/40), cataract (graded according to LOCS III grading scale), dry eye, retinopathy, elevated intraocular pressure (> 21 mmHg) in patients on treatment for Multiple Myeloma;12 months,;Completed,
307;A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan;Number of Dose-Limiting Toxicities (DLT);Up to Approximately 12 Months;Objective Response Rate (ORR);Active, not recruiting;Phase 1
307;A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan;Number of Participants with Adverse Events (AE);Up to Approximately 24 Months;Progression Free Survival (PFS);Active, not recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Number of participants with Adverse Events (AEs);Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Number of Participants by Best Tumor response;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Number of Participants with Overall Response;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Number of Participants with Clinical Benefit;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Duration of Response;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Progression Free Survival (PFS);Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Maximum concentration (Cmax) of NMS-03597812 after single and multiple doses of drug;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Time to maximum plasma concentration (Tmax) of NMS-03597812 after single and multiple doses of drug;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Area under the plasma concentration versus time curve up to the last detectable plasma concentration (AUClast) of NMS-03597812 after single and multiple doses of drug;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Minimum plasma concentration (Cmin) of NMS-03597812 after single and multiple doses of drug.;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Average plasma concentration (Cave) of NMS-03597812 after multiple doses of drug;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Area under the plasma concentration versus time curve to infinity (AUCinf) of NMS-03597812 after multiple doses of drug;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Terminal elimination half-life (t1/2) of NMS-03597812 after multiple doses of drug;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Oral plasma clearance (CL/F) of NMS-03597812 after multiple doses of drug;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Apparent volume of distribution (Vd/F) of NMS-03597812 after multiple doses of drug;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Accumulation ratio (Rac) of NMS-03597812 after multiple doses of drug;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Renal clearance of NMS-03597812 after multiple doses of drug.;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Cumulative amount recovered unchanged in the urine (Ae) of NMS-03597812 after multiple doses of drug;Recruiting;Phase 1
308;Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants with first-cycle dose limiting toxicity;Time interval between the date of the first dose administration in Cycle 1 (each cycle is 28 days) and the date of the first dose administration in Cycle 2 which is expected to be 28 days or up to 42 days in case of dose delay due to toxicity;Cumulative amount recovered unchanged in the urine expressed as a fraction of administered dose (Ae%) of NMS-03597812 after multiple doses of drug.;Recruiting;Phase 1
309;Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients;The number of subjects who achieve very good partial response.;100 days following autologous stem cell transplant;The number of subjects who achieve complete response.;Recruiting;Phase 2
309;Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients;The number of subjects who achieve very good partial response.;100 days following autologous stem cell transplant;The number of subjects who achieve partial response.;Recruiting;Phase 2
310;Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma;Hematopoietic Engraftment;Up to 1 year;T-cell Reconstitution as Determined by Absolute Lymphocyte Count (ALC);Completed;Phase 1
310;Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma;Disease Response;Up to 2 years;Survival;Completed;Phase 2
311;Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma;Response rate, time to maximum response, toxicities;3 years,;Completed;Phase 2
312;Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma;all cause mortality;one year;response rate;Completed;Phase 2
312;Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma;all cause mortality;one year;response rate;Completed;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Overall Survival (OS);Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Minimal Residual Disease (MRD) negativity rate;Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Overall Response Rate (ORR);Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Time to response (TTR);Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Duration of Response (DoR);Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Time to Progression (TTP);Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Time to Next Treatment (TTNT);Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Progression-free Survival 2 (PFS2);Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Safety;Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30);Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20);Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Recommended iberdomide dose for Stage 2;Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Area under the plasma concentration-time curve from time zero to tau (AUC(TAU));Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Maximum plasma concentration (Cmax);Recruiting;Phase 3
313;Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);Up to approximately 5 years;Time to maximum plasma concentration (Tmax);Recruiting;Phase 3
314;Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma;Overall Survival (OS);these outcome measures will be assessed at 2 year from transplant;Progression Free Survival 1 (PFS1);Completed,
314;Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma;Overall Survival (OS);these outcome measures will be assessed at 2 year from transplant;Progression Free Survival 2 (PFS2);Completed,
314;Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma;Overall Survival (OS);these outcome measures will be assessed at 2 year from transplant;Acute Graft-versus-Host Disease (aGVHD);Completed,
314;Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma;Overall Survival (OS);these outcome measures will be assessed at 2 year from transplant;Chronic Graft-versus-Host Disease (cGVHD);Completed,
314;Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma;Overall Survival (OS);these outcome measures will be assessed at 2 year from transplant;Non-Relapse Mortality (NRM);Completed,
315;Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients;Dose Limiting Toxicity (DLT);1 year;Response rate (RR);Active, not recruiting;Phase 1
315;Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients;Dose Limiting Toxicity (DLT);1 year;Progression-free survival (PFS);Active, not recruiting;Phase 2
316;Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma;Event Free Survival (ESF);"from randomization till the date of development clinical relapse or death from any cause; up to 129 weeks";Overall Response Rate;Recruiting;Phase 2
316;Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma;Event Free Survival (ESF);"from randomization till the date of development clinical relapse or death from any cause; up to 129 weeks";Overall Survival;Recruiting;Phase 2
317;Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib;Incremental cost-utility ratio (ICUR) expressed in euros per QALY.;Up to 20 months;Healthcare resource utilization;Not yet recruiting;Not Applicable
317;Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib;Differences of quality of life in cancer patients between each group;Up to 20 months;Adverse events related to myeloma treatment;Not yet recruiting;Not Applicable
317;Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib;Differences of quality of life in myeloma patients between each group;Up to 20 months;Patients and caregivers' satisfaction;Not yet recruiting;Not Applicable
318;AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma,,,;Completed;Phase 2
319;Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma;Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria;"From the first dose until the data cut-off date of 03 Sept 2014; Maximum time in follow-up was 36.0 weeks.";Myeloma Response Rate Based on European Group for Blood and Marrow Transplantation (EBMT) Criteria;Completed;Phase 2
319;Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma;Myeloma Response Rate Based on the International Myeloma Working Group (IMWG) Uniform Response Criteria (Later Cut-off Date);"From the first dose until the final data cut-off date of 25 September 2015; maximum duration on treatment was 80.9 weeks";Time to Response;Completed;Phase 2
320;Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma;Progression-Free Survival (PFS);through study completion, a average of 1 year;Very Good Partial Response (VGPR) + Complete Response (CR) Rate;Recruiting;Phase 4
320;Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma;Progression-Free Survival (PFS);through study completion, a average of 1 year;Overall Survival (OS);Recruiting;Phase 4
320;Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma;Progression-Free Survival (PFS);through study completion, a average of 1 year;Percentage of Participants with Adverse Events (AEs);Recruiting;Phase 4
321;Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma;Rate of Improvement in Response;From time of first dose (Cycle 1 day 1) through end of study period (12 mos. after last participant is enrolled);Progression-free Survival (PFS);Completed;Phase 2
321;Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma;Rate of Improvement in Response;From time of first dose (Cycle 1 day 1) through end of study period (12 mos. after last participant is enrolled);Safety and Tolerability;Completed;Phase 2
322;Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma;Safety of STI-1492;Baseline through study completion at up to approximately 54 months;Overall response and duration;Recruiting;Phase 1
322;Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma;Safety of STI-1492;Baseline through study completion at up to approximately 54 months;Assessment of improvements in hypercalcemia, renal function, anemia and lytic bone lesions (CRAB criteria);Recruiting;Phase 1
322;Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma;Safety of STI-1492;Baseline through study completion at up to approximately 54 months;Assessment of serum immunoglobulin levels;Recruiting;Phase 1
323;SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma,,,;Completed;Phase 2
324;An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice;Progression Free Survival (PFS);Up to approximately 6 months;Overall Response Rate (ORR);Completed,
324;An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice;Progression Free Survival (PFS);Up to approximately 6 months;Duration of Response (DOR);Completed,
324;An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice;Progression Free Survival (PFS);Up to approximately 6 months;Overall Survival (OS);Completed,
324;An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice;Progression Free Survival (PFS);Up to approximately 6 months;Time to Progression (TTP);Completed,
324;An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice;Progression Free Survival (PFS);Up to approximately 6 months;Time to Treatment Failure (TTF);Completed,
324;An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice;Progression Free Survival (PFS);Up to approximately 6 months;Adverse Events (AEs);Completed,
325;Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma;Treatment-related mortality;6 months;Treatment Completion Rate;Completed;Phase 2
325;Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma;Treatment-related mortality;6 months;Respone Rate;Completed;Phase 2
325;Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma;Treatment-related mortality;6 months;Chimerism Rate;Completed;Phase 2
325;Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma;Treatment-related mortality;6 months;GVHD Incidence;Completed;Phase 2
325;Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma;Treatment-related mortality;6 months;Survival;Completed;Phase 2
325;Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma;Treatment-related mortality;6 months;Correlation of cytogenetics and response;Completed;Phase 2
326;Real-World Use of Selinexor, Daratumumab and Dexamethasone in Chinese Patients With Multiple Myeloma at First Relapse;Overall Response Rate (ORR);28 days after the last therapy,;Not yet recruiting,
327;MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma;Sub-Study A Phase 1: Dose Limiting Toxicity;35 days;Sub-Study A Phase 1: Objective Response Rate;Recruiting;Phase 2
327;MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma;Sub-Study A Phase 2: Objective Response Rate;assessed every 4 weeks (for approximately 2 years);Sub-Study A Phase 1 and Phase 2: Complete Response Rate;Recruiting;Phase 2
327;MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma;Sub-Study B Phase 1 Escalation: Dose Limiting Toxicity;42 days;Sub-Study A Phase 1 and Phase 2: Time to Response;Recruiting;Phase 2
327;MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma;Sub-Study B Phase 1 Expansion: Frequency of Treatment-Emergent Adverse Events;assessed for approximately 2 years;Sub-Study A Phase 1 and 2: Duration of Response;Recruiting;Phase 2
327;MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma;Sub-Study B Phase 1 Expansion: Frequency of Laboratory Abnormalities;assessed every cycle (each cycle approximately 28 days);Sub-Study A Phase 1 and Phase 2: Duration of Complete Response;Recruiting;Phase 2
328;Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD);DLT;1 year;Toxicities;Active, not recruiting;Phase 1
328;Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD);Partial response;3 years;PFS;Active, not recruiting;Phase 2
329;Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma;Best Response 4 months;0-4 months,;Recruiting,
330;Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma;Toxicity as measured by CTCAE v 3.0;19 Months;Response (complete response, very good partial response, partial response);Completed;Phase 1
330;Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma;Clonotypic B cells;19 months;Time to progression and duration of response;Completed;Phase 1
331;Combination Study for High Risk Multiple Myeloma Patients;Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability);34 Months;PFS;Terminated;Phase 2
331;Combination Study for High Risk Multiple Myeloma Patients;Overall Rate of Response (Efficacy);34 Months;DOR;Terminated;Phase 2
332;Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma;· To examine the effect of intravenous zoledronic acid at the dose of 4 mg given every three months compared with observation, on percent change in bone mineral density of the spine at one year in patients with asymptomatic, smoldering and stage I MM.;18 months;· To examine the effect of intravenous zoledronic acid at the above schedule on percent change in bone mineral density of the total hip and femur.;Terminated;Phase 2
333;Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma;Median Investigator-Assessed Progression-free Survival (PFS) Time (Months) From Randomization to Date of First Tumor Progression or Death Due to Any Cause - Randomized Participants;Randomization until 111 events (disease progression or death), up to May 2014, approximately 2 years;Median Progression-free Survival Time (Months) From Randomization to Date of First Tumor Progression or Death Due to Any Cause, in Randomized Participants With at Least One FcγRIIIa V Allele;Completed;Phase 2
333;Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma;Number of Investigator-Assessed Progression-free Survival Events From Randomization to Date of First Tumor Progression or Death Due to Any Cause - All Randomized Participants;Randomization until 111 events, up to May 2014, approximately 2 years;Investigator-Assessed Objective Response Rate (ORR) - All Randomized Participants;Completed;Phase 2
333;Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma;1 Year Progression-Free Survival Rate - Randomized Participants;Year 1 after last participant was randomized;Investigator-Assessed Objective Response Rate in Randomized Participants With at Least One FcγRIIIa V Allele;Completed;Phase 2
334;Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients;The toxicity and safety of Fludarabine when added to induction therapy by registration of side effects and adverse events in accordance with the common toxicity criteria (CTC).,;Quantification of clonal cells in bone marrow and blood by flow cytometry (MRD) and to study new potential prognostic markers identified by cytomic, genomic and proteomic analysis.;Unknown status;Phase 2
334;Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients;The toxicity and safety of Fludarabine when added to induction therapy by registration of side effects and adverse events in accordance with the common toxicity criteria (CTC).,;Estimation of the efficacy of Fludarabine when added to induction chemotherapy (CyDex) in patients with multiple myeloma by clinical end points: disease response and progression free survival;Unknown status;Phase 2
335;An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma;Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment;From start of the treatment to end of study;Maximum Plasma Concentration (Cmax) of IPH2101 After Cycle 1 Administration;Completed;Phase 1
335;An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma;Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment;From start of the treatment to end of study;Area Under the Plasma-concentration-time Curve [AUC (INF)] of IPH2101 After Cycle 1 Administration;Completed;Phase 1
335;An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma;Maximum Tolerated Dose (MTD) of IPH2101 as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to IPH2101 Treatment;From start of the treatment to end of study;Number of Evaluable Patients With Stable Disease. Evaluable is Defined as 2 Consecutive M Protein Assessments;Completed;Phase 1
336;Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment;To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.;1 Month;To determine at the time of initial diagnosis, the specificity, the positive predictive value (PPV) and negative predictive value (NPV) of [68Ga]Ga-PentixaFor-PET;Recruiting;Phase 2
336;Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment;To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.;1 Month;To determine at the time of initial diagnosis the prognostic impact of FDG PET and of [68Ga]Ga-PentixaFor-PET depending on the positivity, number and intensity of uptake detected by each imaging technique;Recruiting;Phase 2
336;Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment;To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.;1 Month;To determine at the time of initial diagnosis the discrepancies rate between FDG PET and [68Ga]Ga-PentixaFor-PET;Recruiting;Phase 2
336;Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment;To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.;1 Month;To determine at the time of initial diagnosis the factors associated with discrepancies between FDG PET and [68Ga]Ga-PentixaFor-PET;Recruiting;Phase 2
336;Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment;To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.;1 Month;To determine at the time of initial diagnosis the correlation between PET-FDG and [68Ga]Ga-PentixaFor-PET uptakes evaluated by SUV and the cytogenetic data evaluated on the myelogram (particularly the measurement of the expression of the gene coding;Recruiting;Phase 2
336;Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment;To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.;1 Month;To determine at the time of initial diagnosis the tolerance of [68Ga]Ga-PentixaFor-PET;Recruiting;Phase 2
336;Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment;To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.;1 Month;To determine at the time of initial diagnosis the tolerance of [68Ga]Ga-PentixaFor-PET;Recruiting;Phase 2
336;Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment;To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.;1 Month;To determine at the time of therapeutic evaluation the discrepancies rate between FDG PET and [68Ga]Ga-PentixaFor-PET and if available their link with histology.;Recruiting;Phase 2
336;Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment;To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.;1 Month;To determine at the time of therapeutic evaluation the prognostic impact of FDG PET and [68Ga]Ga-PentixaFor-PET depending on the positivity, number and intensity of uptake detected by each imaging technique.;Recruiting;Phase 2
336;Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment;To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.;1 Month;To determine at the time of therapeutic evaluation the prognostic impact of FDG PET and [68Ga]Ga-PentixaFor-PET depending on the positivity, number and intensity of uptake detected by each imaging technique.;Recruiting;Phase 2
336;Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment;To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.;1 Month;To determine at the time of therapeutic evaluation the link between PET-FDG, [68Ga]Ga-PentixaFor-PET results and minimal residual disease evaluated by flow cytometry;Recruiting;Phase 2
336;Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma in First Line Treatment;To determine the sensitivity of [68Ga]Ga-PentixaFor-PET to detect Multiple Myeloma (MM) lesions [Bone marrow (BM) lesions and/or extra-medullary disease (EMD) ] at the time of initial diagnosis.;1 Month;To determine at the time of therapeutic evaluation the tolerance of [68Ga]Ga-PentixaFor-PET;Recruiting;Phase 2
337;Long-term KRd in Relapsed and/or Refractory Multiple Myeloma;Progression-free survival;up to 54 months;Overall survival;Not yet recruiting,
337;Long-term KRd in Relapsed and/or Refractory Multiple Myeloma;Progression-free survival;up to 54 months;Overall response rate, clinical benefit rate;Not yet recruiting,
337;Long-term KRd in Relapsed and/or Refractory Multiple Myeloma;Progression-free survival;up to 54 months;Duration of response;Not yet recruiting,
337;Long-term KRd in Relapsed and/or Refractory Multiple Myeloma;Progression-free survival;up to 54 months;Toxicity profile;Not yet recruiting,
338;Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma,,,;No longer available,
339;Oligosecretary Myeloma: Prevalence and Its Clinical Significance;Number of patients with oligosecretary myeloma among multiple myeloma patients;up to 1 year,;Completed,
340;Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM),,,;Terminated;Phase 2
341;Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183);Progression Free Survival (PFS) Assessed by Clinical Adjudication Committee (CAC) Blinded Central Review According to the International Myeloma Working Group (IMWG) Response Criteria;Up to approximately 30 months;Overall Response Rate (ORR) Evaluated According to the IMWG Response Criteria by CAC Blinded Central Review;Terminated;Phase 3
341;Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183);Overall Survival (OS);Up to approximately 54 months;Participants Experiencing One or More Adverse Events (AEs);Terminated;Phase 3
342;S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma;PFS;18 months,;Terminated;Phase 3
343;Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma;Final Response Rate After 4 Courses of Treatment;2 years,;Terminated;Phase 2
344;A Safety Study of SGN-CD48A in Patients With Multiple Myeloma;Type, incidence, severity, seriousness, and relatedness of adverse events;Through 1 month following last dose;Objective response rate;Terminated;Phase 1
344;A Safety Study of SGN-CD48A in Patients With Multiple Myeloma;Incidence of laboratory abnormalities;Through 1 month following last dose;Complete response rate;Terminated;Phase 1
344;A Safety Study of SGN-CD48A in Patients With Multiple Myeloma;Incidence of dose limiting toxicity;Through 3 weeks following first dose;Duration of objective response;Terminated;Phase 1
345;A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases;Real-World Overall Response Rate (ORR) for each TCR MM therapy;3-18 months;Not yet recruiting,
345;A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases;Real-World Progression Free Survival (PFS);3-18 months;Not yet recruiting,
345;A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases;Real-World Overall Survival (OS);3-18 months;Not yet recruiting,
345;A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases;Real-World Duration of response (DOR);3-18 months,;Not yet recruiting,
346;A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma;Bone Formation Markers Measurement;Up to Cycle 4 with 28 days per cycle;Measurement of Bone Mineral Density;Completed;Phase 2
346;A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma;Bone Formation Markers Measurement;Up to Cycle 4 with 28 days per cycle;Skeletal Related Events' Evaluation;Completed;Phase 2
347;A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma;Maximum Tolerated Dose of the Combination of ASP7487 (OSI-906) With Velcade and Dexamethasone;45 months,;Terminated;Phase 1
347;A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma;Maximum Tolerated Dose of the Combination of ASP7487 (OSI-906) With Velcade and Dexamethasone;45 months,;Terminated;Phase 2
348;BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma;Incidence and severity of adverse events after GC012F injection;Minimum 2 years after GC012F infusion;Percentage of MRD negative patients after GC012F infusion;Unknown status;Early Phase 1
348;BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma;Incidence and severity of adverse events after GC012F injection;Minimum 2 years after GC012F infusion;ORR(PR, VGPR, CR and sCR) of patients after GC012F treatment;Unknown status;Early Phase 1
348;BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma;Incidence and severity of adverse events after GC012F injection;Minimum 2 years after GC012F infusion;Progression free survival after GC012F treatment;Unknown status;Early Phase 1
348;BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma;Incidence and severity of adverse events after GC012F injection;Minimum 2 years after GC012F infusion;Duration of response of subjects after GC012F treatment;Unknown status;Early Phase 1
348;BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma;Incidence and severity of adverse events after GC012F injection;Minimum 2 years after GC012F infusion;Overall survivalof subjects after GC012F treatment;Unknown status;Early Phase 1
348;BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma;Incidence and severity of adverse events after GC012F injection;Minimum 2 years after GC012F infusion;Cytokines in serum after GC012F infusion;Unknown status;Early Phase 1
348;BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma;Incidence and severity of adverse events after GC012F injection;Minimum 2 years after GC012F infusion;Subset of lymphocytes in blood after GC012F infusion;Unknown status;Early Phase 1
348;BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma;Incidence and severity of adverse events after GC012F injection;Minimum 2 years after GC012F infusion;Anti-GC012F antibodies in blood after GC012F infusion;Unknown status;Early Phase 1
348;BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma;Incidence and severity of adverse events after GC012F injection;Minimum 2 years after GC012F infusion;Cell counts of GC012F in blood and bone marrow(if available) after GC012F infusion;Unknown status;Early Phase 1
348;BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma;Incidence and severity of adverse events after GC012F injection;Minimum 2 years after GC012F infusion;Copies of GC012F in blood and bone marrow(if available) after GC012F infusion;Unknown status;Early Phase 1
349;Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma;Incidence of dose limiting toxicity (DLTs);within 4 weeks after infusion;Best Overall Response;Recruiting;Early Phase 1
349;Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma;Incidence and severity of AEs and SAEs;Up to 24 months;Duration of Response;Recruiting;Early Phase 1
350;Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders,,,;Terminated;Phase 1
351;Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma;Tumor-specific immune response;Up to 1 year;Grade 3-4 toxicity;Completed;Phase 1
351;Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma;Tumor-specific immune response;Up to 1 year;Grade 3-4 toxicity;Completed;Phase 2
352;Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma;Overall response rate (Complete Response + Partial Response + Minimal Response) of patients achieving an objective response (defined according to the IMWG uniform response criteria by the Frequency of response of serum or urine M-protein to BHQ880A;at 6 month;Safety and tolerability of BHQ880 in patients with smoldering multiple myeloma by assessing AEs, SAEs, clinical laboratory values;Completed;Phase 2
352;Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma;Overall response rate (Complete Response + Partial Response + Minimal Response) of patients achieving an objective response (defined according to the IMWG uniform response criteria by the Frequency of response of serum or urine M-protein to BHQ880A;at 6 month;Characterize the PK profile of BHQ880 as a single agent administered monthly by assessing BHQ880 levels in plasma;Completed;Phase 2
352;Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma;Overall response rate (Complete Response + Partial Response + Minimal Response) of patients achieving an objective response (defined according to the IMWG uniform response criteria by the Frequency of response of serum or urine M-protein to BHQ880A;at 6 month;Evaluate the effect of BHQ880 on bone metabolism by assessing serum and urine bone biomarkers;Completed;Phase 2
352;Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma;Overall response rate (Complete Response + Partial Response + Minimal Response) of patients achieving an objective response (defined according to the IMWG uniform response criteria by the Frequency of response of serum or urine M-protein to BHQ880A;at 6 month;Evaluate the effect of BHQ880 on bone mineral density by DXA scan and QCT;Completed;Phase 2
353;Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma;maximum tolerated dose of hydroxychloroquine when added to standard-dose regimen of carfilzomib/dexamethasone;3 months;estimate of toxicity rate of hydroxychloroquine when added at a maximum tolerated dose to standard-dose regimen of carfilzomib/dexamethasone;Completed;Phase 1
354;The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients;Serum M protein;[Time Frame:Baseline, at the end of each cycle (each cycle is 35 days). From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months];Imaging（X ray/CT/MRI）;Recruiting;Phase 3
354;The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients;Proportion of bone marrow plasma cells;[Time Frame:Baseline, at the end of each cycle (each cycle is 35 days). From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months];Complete blood count (CBC);Recruiting;Phase 3
354;The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients;Serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP）;[Time Frame:Baseline, at the end of each cycle (each cycle is 35 days). From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months];Blood biochemistries;Recruiting;Phase 3
354;The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients;Serum free light chain (FLC);[Time Frame:Baseline, at the end of each cycle (each cycle is 35 days). From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months];Eastern Cooperative Oncology Group (ECOG) Score;Recruiting;Phase 3
355;A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain;Health-related quality of life (HRQoL);4 years;Time to progression (TTP);Completed,
355;A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain;EuroQoL 5-Dimension, 5-Level Questionnaire (EQ-5D-5L);4 years;Progression-free survival (PFS);Completed,
355;A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain;Quality of Life Questionnaire (QLQ-C30);4 years;Overall survival (OS);Completed,
355;A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain;Quality of Life Questionnaire - Multiple Myeloma Module 20 (QLQ-MY20);4 years;Overall response rate;Completed,
355;A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain;Health care cost for Multiple Myeloma (MM) patients;4 years;Response duration;Completed,
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Complete Response (CR) Rate;Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Time to Response;Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Duration of Response;Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Progression-free Survival (PFS);Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Time to Progression (TTP);Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Overall Survival (OS);Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Adverse Events (AEs);Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Pharmacokinetics - Cmax;Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Pharmacokinetics - Tmax;Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Pharmacokinetics - AUC;Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Immunogenicity;Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Minimal Residual Disease (MRD);Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30);Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Subject-reported outcomes as measured by EuroQoL Group EQ-5D-5L Health Questionnaire;Active, not recruiting;Phase 2
356;Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Minimum of 24 months post-bb2121 infusion;Subject-reported outcomes as measured by EORTC-QLQ-MY20;Active, not recruiting;Phase 2
357;Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma;No Dose-limiting toxicity;up to 5 mouths after T cell infusion,;Unknown status;Phase 1
358;Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma;Comparison of the prognostic of the MRD negative and MRD positive defined by UCAD;36month;The applicability analysis of UCAD;Unknown status,
358;Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma;The concordance rate analysis between UCAD and multiparameter flow cytometry(MFC);36month;The MRD negative rate analysis among VGPR patients;Unknown status,
359;Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.;Overall Response Rate (ORR);2 years;Progression-Free Survival (PFS);Withdrawn;Phase 1
359;Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.;Overall Response Rate (ORR);2 years;Overall Survival (OS);Withdrawn;Phase 2
360;IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients;Percentage of Participants With Overall Disease Response at Month 6;6 Months;Overall Survival;Completed;Phase 2
360;IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients;Percentage of Participants With Overall Disease Response at Month 6;6 Months;Percentage of Participants With Overall Survival Events;Completed;Phase 2
360;IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients;Percentage of Participants With Overall Disease Response at Month 6;6 Months;Progression-free Survival;Completed;Phase 2
360;IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients;Percentage of Participants With Overall Disease Response at Month 6;6 Months;Percentage of Participants With Progression-free Survival Events;Completed;Phase 2
360;IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients;Percentage of Participants With Overall Disease Response at Month 6;6 Months;Percent Change in IV Busulfan Dose;Completed;Phase 2
360;IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients;Percentage of Participants With Overall Disease Response at Month 6;6 Months;Ratio Area Under Curve (AUC)/Target AUC;Completed;Phase 2
360;IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients;Percentage of Participants With Overall Disease Response at Month 6;6 Months;Percent Difference Between Area Under Curve (AUC) and Target AUC;Completed;Phase 2
360;IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients;Percentage of Participants With Overall Disease Response at Month 6;6 Months;Percentage of Participants With Transplant-Related Mortality;Completed;Phase 2
360;IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients;Percentage of Participants With Overall Disease Response at Month 6;6 Months;Percentage of Participants With Hepatic Veno-Occlusive Disease Based on Baltimore Criteria;Completed;Phase 2
361;EMMA-1 (Erbitux for Multiple Myeloma);Overall response rate (CR+PR+MR)at 16 weeks and during follow-up (every 3 months);After 16 weeks;Safety profile of Cetuximab +/- Dexamethasone;Terminated;Phase 2
361;EMMA-1 (Erbitux for Multiple Myeloma);Overall response rate (CR+PR+MR)at 16 weeks and during follow-up (every 3 months);After 16 weeks;Freedom from treatment failure;Terminated;Phase 2
361;EMMA-1 (Erbitux for Multiple Myeloma);Overall response rate (CR+PR+MR)at 16 weeks and during follow-up (every 3 months);After 16 weeks;Progression-free survival;Terminated;Phase 2
361;EMMA-1 (Erbitux for Multiple Myeloma);Overall response rate (CR+PR+MR)at 16 weeks and during follow-up (every 3 months);After 16 weeks;Overall survival;Terminated;Phase 2
361;EMMA-1 (Erbitux for Multiple Myeloma);Overall response rate (CR+PR+MR)at 16 weeks and during follow-up (every 3 months);After 16 weeks;Pharmacogenomic evaluation of response to treatment;Terminated;Phase 2
362;Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma;Number of Phase I Patients (Dose Level 1-6) Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage;28 days from the start of study treatment;Time-to-progression (TTP);Completed;Phase 1
362;Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma;Phase II: Overall Response Rate;up to 6 years;Progression-free-survival (PFS);Completed;Phase 2
363;Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma;Comparison of response rates,;Time to achieve a maximal response;Completed;Phase 3
363;Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma;Comparison of response rates,;Duration of response;Completed;Phase 3
364;Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients;Incidence of deaths;Throughout the study period. Approximately 48 months;Overall Response Rate (ORR);Recruiting;Phase 2
364;Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients;Incidence of adverse events (AEs);Throughout the study period. Approximately 48 months;Complete Response Rate (CRR);Recruiting;Phase 2
364;Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients;Incidence of analytical alterations;Throughout the study period. Approximately 48 months;Minimal Residual Disease (MRD) negativity rate;Recruiting;Phase 2
364;Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients;Incidence of ocular events;Throughout the study period. Approximately 48 months;Time to Response (TTR);Recruiting;Phase 2
365;Quality of Life in Patients With Multiple Myeloma-validation Study;Psychometric properties of the culturally-adapted Swiss-German Myeloma Patient Outcome Scale (MyPOS);upon enrollment,;Terminated,
366;Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma;Maximal tolerable dose of lenalidomide after allogeneic stem cell transplantation in patients with multiple myeloma;2 years post-transplantation;Determination of remission status after lenalidomide treatment;Completed;Phase 1
366;Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma;Maximal tolerable dose of lenalidomide after allogeneic stem cell transplantation in patients with multiple myeloma;2 years post-transplantation;Effect on T-cell/ NK-cell recovery;Completed;Phase 2
367;Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma;The Clinical Benefit Response (CBR);From the date of first study treatment until disease progression per IMWG, up to 60 months;To Evaluate the Efficacy of PCI-32765 by Assessing ORR;Completed;Phase 2
367;Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma;The Clinical Benefit Response (CBR);From the date of first study treatment until disease progression per IMWG, up to 60 months;Pharmacokinetics (PK). (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Maximum Observed Plasma Concentration (Cmax);Completed;Phase 2
367;Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma;The Clinical Benefit Response (CBR);From the date of first study treatment until disease progression per IMWG, up to 60 months;Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Time to Maximum Observed Plasma Concentration (Tmax).;Completed;Phase 2
367;Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma;The Clinical Benefit Response (CBR);From the date of first study treatment until disease progression per IMWG, up to 60 months;Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h).;Completed;Phase 2
367;Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma;The Clinical Benefit Response (CBR);From the date of first study treatment until disease progression per IMWG, up to 60 months;Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Terminal Elimination Half-life (t1/2,Term).;Completed;Phase 2
367;Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma;The Clinical Benefit Response (CBR);From the date of first study treatment until disease progression per IMWG, up to 60 months;Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Accumulation Ratio for AUC0-24h (Acc. Ratio AUC0-24h);Completed;Phase 2
367;Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma;The Clinical Benefit Response (CBR);From the date of first study treatment until disease progression per IMWG, up to 60 months;Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for Cmax (M/P Cmax);Completed;Phase 2
367;Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma;The Clinical Benefit Response (CBR);From the date of first study treatment until disease progression per IMWG, up to 60 months;Pharmacokinetics (PK) (Assessed by Sampling and Testing for Drug and Metabolite Levels at Designated Time Points). Mean Metabolite-to-Parent Ratio for AUC0-24h (M/P AUC0-24h);Completed;Phase 2
367;Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma;The Clinical Benefit Response (CBR);From the date of first study treatment until disease progression per IMWG, up to 60 months;Duration of Clinical Benefit Response (DCB);Completed;Phase 2
367;Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma;The Clinical Benefit Response (CBR);From the date of first study treatment until disease progression per IMWG, up to 60 months;Duration of Response (DOR);Completed;Phase 2
368;Thalidomide to Patients With Previously Untreated Multiple Myeloma;overall survival;october 2007;Quality of life;Completed;Phase 3
368;Thalidomide to Patients With Previously Untreated Multiple Myeloma;overall survival;october 2007;Time to response;Completed;Phase 3
368;Thalidomide to Patients With Previously Untreated Multiple Myeloma;overall survival;october 2007;Frequency of response;Completed;Phase 3
368;Thalidomide to Patients With Previously Untreated Multiple Myeloma;overall survival;october 2007;Time to progression;Completed;Phase 3
368;Thalidomide to Patients With Previously Untreated Multiple Myeloma;overall survival;october 2007;Time to 2. response;Completed;Phase 3
368;Thalidomide to Patients With Previously Untreated Multiple Myeloma;overall survival;october 2007;Frequency of 2. response;Completed;Phase 3
368;Thalidomide to Patients With Previously Untreated Multiple Myeloma;overall survival;october 2007;Time to 2. progression;Completed;Phase 3
368;Thalidomide to Patients With Previously Untreated Multiple Myeloma;overall survival;october 2007;Toxicity;Completed;Phase 3
368;Thalidomide to Patients With Previously Untreated Multiple Myeloma;overall survival;october 2007;Time to definitive treatment failure;Completed;Phase 3
369;Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1);Phase 1, Safety and tolerability: dose limiting toxicity;28days post administration of CAR-T-cells;Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion;Recruiting;Phase 1
369;Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1);Phase 2, efficacy of CT053 CAR-BCMA T cells: overall response rate;3 months post administration of CAR-T-cells;Additional efficacy evaluation after 12 weeks of CT053 CAR-BCMA T cells infusion;Recruiting;Phase 2
370;Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab;Complete Response or Partial Response Based on M-Protein Assessments Only;Up to 18 months;Complete Response, Partial Response or Minimal Response Based on M-Protein Assessments Only;Completed;Phase 2
370;Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab;Complete Response or Partial Response Based on M-Protein Assessments Only;Up to 18 months;Complete Response Based on M-Protein Assessments Only;Completed;Phase 2
371;Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.;very good partial response rate (monclonal protein decrease of 90 % or more)at the end induction phase (MY-TAG and MY-DECT), progression free survival during consolidation/maintenance treatment (MY-PLAT);before autotransplant (MY-TAG), after 4 cycles (MY-DECT), every 6 months (MY-PLAT);partial response rate (> or = 50%), PFS and OS since diagnosis, safety thalidomide + chemotherapy;Completed;Phase 3
372;BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma;Determination of optimal dose of BT062 (Phase I part);6 months;Qualitative toxicities of BT062 in combination with lenalidomide/dexamethasone or pomalidomide/dexamethasone;Completed;Phase 1
372;BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma;Evaluation of response (Phase IIa part);18 months;Pharmacokinetics of BT062 in combination with lenalidomide/dexamethasone or pomalidomide/dexamethasone;Completed;Phase 2
373;Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma;Progression Free Survival;Subjects will be followed for progression-free survival for at least 36 months;Overall Survival (OS);Completed;Phase 2
373;Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma;Progression Free Survival;Subjects will be followed for progression-free survival for at least 36 months;Overall Response Rate;Completed;Phase 2
374;Autologous Transplant for Multiple Myeloma;Number of Participants Achieving a Complete Response;100 Days post transplant;Number of Patients With Extended Disease-free Survival;Completed;Phase 2
374;Autologous Transplant for Multiple Myeloma;Number of Participants Achieving a Complete Response;6 months post transplant;Number of Participants With Overall Survival;Completed;Phase 3
375;Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients;Toxicity: Assessment of adverse events will be performed at the end of third cycle according to the National Cancer Institute Common Terminology Criteria of Adverse Events (CTCAE version 4.0);4 years;Response rate;Active, not recruiting;Phase 2
375;Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients;Efficacy will be assessed by considering partial response (PR) following the proposed regimen. Assessment of Partial Response rate will be performed at the end of third cycle according to the criteria of the International Myeloma Working Group.;4 years;Duration of Progression Free Survival;Active, not recruiting;Phase 2
376;Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma,,,;No longer available,
377;Therapeutic Research in Multiple Myeloma,,,;Completed,
378;Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation,,,;Completed;Phase 2
379;Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma,,,;No longer available,
380;Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma;To evaluate GCS-100 related dose-limiting toxicity and to identify the maximum tolerated dose and/or the recommended dose for further studies.;Up to 12 consecutive 21-day treatment cycles;To evaluate the safety of treatment with GCS-100 in combination with bortezomib (VelcadeTM) and dexamethasone in subjects whose disease has progressed on GCS-100 alone.;Terminated;Phase 1
381;Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma,,,;Unknown status;Phase 3
382;MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning;Analyze the efficacy of allogeneic bone marrow transplantation in a reduced-intensity manner combined with bortezomib;2 years,;Completed;Phase 2
383;PRospective Multiple Myeloma Impact Study;Change in treatment intention;Treatment intention is measured before MMprofiler SKY92 and within 4 weeks after MMprofiler;3 year Progression Free Survival;Active, not recruiting;Not Applicable
383;PRospective Multiple Myeloma Impact Study;Change in treatment intention;Treatment intention is measured before MMprofiler SKY92 and within 4 weeks after MMprofiler;3 year Overall Survival;Active, not recruiting;Not Applicable
383;PRospective Multiple Myeloma Impact Study;Change in treatment intention;Treatment intention is measured before MMprofiler SKY92 and within 4 weeks after MMprofiler;5 year Progression Free Survival;Active, not recruiting;Not Applicable
383;PRospective Multiple Myeloma Impact Study;Change in treatment intention;Treatment intention is measured before MMprofiler SKY92 and within 4 weeks after MMprofiler;5 year Overall Survival;Active, not recruiting;Not Applicable
384;Descartes-25 in Relapsed/Refractory Multiple Myeloma;Maximum Tolerated Dose;1 Year,;Recruiting;Phase 1
384;Descartes-25 in Relapsed/Refractory Multiple Myeloma;Maximum Tolerated Dose;1 Year,;Recruiting;Phase 2
385;Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma,,,;Completed;Phase 2
386;Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant;MRD conversion rate;At 1 year after transplant;Progression Free Survival (PFS) at 1 Year;Recruiting,
386;Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant;MRD conversion rate;At 1 year after transplant;Progression Free Survival (PFS) at 2 Years;Recruiting,
386;Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant;MRD conversion rate;At 1 year after transplant;MRD by NGS Clonoseq testing;Recruiting,
387;Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma;Incidence of Adverse events after C-4-29 infusion [Safety and Tolerability];28 days;Objective response rate after C-4-29 infusion [Effectiveness];Enrolling by invitation;Phase 1
387;Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma;Obtain the maximum tolerated dose of C-4-29 cells[Safety and Tolerability];28 days;AUCS of C-4-29 cells [Cell dynamics];Enrolling by invitation;Phase 1
388;Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma;Time to Disease Progression (TTP);randomization to progression (up to 5 years);12-month Progression-free Survival (PFS);Completed;Phase 3
388;Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma;Time to Disease Progression (TTP);randomization to progression (up to 5 years);Number of Participants With a Confirmed Response (Complete Response [CR], Very Good Partial Response [VGPR] or Partial Response [PR]) on Two Consecutive Evaluations at Least 2 Weeks Apart in the First 12 Months of Treatment;Completed;Phase 3
388;Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma;Time to Disease Progression (TTP);randomization to progression (up to 5 years);Duration of Response (Complete Response, Partial Response, and Very Good Partial Response);Completed;Phase 3
388;Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma;Time to Disease Progression (TTP);randomization to progression (up to 5 years);Time to Subsequent Treatment;Completed;Phase 3
388;Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma;Time to Disease Progression (TTP);randomization to progression (up to 5 years);Time to Treatment Failure;Completed;Phase 3
388;Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma;Time to Disease Progression (TTP);randomization to progression (up to 5 years);Number of Participants With Severe (Grade 3, 4 or 5) Adverse Events;Completed;Phase 3
389;Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.;Disease history and VETD risk factors. Chemotherapy protocol for multiple myeloma. Therapeutic used for VETD prevention (LWMH, anticoagulants, antiplatelets or none);4 months;PE and DVT rate at 4 months and one year. Bleedings and all relevant SAE and AE at 4 months and one year.;Completed,
390;Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma;Progression Free Survival;2 years;Minimal residual disease negativity;Completed;Phase 2
390;Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple Myeloma;Progression Free Survival;2 years;Overall Survival (OS);Completed;Phase 2
391;Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma;Conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin plus lenalidomide.;through study completion, an average of 1 year,;Recruiting;Phase 2
392;Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON);Time to Progression (TTP) and WHO (World Health Organization) Toxicity scale;three years;Increase of Response (anti-tumoral effect) and Dose Tolerance;Unknown status;Phase 2
393;S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma;Progression-Free Survival;From date of initial registration to date of progression/relapse of disease or death from any cause, whichever came first, up to 5 years;Toxicity;Completed;Phase 3
394;Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma,,,;Completed;Phase 3
395;Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.;Overall Response;30 months;Adverse Events Occurrences;Recruiting;Phase 1
395;Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.;Clinical Benefit Rate;30 months;Time to progression (TTP);Recruiting;Phase 1
396;A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant;Incidence of cardiovascular events;Approximately 8 years;Incidence of renal impairment in NDMM patients;Active, not recruiting,
396;A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant;Incidence of cardiovascular events;Approximately 8 years;Incidence of infections in NDMM patients;Active, not recruiting,
396;A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant;Incidence of cardiovascular events;Approximately 8 years;Incidence of Second primary malignancy (SPM) in TNE NDMM patients treated with any first line regimen;Active, not recruiting,
397;Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.;Determinate the efficacy of combination velcade, melphalan, prednisone;1 year;Assess safety and tolerability;Completed;Phase 1
397;Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.;Determinate the efficacy of combination velcade, melphalan, prednisone;1 year;Assess potential superiority of this regimen versus historical controls with melphalan and prednisone alone;Completed;Phase 2
398;Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT;Engraftment, chimerism, toxicity, non-relapse mortality;Follow-up until day +1095;Evaluation of response/GvHD/ infectious complications/ disease-free survival, Prognostic impact of cytogenetic, Evaluation of incidence and prognostic impact of molecular remission in patients with clinically complete remission.;Completed;Phase 2
399;Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma;Maximum Tolerated Dose;Up to 2 years;Adverse events;Completed;Phase 1
399;Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma;Maximum Tolerated Dose;Up to 2 years;Overall Survival;Completed;Phase 1
399;Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma;Maximum Tolerated Dose;Up to 2 years;Response Rate;Completed;Phase 1
399;Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma;Maximum Tolerated Dose;Up to 2 years;Duration of response;Completed;Phase 1
399;Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma;Maximum Tolerated Dose;Up to 2 years;Time to response;Completed;Phase 1
400;E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma;Proportion of patients who are progression free at 2 years;2 Years;Response rate;Active, not recruiting;Phase 2
400;E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma;Proportion of patients who are progression free at 2 years;2 Years;Safety of the combination therapy;Active, not recruiting;Phase 2
400;E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma;Proportion of patients who are progression free at 2 years;2 Years;Time to progression;Active, not recruiting;Phase 2
400;E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma;Proportion of patients who are progression free at 2 years;2 Years;Overall survival;Active, not recruiting;Phase 2
401;A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Number of participants with Adverse events (AEs);Up to 15 months;Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) (Millimeters of mercury);Completed;Phase 1
401;A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Number of participants with serious adverse events (SAEs);Up to 15 months;Change from Baseline in temperature (degrees Celsius);Completed;Phase 1
401;A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Number of participants with dose limited toxicities (DLTs);Day 1 to Day 21 (Cycle 1);Change from Baseline in pulse rate (beats per minute);Completed;Phase 1
402;Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma;Best Overall Response Rate (ORR);A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.;Clinical Benefit Response (CBR) (A0 Only);Completed;Phase 2
402;Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma;Best Overall Response Rate (ORR);A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.;Clinical Benefit Response (CBR) (A1 Only);Completed;Phase 2
402;Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma;Best Overall Response Rate (ORR);A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.;Duration of Response (A0 Only);Completed;Phase 2
402;Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma;Best Overall Response Rate (ORR);A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.;Duration of Response (A1 Only);Completed;Phase 2
402;Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma;Best Overall Response Rate (ORR);A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.;Time to Progression (A0 Only);Completed;Phase 2
402;Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma;Best Overall Response Rate (ORR);A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.;Time to Progression (A1 Only);Completed;Phase 2
402;Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma;Best Overall Response Rate (ORR);A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.;Progression-free Survival (A0 Only);Completed;Phase 2
402;Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma;Best Overall Response Rate (ORR);A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.;Progression-free Survival (A1 Only);Completed;Phase 2
402;Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma;Best Overall Response Rate (ORR);A0: Subjects evaluated for disease response on Day 24 of Cycles 2, 4, 6, 9, and 12. Onset of response measured on Day 15 of Cycle 1. A1: Subjects evaluated for disease response on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12 and at End of Study.;Overall Survival (A1 Only);Completed;Phase 2
403;A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma;stringent complete response (sCR) after consolidation therapy;Up to 9 months;PFS (Progression-Free Survival) (from first randomization);Active, not recruiting;Phase 3
403;A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma;Progression free survival after maintenance therapy;up to 60 months;Time to Progression (TTP);Active, not recruiting;Phase 3
404;Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma;Event-free survival,;Partial response and complete response;Unknown status;Phase 3
404;Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma;Event-free survival,;Overall survival;Unknown status;Phase 3
404;Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma;Event-free survival,;Progression-free survival;Unknown status;Phase 3
404;Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma;Event-free survival,;Toxicity;Unknown status;Phase 3
405;Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma;Time to Progression of Disease;From the date of randomization until the disease progression or participant's death from any cause whichever occurred first, as assessed up to 72 weeks after end of treatment visit (ie, 46 days after last dose of study medication);Progression-Free Survival (PFS);Completed;Phase 3
405;Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma;Time to Progression of Disease;From the date of randomization until the disease progression or participant's death from any cause whichever occurred first, as assessed up to 72 weeks after end of treatment visit (ie, 46 days after last dose of study medication);Overall Survival (OS);Completed;Phase 3
405;Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma;Time to Progression of Disease;From the date of randomization until the disease progression or participant's death from any cause whichever occurred first, as assessed up to 72 weeks after end of treatment visit (ie, 46 days after last dose of study medication);Overall Response Rate (ORR) - International Myeloma Working Group (IMWG) Response Criteria;Completed;Phase 3
406;A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma;All patients administered any dose of study drug will be included in the evaluation of safety;Before infusion, 5 min after start, every 15 min until completion, then 30, 60, 90 and 120 min later of each dose of study drug;Determine the therapeutic efficacy of hLL1-DOX in this patient population;Terminated;Phase 1
406;A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma;All patients administered any dose of study drug will be included in the evaluation of safety;Before infusion, 5 min after start, every 15 min until completion, then 30, 60, 90 and 120 min later of each dose of study drug;Determine the therapeutic efficacy of hLL1-DOX in this patient population;Terminated;Phase 2
407;A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma;Complete Response Rate;Up to cycle 4 (with 28 days per cycle).;Safety;Unknown status;Phase 4
407;A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma;Complete Response Rate;Up to cycle 4 (with 28 days per cycle).;Overall Response Rate;Unknown status;Phase 4
407;A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma;Complete Response Rate;Up to cycle 4 (with 28 days per cycle).;Time To Response;Unknown status;Phase 4
407;A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma;Complete Response Rate;Up to cycle 4 (with 28 days per cycle).;1-year Survival Rate;Unknown status;Phase 4
407;A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma;Complete Response Rate;Up to cycle 4 (with 28 days per cycle).;Overall Survival;Unknown status;Phase 4
408;A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma;To determine the maximum tolerated dose (MTD) and recommended phase II doses (RP2D) of vorinostat in combination with lenalidomide, bortezomib, and dexamethasone.;Every 3 weeks;Efficacy by standard myeloma measurements (SPEP, UPEP [urine protein electrophoresis], bone marrow);Completed;Phase 1
409;Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma,,,;Completed;Phase 2
410;Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma;Confirmed response (complete response, very good partial response, partial response, or minimal response) of serum and urine monoclonal protein,;Toxicity;Completed;Phase 2
411;A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study;Progression-free Survival (PFS) - Primary Analysis;From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.;Number of Participants With Adverse Events (AEs);Completed;Phase 3
411;A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study;Progression-free Survival (PFS) With a Later Cut-off Date;From randomization until the data cut-off date of 01 March 2013. Maximum duration of follow-up for PFS assessments was 74 weeks.;Overall Survival - Primary Analysis;Completed;Phase 3
412;A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma;Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response;Every 2 weeks until progression or death occurs.;Time to Progression (TTP);Completed;Phase 2
412;A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma;Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response;Every 2 weeks until progression or death occurs.;Progression Free Survival (PFS);Completed;Phase 2
412;A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma;Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response;Every 2 weeks until progression or death occurs.;Number of Patients With Overall Survival (OS);Completed;Phase 2
413;Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma;Progression Free Survival;Up to 1 year;Overall Survival;Completed;Phase 3
413;Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma;Progression Free Survival;Up to 1 year;Adverse Event;Completed;Phase 3
413;Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma;Progression Free Survival;Up to 1 year;Overall Response Rate;Completed;Phase 3
413;Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma;Progression Free Survival;Up to 1 year;Duration of Response;Completed;Phase 3
414;Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma;overall Survival;May 2007;Progression Free Survival;Terminated;Phase 3
414;Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma;overall Survival;May 2007;Response rates;Terminated;Phase 3
414;Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma;overall Survival;May 2007;Safety;Terminated;Phase 3
415;Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma;Efficacy (combined CR-/VGPR-rate) achieved during the induction treatment phase or within four weeks after the last administration of six induction cycles of the BRd regimen;Every 4 weeks up to 7 months;Objective response rates (sCR, CR, VGPR, PR, MR);Completed;Phase 2
415;Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma;Efficacy (combined CR-/VGPR-rate) achieved during the induction treatment phase or within four weeks after the last administration of six induction cycles of the BRd regimen;Every 4 weeks up to 7 months;Best response (sCR, CR, VGPR, PR, MR);Completed;Phase 2
415;Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma;Efficacy (combined CR-/VGPR-rate) achieved during the induction treatment phase or within four weeks after the last administration of six induction cycles of the BRd regimen;Every 4 weeks up to 7 months;Time to progression (TTP);Completed;Phase 2
415;Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma;Efficacy (combined CR-/VGPR-rate) achieved during the induction treatment phase or within four weeks after the last administration of six induction cycles of the BRd regimen;Every 4 weeks up to 7 months;Overall survival (OS);Completed;Phase 2
415;Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma;Efficacy (combined CR-/VGPR-rate) achieved during the induction treatment phase or within four weeks after the last administration of six induction cycles of the BRd regimen;Every 4 weeks up to 7 months;Safety and tolerability;Completed;Phase 2
416;Imaging Studies and the Development of Multiple Myeloma;To explore the distribution of 18F-Fluciclatide PET/CT in bone marrow microenvironment in patients with multiple myeloma and its precursor disease (MGUS and SMM);1 year;Distribution of agent;Withdrawn;Phase 2
417;A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody;Overall Response Rate (ORR) by Independent Review Committee (IRC) (Full Analysis Population);Up to 48 weeks;Overall Response Rate by Investigator Assessment (IA) (Full Analysis Population);Active, not recruiting;Phase 2
417;A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody;Overall Response Rate by Independent Review Committee (Efficacy Population);Up to 48 weeks;Overall Response Rate by Investigator Assessment (Efficacy Population);Active, not recruiting;Phase 2
418;Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma;Comparison of frequency of infections in patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic;One year;Response rates in the group of patients treated with clarithromycin compared to the other patients in the study;Unknown status;Phase 2
418;Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma;Comparison of frequency of infections in patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic;One year;Comparison of adverse events assessed by CTCAE v4.0 in patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic;Unknown status;Phase 2
418;Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma;Comparison of frequency of infections in patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic;One year;Comparison of overall survival between patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic;Unknown status;Phase 2
418;Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma;Comparison of frequency of infections in patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic;One year;Quality of life assessed by EORTC QLQ-MY20;Unknown status;Phase 2
418;Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma;Comparison of frequency of infections in patients treated with clarithromycin, sulfamethoxazole/trimethoprim or observed without prophylactic antibiotic;One year;Quality of life assessed by EORTC QLQ-C30;Unknown status;Phase 2
419;A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate;From first dose until the data cut-off date of 15 July 2014. Median time on follow-up was 61.6 weeks.;Time to Response;Completed;Phase 2
419;A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate;From first dose until the data cut-off date of 15 July 2014. Median time on follow-up was 61.6 weeks.;Duration of Response;Completed;Phase 2
419;A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate;From first dose until the data cut-off date of 15 July 2014. Median time on follow-up was 61.6 weeks.;Progression Free Survival (PFS);Completed;Phase 2
419;A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate;From first dose until the data cut-off date of 15 July 2014. Median time on follow-up was 61.6 weeks.;Overall Survival (OS);Completed;Phase 2
419;A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate;From first dose until the data cut-off date of 15 July 2014. Median time on follow-up was 61.6 weeks.;Number of Participants With Adverse Events;Completed;Phase 2
420;Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients;Phase I: Maximum Tolerated Dose (MTD). Phase II: To determine response rate.;Every 3 weeks;Phase II: Tolerability and Safety;Completed;Phase 1
420;Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients;Phase I: Maximum Tolerated Dose (MTD). Phase II: To determine response rate.;Every 3 weeks;Phase II: Correlative data;Completed;Phase 2
421;Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea;Adverse events;From enrollment until at least 28 days after completion of study treatment;Overall response rate;Recruiting,
422;Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma;Number of Participants Reporting One or More Treatment-Emergent Adverse Events and Serious Adverse Events;From the first dose through 30 days after last dose of ixazomib citrate or until the start of subsequent antineoplastic therapy (Up to 354 days);Cmax: Maximum Observed Plasma Concentration for MLN2238;Completed;Phase 1
422;Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma;Neurotoxicity Grading;Cycle 1 Day 1 and End of Study (Up to 354 days);Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for MLN2238;Completed;Phase 1
423;WB-DCE-MRI in Multiple Myeloma as an Independent Prognostic Factor for Disease-free Survival;Maximal percentage of bone marrow measurement on last WB DCE MRI;Measurements will be performed on initialWB DCE MRI Examination. Follow-up = Five year;Maximal percentage of bone marrow measurement on initial WB DCE MRI;Completed;Not Applicable
424;A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma;Kaplan-Meier Estimate of Time to Tumor Progression (TTP);"From randomization up to cut-off date of 03 August 2005; up to 24 months";Kaplan-Meier Estimate of Overall Survival (OS);Completed;Phase 3
424;A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma;Kaplan-Meier Estimate of Time to Tumor Progression (TTP) (Later Cut-off Date of 02 Mar 2008);"From randomization up to cut-off date of 02 March 2008; up to 51 months";Kaplan-Meier Estimate of Overall Survival (OS) (Later Cut-off Date of 02 March 2008);Completed;Phase 3
425;Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd);Identification of Dose-limiting toxicity (DLT);1 year;Response rate (RR);Active, not recruiting;Phase 1
425;Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd);Partial Response (PR);1 year;Progression free-survival (PFS);Active, not recruiting;Phase 2
426;Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma;Incidence of treatment-emergent adverse events (TEAEs), including DLT(s);24 months;Best overall response (BOR) by IMWG Consensus Criteria;Recruiting;Phase 1
426;Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma;Establish the RP2D of the investigational agent;24 months;ORR by IMWG Consensus Criteria;Recruiting;Phase 1
427;Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma,,,;Completed,
428;BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma;Dose-limiting toxicity;through cycle 1;Qualitative and quantitative toxicities;Completed;Phase 1
428;BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma;Maximum tolerated dose;for the duration of the study;Pharmacokinetics;Completed;Phase 1
429;Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma;Objective Response (OR) Rate;Response was assessed every two cycles on treatment. Treatment duration in months was a median (range) of 5.1 (0.8-6.1).;Very Good Partial Response (VGPR) Rate;Completed;Phase 2
429;Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma;Objective Response (OR) Rate;Response was assessed every two cycles on treatment. Treatment duration in months was a median (range) of 5.1 (0.8-6.1).;Time to Progression (TTP);Completed;Phase 2
429;Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma;Objective Response (OR) Rate;Response was assessed every two cycles on treatment. Treatment duration in months was a median (range) of 5.1 (0.8-6.1).;Progression-Free Survival (PFS);Completed;Phase 2
429;Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma;Objective Response (OR) Rate;Response was assessed every two cycles on treatment. Treatment duration in months was a median (range) of 5.1 (0.8-6.1).;Number of Participants With Treatment-Emergent Sensory Neuropathy;Completed;Phase 2
429;Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma;Objective Response (OR) Rate;Response was assessed every two cycles on treatment. Treatment duration in months was a median (range) of 5.1 (0.8-6.1).;Number of Participants With Treatment-Emergent Neuropathic Pain;Completed;Phase 2
430;Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma;Tolerability as assessed by CTCAE v3.0 (Phase I);100 days;Rate of grades II-IV and grades III-IV acute graft-vs-host disease (GVHD);Withdrawn;Phase 1
430;Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma;Assessment of toxicity (Phase I);100 days;Cumulative rate of chronic GVHD;Withdrawn;Phase 2
431;A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM);Dose-Limiting Toxicity (DLT);Up to 28 days;Response Rate;Completed;Phase 1
431;A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM);Maximum Tolerated Dose (MTD);Up to 28 days;Response Rate;Completed;Phase 1
431;A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM);Dose Timing After Autologous Stem Cell Transplant;Up to 28 days;Response Rate;Completed;Phase 1
431;A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM);Adverse Events (AEs);Up to 12 months;Response Rate;Completed;Phase 1
432;The Effect of High Dose Simvastatine on Multiple Myeloma;Response estimated by internationally approved criteria after 8 weeks of intermittend treatment with simvastatine;8 weeks after treatment start;Changes in markers of bone metabolisme after 8 weeks of intermittend treatment with simvastatine;Completed;Phase 1
432;The Effect of High Dose Simvastatine on Multiple Myeloma;Response estimated by internationally approved criteria after 8 weeks of intermittend treatment with simvastatine;8 weeks after treatment start;Toxicity according to CTC after 8 weeks of intermittend treatment with simvastatine;Completed;Phase 2
433;Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma;Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria;8 months;Percentage of Participants That Have Minimal Residual Disease (MRD)-Negative Complete Response (CR) for a Minimum of 1 Year;Active, not recruiting;Phase 2
433;Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma;Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria;8 months;Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0);Active, not recruiting;Phase 2
433;Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma;Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria;8 months;Clinical Progression Free Survival;Active, not recruiting;Phase 2
433;Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma;Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria;8 months;Biochemical Progression Free Survival;Active, not recruiting;Phase 2
433;Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma;Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria;8 months;Duration of Response;Active, not recruiting;Phase 2
433;Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma;Percentage of Participants With Minimal Residual Disease (MRD)Negative Complete Response (CR) Per International Myeloma Working Group (IMWG) Criteria;8 months;Overall Response Rate;Active, not recruiting;Phase 2
434;A Study of Belantamab Mafodotin and Nirogacestat in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment;Number of Participants who Experienced Dose-Limiting Toxicities (DLTs);up to six weeks;Clinical Response;Recruiting;Phase 1
435;ctDNA Methylation Sequencing for Myeloma;Sample Collection Completed;From Aug 31 2022 to Jun 30 2025,;Recruiting,
436;A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma;Maximum tolerated dose (MTD) of ganetespib in combination with bortezomib and dexamethasone.;30 days after final cycle,;Completed;Phase 1
437;BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma;Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0;6 months;Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm;Unknown status;Phase 1
437;BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma;Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0;6 months;Duration of CAR-positive T cells in circulation;Unknown status;Phase 1
437;BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma;Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0;6 months;Total number of CAR-positive T cells infiltrated into lymphoma tissue;Unknown status;Phase 1
438;APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma;Dose-limiting toxicity (DLT);Baseline up to 28 days after APRIL targeted CAR T-cells infusion;Multiple Myeloma (MM), Overall response rate (ORR);Recruiting;Early Phase 1
438;APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma;Incidence of treatment-emergent adverse events (TEAEs);Time Frame: Up to 2 years after APRIL targeted CAR T-cells infusion;MM, Overall survival (OS);Recruiting;Early Phase 1
439;AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma;Dose-limiting toxicity (DLT);Baseline up to 28 days after BCMA CAR T-cells infusion;overall response rate;Recruiting;Phase 1
439;AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma;Incidence of treatment-emergent adverse events (TEAEs);24 months after cell infusion;Complete response rate(CRR);Recruiting;Phase 1
440;Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma;Response Rates After Amrubicin + Lenalidomide + Dexamethasone, Per International Myeloma Working Group Uniform Response Criteria;12 weeks;Duration of Response (DOR);Completed;Phase 1
440;Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma;Response Rates After Amrubicin + Lenalidomide + Dexamethasone, Per International Myeloma Working Group Uniform Response Criteria;12 weeks;Progression-free Survival (PFS);Completed;Phase 2
441;Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma;Maximum Tolerated Dose;Cycle 1 (28 days from first dose);Response to treatment;Unknown status;Phase 1
441;Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma;Maximum Tolerated Dose;Cycle 1 (28 days from first dose);Time to response;Unknown status;Phase 2
442;Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma;Dose limitinged toxicity（DLT）after GC012F infusion;Up to 21 days after patients infused with GC012F injectiom;Overall Response Rate(ORR);Recruiting;Phase 1
442;Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma;Adverse Events (AE) after infusion;Up to 48 weeks after patients infused with GC012F injectiom;Progression-free survival (PFS), Overall Survival (OS), Duration Of Response (DOR);Recruiting;Phase 1
443;Interleukin-12 in Treating Patients With Multiple Myeloma,,,;Completed;Phase 2
444;Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma;Number of Patients Exhibiting a Given Overall Response as Determined by Investigator;Through study completion, an average of 6.09 weeks.;Duration of MRZ Treatment;Completed;Phase 2
444;Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma;Number of Patients Exhibiting a Given Overall Response as Determined by Investigator;Through study completion, an average of 6.09 weeks.;Number of Cycles of Marizomib (MRZ);Completed;Phase 2
444;Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma;Number of Patients Exhibiting a Given Overall Response as Determined by Investigator;Through study completion, an average of 6.09 weeks.;Number of Patients Receiving Marizomib (MRZ) in Each Cycle;Completed;Phase 2
444;Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma;Number of Patients Exhibiting a Given Overall Response as Determined by Investigator;Through study completion, an average of 6.09 weeks.;Number of Patients With Treatment Emergent Adverse Events (TEAEs);Completed;Phase 2
444;Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma;Number of Patients Exhibiting a Given Overall Response as Determined by Investigator;Through study completion, an average of 6.09 weeks.;Number of Treatment Emergent Adverse Events (TEAEs);Completed;Phase 2
444;Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma;Number of Patients Exhibiting a Given Overall Response as Determined by Investigator;Through study completion, an average of 6.09 weeks.;Maximum Observed Blood Drug Concentration (Cmax);Completed;Phase 2
445;Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma;Complete and partial remission,;Relationship between molecular and clinical outcomes;Completed;Phase 2
446;Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM);Number of Participants with Adverse Events;First dose of study drug through at least 30 days after end of treatment (approximately 2 years);Very Good Partial Response (VGPR) or Better Response Rate in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression;Recruiting;Phase 2
446;Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM);"Very Good Partial Response (VGPR) or Better Response Rate of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM";First dose of study drug through at least 30 days after end of treatment (approximately 2 years);Progression-free survival (PFS) in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression;Recruiting;Phase 2
446;Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM);"Objective Response Rate (ORR) of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM";First dose of study drug through at least 30 days after end of treatment (approximately 2 years);Minimal residual disease (MRD);Recruiting;Phase 2
446;Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM);"Complete Response (CR) or Better Rate of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM";First dose of study drug through at least 30 days after end of treatment (approximately 2 years);Duration of Overall Response (DOR) in Participants with Relapsed or Refractory Multiple Myeloma and in a Subset of Participants with High B-cell lymphocyte-2 (BCL-2) Expression;Recruiting;Phase 2
447;A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Progression-free survival (PFS).;Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose.;Brief Pain Inventory - Short Form [BPI-SF] - Worst Pain;Completed;Phase 3
447;A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Progression-free survival (PFS).;Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose.;Duration of Response (DOR).;Completed;Phase 3
447;A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Progression-free survival (PFS).;Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose.;Progression-Free Survival (PFS) in subjects with high B-cell lymphoma 2 (BCL-2) expression.;Completed;Phase 3
447;A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Progression-free survival (PFS).;Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose.;Minimal Residual Disease (MRD) status.;Completed;Phase 3
447;A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Progression-free survival (PFS).;Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose.;Objective Response Rate (ORR).;Completed;Phase 3
447;A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Progression-free survival (PFS).;Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose.;Patient Reported Outcomes Measurement Information System - (PROMIS);Completed;Phase 3
447;A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Progression-free survival (PFS).;Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose.;European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) - Physical Functioning;Completed;Phase 3
447;A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Progression-free survival (PFS).;Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose.;Overall survival (OS).;Completed;Phase 3
447;A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Progression-free survival (PFS).;Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose.;European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) - Global Health Status;Completed;Phase 3
447;A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Progression-free survival (PFS).;Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose.;Very Good Partial Response (VGPR) or better response rate.;Completed;Phase 3
447;A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Progression-free survival (PFS).;Measured at subject's baseline (prior to subject's first dose) and at Day 1 of every Cycle thereafter for up to 3 years following the last subject first dose.;Time to disease progression (TTP).;Completed;Phase 3
448;Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma;Phase I: Number of Patients With Dose Limiting Toxicity;up to 1 month;Phase II: Treatment-Related Adverse Events Grade 3 or Higher;Completed;Phase 1
448;Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma;Phase II: Overall Response Rate;up to 5 years;Phase II: Treatment-Related Adverse Events Grade 3 or Higher;Completed;Phase 2
449;INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma;Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE);up to 454 days;Phase 1: ORR: Number of Participants With a Documented Response of CR, VGPR, or PR, as Per IMWG Criteria;Terminated;Phase 1
449;INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma;Phase 2: Overall Response Rate (ORR): Number of Participants With a Documented Response of Complete Response (CR), Very Good Partial Response (VGPR), or PR, as Per International Myeloma Working Group (IMWG) Criteria;up to Day 386;Phase 2: Number of Participants With Any TEAE;Terminated;Phase 2
450;Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients;Determine the maximally tolerated dose of imexon in multiple myeloma patients;Evaluate biomarker responses.;Completed;Phase 1
450;Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients;evaluate the toxicity of imexon;Evaluate biomarker responses.;Completed;Phase 2
451;Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma;change in urinary protein/creatinine ratio;Change from baseline in urinary protein/creatinine ratio at 8 AM, 12 AM, 4 PM;changes in urinary excretion of FLC;Completed,
451;Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma;change in urinary protein/creatinine ratio;Change from baseline in urinary protein/creatinine ratio at 8 AM, 12 AM, 4 PM;methods for estimating the urinary concentration of FLC;Completed,
452;Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma;Maximum Tolerated Dose (Phase 1);35 days post-transplant;Progression-Free Survival (Phase 1);Completed;Phase 1
452;Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma;Overall Response Rate (Phase 2) - Number of Participants Achieving at Least a Partial Response or Better in Disease Status at Day 100 Post-transplant;100 days post-transplant;Progression-Free Survival (Phase 2);Completed;Phase 2
453;Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma;Phase Ib: Number of Total Dose-limiting Toxicities (DLT);Cycle 1 (28 days);Phase II: Percent change of ORR (Overall Response Rate) between the two arms;Completed;Phase 1
453;Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma;Phase II: Overall Response Rate (ORR) as assessed by Investigators;29 months (End of Study);Number of participants with adverse events, serious adverse events, changes in laboratory values, and electrocardiograms (ECGs), as a measure of safety and tolerability.;Completed;Phase 1
454;Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants With a Grade 3 and 4 Adverse Event (Phase I);up to 3 years;Overall Survival (Phase II);Terminated;Phase 1
454;Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma;Number of Participants Who Achieve a Confirmed Response (Partial Response [PR], Very Good PR [VGPR], Complete Response [CR], or Stringent CR [sCR]) (Phase II);Duration on Treatment (up to 3 years);Time to Disease Progression (Phase II);Terminated;Phase 1
455;B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma;complete remission rate;at the time point 3 months after CAR-T cell transfusion;progression free survival;Unknown status;Phase 2
455;B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma;incidence and severity of adverse events;from the date of the start of treatment to 36 months after last patient's enrollment;overall survival;Unknown status;Phase 2
456;Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients;Number of Participants With Serious and Non-serious Adverse Events;4 years and 9 months and 2 days;Overall Response Rate;Completed;Phase 2
456;Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients;Number of Participants With Serious and Non-serious Adverse Events;4 years and 9 months and 2 days;Progression Free Survival (PFS) at 48 Months;Completed;Phase 2
456;Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients;Number of Participants With Serious and Non-serious Adverse Events;4 years and 9 months and 2 days;Percentage of Responders With Duration of Response (DOR) at 48 Months;Completed;Phase 2
456;Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients;Number of Participants With Serious and Non-serious Adverse Events;4 years and 9 months and 2 days;Overall Survival (OS) Rate;Completed;Phase 2
456;Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients;Number of Participants With Serious and Non-serious Adverse Events;4 years and 9 months and 2 days;Cluster of Differentiation 138 (CD138) + Plasma Cells Gene Expression Profiling on Pre and Post Carfilzomib Exposure Bone Marrow Samples;Completed;Phase 2
456;Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients;Number of Participants With Serious and Non-serious Adverse Events;4 years and 9 months and 2 days;Rate of Minimal Residual Disease (MRD) by Flow Cytometry;Completed;Phase 2
456;Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients;Number of Participants With Serious and Non-serious Adverse Events;4 years and 9 months and 2 days;Complete Response (CR) and Minimal Residual Disease Neg (MRDneg) CR Rates at Treatment Intervals With Carfilzomib, Lenalidomide & Dexamethasone (CRd) in New Multiple Myeloma Patients After 8 Cycles of Induction, 1 Year Maintenance, and 2 Years Maintenance;Completed;Phase 2
457;Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients;Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE);Day 1 to approximately Day 38 (before start of chemotherapy);Number of Participants Achieving a Two-Fold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL Following the First Dose of Plerixafor;Completed;Phase 2
457;Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients;Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE);Day 1 to approximately Day 38 (before start of chemotherapy);Number of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant;Completed;Phase 2
458;Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma;Progression free survival rates in participants receiving drug combination;4 years;Rate of minimal residual negative disease (MRD) in participants receiving drug combination;Active, not recruiting;Phase 3
458;Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma;Progression free survival rates in participants receiving drug combination;4 years;Response rate in participants receiving drug combination;Active, not recruiting;Phase 3
458;Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma;Progression free survival rates in participants receiving drug combination;4 years;Treatment-related side effects;Active, not recruiting;Phase 3
459;Thalidomide for Multiple Myeloma;Maximum Tolerated Dose of Thalidomide;14 day cycles,;Completed;Phase 3
460;Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma;Maximum Tolerated Dose of Pomalidomide and Bendamustine;2 cycles (approximately 2 months);Overall Response Rate;Unknown status;Phase 1
460;Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma;Initial Response Rate;2 cycles (approximately 2 months);Time to Progression;Unknown status;Phase 2
461;A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma;Rate of complete response, partial response and stable disease (clinical benefit rate),;Progression-free survival;Completed;Phase 2
461;A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma;Rate of complete response, partial response and stable disease (clinical benefit rate),;Safety and tolerability;Completed;Phase 2
462;Clarithromycin in Multiple Myeloma Induction Therapy;Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo;10 weeks;Comparison of number of participants with very good partial response or better response after HDT in patients treated with three courses of VCD combined with clarithromycin or placebo;Terminated;Phase 2
462;Clarithromycin in Multiple Myeloma Induction Therapy;Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo;10 weeks;Comparison of number of participants with sCR, CR, PR, PD or SD in the treatment groups after induction therapy and HDT, respectively;Terminated;Phase 2
462;Clarithromycin in Multiple Myeloma Induction Therapy;Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo;10 weeks;Comparison of frequency of infections in patients treated VCD combined with clarithromycin or placebo;Terminated;Phase 2
462;Clarithromycin in Multiple Myeloma Induction Therapy;Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo;10 weeks;Comparison of number of stem cells harvested in patients treated with clarithromycin and placebo in combination with VCD;Terminated;Phase 2
462;Clarithromycin in Multiple Myeloma Induction Therapy;Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo;10 weeks;Neurotoxicity assessed by FACT/GOG-Ntx, Version 4.0;Terminated;Phase 2
462;Clarithromycin in Multiple Myeloma Induction Therapy;Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo;10 weeks;Quality of life assessed by EORTC QLQ-MY20;Terminated;Phase 2
462;Clarithromycin in Multiple Myeloma Induction Therapy;Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo;10 weeks;Quality of life assessed by EORTC QLQ-C30;Terminated;Phase 2
462;Clarithromycin in Multiple Myeloma Induction Therapy;Comparison of number of participants with very good partial response or better response after three courses of VCD combined with clarithromycin or placebo;10 weeks;Comparison of adverse events in patients treated VCD combined with clarithromycin or placebo assessed by CTCAE v4.0;Terminated;Phase 2
463;Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma;Number of Participants With One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs);From first dose of the study drug through 30 days after the last dose of study drug or start of subsequent antineoplastic therapy (Up to 81.1 months);Cmax: Maximum Observed Plasma Concentration for Ixazomib;Completed;Phase 1
463;Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma;Number of Participants With Clinically Significant Abnormalities Reported as TEAEs;From first dose of the study drug through 30 days after the last dose of study drug or start of subsequent antineoplastic therapy (Up to 81.1 months);Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib;Completed;Phase 1
463;Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma;Number of Participants With a TEAE of Peripheral Neuropathy;From first dose of the study drug through 30 days after the last dose of study drug or start of subsequent antineoplastic therapy (Up to 81.1 months);AUC(0-last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Ixazomib;Completed;Phase 1
463;Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma;Number of Participants With Clinically Significant Changes in Vital Signs Reported as TEAEs;From first dose of the study drug through 30 days after the last dose of study drug or start of subsequent antineoplastic therapy (Up to 81.1 months);AUC(0-72): Area Under the Plasma Concentration-Time Curve From Time 0 to 72 Hours Postdose for Ixazomib;Completed;Phase 1
463;Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma;Maximum Tolerated Dose (MTD) of Ixazomib;Cycle 1 (21 days);λz: Terminal Disposition Phase Rate Constant for Ixazomib;Completed;Phase 1
463;Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma;Recommended Phase 2 Dose (RP2D) of Ixazomib;Cycle 1 through Cycle 39 (Up to 28.3 months);T1/2: Terminal Disposition Phase Elimination Half-life for Ixazomib;Completed;Phase 1
464;Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma;Cost-effectiveness analysis;1 year,;Completed,
465;MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation;Assessment of Safety of recMAGE-A3 + AS15;Continuously for up to 14 months;Induction or Augmentation of MAGE-A3-Specific Humoral Immunity;Completed;Phase 1
465;MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation;Assessment of Safety of recMAGE-A3 + AS15;Continuously for up to 14 months;Induction or Augmentation of MAGE-A3-Specific Cellular Immunity;Completed;Phase 1
465;MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation;Assessment of Safety of recMAGE-A3 + AS15;Continuously for up to 14 months;Assessment of Tumor Response;Completed;Phase 1
465;MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation;Assessment of Safety of recMAGE-A3 + AS15;Continuously for up to 14 months;Assessment of Survival and Time to Subsequent Therapy;Completed;Phase 1
466;Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma,,,;Completed;Phase 2
467;Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD;To validate the sensitivity of Telo Genomics assay (measurement tool) to detect MRD (measurement expressed in the number of plasma cells per 100000 cells) and establish the clinical utility of TELO - DMRD for MRD enumeration;Approximately 5 years;Not yet recruiting,
467;Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD;To assess the utility of TeloView® technology genomic profiling (measurement tool) to stratify post-transplant MM patients into relapse risk groups (dichotomous measure of high or low) by analyzing the residual MRD plasma cells;Approximately 5 years,;Not yet recruiting,
468;Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma;Best Response Prior to Tandem Autologous Stem Cell Transplant;From enrollment in the study until day -8: before dilantin given pre-first high-dose chemo preceeding first cycle of tandem autologous cell transplant;Completed;Phase 2
468;Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma;Response After Tandem Autologous Stem Cell Transplant;After second cycle of tandem autologous stem cell transplant: Day 0 of second transplant to 12 weeks post-cycle 2 cell infusion of the tandem transplant.;Completed;Phase 2
468;Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma;Three-year Overall Survival;Estimate reported at three years after day 0 of the first cycle of infusion of cells of the tandem transplant.;Completed;Phase 2
468;Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma;Progression-free Survival;Estimate reported at three years after day 0 of the first cycle of infusion of cells of the tandem transplant.;Completed;Phase 2
468;Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma;Best Response at 6 Months Post Tandem Autologous Stem Cell Transplant;Six months after day 0 of the first cycle of the tandem autologous stem cell transplant. This will be used to determine administration of thalidomide.;Completed;Phase 2
468;Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma;Best Response After Tandem Autologous Stem Cell Transplant and Maintenance;Response after six months after day 0 of the first cycle of the tandem transplant, after administration of maintenance thalidomide if necessary, until three years post-day 0 of the first cycle of the tandem transplant.,;Completed;Phase 2
469;A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR;Adverse Events (AEs);Up to 5 years,;Unknown status,
470;MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma;Progression Free Survival;5 years,;Terminated;Phase 2
471;Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment;After 4 months of treatment;Progression Free Survival (PFS);Completed;Phase 2
471;Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment;After 4 months of treatment;Overall Survival (OS);Completed;Phase 2
471;Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment;After 4 months of treatment;"Number of Participants Who Responded to Treatment (Complete Response,CR; Near Complete Response, nCR; Very Good Partial Response, VGPR; or Partial Response, PR) After 4 Cycles";Completed;Phase 2
471;Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment;After 4 months of treatment;Duration of Response;Completed;Phase 2
471;Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment;After 4 months of treatment;Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 8 Cycles;Completed;Phase 2
471;Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment;After 4 months of treatment;Number of Participants Who Responded to Treatment (CR, nCR, VGPR or PR) After 12 Cycles;Completed;Phase 2
471;Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment;After 4 months of treatment;Number of Participants With Severe Adverse Events;Completed;Phase 2
471;Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Number of Participants Who Achieved a Confirmed Responses Defined as a Complete Response (CR), Near CR or Very Good Partial Response (VGPR) After the First 4 Months of Treatment;After 4 months of treatment;Participants Who Successfully Completed Collection of Peripheral Blood Stem Cells for Transplant;Completed;Phase 2
472;A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma;Dose-limiting toxicity (DLT);Baseline up to 28 days after BCMA CAR T-cells infusion;Multiple Myeloma (MM), Overall response rate (ORR);Recruiting;Phase 2
472;A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma;Incidence of treatment-emergent adverse events (TEAEs);Baseline up to 2 years after BCMA CAR T-cells infusion;Complete response rate(CRR);Recruiting;Phase 2
473;"Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance";Toxicity of induction chemotherapy according to CTCAE version 3.0;5 years;Progression Free Survival;Completed;Phase 2
473;"Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance";Toxicity of induction chemotherapy according to CTCAE version 3.0;5 years;Overall Survival;Completed;Phase 2
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);Overall Survival (OS);Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);Overall Survival in High-Risk Participants Carrying Deletion 17 [Del(17)];Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);Overall Response Rate (ORR) as Assessed by the IRC;Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) as Assessed by the IRC;Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);Duration of Response (DOR);Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);Time to Progression (TTP) as Assessed by the IRC;Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);Number of Participants With Change From Baseline in Pain Response;Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) Questionnaire (EORTC-QLQ-C30);Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Multiple Myeloma Module (QLQ-MY-20);Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);OS in High-Risk Participants;Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);PFS in High-Risk Participants;Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);Plasma Concentration Over Time for Ixazomib;Completed;Phase 3
474;A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma;Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC);From date of randomization until disease progression or death up to approximately 27 months (approximate median follow-up 15 months);Overall Response Rate in Participants Defined by Polymorphism;Completed;Phase 3
475;Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma;1. To determine response rates (RR) and disease progression rates in all MM patients treated with dtZ regimen.;4 months;To assess overall survival (OS) in all patients treated with dtZ regimen.;Completed;Phase 2
475;Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma;1. To determine response rates (RR) and disease progression rates in all MM patients treated with dtZ regimen.;4 months;Assessment of incidence of skeletal related events (SREs).;Completed;Phase 2
475;Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma;1. To determine response rates (RR) and disease progression rates in all MM patients treated with dtZ regimen.;4 months;Assessment of percent change in renal function in all patients.;Completed;Phase 2
476;Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma;Patients With Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response) on 2 Consecutive Months During the First 6 Months of Treatment With Anakinra Alone;6 months;Number of Patients With Response to Treatment With Dexamethasone and Anakinra;Completed;Phase 2
476;Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma;Patients With Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response) on 2 Consecutive Months During the First 6 Months of Treatment With Anakinra Alone;6 months;Number of Patients Who Are Progression-free and Alive at 6 Months;Completed;Phase 2
476;Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma;Patients With Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response) on 2 Consecutive Months During the First 6 Months of Treatment With Anakinra Alone;6 months;Number of Patients With Severe Non-hematological Adverse Events in Patients Receiving Anakinra Alone or in Combination With Dexamethasone.;Completed;Phase 2
476;Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma;Patients With Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response) on 2 Consecutive Months During the First 6 Months of Treatment With Anakinra Alone;6 months;Progression Free Survival (PFS) in Patients Treated With Anakinra Alone or in Combination With Dexamethasone;Completed;Phase 2
476;Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma;Patients With Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response) on 2 Consecutive Months During the First 6 Months of Treatment With Anakinra Alone;6 months;Number of Patients With Severe Non-hematological Adverse Events in Participants Receiving Anakinra in Combination With Dexamethasone;Completed;Phase 2
476;Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma;Patients With Confirmed Response (Complete Response, Very Good Partial Response, Partial Response, or Minimal Response) on 2 Consecutive Months During the First 6 Months of Treatment With Anakinra Alone;6 months;Duration of Response;Completed;Phase 2
477;Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma;Dose-limiting Toxicity (DLT) (Phase I);28 days;Progression-free Survival;Completed;Phase 1
477;Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma;Overall Response Rate to the Combination of MLN8237 and Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma.;Every 28 day cycle(up to 10 cycles);Overall Survival;Completed;Phase 2
478;Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma;Toxicity. Number of Patients With Specific Toxicities Are Reported.;10 months;Progression-Free Survival;Completed;Phase 1
478;Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma;Best Response to Combination Treatment;10 months;Progression-Free Survival;Completed;Phase 2
479;Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM);Multiparametric Flow Cytometry - Minimum Residual Disease;Day 0 for all subjects (Day 0 is the day of stem cell collection);Multiparametric Flow Cytometry - Cluster of Differentiation 34 (CD34)Assessment;Completed;Phase 2
479;Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM);Multiparametric Flow Cytometry - Minimum Residual Disease;Day 0 for all subjects (Day 0 is the day of stem cell collection);Cluster of Differentiation 34 (CD34) Enumeration;Completed;Phase 2
480;Role of BCL-B in Multiple Myeloma;To determine whether BCL-B is a survival factor in malignant plasmocytes, we will analyse the level of expression of Bcl-B at the both mRNA and protein levels in a cohort of MGUS and MM patients.;6 months;To determine whether deregulation of BCL-B expression is associated to chimioresistances commonly observed in Multiple Myeloma, We will compare Bcl-B expression in MM patients either sensitive or resistant to conventional therapies.;Unknown status,
481;Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma;SAFETY AND EFFICACY,;PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL;Completed;Phase 1
481;Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma;SAFETY AND EFFICACY,;PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL;Completed;Phase 2
482;Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy;Complete Response Rate;every 8 weeks for approximately 48 months;Progression Free Survival;Completed;Phase 2
482;Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy;Number of Patients Who Experienced Serious and Non-serious Adverse Events;approximately 36 weeks;Overall Survival;Completed;Phase 2
483;Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma;Overall Survival;11 years;Disease Progression-free Survival;Completed;Phase 3
484;Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma;International Myeloma Working Group (IMWG) Response Criteria;Up to 7.5 months (eight 28-day cycles);Time to First Response;Completed;Phase 2
484;Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma;International Myeloma Working Group (IMWG) Response Criteria;Up to 7.5 months (eight 28-day cycles);Time to Best Response;Completed;Phase 2
484;Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma;International Myeloma Working Group (IMWG) Response Criteria;Up to 7.5 months (eight 28-day cycles);Duration of Response;Completed;Phase 2
484;Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma;International Myeloma Working Group (IMWG) Response Criteria;Up to 7.5 months (eight 28-day cycles);Time to Progression;Completed;Phase 2
484;Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma;International Myeloma Working Group (IMWG) Response Criteria;Up to 7.5 months (eight 28-day cycles);Progression-free Survival;Completed;Phase 2
484;Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma;International Myeloma Working Group (IMWG) Response Criteria;Up to 7.5 months (eight 28-day cycles);Follow-up Time;Completed;Phase 2
485;Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients;Number of Patients With Combined Complete Response and Very Good Partial Response;Up to 48 weeks or until disease progression;Number of Patients With Adverse Events (AEs);Completed;Phase 1
485;Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients;Number of Patients With Combined Complete Response and Very Good Partial Response;Up to 48 weeks or until disease progression;Number of Patients With Overall Response;Completed;Phase 2
486;Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma;Pharmacokinetic parameters for plasma thalidomide: Tmax Cmax AUC t1/2 CL/F V/F;predose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours postdose,;Completed;Phase 1
487;Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma;Immune Response;105 days;Completed;Phase 2
487;Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma;Number of Participants With Adverse Events;9 years,;Completed;Phase 2
488;Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma,,,;Completed;Phase 2
489;A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants With Adverse Events;From first dose of study drug until 30 days following last dose of study drug (up to 70 weeks);Progression-Free Survival (PFS);Terminated;Phase 2
489;A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Approximately 15 months;Duration of Response (DOR);Terminated;Phase 2
490;Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma;Efficacy of Drug Combination as Therapy for Myeloma (Overall Response Rate);Best response at any point during each respective study phase was collected - once after consolidation/prior to mobilization (approximately 6 cycles after start of treatment), and once after mobilization;Yield of CD34+ Stem Cells;Completed;Phase 2
490;Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma;Efficacy of Drug Combination as Therapy for Myeloma (Overall Response Rate);Best response at any point during each respective study phase was collected - once after consolidation/prior to mobilization (approximately 6 cycles after start of treatment), and once after mobilization;Progression Free Survival;Completed;Phase 2
491;Health Through Activity: A Pilot Study of a Rehabilitation Intervention for People Living With Multiple Myeloma;Rate of Participant Enrollment;At screening;Intervention Completion Rate;Not yet recruiting;Not Applicable
491;Health Through Activity: A Pilot Study of a Rehabilitation Intervention for People Living With Multiple Myeloma;Assessment Completion Rate;Up to 4 months;Participant Satisfaction;Not yet recruiting;Not Applicable
492;A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma;Number of participants with Adverse Events (AEs);Up to 2 years after CC-95266 infusion;Pharmacokinetics - Maximum plasma concentration of drug (Cmax);Recruiting;Phase 1
492;A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma;Number of participants with significant laboratory abnormalities;Up to 2 years after CC-95266 infusion;Pharmacokinetics - Time to peak (maximum) serum concentration (tmax);Recruiting;Phase 1
492;A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma;Number of participants with Dose Limiting Toxicities (DLTs);Up to 2 years after CC-95266 infusion;Pharmacokinetics - Area under the curve for days 1-29 after CC-95266 infusion (AUC1-29);Recruiting;Phase 1
492;A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma;Maximum Tolerated Dose (MTD);Up to 2 years after CC-95266 infusion;Overall response rate (ORR);Recruiting;Phase 1
492;A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma;Recommended Phase 2 Dose (RP2D);Up to 2 years after CC-95266 infusion;Complete response rate (CRR);Recruiting;Phase 1
493;Multiple Myeloma Turkish Prospective Patient Registry;Overall Survival;[Time Frame: 5 Years];Recruiting,
493;Multiple Myeloma Turkish Prospective Patient Registry;Progression Free Survival;[Time Frame: 5 Years],;Recruiting,
494;Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma;Overall incidence and severity of AEs in Dose Escalation;Up to 6 weeks;Time to progression;Recruiting;Phase 1
494;Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma;Response rate in Expansion Cohort;Up to 12 weeks;Progression free survival;Recruiting;Phase 2
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Duration of response (DoR);Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Minimal residual disease (MRD) negativity rate;Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Overall survival (OS);Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Overall response rate (ORR);Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Complete response rate (CRR);Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Very good partial response (VGPR) or better rate;Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Time to best response (TTBR);Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Time to response (TTR);Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Time to progression (TTP);Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Progression-free survival on subsequent line of therapy (PFS2);Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Number of participants with adverse events (AEs) and serious adverse events (SAEs);Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters;Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Number of participants with abnormal ocular findings on ophthalmic examination;Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Plasma concentrations of belantamab mafodotin at indicated time points;Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Plasma concentrations of monomethyl auristatin-F with a cysteine linker (cys-mcMMAF) at indicated time points;Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Maximum observed concentration (Cmax) for pomalidomide;Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Time of Cmax (Tmax) for pomalidomide;Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC[0-t]) for pomalidomide;Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin;Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Titers of ADAs against belantamab mafodotin;Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Number of participants with maximum post-baseline changes in patient-reported outcome version of the common terminology criteria for adverse events (PRO-CTCAE) scores for each item attribute;Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Change from Baseline in health related quality of life (HRQoL) as measured by European Organization for Research and Treatment of Cancer Quality of life Questionnaire 30-item core module (EORTC QLQ-C30);Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Change from Baseline in HRQoL as measured by EORTC item library 52 (IL52);Recruiting;Phase 3
495;Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma;Progression-free survival (PFS);Up to 84 months;Change from Baseline in HRQoL as measured by EORTC QLQ-20-item Multiple Myeloma Module (MY20);Recruiting;Phase 3
496;Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma;Number of Participants Reporting a Dose Limiting Toxicity (DLT);First cycle (28 days) of study treatment;Survival Time;Completed;Phase 1
496;Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma;Proportion of Confirmed Tumor Responses;Up to 12 cycles of treatment;Progression Free Survival;Completed;Phase 2
497;Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease,,,;Completed;Phase 2
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;Determine the CAR2 Anti-CD38 A2 CAR-T cell blood concentrations (Pharmacokinetic [PK] Profile) to evaluate the Cmax;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;Determine the CAR2 Anti-CD38 A2 CAR-T cell blood concentrations (Pharmacokinetic [PK] Profile) to evaluate the AUC;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;Evaluate the safety of Anti-CD38 A2 CAR-T cells in Patients with RRMM by incidence of treatment-emergent adverse events;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;Assess preliminary efficacy by response rate in accordance with the modified International Myeloma Working Group (IMWG) criteria;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;Assess preliminary efficacy by depth of response in accordance with the modified International Myeloma Working Group (IMWG) criteria.;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;Assess preliminary efficacy by duration of response in accordance with the modified International Myeloma Working Group (IMWG) criteria.;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;Assess preliminary efficacy by progression-free survival.;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;Assess preliminary efficacy by overall survival.;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;The determination of the recommended phase 2 dose (RP2D) will be based on an evaluation of treatment-emergent events.;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;The determination of the recommended phase 2 dose will be based on an evaluation of overall response rate.;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;The determination of the recommended phase 2 dose (RP2D) will be based on an evaluation of depth of response.;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;The determination of the recommended phase 2 dose (RP2D) will be based on an evaluation of duration of response.;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;The determination of the recommended phase 2 dose (RP2D) will be based on an evaluation of progression-free survival.;Completed;Phase 1
498;Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients;Determine the MTD;28 days;The determination of the recommended phase 2 dose (RP2D) will be based on an evaluation of overall survival.;Completed;Phase 1
499;Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Progression-free Survival (PFS) Rate at 12 Months;12 months from registration;Confirmed Response Rate;Completed;Phase 2
499;Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Progression-free Survival (PFS) Rate at 12 Months;12 months from registration;Overall Survival (OS);Completed;Phase 2
499;Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Progression-free Survival (PFS) Rate at 12 Months;12 months from registration;Progression-free Survival (PFS);Completed;Phase 2
499;Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Progression-free Survival (PFS) Rate at 12 Months;12 months from registration;Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event at Least Possibly Related to Treatment (Toxicity);Completed;Phase 2
500;Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma;Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment;"From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.";Percentage of Participants With Objective Response According to European Group for Blood and Marrow Transplantation (EBMT) Criteria Based on Investigator Assessment;Completed;Phase 3
500;Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma;Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment;"From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.";Number of Participants With Adverse Events and Type of Adverse Events;Completed;Phase 3
500;Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma;Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment;"From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.";Kaplan Meier Estimates for Progression Free Survival (PFS) by Investigator Based on IMWG;Completed;Phase 3
500;Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma;Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment;"From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.";Kaplan-Meier Estimate for Time to Progression (TTP) Based on Investigator Assessment Using IMWG Criteria;Completed;Phase 3
500;Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma;Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment;"From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.";Kaplan-Meier Estimate Duration of Response Based on Investigator Assessment Using IMWG Criteria;Completed;Phase 3
500;Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma;Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment;"From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.";Kaplan-Meier Estimate for Overall Survival;Completed;Phase 3
500;Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma;Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment;"From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.";Time to Response Based on IMWG and Assessed by the Investigator;Completed;Phase 3
501;Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma;Progression-free Survival;signed consent to progression or end of trial. Up to 5 years.;Overall Survival;Completed;Phase 1
501;Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma;Progression-free Survival;signed consent to progression or end of trial. Up to 5 years.;Overall Survival;Completed;Phase 2
502;Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1);Overall Response Rate (ORR);24 Months;Stringent complete response (sCR) or complete response (CR) rate;Recruiting;Phase 2
502;Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1);Overall Response Rate (ORR);24 Months;Overall Response Rate (ORR) of subjects limited to three lines of prior treatment;Recruiting;Phase 2
502;Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1);Overall Response Rate (ORR);24 Months;Duration of Response (DoR);Recruiting;Phase 2
502;Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1);Overall Response Rate (ORR);24 Months;Very Good Partial Response (VGPR) Rate and Partial Response (PR) Rate;Recruiting;Phase 2
502;Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1);Overall Response Rate (ORR);24 Months;Time to Initial Response;Recruiting;Phase 2
502;Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1);Overall Response Rate (ORR);24 Months;Progression Free Survival (PFS);Recruiting;Phase 2
502;Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1);Overall Response Rate (ORR);24 Months;Overall Survival (OS);Recruiting;Phase 2
502;Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1);Overall Response Rate (ORR);24 Months;Safety Profile of CART-ddBCMA;Recruiting;Phase 2
502;Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1);Overall Response Rate (ORR);24 Months;Define the Pharmacokinetics of CART-ddBCMA;Recruiting;Phase 2
502;Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1);Overall Response Rate (ORR);24 Months;Anti-CART-ddBCMA Antibodies;Recruiting;Phase 2
502;Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1);Overall Response Rate (ORR);24 Months;Health Related Quality of Life (HRQoL);Recruiting;Phase 2
503;Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma;Best Overall Response Rate (ORR) in the Response Evaluable Subset Population;Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.;Best Overall Response Rate (ORR) in the Response Evaluable Population;Completed;Phase 2
503;Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma;Best Overall Response Rate (ORR) in the Response Evaluable Subset Population;Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.;Clinical Benefit Rate (CBR);Completed;Phase 2
503;Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma;Best Overall Response Rate (ORR) in the Response Evaluable Subset Population;Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.;Duration of Response (DOR);Completed;Phase 2
503;Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma;Best Overall Response Rate (ORR) in the Response Evaluable Subset Population;Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.;Time to Progression (TTP);Completed;Phase 2
503;Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma;Best Overall Response Rate (ORR) in the Response Evaluable Subset Population;Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.;Progression-free Survival (PFS);Completed;Phase 2
503;Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma;Best Overall Response Rate (ORR) in the Response Evaluable Subset Population;Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.;Overall Survival (OS);Completed;Phase 2
504;FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM);number of hypermetabolic foci of myeloma detected by FCH PET versus by FDG PET during the initial extension assessment;before maintenance treatment,;Recruiting;Not Applicable
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Number of adverse events;Recruiting;Phase 2
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Number of responses;Recruiting;Phase 2
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Number of responses;Recruiting;Phase 2
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Number of the death;Recruiting;Phase 2
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Number of progression;Recruiting;Phase 2
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Percentage of time to progression;Recruiting;Phase 2
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Percentage of duration of response;Recruiting;Phase 2
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Percentage of duration of therapy;Recruiting;Phase 2
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Percentage of time to response;Recruiting;Phase 2
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Percentage of Overall Response Rate;Recruiting;Phase 2
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Percentage of value of biological prognostic factors;Recruiting;Phase 2
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Percentage of frailty scores;Recruiting;Phase 2
505;A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse.;Percentage of patients have very good partial response (VGPR) or better;approximate 18 months;Percentage of score of quality of life;Recruiting;Phase 2
506;Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma;Response Rate as Assessed by Number of Participants With Partial or Complete Response by Bladé Criteria.;Up to 5 months;Terminated;Early Phase 1
506;Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma;Toxicity as Measured by Number of Participants Who Discontinued Treatment Due to Adverse Events;Up to 5 months;Terminated;Early Phase 1
506;Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma;Optimal Dose of Interleukin-6;Up to 5 months;Terminated;Early Phase 1
506;Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma;Impact of Treatment on Growth of Myeloma Cells;Day 0, Day 14, Months 1, 2, 4, and 6 of combined therapy, and end of study,;Terminated;Early Phase 1
507;Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma;Percentage of Participants With Deterioration in Renal Function According to Reduction in Creatinine Clearance (CrCl) From Baseline to Week 44;Baseline, Week 44;Percentage of Participants With Skeletal-Related Events (SREs);Terminated;Phase 3
507;Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma;Percentage of Participants With Deterioration in Renal Function According to Reduction in CrCl From Baseline to Week 92;Baseline, Week 92;Time to First SRE;Terminated;Phase 3
508;Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment;To Determine Whether, in Comparison to TT II, the Median EFS Can be Increased From 4.8 Years to 6.2 Years, Which Represents an Increase in Median EFS of Approximately 30%;After enrollment of 204 subjects is completed;Overall Survival Will be Compared to a Historical Control (UARK 98-026, TT2)as a Secondary Outcome.;Completed;Phase 2
508;Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment;In Assessing Patient Safety, we Will Examine Treatment Toxicity Related Mortality and SAEs. Historical Study Results Indicate That a Mortality Rate of Greater Than 10% is Not Acceptable in This Population, Nor is an SAE Rate of Greater Than 15%.;Interim analyses for safety will be performed after 20, 100, 200, and 300 patients have been enrolled.;Overall Survival Will be Compared to a Historical Control (UARK 98-026, TT2)as a Secondary Outcome.;Completed;Phase 2
509;A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by CTCAE v4.0;Week 8;Response according to IMWG Criteria;Terminated;Phase 1
509;A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by CTCAE v4.0;Week 8;Percentage change of myeloma-related measures;Terminated;Phase 2
510;Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma;Phase 1: MTD/RP2D Determined by the Incidence of DLTs;From the start of study medication through 3 weeks after administration of the second dose of radium-223 dichloride, assessed up to 9 weeks;Phase 1: The Number of Subjects With Complete Response (CR) and Very Good Partial Response (VGPR);Terminated;Phase 1
510;Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma;Phase 1: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Drug-related TEAEs, and Treatment-emergent Serious AE;From the start of study drug (radium-223 dichloride) to 30 days after last dose of study treatment (radium-223 dichloride, BOR, or DEX, whichever is last), assessed up to approximately 2 years;Phase 1: The Number of Subjects With Complete Response (CR) and Very Good Partial Response (VGPR);Terminated;Phase 2
511;DARA RVD For High Risk SMM;Proportion of high risk smoldering multiple myeloma (SMM) patients who are MRD negative (MRD-);2 years;Objective Response Rate;Recruiting;Phase 2
511;DARA RVD For High Risk SMM;Proportion of high risk smoldering multiple myeloma (SMM) patients who are MRD negative (MRD-);2 years;Duration of Response;Recruiting;Phase 2
511;DARA RVD For High Risk SMM;Proportion of high risk smoldering multiple myeloma (SMM) patients who are MRD negative (MRD-);2 years;Progression-free survival;Recruiting;Phase 2
511;DARA RVD For High Risk SMM;Proportion of high risk smoldering multiple myeloma (SMM) patients who are MRD negative (MRD-);2 years;Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v4.0;Recruiting;Phase 2
512;Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma,,,;No longer available,
513;Xcellerated T CellsTM in Patients With Multiple Myeloma,,,;Completed;Phase 2
514;Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma;Dose limiting toxicity;On a weekly basis for the duration of the study;Qualitative and quantitative toxicities;Completed;Phase 1
514;Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma;Maximum tolerated dose;About every 2 months for the duration of the study;Pharmacokinetics;Completed;Phase 1
515;Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma;Patient Activation;24 months;Evaluate associations between Patient Activation and symptom burden;Not yet recruiting,
515;Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma;Patient Activation;24 months;Evaluate the feasibility and acceptability of participation in All4Cure's digital platform for survivors with multiple myeloma;Not yet recruiting,
516;A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma;Initial Observed Plasma Drug Concentration (Co);"72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14";Completed;Phase 4
516;A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma;Maximum Observed Plasma Concentration (Cmax);"72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14";Completed;Phase 4
516;A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma;Area Under Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Time Point;"72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14";Completed;Phase 4
516;A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma;Area Under Plasma Concentration-Time Curve From Time 0 to Infinity (AUC-Infinity);"72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14";Completed;Phase 4
516;A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma;Terminal Half-life (t1/2);"72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14";Completed;Phase 4
516;A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma;Terminal rate constant (lamda[z]);"72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14";Completed;Phase 4
516;A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma;Systemic clearance (CL);"72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14";Completed;Phase 4
516;A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma;Apparent Volume of Distribution (Vd);"72 hours pre-dose on Day 1 (Baseline); post-dose on Day 11, 12, 13 and 14,";Completed;Phase 4
517;A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma;Dose limited toxicity (DLT);From date of initial treatment to Day 28 post GPRC5D CAR-T infusion.;Concentration of CAR-T cells;Active, not recruiting;Early Phase 1
517;A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma;AE and SAE;From admission to the end of the follow-up, up to 2 years;Objective Response Rate, ORR;Active, not recruiting;Early Phase 1
518;Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma;Incidence of dose-limiting toxicity within first 3 courses of treatment,;Toxicity;Completed;Phase 2
518;Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma;Incidence of dose-limiting toxicity within first 3 courses of treatment,;Disease response after 2 courses, 6 courses, 12 courses, and 6 months of maintenance therapy;Completed;Phase 2
518;Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma;Incidence of dose-limiting toxicity within first 3 courses of treatment,;Time to progression;Completed;Phase 2
518;Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma;Incidence of dose-limiting toxicity within first 3 courses of treatment,;Overall survival;Completed;Phase 2
518;Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma;Incidence of dose-limiting toxicity within first 3 courses of treatment,;Duration of disease-free interval;Completed;Phase 2
518;Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma;Incidence of dose-limiting toxicity within first 3 courses of treatment,;Time to dose modification;Completed;Phase 2
518;Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma;Incidence of dose-limiting toxicity within first 3 courses of treatment,;Time to dose discontinuation;Completed;Phase 2
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Event-free survival at 1 year after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Event-free survival at 3 years after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Event-free survival at 5 years after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Change from baseline in total EORTC score at 1 year after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Change from baseline in total EORTC score at 3 years after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Change from baseline in total EORTC score at 5 years after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Time to first occurrence of remission after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Non-relapse mortality (NRM) at 1 year after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Non-relapse mortality (NRM) at 3 years after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Non-relapse mortality (NRM) at 5 years after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Cumulative incidence of acute GvHD after allogeneic stem cell transplantation at 1 year after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Cumulative incidence of acute GvHD after allogeneic stem cell transplantation at 3 years after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Cumulative incidence of acute GvHD after allogeneic stem cell transplantation at 5 years after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Cumulative incidence of chronic GvHD after allogeneic stem cell transplantation at 1 year after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Cumulative incidence of chronic GvHD after allogeneic stem cell transplantation at 3 years after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Cumulative incidence of chronic GvHD after allogeneic stem cell transplantation at 5 years after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Time to first occurrence of infection reported as cumulative incidence of infection with CTCAE grade 3 - 5 at 1 year after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Time to first occurrence of infection reported as cumulative incidence of infection with CTCAE grade 3 - 5 at 3 years after randomization;Recruiting;Phase 3
519;Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy;Overall survival at five years after randomization;at 5 years after randomization;Time to first occurrence of infection reported as cumulative incidence of infection with CTCAE grade 3 - 5 at 5 years after randomization;Recruiting;Phase 3
520;Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment;Duration of Treatment (up to 5 years);Overall Survival (OS);Completed;Phase 2
520;Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment;Duration of Treatment (up to 5 years);Progression-free Survival (PFS);Completed;Phase 2
520;Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Number of Participants Who Achieved a Confirmed Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR) During Treatment;Duration of Treatment (up to 5 years);Duration of Response (DOR);Completed;Phase 2
521;A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma;Part A (dose escalation): Incidence of adverse events;From CTX120 infusion up to 28 days post-infusion;Progression Free Survival;Active, not recruiting;Phase 1
521;A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma;Part B (cohort expansion): Objective response rate;From CTX120 infusion up to 60 months post-infusion;Overall Survival;Active, not recruiting;Phase 1
522;Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma;Maximum Tolerated Dose (MTD) of LDE225 Plus Bortezomib;every 3 weeks up to 48 weeks;Overall Response;Terminated;Phase 2
522;Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma;Time to Disease Progression;every 3 weeks up to 48 weeks, then every 3 months thereafter up to 3 years from initiation of study treatment.;Overall Response;Terminated;Phase 2
523;Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month;Physical function at 12 months estimated by EORTC QLQ-C30 questionnaire,;Skeletal related event (time to first SRE);Completed;Phase 3
523;Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month;Physical function at 12 months estimated by EORTC QLQ-C30 questionnaire,;Cost-utility analysis;Completed;Phase 3
523;Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month;Physical function at 12 months estimated by EORTC QLQ-C30 questionnaire,;Subgroup analysis (conventional chemotherapy vs. high dose chemotherapy with stem cell support);Completed;Phase 3
523;Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month;Physical function at 12 months estimated by EORTC QLQ-C30 questionnaire,;Response, recons duration, survival;Completed;Phase 3
523;Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month;Physical function at 12 months estimated by EORTC QLQ-C30 questionnaire,;Quality of Life estimated by fatigue and pain according to EORTC QLQ-C30;Completed;Phase 3
524;An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma;Safety Profile of Acalabrutinib With and Without Dexamethasone;From first dose of study drug up to Cycle 12 (48 weeks). Subjects who showed benefit from study drugs were allowed to continue until disease progression.;Pharmacokinetic (PK) Parameters Calculated for Acalabrutinib: AUC0-4, AUClast, AUCINF, Cmax, Tmax, λz, t1/2, CL/F, and Vz/F. PK Parameters Calculated for Dexamethasone: Tmax, Cmax, AUC0-4 and AUClast.;Completed;Phase 1
524;An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma;Safety Profile of Acalabrutinib With and Without Dexamethasone;From first dose of study drug up to Cycle 12 (48 weeks). Subjects who showed benefit from study drugs were allowed to continue until disease progression.;Bruton Tyrosine Kinase (BTK) Occupancy;Completed;Phase 1
524;An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma;Safety Profile of Acalabrutinib With and Without Dexamethasone;From first dose of study drug up to Cycle 12 (48 weeks). Subjects who showed benefit from study drugs were allowed to continue until disease progression.;Response Assessed According to Guidelines Proposed by the International Myeloma Workshop Consensus Panel and European Group for Blood and Marrow Transplant;Completed;Phase 1
525;Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib;Overall response rate (ORR);up to 30 months;Time to Progression (TTP);Unknown status;Phase 2
525;Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib;Clinical Benefit Rate (CBR);up to 30 months;Progression-Free Survival (PFS);Unknown status;Phase 2
525;Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib;Number of patients undergoing adverse events;up to 36 months;Time to Response (TTR);Unknown status;Phase 2
526;Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma;event-free survival;6 years;safety, tolerability and feasibility;Completed;Phase 3
526;Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma;event-free survival;6 years;Improvement of remission rate;Completed;Phase 3
526;Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma;event-free survival;6 years;evaluate quality of life;Completed;Phase 3
527;Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma.,,,;Withdrawn;Phase 4
528;Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma,,,;Completed;Phase 3
529;VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma;Time to progression,;Progression-free survival, overall response rate, overall survival, time to first response, duration of response, CR rate, and patient reported outcomes as assessed using the EORTC QLQ-C30, FACIT-F and EQ-5D instruments.;Completed;Phase 3
530;Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma;Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample;at the first Day of Cycle n°2 (each cycle is 28 days or 21 days);Evaluate the specificity of urine monoclonal component detection on spot urine sample;Recruiting,
530;Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma;Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample;at the first Day of Cycle n°2 (each cycle is 28 days or 21 days);Evaluate the sensitivity and specificity of urine monoclonal component detection on spot urine sample;Recruiting,
530;Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma;Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample;at the first Day of Cycle n°2 (each cycle is 28 days or 21 days);Compare the responses rate;Recruiting,
530;Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma;Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample;at the first Day of Cycle n°2 (each cycle is 28 days or 21 days);Compare the monoclonal component / creatininuria ratios;Recruiting,
530;Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma;Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample;at the first Day of Cycle n°2 (each cycle is 28 days or 21 days);Define the equivalent of 200 mg / 24H (current consensus threshold of measurable urinary disease);Recruiting,
530;Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma;Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample;at the first Day of Cycle n°2 (each cycle is 28 days or 21 days);Assess the association between the rate of serum light chains and concentration of monoclonal components;Recruiting,
530;Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma;Evaluate the detection sensitivity of the urine monoclonal component on spot urine sample;at the first Day of Cycle n°2 (each cycle is 28 days or 21 days);Evaluate the urine monoclonal component by the difference between proteinuria and albuminuria;Recruiting,
531;A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma;Dose-limiting toxicity (DLT);Baseline up to 28 days after BCMA targeted CAR T-cells infusion;Overall response rate (ORR);Recruiting;Early Phase 1
531;A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma;Incidence of treatment-emergent adverse events (TEAEs);Up to 2 years after BCMA targeted CAR T-cells infusion;Overall survival (OS);Recruiting;Early Phase 1
532;Rituximab in Treating Patients With Multiple Myeloma,,,;Completed;Phase 2
533;Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma;The recommended Phase II dose (RP2D) and schedule of GSK2110183, bortezomib and dexamethasone dosed in combination.;Estimation is that each subject may be assessed for up to 48 months.;Pharmacokinetics of GSK2110183, bortezomib and dexamethasone. Composite (or Profile) of Pharmacokinetics Time Frame: predose, 0, 5 min, 15 min, 1, 2, 3, 4, 6, 8, 10-12, 14-22, and 24 hrs post-dose.;Completed;Phase 1
533;Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma;The recommended Phase II dose (RP2D) and schedule of GSK2110183, bortezomib and dexamethasone dosed in combination.;Estimation is that each subject may be assessed for up to 48 months.;Clinical activity;Completed;Phase 1
533;Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma;The recommended Phase II dose (RP2D) and schedule of GSK2110183, bortezomib and dexamethasone dosed in combination.;Estimation is that each subject may be assessed for up to 48 months.;Relationships between GSK2110183, Pharmacokinetic (PK), Pharmacodynamic (PD) and clinical activity. Composite (or Profile) of Serial Pharmacokinetics Time Frame: predose, 5 min, 15 min, 1,2,3,4,6,8, 10-12, 14-22, and 24 hours post-dose.;Completed;Phase 1
533;Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma;The recommended Phase II dose (RP2D) and schedule of GSK2110183, bortezomib and dexamethasone dosed in combination.;Estimation is that each subject may be assessed for up to 48 months.;Exploratory Translational Research;Completed;Phase 1
534;A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment;Maximum tolerated dose (MTD), and recommended phase two dose (RPTD) of venetoclax and ABBV-838 combination therapy when administered with dexamethasone;Minimum first cycle of dosing (21 or 28 days, depending on arm);Maximum observed plasma concentration (Cmax) of venetoclax;Withdrawn;Phase 1
534;A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment;Number of participants with adverse events;Up to approximately 2 years following the first dose of the last subject enrolled;Time to Cmax (Tmax) of venetoclax;Withdrawn;Phase 1
535;A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma;Progression free survival (PFS);up to 10 years ( or 300 PFS events);Overall Response (OR);Not yet recruiting;Phase 3
535;A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma;Sustained MRD-negative CR;up to 24 months;Complete Response (CR) or better status;Not yet recruiting;Phase 3
536;A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM),,,;Completed;Phase 1
537;Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma;Progression-free Survival (PFS) as Assessed by IRC;From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 32 months);Overall Response Rate (ORR) as Assessed by IRC;Active, not recruiting;Phase 3
537;Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma;Progression-free Survival (PFS) as Assessed by IRC;From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 32 months);Percentage of Participants With Response Rates;Active, not recruiting;Phase 3
537;Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma;Progression-free Survival (PFS) as Assessed by IRC;From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 32 months);Overall Survival (OS);Active, not recruiting;Phase 3
537;Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma;Progression-free Survival (PFS) as Assessed by IRC;From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 32 months);Duration of Response (DOR) as Assessed by IRC;Active, not recruiting;Phase 3
537;Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma;Progression-free Survival (PFS) as Assessed by IRC;From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 32 months);Time-to-next-treatment (TTNT);Active, not recruiting;Phase 3
537;Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma;Progression-free Survival (PFS) as Assessed by IRC;From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 32 months);Time-to-response (TTR) as Assessed by IRC;Active, not recruiting;Phase 3
537;Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma;Progression-free Survival (PFS) as Assessed by IRC;From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 32 months);Number of Participants With Grade >= 2 Peripheral Neuropathy Events;Active, not recruiting;Phase 3
537;Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma;Progression-free Survival (PFS) as Assessed by IRC;From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 32 months);Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs;Active, not recruiting;Phase 3
537;Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma;Progression-free Survival (PFS) as Assessed by IRC;From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 32 months);Patient-reported Peripheral Neuropathy Measured by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-CIPN20 Instrument;Active, not recruiting;Phase 3
538;A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma;Dose-limiting toxicity (DLT);Baseline up to 28 days after BCMA targeted CAR T-cells infusion;Overall response rate (ORR);Not yet recruiting;Early Phase 1
538;A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma;Incidence of treatment-emergent adverse events (TEAEs);Up to 2 years after BCMA targeted CAR T-cells infusion;Overall survival (OS);Not yet recruiting;Early Phase 1
539;Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma;Number of participants with any adverse events (AEs) and serious adverse events (SAEs);From first study treatment administration up to 120 days after the last dose;Progression-free-survival (PFS);Recruiting;Phase 1
539;Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma;Number of participants with dose limiting toxicity (DLT);From first study treatment administration up to 120 days after the last dose;Duration of Response (DOR);Recruiting;Phase 2
540;Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma;Serious Adverse Events;Data was collected for each subject for the duration of the participation in the study, ranging between 75 to 475 days.;Completed;Phase 2
540;Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma;Duration Until Best Response (at Least MR or Minimal Response);Data was collected for each subject for the duration of the participation in the study, ranging between 75 to 475 days.,;Completed;Phase 2
541;Study of ZIO-101 in Multiple Myeloma;Phase I: toxicity defined in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 12/12/03;6 months;Pharmacokinetics of ZIO-101;Completed;Phase 1
541;Study of ZIO-101 in Multiple Myeloma;Phase II efficacy using EMBT criteria.;6 months;Pharmacokinetics of ZIO-101;Completed;Phase 2
542;Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma;Estimate an overall response rate to combination therapy with VELCADE, Doxil, and Dexamethasone, defined as at least partial response (PR), i.e. > 50% reduction in serum monoclonal protein and/or >90% reduction in Bence-Jones protein by EBMT criteria.;6 months;Estimate a rate of complete response (CR), very good partial response (VGPR, >90% reduction in serum monoclonal protein), minimal response (MR, >25% and <50% reduction in monoclonal);Completed;Not Applicable
542;Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma;Estimate an overall response rate to combination therapy with VELCADE, Doxil, and Dexamethasone, defined as at least partial response (PR), i.e. > 50% reduction in serum monoclonal protein and/or >90% reduction in Bence-Jones protein by EBMT criteria.;6 months;Estimate the duration of response, progression-free survival, overall survival;Completed;Not Applicable
543;Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib;Best response;Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.;Time to Response;Terminated;Phase 2
543;Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib;Best response;Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.;Duration of Response;Terminated;Phase 2
543;Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib;Best response;Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.;Time to Progression;Terminated;Phase 2
543;Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib;Best response;Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.;Global Survival;Terminated;Phase 2
543;Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib;Best response;Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.;Progression Free Survival;Terminated;Phase 2
543;Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib;Best response;Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.;Tolerability of the study medication;Terminated;Phase 2
543;Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib;Best response;Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.;Angiogenesis markers of metronomic chemotherapy activity;Terminated;Phase 2
543;Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib;Best response;Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.;Angiogenesis markers of metronomic chemotherapy activity 2;Terminated;Phase 2
543;Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib;Best response;Every 28 days (each cycle is 28 days) from randomization until progression or withdrawal of the subject, whichever came first, assessed up to 60 months.;Immune system evaluation of metronomic chemotherapy activity;Terminated;Phase 2
544;ASCT With Nivolumab in Patients With Multiple Myeloma;Overall response;3 months;Progression free survival (PFS);Recruiting;Phase 1
544;ASCT With Nivolumab in Patients With Multiple Myeloma;Overall response;3 months;Overall Survival (OS);Recruiting;Phase 2
545;Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM);Overall Response Rate (ORR) - Percentage of Participants With Partial Response or Better With Induction Regimen;24 Months;Median Progression Free Survival (PFS) in Months;Completed;Phase 2
545;Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM);Percentage of Participants With Very Good Partial Remission (VGPR) or Better;24 Months;2 Year Overall Survival (OS) Rate;Completed;Phase 2
546;Arsenic Trioxide in Treating Patients With Multiple Myeloma,,,;Terminated;Phase 2
547;Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab;Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response;Up to 6 years and 9 months;Overall Response Rate (ORR);Terminated;Phase 2
547;Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab;Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response;Up to 6 years and 9 months;Percentage of Participants Achieving Complete Response (CR) or Stringent Complete Response (sCR);Terminated;Phase 2
547;Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab;Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response;Up to 6 years and 9 months;Progression Free Survival (PFS);Terminated;Phase 2
547;Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab;Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response;Up to 6 years and 9 months;Overall Survival (OS);Terminated;Phase 2
547;Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab;Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response;Up to 6 years and 9 months;Percentage of Participants With Negative Minimal Residual Disease (MRD);Terminated;Phase 2
547;Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab;Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response;Up to 6 years and 9 months;Time to Next Treatment;Terminated;Phase 2
547;Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab;Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response;Up to 6 years and 9 months;Serum Concentrations of Daratumumab;Terminated;Phase 2
547;Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab;Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response;Up to 6 years and 9 months;Number of Participants with Anti-Daratumumab Antibodies;Terminated;Phase 2
547;Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab;Percentage of Participants Achieving Very Good Partial Response (VGPR) or Better Response;Up to 6 years and 9 months;Number of Participants with Anti-recombinant Human Hyaluronidase (rHuPH20) Antibodies;Terminated;Phase 2
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Percentage of Participants With Complete Response (CR) or Better;Active, not recruiting;Phase 3
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Percentage of Participants With Very Good Partial Response (VGPR) or Better;Active, not recruiting;Phase 3
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Percentage of Participants With Negative Minimal Residual Disease (MRD);Active, not recruiting;Phase 3
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Overall Response Rate (ORR);Active, not recruiting;Phase 3
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Overall Survival (OS);Active, not recruiting;Phase 3
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Time to Disease Progression (TTP);Active, not recruiting;Phase 3
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Time to Response;Active, not recruiting;Phase 3
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Duration of Response (DoR);Active, not recruiting;Phase 3
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Time to Subsequent Anti-myeloma Treatment;Active, not recruiting;Phase 3
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Progression-free Survival on Next Line of Therapy (PFS2);Active, not recruiting;Phase 3
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 Global Health Status Score to Day 1 of Cycle 3, 6, 9 and 12;Active, not recruiting;Phase 3
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) to Day 1 of Cycle 3, 6, 9 and 12;Active, not recruiting;Phase 3
548;Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma;Primary: Progression-free Survival (PFS);From randomization to disease progression, death, subsequent anti-myeloma therapy, withdrawal of consent to study participation or clinical cut-off (CCO) whichever occurs first (up to 3.5 years);Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Utility Score to Day 1 of Cycle 3, 6, 9 and 12;Active, not recruiting;Phase 3
549;Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide;Overall Response;From the date of first drug administration to the date of at least one disease assessment, up to 100 weeks;Clinical Benefit Rate;Terminated;Phase 2
549;Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide;Overall Response Rate;From the date of first drug administration to the date of at least one disease assessment, up to 100 weeks;Disease Control Rate;Terminated;Phase 2
550;Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma;Objective Response Rate (ORR);26 months,;Completed;Phase 2
551;Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma,,,;Approved for marketing,
552;S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma;Progression-free survival at 3 years;3 years;Overall survival;Withdrawn;Phase 2
552;S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma;Progression-free survival at 3 years;3 years;Frequency and severity of toxicities;Withdrawn;Phase 2
552;S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma;Progression-free survival at 3 years;3 years;Gene expression profiling analysis of CD138+ purified plasma cells;Withdrawn;Phase 2
553;A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma;Participants With Dose-Limiting Toxicities (DLTs) During the Dose-Determining Timeframe (Day 1 - Day 28);First treatment cycle: Day 1 to Day 28;Participants With Treatment Emergent Adverse Events (TEAE);Completed;Phase 1
553;A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma;Participants With Dose-Limiting Toxicities (DLTs) During the Dose-Determining Timeframe (Day 1 - Day 28);First treatment cycle: Day 1 to Day 28;Overall Response Rate (ORR) for Cohorts A and B: Percentage of Participants Who Achieved a Partial Response or Better According to the International Myeloma Working Group (IMWG) Uniform Response Criteria;Completed;Phase 2
554;A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma;Number of patients with adverse events as a measure of safety and tolerability;Up to 21 days;Number of subjects who achieved a complete response or partial response;Completed;Phase 1
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Sustained Minimal Residual Disease (MRD) Negative CR;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;MRD Negative CR at 9 Months;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Overall MRD Negative CR;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Overall Survival (OS);Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Complete Response or Better;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Time to Subsequent Anti-myeloma Therapy;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Progression Free Survival on Next-line Therapy (PFS2);Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Number of Participants with Adverse Events (AEs), Abnormalities in Laboratory Parameters, 12-Lead Electrocardiogram (ECG), Physical Examination, and Vital Signs;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Arm B: Systemic Cytokine Concentrations;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Arm B: Levels of Chimeric Antigen Receptor T cell (CAR-T) Cell Activation Markers;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Arm B: Levels of Soluble B-cell Maturation Antigen (BCMA);Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Arm B: Levels of Cilta-cel Expansion (proliferation), and Persistence;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Arm B: Number of Participants with Anti-cilta-cel Antibodies;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Arm B: Number of Participants with Presence of Replication Competent Lentivirus;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Change from Baseline in Health-Related Quality of Life as Assessed by MySIm-Q Scale Score;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Change from Baseline in Health-Related Quality of Life as Assessed by European Quality of Life - 5 Dimensions-5 Levels (EQ-5D-5L) Scale Score;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Change from Baseline in Health-Related Quality of Life as Assessed by Patient Global Impression of Symptom Severity (PGIS) Scale Score;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Items;Recruiting;Phase 3
555;A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy;Progression Free Survival (PFS);Up to 4 years and 5 months;Time to Worsening of Symptoms, Functioning and Overall Well-being;Recruiting;Phase 3
556;An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.;Maximum Tolerated Dose (MTD) of PD-0332991: Phase 1;Day 1 up to Day 28 during Cycle 1 in schedule A, Day 1 up to Day 21 during Cycle 1 in schedule B;Percent Change From Screening in Phosphorylated Retinoblastoma (Rb), Tumor Biomarkers and Soluble Biomarkers Levels: Phase 1;Completed;Phase 2
556;An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.;Recommended Phase II Dose (RP2D) of PD-0332991: Phase 1;Day 1 up to Day 28 during Cycle 1 in schedule A, Day 1 up to Day 21 during Cycle 1 in schedule B;Best Overall Response: Phase 1;Completed;Phase 2
556;An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.;Percentage of Participants With Objective Response (OR): Phase 2;Cycle 1 Day 1 (baseline) up to end of study (up to cycle 22 for schedule B);Time to Tumor Progression (TTP): Phase 2;Completed;Phase 2
557;First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM);Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period;Up to 35 Days;Concentrations of REGN5459 in the serum over time;Active, not recruiting;Phase 1
557;First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM);Incidence and severity of treatment-emergent adverse events (TEAEs) during REGN5459 treatment period;Up to 12 Weeks After the Last Dose;Incidence over time of anti-drug antibodies (ADAs) to REGN5459;Active, not recruiting;Phase 2
558;T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma;Incidence of Treatment-related Adverse Events;within 2 years after infusion;Overall response rate(ORR) and complete response rate(CRR) of administering T cells Expressing a bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma;Recruiting;Phase 1
558;T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma;Incidence of Treatment-related Adverse Events;within 2 years after infusion;Overall survival(OS), duration of Response(DOR), progress-free survival(PFS) of administering T cells Expressing a bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma;Recruiting;Phase 1
559;MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Part 1 Safety Lead-In: Incidence of dose limiting toxicities;First 42 days after first elranatamab dose;Part 1 Safety Lead-In: Progression free survival per International Myeloma Working Group criteria;Recruiting;Phase 3
559;MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria;From date of randomization to date of progressive disease, discontinuation from the study, death, or censoring, whichever occurs first, assessed up to 32 months;Overall survival;Recruiting;Phase 3
560;MMRF CureCloud Research Initiative;Collection and Analyses of Clinical Information and Peripheral Blood Samples;5 years,;Active, not recruiting,
561;Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma;2-year progression-free survival(2y-PFS);up to 24 months.;2-year overall survival(2y-OS);Recruiting;Not Applicable
561;Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma;2-year progression-free survival(2y-PFS);up to 24 months.;Complete remission(CR);Recruiting;Not Applicable
561;Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma;2-year progression-free survival(2y-PFS);up to 24 months.;very good partial remission(VGPR);Recruiting;Not Applicable
561;Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma;2-year progression-free survival(2y-PFS);up to 24 months.;negative rate of minimal residual disease;Recruiting;Not Applicable
561;Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma;2-year progression-free survival(2y-PFS);up to 24 months.;adverse events;Recruiting;Not Applicable
562;Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care;Changes in bone turnover markers;Baseline, then every 2 months in 12 months;time to maximum variation of bone turnover markers;Recruiting,
562;Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care;Changes in bone turnover markers;Baseline, then every 2 months in 12 months;Doses of intravenous bisphosphonate;Recruiting,
562;Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care;Changes in bone turnover markers;Baseline, then every 2 months in 12 months;Rate of intravenous bisphosphonate;Recruiting,
562;Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care;Changes in bone turnover markers;Baseline, then every 2 months in 12 months;evolution of bone lesions by imaging;Recruiting,
562;Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care;Changes in bone turnover markers;Baseline, then every 2 months in 12 months;Number of new bone events;Recruiting,
562;Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care;Changes in bone turnover markers;Baseline, then every 2 months in 12 months;Number of adverse events likely to be related to bisphosphonate;Recruiting,
562;Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care;Changes in bone turnover markers;Baseline, then every 2 months in 12 months;Changes in Monoclonal protein;Recruiting,
563;CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma;Adverse events;approximately 18 months after study start;Recommended Phase 2 dose;Active, not recruiting;Phase 1
563;CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma;Adverse events;approximately 18 months after study start;Optimal pre- and post-medication regimens;Active, not recruiting;Phase 1
563;CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma;Adverse events;approximately 18 months after study start;Target engagement assays and ex vivo testing;Active, not recruiting;Phase 1
563;CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma;Adverse events;approximately 18 months after study start;PK - AUC of CID-103;Active, not recruiting;Phase 1
563;CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma;Adverse events;approximately 18 months after study start;PK - Cmax of CID-103;Active, not recruiting;Phase 1
563;CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma;Adverse events;approximately 18 months after study start;PK - t1/2 of CID-103;Active, not recruiting;Phase 1
563;CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma;Adverse events;approximately 18 months after study start;PK - Vd of CID-103;Active, not recruiting;Phase 1
563;CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma;Adverse events;approximately 18 months after study start;PK - accumulation of CID-103;Active, not recruiting;Phase 1
563;CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma;Adverse events;approximately 18 months after study start;Objective response rate;Active, not recruiting;Phase 1
563;CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma;Adverse events;approximately 18 months after study start;Duration of response;Active, not recruiting;Phase 1
563;CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma;Adverse events;approximately 18 months after study start;Progression-free survival;Active, not recruiting;Phase 1
563;CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma;Adverse events;approximately 18 months after study start;Overall survival;Active, not recruiting;Phase 1
564;Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma;Maximum tolerated dose (MTD) of carfilzomib when administered in combination with pomalidomide and dexamethasone;28 days;Overall response rate;Recruiting;Phase 1
564;Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma;Partial response rate after 4 courses according to International Myeloma Working Group (IMWG) criteria;4 months;Time to progression;Recruiting;Phase 2
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Overall Survival (OS);Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Complete Response (CR) Rate;Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Pain Response Rate as Assessed by the Brief Pain Inventory- Short Form (BPI-SF) and Analgesic Use;Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Overall Response Rate (ORR);Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Time to Response;Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Duration of Response;Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Time to Progression (TTP);Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Progression Free Survival (PFS)-2;Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Score;Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Percentage of Participants With Abnormal Laboratory Values;Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Change From Baseline in Health-Related Quality of Life (HRQOL) Measured by European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC-QLQ)-C30 Scale Total Score;Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Change From Baseline in HRQOL Measured by EORTC-QLQ)-MY20 Scale;Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);"OS in High-risk Population Carrying Del(17p), Amp(1q21), t(4;14), or t(14;16) Mutations";Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);"PFS in High-risk Population Carrying Del(17p), Amp(1q21), t(4;14), or t(14;16) Mutations";Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Percentage of Participants With MRD-Negative Status as Assessed by Flow Cytometry;Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Time to Pain Progression;Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Cmax: Maximum Plasma Concentration for IXAZOMIB and Its Metabolite MLN2238;Completed;Phase 3
565;IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma;Progression Free Survival (PFS);Up to data cut off: 2 December 2019 (Up to approximately 79 months);Percentage of Participants With New or Worsening of Existing Skeletal-related Events (SREs);Completed;Phase 3
566;Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant;Safety and tolerability of rhMBL;2 months;Pharmacokinetic (PK) of rhMBL;Completed;Phase 1
566;Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant;Safety and tolerability of rhMBL;2 months;Pharmacodynamics (PD) of rhMBL;Completed;Phase 1
566;Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant;Safety and tolerability of rhMBL;2 months;Immunogenicity of rhMBL, incidence of infectious complications;Completed;Phase 1
567;A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy;Dose-limiting toxicity (DLT);Baseline up to 28 days after CS1 targeted CAR T-cells infusion;Overall response rate (ORR);Not yet recruiting;Early Phase 1
567;A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy;Incidence of treatment-emergent adverse events (TEAEs);Up to 2 years after CS1 targeted CAR T-cells infusion;Overall survival (OS);Not yet recruiting;Early Phase 1
568;Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma;Overall Response Rate (Complete and Partial);Every 3 months;Complete Response Rate;Completed;Phase 2
568;Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma;Overall Response Rate (Complete and Partial);Every 3 months;Time to Disease Progression;Completed;Phase 2
569;Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma,,,;Approved for marketing,
570;Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates;Number of Participants With Urinary NTX Levels Less Than or Equal to 50nmol/mmol Cr;6 months,;Completed;Phase 2
571;Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients;Maximum Tolerated Dose (MTD);Cycles 1-3 for selected regimens (up to 3 months);Time to Progression;Unknown status;Phase 2
571;Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients;Number of subjects with adverse events;up to 36 months;Progression-free survival (PFS);Unknown status;Phase 2
571;Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients;Overall Response Rate;up to 36 months;Time to first response (TTP);Unknown status;Phase 2
571;Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients;Clinical Benefit Rate (CBR);up to 36 months;Duration of response (DOR);Unknown status;Phase 2
572;XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease;Safety of Cabozantinib;2 years;Changes in Biochemical Markers;Completed;Phase 1
572;XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease;Safety of Cabozantinib;2 years;Effect of Cabozantinib on Bone Disease;Completed;Phase 1
572;XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease;Safety of Cabozantinib;2 years;Objective Response per IMWG;Completed;Phase 1
572;XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease;Safety of Cabozantinib;2 years;Pain Assessment;Completed;Phase 1
573;Study of bb21217 in Multiple Myeloma;Incidence of adverse events (AEs), DLTs, and changes in laboratory results;Day 1 through Month 60;Disease-specific response criteria;Active, not recruiting;Phase 1
574;Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma;Overall survival;1 year;Completed,
574;Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma;Event-free survival;1 year,;Completed,
575;APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma;Dose Limiting Toxicity;28 days,;Recruiting;Phase 1
575;APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma;Dose Limiting Toxicity;28 days,;Recruiting;Phase 2
576;Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple Myeloma;Time registrations of side effects using an app;18 months;Qualitative perspectives interview;Completed,
576;Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple Myeloma;patient registration of side effects using an app;18 months;Qualitative perspectives interview;Completed,
577;Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I;Days of Progression Free Survival;48 months;Number of Patients With Progression by Individual Criteria;Terminated;Phase 3
577;Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I;Days of Progression Free Survival;48 months;The Number of Participants With the Development of Skeletal Complications;Terminated;Phase 3
578;A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Determination of peak concentration (Cmax) of ABT-199;Approximately 5 days in Cycle 1 then on Day 1 of Cycles 2,4,6,8;Duration of Response;Completed;Phase 1
578;A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Determine maximum tolerated dose (MTD), and recommended phase two dose (RPTD) of ABT-199;Minimum first cycle of dosing (21 days);Objective Response Rate;Completed;Phase 1
578;A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy;Number of participants with adverse events;"From subject's first dose of ABT-199 until 30 days after subject's last dose of ABT-199; up to 2 years following last subject first dose.";Time to Disease Progression;Completed;Phase 1
579;High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma;Number of patients with engraftment after induction chemotherapy,;Number and proportion of patients from whom ≥ 2 x 10e6 CD34-positive cells/kg are harvested;Unknown status;Phase 2
579;High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma;Number of patients with engraftment after induction chemotherapy,;Number and proportion of patients from whom ≥ 4 x 10e6 CD34-positive cells/kg are harvested;Unknown status;Phase 2
579;High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma;Number of patients with engraftment after induction chemotherapy,;CD34-positive cells/kg yield in each leukapheresis;Unknown status;Phase 2
579;High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma;Number of patients with engraftment after induction chemotherapy,;Number of leukaphereses to collect ≥ 2 x 10e6 CD34-positive cells/kg;Unknown status;Phase 2
579;High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma;Number of patients with engraftment after induction chemotherapy,;Number of leukaphereses to collect ≥ 4 x 10e6 CD34-positive cells/kg;Unknown status;Phase 2
579;High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma;Number of patients with engraftment after induction chemotherapy,;Proportion of patients with platelet recovery ≥ 20 x 10e9/L in the absence of transfusion for at least 7 days;Unknown status;Phase 2
579;High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma;Number of patients with engraftment after induction chemotherapy,;Proportion of patients with ANC recovery of ≥ 0.5 x 10e9/L;Unknown status;Phase 2
579;High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma;Number of patients with engraftment after induction chemotherapy,;Time to neutrophil recovery, defined as the time to neutrophil engraftment (i.e., ANC ≥ 0.5 x 10e9/L for 3 consecutive days);Unknown status;Phase 2
579;High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma;Number of patients with engraftment after induction chemotherapy,;Time to ANC ≥ 1.0 x 10e9/L;Unknown status;Phase 2
579;High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma;Number of patients with engraftment after induction chemotherapy,;Time to platelet recovery, defined as the time to platelets ≥ 20 x 10e9/L in the absence of platelet transfusion support for at least 7 days;Unknown status;Phase 2
579;High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma;Number of patients with engraftment after induction chemotherapy,;Incidence and duration of hospitalization during mobilization phase and during post-transplantation phase;Unknown status;Phase 2
579;High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma;Number of patients with engraftment after induction chemotherapy,;Incidence and severity of adverse events during and after the use of pegfilgrastim 12 mg or pegfilgrastim 18 mg and filgrastim;Unknown status;Phase 2
580;A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab;Best response rate within 8 cycles of induction therapy;Approximately 3 years;Median estimate of months that participants have progression free survival;Recruiting;Phase 2
580;A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab;Best response rate within 8 cycles of induction therapy;Approximately 3 years;Median number of months of participant's overall survival;Recruiting;Phase 2
580;A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab;Best response rate within 8 cycles of induction therapy;Approximately 3 years;Time to Complete Hematologic Response;Recruiting;Phase 2
580;A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab;Best response rate within 8 cycles of induction therapy;Approximately 3 years;Time to Hematologic progression;Recruiting;Phase 2
580;A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab;Best response rate within 8 cycles of induction therapy;Approximately 3 years;Duration of hematologic response;Recruiting;Phase 2
580;A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab;Best response rate within 8 cycles of induction therapy;Approximately 3 years;Time until next treatment therapy;Recruiting;Phase 2
580;A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab;Best response rate within 8 cycles of induction therapy;Approximately 3 years;Time to complete response (CR);Recruiting;Phase 2
580;A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab;Best response rate within 8 cycles of induction therapy;Approximately 3 years;Duration of Very Good Partial Response (VGPR);Recruiting;Phase 2
580;A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab;Best response rate within 8 cycles of induction therapy;Approximately 3 years;Rate of minimal residual disease (MRD) negativity after 8 months;Recruiting;Phase 2
580;A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab;Best response rate within 8 cycles of induction therapy;Approximately 3 years;Rate of minimal residual disease (MRD) negativity after 32 months;Recruiting;Phase 2
580;A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab;Best response rate within 8 cycles of induction therapy;Approximately 3 years;Rate of improvement in response during maintenance therapy;Recruiting;Phase 2
581;Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma,,,;Terminated;Phase 2
582;Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma;Maximum Tolerated Dose (MTD);12 months;Duration of Response;Completed;Phase 1
582;Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma;MTD;12 months;Time to Progression;Completed;Phase 2
583;A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma;2 Year Progression Free Rate;2 Year;Objective Response Rate;Suspended;Phase 2
583;A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma;2 Year Progression Free Rate;2 Year;Time to Progression Rate;Suspended;Phase 2
583;A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma;2 Year Progression Free Rate;2 Year;Duration of Response Rate;Suspended;Phase 2
583;A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma;2 Year Progression Free Rate;2 Year;Progression Free Survival (PFS) Rate;Suspended;Phase 2
583;A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma;2 Year Progression Free Rate;2 Year;Overall Survival Rate;Suspended;Phase 2
583;A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma;2 Year Progression Free Rate;2 Year;Progression Free Survival Rate-Without cyclophosphamide;Suspended;Phase 2
583;A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma;2 Year Progression Free Rate;2 Year;Number of Participants with Adverse Events;Suspended;Phase 2
584;Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients;Dose limiting toxicities following Combination Product dministration;100 days post Combination Product administration;Rate of MRD conversion from positive to negative;Recruiting;Phase 1
584;Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients;Incidence and severity of side effects related to the Combination Product;100 days post Combination Product administration;Rate of MRD conversion from positive to negative;Recruiting;Phase 1
585;Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma;Overall Response Rate;Up to 8 months;Progression Free Survival;Active, not recruiting;Phase 2
585;Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma;Overall Response Rate;Up to 8 months;Overall Survival;Active, not recruiting;Phase 2
586;An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma,,,;No longer available,
587;Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma;Maximal tolerated dose (MTD) and/or recommended part 2 dose (RP2D) of ISB 1342 (Part 1);28 days;Number of subjects with adverse events based on frequency and severity as assessed by common terminology criteria for adverse events (CTCAE) v5.0 (Part 1 and Part 2);Recruiting;Phase 1
587;Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma;Proportion of subjects with an investigator-assessed objective response (at least a partial response or better), complete response, disease control (stable disease or better) to ISB 1342, per International Myeloma Working Group (IMWG) criteria (Part 2);28 days;Maximum serum concentration (Cmax) of ISB 1342 (Part 1 and Part 2);Recruiting;Phase 1
588;Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation;Cmax (Pharmacokinetics);Day -2;Transplant-Related Mortality (TRM) Following Autologous Stem-Cell Transplantation (ASCT);Completed;Phase 2
588;Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation;AUC0-t (Pharmacokinetics);Day -2;Transplant-Related Mortality (TRM) Following Autologous Stem-Cell Transplantation (ASCT);Completed;Phase 2
589;Phase 1/2 Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma;Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period;Up to 28 days;Concentrations of REGN5458 in the serum over time;Active, not recruiting;Phase 1
589;Phase 1/2 Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma;Incidence and severity of treatment-emergent adverse events (TEAEs);Up to 5 years;Incidence over time of anti-drug antibodies (ADAs) to REGN5458;Active, not recruiting;Phase 2
590;Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT);Average duration of absolute neutropenia;1 year;Incidence of toxicities;Recruiting;Phase 2
591;Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma;Efficacy of a sequential scheme treatment with Bortezomib, Melfalan,Prednisone (V-MP) or Bortezomib, Adriamycine, Melfalan,Prednisone (VAMP) followed by Thalidomide, Cyclophosphamide and Dexamethasone (TaCyDex) in relapsed or refractory MM patients;1 year;Evaluate the response type in function to different initial situation (primary resistance, relapse, progression);Completed;Phase 4
591;Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma;Efficacy of a sequential scheme treatment with Bortezomib, Melfalan,Prednisone (V-MP) or Bortezomib, Adriamycine, Melfalan,Prednisone (VAMP) followed by Thalidomide, Cyclophosphamide and Dexamethasone (TaCyDex) in relapsed or refractory MM patients;1 year;To analyze the response duration;Completed;Phase 4
592;Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma;Proportion of participants with dose limiting toxicities as a measure of maximum tolerated dose of CAR138 T cells;4 weeks from infusion of the CAR138 T cells;Survival of CAR138 T cells in vivo as assessed by PCR and flow cytometry;Recruiting;Phase 1
592;Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma;Proportion of participants with dose limiting toxicities as a measure of maximum tolerated dose of CAR138 T cells;4 weeks from infusion of the CAR138 T cells;Overall survival after infusion of CAR138 T cells;Recruiting;Phase 1
592;Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma;Proportion of participants with dose limiting toxicities as a measure of maximum tolerated dose of CAR138 T cells;4 weeks from infusion of the CAR138 T cells;Progression free survival after infusion of CAR138 T cells;Recruiting;Phase 1
592;Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma;Proportion of participants with dose limiting toxicities as a measure of maximum tolerated dose of CAR138 T cells;4 weeks from infusion of the CAR138 T cells;Overall response rate (ORR) as defined as the percentage of subjects achieving a confirmed partial response or better based on the International Myeloma Working Group (IMWG) response criteria.;Recruiting;Phase 1
593;Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma;To determine the maximum tolerated dose (MTD) or maximum tested dose level of Vactosertib given in combination with POM for the treatment of relapsed or RRMM;Up to 30 days after treatment ends (24 weeks + 30 days);Overall response rate;Active, not recruiting;Phase 1
593;Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma;To determine the maximum tolerated dose (MTD) or maximum tested dose level of Vactosertib given in combination with POM for the treatment of relapsed or RRMM;Up to 30 days after treatment ends (24 weeks + 30 days);Progression-free survival (PFS);Active, not recruiting;Phase 1
593;Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma;To determine the maximum tolerated dose (MTD) or maximum tested dose level of Vactosertib given in combination with POM for the treatment of relapsed or RRMM;Up to 30 days after treatment ends (24 weeks + 30 days);Progression-free survival at 6 months (PFS-6);Active, not recruiting;Phase 1
593;Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma;To determine the maximum tolerated dose (MTD) or maximum tested dose level of Vactosertib given in combination with POM for the treatment of relapsed or RRMM;Up to 30 days after treatment ends (24 weeks + 30 days);Duration of Response;Active, not recruiting;Phase 1
593;Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma;To determine the maximum tolerated dose (MTD) or maximum tested dose level of Vactosertib given in combination with POM for the treatment of relapsed or RRMM;Up to 30 days after treatment ends (24 weeks + 30 days);clinical benefit rate;Active, not recruiting;Phase 1
593;Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma;To determine the maximum tolerated dose (MTD) or maximum tested dose level of Vactosertib given in combination with POM for the treatment of relapsed or RRMM;Up to 30 days after treatment ends (24 weeks + 30 days);Overall Survival;Active, not recruiting;Phase 1
594;64Cu-LLP2A for Imaging Multiple Myeloma;Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by average organ activity concentration of 64Cu-LLP2A;Up to 30 hours after imaging;Comparison of tumor burden (SUVmax) of 64Cu-LLP2A to clinical stage;Recruiting;Early Phase 1
594;64Cu-LLP2A for Imaging Multiple Myeloma;Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by the number of participants who experience an adverse event related to 64Cu-LLP2A;Through 48 hours after last administration of 64Cu-LLP2A (estimated to be at most 4 days);Comparison of tumor burden (SUVmax) of 64Cu-LLP2A to clinical tumor measurement of tumor burden as measured by M-protein of myeloma;Recruiting;Early Phase 1
594;64Cu-LLP2A for Imaging Multiple Myeloma;Feasibility of imaging MM patients with 64Cu-LLP2A-PET/MR as measured by the optimal image time after injection of 64Cu-LLP2A;Up to 30 hours after imaging;Comparision of tumor burden (SUVmax) of 64Cu-LLP2A to clinical measurement of tumor burden as measured by the plasma cell fraction within the bone marrow;Recruiting;Early Phase 1
595;Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma;Percentage of Participants With Response, Analyzed Per International Myeloma Working Group Response Criteria;Efficacy assessments will be made after the first two cycles of therapy (approximately 56 days--each cycle is 28 days);To Compare the Effect of Continuous Versus Intermittent Regimens on F Actin Polymerization in Peripheral Blood Mononuclear Cells and Activation of Tumor Antigen-specific T Cells, as Well as Innate Lymphocytes (Natural Killer or Natural Killer T Cells).;Completed;Phase 2
595;Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma;Percentage of Participants With Response, Analyzed Per International Myeloma Working Group Response Criteria;After the initial efficacy assessment at the completion of cycle 2 (at approximately 56 days), efficacy assessments will be made after every other cycle (approximately every 56 days).;To Correlate Drug Induced Changes in F Actin Polymerization With Adverse Effects and Clinical Responses.;Completed;Phase 2
596;Myeloma Registry Platform (MYRIAM);Course of treatment (treatment reality);5 years per patient;Best Response;Recruiting,
596;Myeloma Registry Platform (MYRIAM);Course of treatment (treatment reality);5 years per patient;Progression-free survival;Recruiting,
596;Myeloma Registry Platform (MYRIAM);Course of treatment (treatment reality);5 years per patient;Overall survival;Recruiting,
596;Myeloma Registry Platform (MYRIAM);Course of treatment (treatment reality);5 years per patient;Health-related quality of life (Patient-reported outcome);Recruiting,
596;Myeloma Registry Platform (MYRIAM);Course of treatment (treatment reality);5 years per patient;Myeloma-specific health-related quality of life (Patient-reported outcome);Recruiting,
596;Myeloma Registry Platform (MYRIAM);Course of treatment (treatment reality);5 years per patient;Quality of life (Patient-reported outcome);Recruiting,
597;MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma;Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests;2 days;Other Measures of Hematopoietic Stem Cell (HSC) Yield in the Apheresis Product;Completed;Phase 2
597;MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma;Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests;2 days;Time To Neutrophil Engraftment;Completed;Phase 2
597;MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma;Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests;2 days;Maintenance of Neutrophil Engraftment [Absolute Neutrophil Count (ANC) ≥ 0.5 x 10e9/L];Completed;Phase 2
597;MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma;Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests;2 days;Time To Platelet Engraftment ≥ 20 x 10e9/L;Completed;Phase 2
597;MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma;Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests;2 days;Time To Platelet Engraftment ≥ 50 x 10e9/L;Completed;Phase 2
597;MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma;Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests;2 days;Infusion-related Toxicities;Completed;Phase 2
597;MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma;Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests;2 days;Progression-free Survival (PFS);Completed;Phase 2
597;MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma;Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests;2 days;Transplant-related Mortality;Completed;Phase 2
597;MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma;Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests;2 days;Non-relapse-related Mortality;Completed;Phase 2
597;MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma;Number of Participants For Whom 2.0 x 10e6 CD34+ HSC Cells/kg Could be Collected in 1 or 2 Apheresis Harvests;2 days;Overall Survival (OS);Completed;Phase 2
598;Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma;Paraprotein level;18 months,;Withdrawn;Phase 2
599;A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b;Response Rate;6 months;Survival (overall and progression free);Unknown status;Phase 2
599;A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b;Response Rate;6 months;toxicities;Unknown status;Phase 2
600;Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support;Comparison of time to progression after high-dose melphalan with stem cell support (HDT) performed at diagnosis and time to progression after a salvage HDT combined with carfilzomib-cyclophosphamide-dexamethasone;3 years;Adverse events assessed by CTCAE v4.0 in carfilzomib-cyclophosphamide-dexamethasone induction regime and carfilzomib as part of the high-dose melphalan conditioning;Unknown status;Phase 2
600;Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support;Comparison of time to progression between carfilzomib-dexamethasone maintenance and observation in patients treated with salvage HDT.;3 years;Response rates of carfilzomib-cyclophosphamide-dexamethasone induction therapy and HDT;Unknown status;Phase 2
601;A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma,,,;Terminated;Phase 1
601;A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma,,,;Terminated;Phase 2
602;CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis;The Number of Confirmed Hematologic Responses (Complete, Partial, or Very Good Partial Response);Duration of study (up to 3 years);Progression Free Survival (PFS);Completed;Phase 2
602;CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis;The Number of Confirmed Hematologic Responses (Complete, Partial, or Very Good Partial Response);Duration of study (up to 3 years);Duration of Response;Completed;Phase 2
603;A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma;Establish maximum tolerated doses (MTDs) of CC-220 as monotherapy and in combination with other treatment;Approximately 1 year;Adverse Events (AEs);Recruiting;Phase 1
603;A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma;Establish Recommended Phase 2 doses (RP2Ds) of CC-220 as monotherapy and in combination with other treatment;Approximately 1 year;Overall response rate (ORR);Recruiting;Phase 2
604;Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma;To evaluate the overall response rate (ORR) after 4 induction cycles;After 4 cycles (84 days);a) To evaluate the rate and severity of Peripheral Neuropathy (PN) of SQ bortezomib in combination with lenalidomide, and dexamethasone after the 4th and after the final cycle of induction therapy.;Completed;Phase 2
604;Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma;To evaluate the overall response rate (ORR) after 4 induction cycles;After 4 cycles (84 days);Progression of disease;Completed;Phase 2
604;Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma;To evaluate the overall response rate (ORR) after 4 induction cycles;After 4 cycles (84 days);Progression free survival;Completed;Phase 2
604;Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma;To evaluate the overall response rate (ORR) after 4 induction cycles;After 4 cycles (84 days);Duration of response;Completed;Phase 2
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Number of Participants With Response to Treatment at Day 1 of Cycle 5;Day 1 of Cycle 5;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Number of Participants With Response to Treatment at Day 1 of Cycle 7;Day 1 of Cycle 7;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Number of Participants With Response to Treatment at Day 11 of Cycle 8;Day 11 of Cycle 8;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Number of Participants With Karnofsky Performance Status (KPS) Score at Baseline;Baseline;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Number of Participants With KPS Score at Day 1 of Cycle 1;Day 1 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Number of Participants With KPS Score at Day 1 of Cycle 3;Day 1 of Cycle 3;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Number of Participants With KPS Score at Day 1 of Cycle 5;Day 1 of Cycle 5;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Number of Participants With KPS Score at Day 1 of Cycle 7;Day 1 of Cycle 7;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Number of Participants With KPS Score at Day 11 of Cycle 8;Day 11 of Cycle 8;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 1 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Maximum Observed Plasma Concentration (Cmax) of Bortezomib on Day 11 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 1 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Time to Reach Maximum Observed Plasma Concentration (Tmax) of Bortezomib on Day 11 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Elimination Half-Life Period (T1/2) of Bortezomib on Day 1 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Elimination Half-Life Period (T1/2) of Bortezomib on Day 11 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 1 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Terminal Rate Constant (Lambda[z]) of Bortezomib on Day 11 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 1 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Area Under the Plasma Concentration-Time Curve From Time Zero to Time at Last Observed Quantifiable Concentration (AUC[0-t]) of Bortezomib on Day 11 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 1 of Cycle 1;Day 1 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Bortezomib on Day 11 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 1 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Area Under First Moment Plasma Concentration-Time Curve (AUMC) of Bortezomib on Day 11 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Mean Residence Time (MRT) of Bortezomib in the Body on Day 1 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Mean Residence Time (MRT) of Bortezomib in the Body on Day 11 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Systemic Clearance (CL) of Bortezomib on Day 1 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Systemic Clearance (CL) of Bortezomib on Day 11 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 1 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 1 of Cycle 1;Completed;Phase 3
605;A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma;Volume of Distribution at Steady-State (Vss) of Bortezomib on Day 11 of Cycle 1;0 hour (Pre-dose) and 0.08, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours (post-dose) on Day 11 of Cycle 1,;Completed;Phase 3
606;UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma;Therapeutic Efficacy;180 days,;Completed;Phase 2
607;Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation;Progression Free Survival;Time elapsed from start of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 102 months.;Completed;Not Applicable
607;Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation;Overall Survival;Time elapsed from start of treatment to end of follow-up or patient death, whichever came first, assessed up to 102 months.;Completed;Not Applicable
607;Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation;Proportion of patients with serious adverse effects;Time elapsed from start of treatment to end of follow-up or patient death, whichever came first, assessed up to 102 months.;Completed;Not Applicable
607;Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation;Average grade 3 or higher adverse events per patient;Time elapsed from start of treatment to end of follow-up or patient death, whichever came first, assessed up to 102 months.;Completed;Not Applicable
607;Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation;Annual incidence of grade 3 or higher adverse effects;Time elapsed from start of treatment to end of follow-up or patient death, whichever came first, assessed up to 102 months.,;Completed;Not Applicable
608;Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma;Disease response as measured by M protein quantitation and the percentage of plasma cell infiltration in bone marrow biopsies after every course,;Toxicity as measured by CTCAE criteria;Completed;Phase 1
608;Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma;Disease response as measured by M protein quantitation and the percentage of plasma cell infiltration in bone marrow biopsies after every course,;Toxicity as measured by CTCAE criteria;Completed;Phase 2
609;ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma;Maximum Tolerated Dose;6 months;To Assess the Antitumor Activity of Single Agent Opaganib in Patients With Refractory or Relapsed Multiple Myeloma After 3 Cycles of Treatment.;Terminated;Phase 1
609;ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma;Maximum Tolerated Dose;6 months;Number of Patients With Dose Limiting Toxicity;Terminated;Phase 2
610;Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells;Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.;follow-up 2 years post study;Overall response rate ORR;Recruiting;Phase 1
610;Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells;Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.;follow-up 2 years post study;Progression free survival PFS;Recruiting;Phase 1
610;Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells;Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.;follow-up 2 years post study;Duration of Response DOR;Recruiting;Phase 1
610;Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells;Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.;follow-up 2 years post study;Time to Response TTR;Recruiting;Phase 1
610;Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells;Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.;follow-up 2 years post study;Depth of Best Response (DpR);Recruiting;Phase 1
610;Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells;Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.;follow-up 2 years post study;Time to progression (TTP);Recruiting;Phase 1
610;Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells;Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.;follow-up 2 years post study;Overall Survival (OS);Recruiting;Phase 1
610;Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells;Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.;follow-up 2 years post study;Extramedullary progression;Recruiting;Phase 1
610;Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells;Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.;follow-up 2 years post study;Extramedullary progression;Recruiting;Phase 1
610;Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells;Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.;follow-up 2 years post study;Percentage of cyclosporine trough levels tests in acceptable range;Recruiting;Phase 1
610;Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells;Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment parameters.;follow-up 2 years post study;Mean % of levels in acceptable range will be calculated for the efficacy population.;Recruiting;Phase 1
611;A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma;Safety: Incidence of adverse events;approximately 3.5 years;Immunogenicity: Serum antitherapeutic antibody levels;Completed;Phase 1
611;A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma;Safety: Maximum tolerated dose/dose-limiting toxicities;approximately 1.5 years;Pharmacokinetics: Area under the concentration - time curve (AUC);Completed;Phase 1
611;A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma;Recommended Phase II dose for every-3-week or weekly administration of DFRF4539A;approximately 3.5 years;Objective response, tumor assessments according to International Myeloma Working Group (IMWG) Uniform Response Criteria and/or European Bone Marrow Transplant (EBMT) Criteria;Completed;Phase 1
612;Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702);Percentage of Participants With Progression-free Survival (PFS);38 months post-randomization;Percentage of Participants With Disease Progression;Completed;Phase 3
612;Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702);Percentage of Participants With Progression-free Survival (PFS);38 months post-randomization;Percentage of Participants With Overall Survival (OS);Completed;Phase 3
612;Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702);Percentage of Participants With Progression-free Survival (PFS);38 months post-randomization;Percentage of Participants With Treatment-related Mortality (TRM);Completed;Phase 3
612;Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702);Percentage of Participants With Progression-free Survival (PFS);38 months post-randomization;Number of Participants With Treatment Response;Completed;Phase 3
612;Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702);Percentage of Participants With Progression-free Survival (PFS);38 months post-randomization;FACT-G Total Score;Completed;Phase 3
612;Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702);Percentage of Participants With Progression-free Survival (PFS);38 months post-randomization;FACT-BMT Score;Completed;Phase 3
612;Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702);Percentage of Participants With Progression-free Survival (PFS);38 months post-randomization;FACT-BMT Trial Outcome Index;Completed;Phase 3
612;Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702);Percentage of Participants With Progression-free Survival (PFS);38 months post-randomization;MOS SF-36 Physical Component Summary;Completed;Phase 3
612;Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702);Percentage of Participants With Progression-free Survival (PFS);38 months post-randomization;MOS SF-36 Mental Component Summary;Completed;Phase 3
613;Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma,,,;Completed;Phase 2
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from M protein content in plasma at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from Blood routine in plasma at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from Blood routine in plasma at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from Blood routine in plasma at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from Blood routine in plasma at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from Blood routine in plasma at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from Blood routine in plasma at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from liver and kidney function at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from liver and kidney function at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from liver and kidney function at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from liver and kidney function at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from liver and kidney function at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Change from liver and kidney function at Week 18;Day 0，Day 1，Week 1，Week4，Week 12，Week 18;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Adverse event: Low blood pressure;Day 1;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Adverse event:;Day 1;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Adverse event: Difficulty breathing;Day 1;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
614;Plasma-free Replacement in Patients With Multiple Myeloma;Adverse event: Numbness;Day 1;Safety and Tolerability Assess patient symptoms;Completed;Phase 1
615;Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma;Number of participants with CAR-BCMA T cell therapy-related adverse events as assessed by CTCAE v4.03;24 weeks;Engraftment;Active, not recruiting;Not Applicable
615;Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma;Number of participants with CAR-BCMA T cell therapy-related adverse events as assessed by CTCAE v4.03;24 weeks;Anti-tumor response of CAR-BCMA T cell infusion;Active, not recruiting;Not Applicable
615;Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma;Number of participants with CAR-BCMA T cell therapy-related adverse events as assessed by CTCAE v4.03;24 weeks;Statistical parameter of efficacy assessment#PFS;Active, not recruiting;Not Applicable
615;Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma;Number of participants with CAR-BCMA T cell therapy-related adverse events as assessed by CTCAE v4.03;24 weeks;Statistical parameter of efficacy assessment#DCR;Active, not recruiting;Not Applicable
615;Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma;Number of participants with CAR-BCMA T cell therapy-related adverse events as assessed by CTCAE v4.03;24 weeks;Statistical parameter of efficacy assessment#ORR;Active, not recruiting;Not Applicable
615;Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma;Number of participants with CAR-BCMA T cell therapy-related adverse events as assessed by CTCAE v4.03;24 weeks;Statistical parameter of efficacy assessment#OS;Active, not recruiting;Not Applicable
616;Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients;MMpredictor as a personalised medicine tool;1 year;- Genetic subtyping with the MMprofiler of 800 bio-banked MM patient samples;Active, not recruiting,
616;Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients;MMpredictor as a personalised medicine tool;1 year;- Clinical validation of genetic subtypes correlating with specific treatment effect;Active, not recruiting,
616;Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients;MMpredictor as a personalised medicine tool;1 year;- Establish a treatment decision matrix that will guide physicians in treatment decision-making;Active, not recruiting,
616;Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients;MMpredictor as a personalised medicine tool;1 year;- Perform a Medical Technology Assessment (MTA) to evaluate health economic benefits;Active, not recruiting,
616;Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients;MMpredictor as a personalised medicine tool;1 year;- File addendum to current CE-IVD registration, while also renaming the test to MMpredictor;Active, not recruiting,
616;Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients;MMpredictor as a personalised medicine tool;1 year;- Develop and execute commercialisation and marketing plan for the MMpredictor;Active, not recruiting,
617;Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma;Safety;Completed;Phase 1
617;Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma;Efficacy,,;Completed;Phase 2
618;Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant;Proportion of patients with delayed engraftment (engraftment after day 18) and severe infection related complications (≥ Grade 4 NCI CTCAE v5).;18 days;proportion of patients reporting frequent or almost constant diarrhea on Day -1 of transplant on the PRO-CTCAE score;Recruiting;Phase 2
618;Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant;incidence of Grade 2 or higher diarrhea from the time of ASCT until day 14 post ASCT as measured by NCI Common-Terminology Criteria (CTCAE).;14 days;proportion of patients reporting frequent or almost constant diarrhea on Day 7 of transplant on the PRO-CTCAE score;Recruiting;Phase 2
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Time-to-treatment failure;Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Time-to-next treatment;Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;PFS2 time;Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Overall survival (OS) time;Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Complete remission (CR);Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Very good partial response (VGPR) or better.;Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Overall response (CR + VGPR + partial response [PR]).;Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Occurrence of grade 3 or more side effects.;Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Safety and tolerability of Daratumumab SC when administered in combination with Revlimid: NCI-CTCAE V5.0.;Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Evaluation of quality of life based on MY20 questionnaires;Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Evaluation of quality of life based on EORTC C30 questionnaires;Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Evaluation of quality of life based on EQ-5D questionnaires;Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Minimal residual disease (MRD) negative rate at 12 months.;Active, not recruiting;Phase 3
619;Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy;Comparison of the efficacy of Daratumumab SC injection when combined with Lenalidomide (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd): PFS;From date of randomization until the date of first documented progression or date of toxicity or date of death from any cause, whichever came first, assessed up to 84months;Event Free Survival;Active, not recruiting;Phase 3
620;A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma;Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE);"Day 1 of study drug through 28 days after the last dose of study drug; maximum treatment duration was 60.3 weeks";Myeloma Response Rate;Completed;Phase 3
620;A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma;Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE);"Day 1 of study drug through 28 days after the last dose of study drug; maximum treatment duration was 60.3 weeks";Kaplan-Meier Estimates of Duration of Response (DoR);Completed;Phase 3
621;A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma;Dose Limiting Toxicity and Recommended Phase 2 dose;Following 4 weeks of treatment;Pharmacokinetic (PK) profile of AV-299, and erlotinib (for subjects enrolled in the Phase 1b only).;Completed;Phase 1
621;A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma;Dose Limiting Toxicity and Recommended Phase 2 dose;Following 4 weeks of treatment;Evaluate the effects of AV-299 and combination of AV-299 and erlotinib on exploratory biomarkers in blood, body fluid, tumor tissue, and/or bone marrow.;Completed;Phase 1
621;A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma;Dose Limiting Toxicity and Recommended Phase 2 dose;Following 4 weeks of treatment;Study the preliminary antineoplastic activity of AV-299 in subjects with advanced solid tumors, lymphoma, or multiple myeloma, and the preliminary antineoplastic activity of AV 299 in combination with erlotinib in subjects with advanced solid tumor.;Completed;Phase 1
621;A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma;Dose Limiting Toxicity and Recommended Phase 2 dose;Following 4 weeks of treatment;Investigate the effect of AV-299 and of the combination of AV-299 and erlotinib on gene expression patterns in peripheral blood mononuclear cells and/or bone marrow.;Completed;Phase 1
621;A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma;Dose Limiting Toxicity and Recommended Phase 2 dose;Following 4 weeks of treatment;Assess dosing schedules of AV-299 (e.g. every 2-week and every 3-week schedules).;Completed;Phase 1
621;A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma;Dose Limiting Toxicity and Recommended Phase 2 dose;Following 4 weeks of treatment;Assess safety and tolerability of the RP2D of AV-299 in expansion cohort(s).;Completed;Phase 1
622;Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma;Percent Change of NF-kB Protein Expression in Peripheral Blood Mononuclear Cells From Baseline Through 4 Weeks of Treatment;Baseline through 4 weeks of treatment,;Completed;Not Applicable
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);Post-consolidation MRD negativity rate,;Active, not recruiting;Phase 3
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);Overall Response Rate (ORR);Active, not recruiting;Phase 3
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);Progression-free survival on the next line of therapy (PFS2);Active, not recruiting;Phase 3
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);Overall Survival (OS);Active, not recruiting;Phase 3
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);Time to response;Active, not recruiting;Phase 3
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);Duration of response;Active, not recruiting;Phase 3
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);Pharmacokinetic concentrations of daratumumab;Active, not recruiting;Phase 3
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);Determine the incidence of anti-daratumumab antibodies (immunogenicity) for all subjects who receive at least 1 dose of daratumumab and determine the incidence of anti-rHuPH20 antibodies;Active, not recruiting;Phase 3
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core module (EORTC QLQ-C30) score and the difference between-treatment arms;Active, not recruiting;Phase 3
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);Change in EORTC QLQ- 20-item Multiple Myeloma module (MY-20) score and the difference between-treatment arms;Active, not recruiting;Phase 3
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);EQ-5D-5L health utility values and the difference between-treatment arms;Active, not recruiting;Phase 3
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);Stem cell yield after mobilization;Active, not recruiting;Phase 3
623;Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 9 years);Time to engraftment post-ASCT;Active, not recruiting;Phase 3
624;Multiple Myeloma (MM) Quality of Life (QOL) Study;Quality of life (QOL) Patient Description;Up to 1 year;QOL-Functional Assessment;Unknown status,
624;Multiple Myeloma (MM) Quality of Life (QOL) Study;Quality of life (QOL) Caregiver Description;Up to 1 year;Patient Burden Assessment-ESAS;Unknown status,
625;Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients;AUC from 3 months Post-Transplantation to 9 months Post-Transplantation;Assessments within +/-3 days of 4 week cycle start date for 6 cycles.,;Withdrawn;Phase 2
626;Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma;Adverse Events;Every cycle;Clinically significant changes in the patient's physical examination, vital signs, and clinical laboratory results;Completed;Phase 1
627;Study of the Immune Response After Vaccination in Multiple Myeloma Patients;Evaluate composition of T cells, B cells, NK cell and monocyte populations from pre-vaccination though 24 weeks post-vaccination;24 weeks;Assess outcomes of MM patients after vaccination;Completed,
627;Study of the Immune Response After Vaccination in Multiple Myeloma Patients;Measure of interferon -gamma in activated T cells from pre-vaccination though 24 weeks post-vaccination;24 weeks;Assess outcomes of MM patients after vaccination;Completed,
627;Study of the Immune Response After Vaccination in Multiple Myeloma Patients;Measure of antigen specific B cells from pre-vaccination though 24 weeks post-vaccination;24 weeks;Assess outcomes of MM patients after vaccination;Completed,
627;Study of the Immune Response After Vaccination in Multiple Myeloma Patients;Total PnC-IgG, IgG2, PnC-IgG1 and IgG3 levels from pre-vaccination though 24 weeks post-vaccination;24 weeks;Assess outcomes of MM patients after vaccination;Completed,
627;Study of the Immune Response After Vaccination in Multiple Myeloma Patients;Evaluate both FcyRIIa and FcyRIII polymorphisms;up to 24 weeks;Assess outcomes of MM patients after vaccination;Completed,
628;Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.,,,;Completed;Phase 2
629;Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma;Safety and MTD;First 3 weeks;PK, PD, and efficacy;Completed;Phase 1
630;Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma;To evaluate the safety and tolerability of ACE-041 in patients with advanced solid tumors or relapsed/refractory multiple myeloma by monitoring adverse events, clinical laboratory tests, vital signs, physical examinations, and anti-drug antibody tests.;4 months;To evaluate the pharmacokinetic effect of ACE-041 through the collection of blood samples and to evaluate the preliminary anti-tumor activity of ACE-041 through tumor response evaluation, collection of blood biomarkers, and imaging techniques.;Completed;Phase 1
631;Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma;Rate of dose limiting toxicities (DLTs) during the DLT evaluation period.;time from cycle one day one until cycle two day one (28 days),;Terminated;Phase 1
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Key Secondary End point: MRD Negativity rate in Bone Marrow;Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Complete response rate (CRR);Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Time to response;Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Duration of Response (DOR);Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Progression free survival (PFS);Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Time to next anti-myeloma treatment (TTNT);Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Overall Survival (OS);Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Durability of Minimal Residual Disease (MRD)negativity;Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Patient Reported Outcomes (PRO): EQ-5D-5L Health Questionnaire;Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Patient Reported Outcomes (PRO): EORTC-QLQ-C30;Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Patient Reported Outcomes (PRO): EORTC-QLQ-MY20;Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;PHE885 manufacturing success rate;Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Manufacturing turnaround time;Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Transgene of PHE885 concentrations over time in peripheral blood and bone marrow;Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Cellular kinetics parameter: Cmax;Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Cellular kinetics parameter: Tmax;Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Cellular kinetics parameter: AUC;Recruiting;Phase 2
632;PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) per Independent Review Committee (IRC) in Efficacy Analysis Set;24 Months;Immunogenicity to PHE885;Recruiting;Phase 2
633;A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma;Number of Grade >= 2 Cytokine Release Syndrome (CRS) Events;Up to Day 28;Number of Cytokine Release Syndrome (CRS) Events;Recruiting;Phase 1
634;Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide;Proportion of patients with failed disease based on expectations for changes in cathepsin G (CG) levels;1 month;Mechanism of development of thalidomide/lenalidomide-induced venous thromboembolism (VTE);Completed,
634;Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide;Proportion of patients with failed disease based on expectations for changes in cathepsin G (CG) levels;1 month;Intensity, dynamics, and specificity of CG upregulation in response to thalidomide and lenalidomide treatment;Completed,
634;Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide;Proportion of patients with failed disease based on expectations for changes in cathepsin G (CG) levels;1 month;Specificity and threshold levels of CG for induction of platelet aggregation in response to thalidomide and lenalidomide and the resulting risk for VTE development;Completed,
635;Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma;Toxicity;30 days post last dose of study drug;Response;Terminated;Phase 1
636;An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma;Best Confirmed Response to Bortezomib Re-Treatment;Day 1 of every alternate cycle starting from Cycle 1 up to End of Treatment (30 to 42 days after last dose administration of bortezomib);Participants With Percent Change in Baseline Serum Monoclonal Protein (M-protein) Best Confirmed Response Category;Completed;Phase 2
636;An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma;Best Confirmed Response to Bortezomib Re-Treatment;Day 1 of every alternate cycle starting from Cycle 1 up to End of Treatment (30 to 42 days after last dose administration of bortezomib);Participants with Percent Change in Baseline Urine Monoclonal Protein (M-protein) Best Confirmed Response Category;Completed;Phase 2
636;An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma;Best Confirmed Response to Bortezomib Re-Treatment;Day 1 of every alternate cycle starting from Cycle 1 up to End of Treatment (30 to 42 days after last dose administration of bortezomib);Duration of Best Confirmed Response (DOR);Completed;Phase 2
636;An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma;Best Confirmed Response to Bortezomib Re-Treatment;Day 1 of every alternate cycle starting from Cycle 1 up to End of Treatment (30 to 42 days after last dose administration of bortezomib);Time to Progression (TTP) for Best Confirmed Response;Completed;Phase 2
637;CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma;Occurrence of treatment related adverse events;Day 1-30 days after injection;Anti-myeloma responses;Unknown status;Phase 1
637;CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma;Occurrence of treatment related adverse events;Day 1-30 days after injection;Anti-myeloma responses;Unknown status;Phase 1
638;Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma;Rate of sCR;At the end of eight months;Number of participants with adverse events of elotuzumab in combination with KRd;Active, not recruiting;Phase 2
638;Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma;Rate of negative MRD;At the end of eight months;Rate of MRD;Active, not recruiting;Phase 2
639;Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma;Overall response rate (complete response [CR], near CR, partial response, and minimal response);Time to response;Completed;Phase 2
639;Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma;Safety and tolerability as assessed by NCI CTCAE v3.0;Progression-free survival;Completed;Phase 2
639;Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma;Proportion of patients responding;Overall survival as assessed by the Kaplan-Meier method;Completed;Phase 2
639;Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma;Time to disease progressionin patients receiving maintenance treatment,;Time to disease progression;Completed;Phase 2
640;Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma;Patients With Overall Confirmed Response;Every cycle during treatment;Progression-free Survival;Completed;Phase 1
640;Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma;Patients With Overall Confirmed Response;Every cycle during treatment;Overall Survival (OS) at 3 Years;Completed;Phase 2
641;TriPRIL CAR T Cells in Multiple Myeloma;Incidence of adverse events (AEs);Week 24 post dosing, and every three months until two years.;Overall Response Rate (ORR);Recruiting;Phase 1
641;TriPRIL CAR T Cells in Multiple Myeloma;Incidence of Dose Limiting Toxicity (DLT);Week 24 post dosing, and every three months until two years.;Overall Survival (OS);Recruiting;Phase 1
642;INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma;The number of subjects with dose-limiting toxicities.;28 days;The recommended phase II dose of INCB053914.;Withdrawn;Phase 1
642;INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma;The number of subjects with dose-limiting toxicities.;28 days;Progression-free survival.;Withdrawn;Phase 1
642;INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma;The number of subjects with dose-limiting toxicities.;28 days;Overall survival.;Withdrawn;Phase 1
642;INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma;The number of subjects with dose-limiting toxicities.;28 days;Duration of response.;Withdrawn;Phase 1
642;INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma;The number of subjects with dose-limiting toxicities.;28 days;Efficacy of bone protective effect of INCB053914 in combination with pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma.;Withdrawn;Phase 1
642;INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma;The number of subjects with dose-limiting toxicities.;28 days;The bone protective effect of INCB053914 in combination with pomalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma.;Withdrawn;Phase 1
642;INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma;The number of subjects with dose-limiting toxicities.;28 days;The number of subjects with reduction of osteolytic lesions.;Withdrawn;Phase 1
642;INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma;The number of subjects with dose-limiting toxicities.;28 days;The number of subjects with reduction of sclerosis formation.;Withdrawn;Phase 1
643;Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma;efficacy;8 cycles à 28 days plus follow-up phase;efficacy and safety;Completed;Phase 2
644;Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma;Phase 1: Percentage of Participants With Overall Response Rate (ORR);Up to 3 years;Phase 2: Time to Progression (TTP);Active, not recruiting;Phase 1
644;Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma;Phase 2: Percentage of Participants With Overall Response Rate (ORR);Up to 3 years;Phase 2: Duration of Response;Active, not recruiting;Phase 2
645;Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma;Evaluation of the Response Rate of Ixazomib With Metronomic Cyclophosphamide and Dexamethasone for First-line Treatment of Multiple Myeloma.;Through study treatment completion, an average of 2 years;Evaluation of the Toxicities Associated With Ixazomib With Metronomic Cyclophosphamide and Dexamethasone.;Active, not recruiting;Phase 2
646;The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma;Proportion of patients requiring transfusion and number of units transfused relative to whether or not patients received transfusion(s) before the study.,;"Increase in hemoglobin, hematocrit, developing red blood cells in the blood; Changes in quality-of-life; Safety evaluations (incidence of adverse events, laboratory tests, and vital signs) including changes in underlying multiple myeloma.";Completed;Phase 3
647;Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma,,,;Completed;Phase 2
648;High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse,,,;Completed;Phase 2
649;Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma;Maximum Tolerated Dose for Combination;19 Months;Progression Free Survival;Recruiting;Phase 1
649;Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma;Objective Response Rate;34 Months;Overall Survival;Recruiting;Phase 1
650;Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma;Recommended Phase 2 Dose (RP2D) of Eftozanermin Alfa in Combination With Bortezomib and Dexamethasone (Safety Lead-In Arm);Up to approximately 3 weeks after the first dose of study drug;Rate of Very Good Partial Response (VGPR) or Better per IMWG Criteria;Active, not recruiting;Phase 1
650;Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma;Objective Response Rate (ORR) (Dose Expansion Arm);Up to approximately 44 weeks after the first dose of study drug;Duration of Response (DOR) for ORR;Active, not recruiting;Phase 1
651;Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma;Evaluate toxicity of the conditioning treatment regimen.;3 ¼ years;Evaluate response and overall survival (OS).;Withdrawn;Phase 1
651;Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma;Evaluate toxicity of the conditioning treatment regimen.;3 ¼ years;Determine what correlative laboratory and clinical parameters, if any, are associated with efficacy;Withdrawn;Phase 1
652;Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Response rate (complete response, very good partial response, partial response, and minimal response) as assessed by modified Bladé criteria at baseline, on day 1 of each course, and at end-of-study,;Safety and tolerability as assessed by NCI CTCAE v3.0;Unknown status;Phase 2
652;Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Response rate (complete response, very good partial response, partial response, and minimal response) as assessed by modified Bladé criteria at baseline, on day 1 of each course, and at end-of-study,;Time to progression;Unknown status;Phase 2
652;Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Response rate (complete response, very good partial response, partial response, and minimal response) as assessed by modified Bladé criteria at baseline, on day 1 of each course, and at end-of-study,;Time to response;Unknown status;Phase 2
652;Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Response rate (complete response, very good partial response, partial response, and minimal response) as assessed by modified Bladé criteria at baseline, on day 1 of each course, and at end-of-study,;Duration of response;Unknown status;Phase 2
652;Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Response rate (complete response, very good partial response, partial response, and minimal response) as assessed by modified Bladé criteria at baseline, on day 1 of each course, and at end-of-study,;Progression-free survival;Unknown status;Phase 2
652;Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Response rate (complete response, very good partial response, partial response, and minimal response) as assessed by modified Bladé criteria at baseline, on day 1 of each course, and at end-of-study,;Overall survival;Unknown status;Phase 2
652;Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Response rate (complete response, very good partial response, partial response, and minimal response) as assessed by modified Bladé criteria at baseline, on day 1 of each course, and at end-of-study,;Changes in serum M-protein;Unknown status;Phase 2
652;Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma;Response rate (complete response, very good partial response, partial response, and minimal response) as assessed by modified Bladé criteria at baseline, on day 1 of each course, and at end-of-study,;Changes in 24-hour urine M-protein;Unknown status;Phase 2
653;PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma,,,;Completed;Phase 3
654;Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma;Progression Free survival;36 months;Overall survival;Completed;Phase 3
654;Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma;Progression Free survival;36 months;safety of thalidomide;Completed;Phase 3
655;Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure;Remission status of multiple myeloma;Throughout study;Graft vs. host disease (GVHD);Completed;Phase 1
655;Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure;Renal allograft acceptance and ability to discontinue immunosuppressive therapy;Throughout study;Opportunistic infections;Completed;Phase 1
656;Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma;Confirmed hematologic response;Toxicity as measured by NCI CTCAE v3.0;Completed;Phase 2
656;Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma;Progression-free survival at 1 year,;Time to progression;Completed;Phase 2
657;Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,,,;Completed;Phase 2
658;Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma;Residual myeloma cell number measured by NGS;At baseline;Toxicity in pre-transplant period assessed according to CTCAE v. 5.0;Recruiting;Early Phase 1
658;Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma;Residual myeloma cell number measured by NGS;After treatment, day 15;Percent of participants with pre-transplant period safety;Recruiting;Early Phase 1
659;Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma;incidence of drop-out or dose reduction;2 years;Response rate;Completed;Phase 2
659;Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma;incidence of drop-out or dose reduction;2 years;Time to progression;Completed;Phase 2
659;Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma;incidence of drop-out or dose reduction;2 years;Overall survival;Completed;Phase 2
660;Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma;Progression-free survival;18 months,;Terminated;Phase 4
661;A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma;Frequency of dose-limiting toxicities (DLTs) associated with CPI-0610 administration during the first cycle (first 21 days) of treatment;DLTs asessed during Cycle 1 (first 21 days on study);"Safety and tolerability of CPI-0610 as assessed by: frequency of adverse events and serious adverse events; changes in hematology and clinical chemistry values; changes in physical examination, vital signs, electrocardiogram, ECHO and ECOG score";Completed;Phase 1
661;A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma;Frequency of dose-limiting toxicities (DLTs) associated with CPI-0610 administration during the first cycle (first 21 days) of treatment;DLTs asessed during Cycle 1 (first 21 days on study);Pharmacokinetic parameters of CPI-0610: AUC(0-t), AUC(0-inf), AUCtau,ss, Tmax, Cmax, Ctrough, T1/2, Vd/F, CL/F;Completed;Phase 1
661;A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma;Frequency of dose-limiting toxicities (DLTs) associated with CPI-0610 administration during the first cycle (first 21 days) of treatment;DLTs asessed during Cycle 1 (first 21 days on study);"Pharmacodynamic effects of CPI-0610: Changes in the expression of MYC and other genes in malignant tumor cells; changes in cellular proliferation and in the extent of apoptosis";Completed;Phase 1
661;A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma;Frequency of dose-limiting toxicities (DLTs) associated with CPI-0610 administration during the first cycle (first 21 days) of treatment;DLTs asessed during Cycle 1 (first 21 days on study);Changes in the expression of a set of genes in peripheral blood mononuclear cells (PBMCs) that are sensitive to BET inhibition;Completed;Phase 1
661;A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma;Frequency of dose-limiting toxicities (DLTs) associated with CPI-0610 administration during the first cycle (first 21 days) of treatment;DLTs asessed during Cycle 1 (first 21 days on study);Anti-myeloma activity associated with CPI-0610 treatment;Completed;Phase 1
662;ATRA, Celecoxib, and Itraconazole as Maintenance;Number of Participants with Adverse Events as a Measure of Safety;6 months;Blood and Bone Marrow Aspirate Samples as a measure of changes to the MMSC (multiple myeloma stem cell) fraction.;Completed;Phase 1
663;Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.;To assess the difference in the mean number of collected CD34+ cells/kg during total harvest between Daratumumab and control group.;12 months;Proportion (%) of patients achieving at least two minimum transplant doses (4x10^6 CD34+ cells/kg) at first day of apheresis in Daratumumab versus control group.;Recruiting,
663;Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.;To assess the difference in the mean number of collected CD34+ cells/kg during total harvest between Daratumumab and control group.;12 months;Proportion (%) of patients who received plerixafor rescue for poor mobilization in Daratumumab versus control group.;Recruiting,
663;Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.;To assess the difference in the mean number of collected CD34+ cells/kg during total harvest between Daratumumab and control group.;12 months;Graft composition in Daratumumab group in term of concentration of CD34+ cells x10^6/kg, TNC (total nucleated cells) x 10^8/kg, and MNC (mononuclear cells) x 10^8/kg.;Recruiting,
663;Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.;To assess the difference in the mean number of collected CD34+ cells/kg during total harvest between Daratumumab and control group.;12 months;Rate (%) of CD38 expression and clonogenic potential of collected CD34+ cells in both groups.;Recruiting,
663;Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients.;To assess the difference in the mean number of collected CD34+ cells/kg during total harvest between Daratumumab and control group.;12 months;To compare transplant outcome in term of time (days) to platelets and neutrophils engraftment in Daratumumab versus control group.;Recruiting,
664;agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma;Number Of Participants With Treatment-related Adverse Events;Baseline through Day 28 post cell infusion;Persistence Of agenT-797 In Peripheral Blood;Active, not recruiting;Phase 1
664;agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma;Number Of Dose-limiting Toxicities;Baseline through Day 14 post cell infusion;Overall Response Rate (ORR);Active, not recruiting;Phase 1
665;Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma,,,;Completed;Phase 2
666;A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1);Phase 1: Incidence and Severity of Adverse Events;Minimum of 2 years post CT103A infusion;Overall response rate (ORR) evaluated by the investigators;Recruiting;Phase 1
666;A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1);Phase 1: Laboratoty tests;Minimum of 2 years post CT103A infusion;Overall Survival (OS);Recruiting;Phase 2
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Sleep Efficiency using Actigraphy at 7 days post-transplant;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Sleep Efficiency using Actigraphy at 3 days after engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Sleep Efficiency using Actigraphy at 4 weeks after engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Inflammatory cytokine CRP levels at Baseline;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Inflammatory cytokine CRP levels at 7 days following transplant;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Inflammatory cytokine CRP levels at 3 days following engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Inflammatory cytokine CRP levels at 4 weeks following engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Number of Neutropenic Fevers at 7 days post-transplant;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Number of Neutropenic Fevers at 3 days after engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Number of Neutropenic Fevers at 4 weeks after engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Circadian Light levels measured with Daysimeter (light monitor) at 7 days post-transplant;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Circadian Light levels measured with Daysimeter (light monitor) at 3 days after engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Circadian Light levels measured with Daysimeter (light monitor) at 4 weeks after engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;MD Anderson Symptom Inventory Score-Multiple Myeloma (MDASI-MM) at Baseline;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;MD Anderson Symptom Inventory Score-Multiple Myeloma (MDASI-MM) at 7 days following transplant;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;MD Anderson Symptom Inventory Score-Multiple Myeloma (MDASI-MM) at 3 days following engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;MD Anderson Symptom Inventory Score-Multiple Myeloma (MDASI-MM) at 4 weeks following engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Perceived Stress Scale Score at Baseline;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Perceived Stress Scale Score at 7 days post-transplant;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Perceived Stress Scale Score at 3 days following engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Perceived Stress Scale Score at 4 weeks following engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Patient-Reported Outcomes Measurement Information System -Sleep Disturbance Short Form (PROMIS-SD) Score at Baseline;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Patient-Reported Outcomes Measurement Information System -Sleep Disturbance Short Form (PROMIS-SD) Score at 7 days post-engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Patient-Reported Outcomes Measurement Information System -Sleep Disturbance Short Form (PROMIS-SD) Score at 3 days following engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Patient-Reported Outcomes Measurement Information System -Sleep Disturbance Short Form (PROMIS-SD) Score at 4 weeks following engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Patient-Reported Outcomes Measurement Information System (PROMIS)- Fatigue Score at Baseline;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Patient-Reported Outcomes Measurement Information System (PROMIS)- Fatigue Score at 7 days following transplant;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Patient-Reported Outcomes Measurement Information System (PROMIS)- Fatigue Score at 3 days following engraftment;Recruiting;Not Applicable
667;The Ambient Light Multiple Myeloma Study;Changes in Urinary Melatonin;Baseline visit and 3 days after the Autologous Stem Cell Transplant;Patient-Reported Outcomes Measurement Information System (PROMIS)- Fatigue Score at 4 weeks following engraftment;Recruiting;Not Applicable
668;Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma;Response rate,;Safety and tolerability;Unknown status;Phase 2
669;Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma;Overall survival,;Best response rate;Completed;Phase 3
669;Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma;Overall survival,;Progression-free survival;Completed;Phase 3
669;Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma;Overall survival,;Survival after progression;Completed;Phase 3
669;Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma;Overall survival,;Toxicity;Completed;Phase 3
670;Study Evaluating AMG 424 in Subjects With Multiple Myeloma;Subject incidence of treatment emergent and treatment related adverse events as assessed by CTCAE version 4.0;12 Months;Anti-tumor activity;Terminated;Phase 1
670;Study Evaluating AMG 424 in Subjects With Multiple Myeloma;Subject incidence of dose limiting toxicities (DLTs);28 Days;Duration of Response;Terminated;Phase 1
671;Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma;Phase1: Dose Limiting Toxicity;Day1~Day28;Recruiting;Phase 1
671;Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma;Phase2: Response rate;Day1~Day366,;Recruiting;Phase 2
672;Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma;Establish maximum tolerated dose (MTD);monthly, up to 24 months;Establish efficacy as assessed by the overall response rate;Unknown status;Phase 1
672;Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma;Establish maximum tolerated dose (MTD);monthly, up to 24 months;Establish efficacy as assessed by the overall response rate;Unknown status;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Disease Response After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Overall Response Rate (ORR) to Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction 3-months Following Autologous Stem Cell Transplant (ASCT).;Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Disease Response 3-months After Autologous Stem Cell Transplant (ASCT);Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Event Free Survival (EFS);Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Overall Survival;Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Assessment of Quality of Life (AQoL) Scores;Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Overall Response Rate (ORR) Stratified by Protein Expression (p53);Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Overall Response Rate (ORR) Stratified by Protein Expression (Cyclin D1).;Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Overall Response Rate (ORR) Stratified by Protein Expression (Bcl-2);Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Overall Response Rate (ORR) Stratified by Protein Expression (FGFR3);Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Overall Survival (OS) Stratified by Protein Expression (p53).;Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Overall Survival (OS) Stratified by Protein Expression (Cyclin D1);Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Overall Survival (OS) Stratified by Protein Expression (Bcl-2);Completed;Phase 2
673;A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma;Overall Response Rate (ORR): Number of Participants Who Are Responders (Had Stringent Complete Response [sCR], CR, Very Good Partial Response [VGPR] or Partial Response [PR]) After 4 Cycles of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction;84 days;Overall Survival (OS) Stratified by Protein Expression (FGFR3);Completed;Phase 2
674;Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma;Percentage of patients with MRD(-) remissions at the completion of consolidation therapy;Baseline until MRD(-) is reached estimated to be up to 15 months.;Serious adverse events (SAEs) from the KRdD treatment;Active, not recruiting;Phase 2
674;Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma;Percentage of patients with MRD(-) remissions at the completion of consolidation therapy;Baseline until MRD(-) is reached estimated to be up to 15 months.;Percentage of patients with MRD(-) status at the completion of induction therapy;Active, not recruiting;Phase 2
674;Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma;Percentage of patients with MRD(-) remissions at the completion of consolidation therapy;Baseline until MRD(-) is reached estimated to be up to 15 months.;Percentage of patients with auto-HCT that convert from positive to negative MRD;Active, not recruiting;Phase 2
674;Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma;Percentage of patients with MRD(-) remissions at the completion of consolidation therapy;Baseline until MRD(-) is reached estimated to be up to 15 months.;Percentage of patients achieving complete remission following complete therapy;Active, not recruiting;Phase 2
674;Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma;Percentage of patients with MRD(-) remissions at the completion of consolidation therapy;Baseline until MRD(-) is reached estimated to be up to 15 months.;Percentage of patients that convert from MRD(-) to MRD(+) following treatment discontinuation;Active, not recruiting;Phase 2
674;Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma;Percentage of patients with MRD(-) remissions at the completion of consolidation therapy;Baseline until MRD(-) is reached estimated to be up to 15 months.;Progression-free survival;Active, not recruiting;Phase 2
674;Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma;Percentage of patients with MRD(-) remissions at the completion of consolidation therapy;Baseline until MRD(-) is reached estimated to be up to 15 months.;Overall survival;Active, not recruiting;Phase 2
675;Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma;Number of Participants With Adverse Events During NKAE Treatment;16 months;Number of Participants With Peripheral Blood Monoclonal Protein Reduction or Stabilization;Completed;Phase 1
676;Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma,,,;Available,
677;A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023);Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0);Up to 28 days in Cycle 1;Objective Response Rate (ORR) Evaluated According to the International Myeloma Working Group (IMWG) 2006 Response Criteria by Confirmed Investigator Assessment;Terminated;Phase 1
677;A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023);Number of Participants Who Experienced One or More Adverse Events (AEs);Up to approximately 72.7 months;Disease Control Rate (DCR) Evaluated According to the International Myeloma Working Group (IMWG) 2006 Response Criteria by Confirmed Investigator Assessment;Terminated;Phase 1
678;A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma;Safety assessed as Adverse Events, ECG, vital signs and clinical laboratory tests;four weeks,;Completed;Phase 1
679;Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma;Incidence of Treatment-emergent Peripheral Neuropathy;Every 4 weeks from start of treatment until end of treatment;Time to Progression (TTP);Terminated;Phase 2
679;Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma;Incidence of Treatment-emergent Peripheral Neuropathy;Every 4 weeks from start of treatment until end of treatment;Number of Participants With Treatment Response;Terminated;Phase 2
679;Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma;Incidence of Treatment-emergent Peripheral Neuropathy;Every 4 weeks from start of treatment until end of treatment;Relative Dose Intensity of Bortezomib;Terminated;Phase 2
680;Multiple Myeloma Molecular Monitoring Study;Sensitivity of Minimal Residual Disease (MRD) Assays;100 days post-treatment;Comparison of Sensitivity of MRD Assays with PET scans;Recruiting,
680;Multiple Myeloma Molecular Monitoring Study;Sensitivity of Minimal Residual Disease (MRD) Assays;12 months post-maintenance therapy;Predicting Progression-Free Survival Using MRD Assessment;Recruiting,
681;Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma;Myeloma response;randomization to progression;Time to tumor progression;Completed;Phase 2
681;Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma;Myeloma response;randomization to progression;Duration of response;Completed;Phase 2
681;Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma;Myeloma response;randomization to progression;Survival (1-year and overall survival);Completed;Phase 2
681;Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma;Myeloma response;randomization to progression;Time to first skeletal-related event (SRE) (clinical need for radiation or surgery to bone);Completed;Phase 2
681;Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma;Myeloma response;randomization to progression;Safety (type, frequency, severity, and relationship of adverse events to study drug);Completed;Phase 2
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Kaplan Meier Estimates of Progression-free Survival (PFS) From Start of Maintenance Therapy Period Based on the Response Assessment by the Central Adjudication Committee (CAC);Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Kaplan Meier Estimates of Overall Survival (OS);Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Kaplan Meier Estimates of Time to Progression (TTP) Based on the Response Assessment by the Central Adjudication Committee (CAC);Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Number of Participants in Disease Response Categories Representing Their Best Response During the Double-blind Treatment Period;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Time to First Response;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Kaplan Meier Estimates for Duration of Response as Determined by the Central Adjudication Committee (CAC);Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Kaplan Meier Estimates for Time to Next Antimyeloma Therapy;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Summary of Participants With Treatment-Emergent Adverse Events (TEAE) During the Double-Blind Treatment Period;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Congitive Functioning Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea and Vomiting Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhoea Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13 and 16 in European Organization for Research and Treatment of Cancer Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Difficulties Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Side Effects of Treatment Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Future Perspective Scale;Completed;Phase 3
682;A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.;Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC);up to 165 weeks;Change From Baseline to Cycles 4, 7, 10, 13, 16 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) In Body Image Scale;Completed;Phase 3
683;Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma;assess the toxicities;21 days;serologic response;Active, not recruiting;Phase 1
683;Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma;maximum tolerated dose (MTD);1 year;survival;Active, not recruiting;Phase 1
684;Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants;Percentage of Participants With ≥1 SRE at the End of 1 Year on Study;1 year;Time to First SRE on Study;Completed;Phase 4
684;Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants;Percentage of Participants With ≥1 SRE at the End of 1 Year on Study;1 year;Percentage of Participants Who Experienced Pathologic Bone Fracture;Completed;Phase 4
684;Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants;Percentage of Participants With ≥1 SRE at the End of 1 Year on Study;1 year;Percentage of Participants Who Experienced Spinal Cord Compression;Completed;Phase 4
684;Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants;Percentage of Participants With ≥1 SRE at the End of 1 Year on Study;1 year;Percentage of Participants Who Experienced Radiation to Bone;Completed;Phase 4
684;Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants;Percentage of Participants With ≥1 SRE at the End of 1 Year on Study;1 year;Percentage of Participants Who Experienced Surgery to Bone;Completed;Phase 4
684;Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants;Percentage of Participants With ≥1 SRE at the End of 1 Year on Study;1 year;Percentage of Participants Who Experienced HCM;Completed;Phase 4
684;Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants;Percentage of Participants With ≥1 SRE at the End of 1 Year on Study;1 year;Skeletal Related Event (SRE) Rate;Completed;Phase 4
684;Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants;Percentage of Participants With ≥1 SRE at the End of 1 Year on Study;1 year;Change From Baseline in Urinary N-telopeptide of Type 1 Collagen (uNTx);Completed;Phase 4
684;Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants;Percentage of Participants With ≥1 SRE at the End of 1 Year on Study;1 year;Time to Death;Completed;Phase 4
685;Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma;Serum M protein levels;one month;Time to progression or death;Terminated;Phase 1
686;Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,,,;Completed;Phase 3
687;Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma;Rate of response during therapy as measured by the European Group for Blood and Marrow Transplantation (EBMT) criteria.;Baseline to Day 168;Time to first response and time to best response;Completed;Phase 2
687;Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma;Rate of response during therapy as measured by the European Group for Blood and Marrow Transplantation (EBMT) criteria.;Baseline to Day 168;Size and number of lytic bone lesions were summarized.;Completed;Phase 2
687;Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma;Rate of response during therapy as measured by the European Group for Blood and Marrow Transplantation (EBMT) criteria.;Baseline to Day 168;Pain was assessed by Pain Intensity Categorical Scale and Pain Intensity Visual Aid Scale.;Completed;Phase 2
687;Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma;Rate of response during therapy as measured by the European Group for Blood and Marrow Transplantation (EBMT) criteria.;Baseline to Day 168;Performance status was evaluated by Karnofsky scale.;Completed;Phase 2
687;Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma;Rate of response during therapy as measured by the European Group for Blood and Marrow Transplantation (EBMT) criteria.;Baseline to Day 168;Bone disease was monitored by assessing various biomarkers.;Completed;Phase 2
687;Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma;Rate of response during therapy as measured by the European Group for Blood and Marrow Transplantation (EBMT) criteria.;Baseline to Day 168;Number of patients with disease progression;Completed;Phase 2
688;Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 8 years);Comparison of efficacy;Recruiting;Phase 3
688;Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 8 years);Overall Survival (OS);Recruiting;Phase 3
688;Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 8 years);Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core module (EORTC QLQ-C30) score and the difference between-treatment arms;Recruiting;Phase 3
688;Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 8 years);EQ-5D-5L health utility values and the difference between-treatment arms;Recruiting;Phase 3
688;Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 8 years);MySIm-Q Symptom and Impacts in Patients With Multiple Myeloma and the difference between treatment arms;Recruiting;Phase 3
688;Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 8 years);PRO-CTCAE to evaluate symptomatic toxicities by self-report and the difference between treatment arms;Recruiting;Phase 3
688;Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation;Progression Free Survival (PFS);from randomization to the date of disease progression or death (approximately up to 8 years);PGIS to evaluate the patient global impression of severity of the Multiple Myeloma and the difference between treatment arms;Recruiting;Phase 3
689;Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma;Objective Response Rate;At 6 weeks of treatment;Duration of Response;Completed;Phase 2
689;Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma;Objective Response Rate;At 12 weeks of treatment;Safety Assessments;Completed;Phase 2
690;Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma,,,;Unknown status;Phase 3
691;The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma;Percentage of participants with adverse events (AEs);Baseline until 30 days after last dose of study drug, up to approximately 3 years;Progression Free Survival (PFS);Not yet recruiting;Phase 1
691;The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma;Percentage of participants discontinuing treatment secondary to treatment-related adverse events;Up to approximately 3 years;Prevalence of TG01-specific T-cell specific cytokine production;Not yet recruiting;Phase 2
692;NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma;Overall response rate (ORR = best response at least partial response (PR));6 months;Effect of NOX A12 alone and combined with VD on the mobilization of peripheral blood CD34+ cells, plasma cells and myeloma cells;Completed;Phase 2
692;NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma;Safety and tolerability of NOX A12 alone and in combination with VD;18 months;Additional response criteria such as Minor Response (MR), immunophenotypic Complete Response and molecular Complete Response;Completed;Phase 2
693;Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma,,,;Terminated;Phase 2
694;A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma;Objective response rate;assessed over at least the first 9 months from index therapy start;Time to response;Completed,
694;A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma;Objective response rate;assessed over at least the first 9 months from index therapy start;Duration of response;Completed,
695;C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT;Pretreatment lesion detection;Within 2 weeks before initiation of therapy;Post-induction response assessment;Completed;Not Applicable
695;C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT;Pretreatment lesion detection;Within 2 weeks before initiation of therapy;Post-ASCT response assessment;Completed;Not Applicable
696;Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3;Tumor Response Rate, based on the criteria published by Blade and on the criteria SWOG;16 weeks;Tumor response rate with AB1010 plus dexamethasone;Completed;Phase 2
696;Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3;Tumor Response Rate, based on the criteria published by Blade and on the criteria SWOG;16 weeks;Time to tumor progression and duration of response in responder patients;Completed;Phase 2
697;Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma;Overall Response Rate (ORR);From cycle 1 to cycle 8, up to 168 days;Number of Participants That Had Progression to Multiple Myeloma;Active, not recruiting;Early Phase 1
697;Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma;Overall Response Rate (ORR);From cycle 1 to cycle 8, up to 168 days;Clinical Benefit Rate;Active, not recruiting;Early Phase 1
697;Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma;Overall Response Rate (ORR);From cycle 1 to cycle 8, up to 168 days;Overall Survival;Active, not recruiting;Early Phase 1
698;Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib;Safety and Efficacy of High Dose Carfilzomib;up to 4 years;Progression Free Survival (PFS);Completed;Phase 2
698;Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib;Safety and Efficacy of High Dose Carfilzomib;up to 4 years;Overall Response Rate (ORR);Completed;Phase 2
698;Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib;Safety and Efficacy of High Dose Carfilzomib;up to 4 years;Duration of Response to High Dose Carfilzomib;Completed;Phase 2
698;Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib;Safety and Efficacy of High Dose Carfilzomib;up to 4 years;Markers of ER Stress;Completed;Phase 2
699;Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma;Maximum Tolerated Dose (MTD);Up to 12 months;Completed;Phase 1
699;Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR) - All Participants;Up to 24 months;Completed;Phase 2
700;Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma,,,;Completed;Phase 2
701;Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients;Maxim Tolerability Dose measured by common toxicity criteria v4.0;6 months;Eficcacy measured by the rate of responses;Completed;Phase 1
701;Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients;Maxim Tolerability Dose measured by common toxicity criteria v4.0;6 months;Eficcacy measured by the rate of responses;Completed;Phase 2
702;High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant;Remission status pre- and post-transplantation, specifically the number of patients who achieve complete remission, as measured by the European Blood and Marrow Transplantation Organization Response Criteria;end of study;Disease response, as measured by changes in serum free light chains (in those patients with serum free light chains that are informative);Terminated;Phase 2
702;High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant;Remission status pre- and post-transplantation, specifically the number of patients who achieve complete remission, as measured by the European Blood and Marrow Transplantation Organization Response Criteria;end of study;Disease response, including the proportion of patients with partial remission, stable disease, and progressive disease and remission duration (time to disease progression);Terminated;Phase 2
702;High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant;Remission status pre- and post-transplantation, specifically the number of patients who achieve complete remission, as measured by the European Blood and Marrow Transplantation Organization Response Criteria;end of study;Engraftment quality, as measured by time to recovery of peripheral blood neutrophils to > 500/mm³ and platelets > 50, 000/mm³ and duration of recovery for > 180 days post-transplantation;Terminated;Phase 2
702;High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant;Remission status pre- and post-transplantation, specifically the number of patients who achieve complete remission, as measured by the European Blood and Marrow Transplantation Organization Response Criteria;end of study;Treatment-related mortality;Terminated;Phase 2
702;High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant;Remission status pre- and post-transplantation, specifically the number of patients who achieve complete remission, as measured by the European Blood and Marrow Transplantation Organization Response Criteria;end of study;Overall survival;Terminated;Phase 2
702;High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant;Remission status pre- and post-transplantation, specifically the number of patients who achieve complete remission, as measured by the European Blood and Marrow Transplantation Organization Response Criteria;end of study;Toxicity profile of yttrium Y 90 anti-CD66 monoclonal antibody BW250/183 in the context of autologous stem cell transplantation;Terminated;Phase 2
702;High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant;Remission status pre- and post-transplantation, specifically the number of patients who achieve complete remission, as measured by the European Blood and Marrow Transplantation Organization Response Criteria;end of study;Pharmacokinetics of indium In 111 anti-CD66 monoclonal antibody BW250/183 as measured by serial blood samples and serial planar and single-photon emission computed tomography (SPECT) gamma camera imaging of selected organs;Terminated;Phase 2
702;High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant;Remission status pre- and post-transplantation, specifically the number of patients who achieve complete remission, as measured by the European Blood and Marrow Transplantation Organization Response Criteria;end of study;Development of a dosimetry model based on SPECT and whole body gamma camera imaging;Terminated;Phase 2
702;High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant;Remission status pre- and post-transplantation, specifically the number of patients who achieve complete remission, as measured by the European Blood and Marrow Transplantation Organization Response Criteria;end of study;Proportion of patients who form human anti-murine antibodies (HAMA) after treatment with targeted radiotherapy in the context of an autologous hematopoietic stem cell transplantation;Terminated;Phase 2
703;Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2);Incidence of Treatment Related adverse events (AEs);Day 1 - Month 60;Evaluate additional clinical efficacy outcomes with zevor-cel treatment in patients with rrMM;Recruiting;Phase 1
703;Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2);Identification of Maximum Tolerated Dose (MTD);Day 1 - Month 60;Determine the efficacy of zevor-cel treatment in patients with rrMM, by investigator assessment;Recruiting;Phase 2
704;Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma;The Number of Participants Experiencing a Response to the Peptide Vaccines.;2 week intervals,;Completed;Phase 2
704;Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma;The Number of Participants Experiencing a Response to the Peptide Vaccines.;2 week intervals,;Completed;Phase 3
705;A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM);Rate of MRD negativity;36 months after study enrollment;Progression free survival;Enrolling by invitation;Phase 2
705;A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM);Rate of MRD negativity;36 months after study enrollment;Overall survival;Enrolling by invitation;Phase 2
706;Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma;Number of Participants With Adverse Events;Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2);Overall Response Rate;Completed;Phase 2
706;Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma;Number of Participants With Adverse Events;Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2);Part 1: Time to Response;Completed;Phase 2
706;Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma;Number of Participants With Adverse Events;Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2);Part 2: Time to Progression (TTP);Completed;Phase 2
706;Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma;Number of Participants With Adverse Events;Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2);Part 2: Duration of Response as Assessed Using the Method of Kaplan-Meier;Completed;Phase 2
706;Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma;Number of Participants With Adverse Events;Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2);Part 2: Progression-Free Survival;Completed;Phase 2
706;Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma;Number of Participants With Adverse Events;Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2);Part 2: Time to Response;Completed;Phase 2
706;Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma;Number of Participants With Adverse Events;Up to Week 28 (for Part 1) and up to approximately 2.5 years (for Part 2);Part 2: Overall Survival;Completed;Phase 2
707;Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma;Percentage of Myeloma-specific T Cells ex Vivo Expanded Using Flow Cytometry;Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.;Cell Counts of Myeloma-specific T Cells ex Vivo Expanded Before and After CD3/CD28 Stimulation;Terminated,
708;Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource;Develop a data and sample resource that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality of patients diagnosed or living with Multiple Myeloma in the state of Ohio;up to 3 years;Surveillance;Recruiting,
708;Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource;Develop a data and sample resource that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality of patients diagnosed or living with Multiple Myeloma in the state of Ohio;up to 3 years;Contact;Recruiting,
708;Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource;Develop a data and sample resource that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality of patients diagnosed or living with Multiple Myeloma in the state of Ohio;up to 3 years;Research;Recruiting,
709;A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma;Safety assessed by frequency, severity and relatedness of AEs;up to 6 months;Clinical benefit rate = Stringent Complete Response + Complete Response + Very Good Partial Response + Partial Response + Minimal Response + Stable Disease;Completed;Phase 1
709;A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma;Overall Response Rate;up to 18 months;Time to response;Completed;Phase 1
710;Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma;Safety and effectivity - Incidence of study related adverse events;24 weeks;Statistical parameter of efficacy assessment：PFS;Active, not recruiting;Phase 1
710;Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma;Engraftment;2 years;Statistical parameter of efficacy assessment：DCR;Active, not recruiting;Phase 1
711;Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma,,,;Completed;Phase 3
712;A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma;Incidence and severity of adverse events;Up to 2 years after CT103A infusion.;Overall response rate (ORR);Not yet recruiting;Phase 1
712;A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma;Incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS);Up to 2 years after CT103A infusion.;Progression-free survival (PFS);Not yet recruiting;Phase 1
712;A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma;Number of participants with laboratory abnormalities;Up to 2 years after CT103A infusion.;Overall survival (OS);Not yet recruiting;Phase 1
713;Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma;Kaplan-Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Independent Review Adjudication Committee (IRAC);From date of randomization until the data cut-off date of 24 May 2013. Median follow-up time for all participants was 17.1 months.;Kaplan Meier Estimates of Overall Survival at the Time of Final Analysis (OS);Completed;Phase 3
713;Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma;Kaplan-Meier Estimates of PFS Based on the Response Assessment by the Investigator At the Time of Final Analysis;"From date of randomization to date of data cut-off date of 21 January 2016; median follow-up for all participants was 17.7 months";Percentage of Participants With an Objective Response Based on IRAC Review;Completed;Phase 3
714;Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma;To determine DLT of ACY-1215 administered in combination with lenalidomide and dexamethasone in patient with relapsed/refractory MM;up to 7 years;Duration of Response;Completed;Phase 1
714;Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma;To determine MTD of ACY-1215 administered in combination with lenalidomide and dexamethasone in patient with relapsed/refractory MM;up to 7 years;Adverse Events (AEs);Completed;Phase 1
714;Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma;Objective Response Rate of ACY-1215;up to 7 years;Disease Control Rate;Completed;Phase 1
715;Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China;pharmacokinetic;6 months;curative effect;Unknown status;Phase 1
715;Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China;pharmacokinetic;6 months;curative effect;Unknown status;Phase 2
716;Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma;Progression-free survival;three years;Rate of complete and very good partial responses;Unknown status;Phase 2
717;A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER);Progression-free Survival (PFS);From randomization to disease progression or death on study (up to 116 weeks).;Number of Participants With an Overall Response;Completed;Phase 2
717;A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER);Progression-free Survival (PFS);From randomization to disease progression or death on study (up to 116 weeks).;Percentage of Participants With an Overall Response;Completed;Phase 2
717;A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER);Progression-free Survival (PFS);From randomization to disease progression or death on study (up to 116 weeks).;Duration of Response;Completed;Phase 2
717;A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER);Progression-free Survival (PFS);From randomization to disease progression or death on study (up to 116 weeks).;Overall Survival (OS);Completed;Phase 2
717;A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER);Progression-free Survival (PFS);From randomization to disease progression or death on study (up to 116 weeks).;Number of Participants With Selected Adverse Events (AEs);Completed;Phase 2
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Overall Response (OR) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);Completed;Phase 3
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Minimal Residual Disease Negative Complete Response Rate (MRD[-]CR) at 12 Months as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);Completed;Phase 3
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Overall Survival;Completed;Phase 3
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (Data Cut-off Date 14 July 2019);Completed;Phase 3
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Kaplan-Meier Estimate for Duration of Response (DOR) (Data Cut-off Date 14 July 2019);Completed;Phase 3
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Kaplan-Meier Estimate for Time to Next Treatment (TTNT) (Data Cut-off Date 14 July 2019);Completed;Phase 3
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Kaplan-Meier Estimates for Time to Progression (TTP) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);Completed;Phase 3
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Time to Progression (TTP): Percentage of Participants Who Had Not Had Disease Progression as Assessed by the Independent Review Committee at Months 3, 6, 12, and 18 (Data Cut-off Date 14 July 2019);Completed;Phase 3
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Time to Overall Response as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);Completed;Phase 3
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Percentage of Participants Who Achieved and Maintained a Minimal Residual Disease Negative Complete Response (MRD[-]CR) for 12 Months or More (Data Cut-off Date 14 July 2019);Completed;Phase 3
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Time to Complete Response (CR) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);Completed;Phase 3
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Percentage of Participants Who Achieved Minimal Residual Disease Negative (MRD[-]) Status as Assessed by Next Generation Sequencing at 12 Months;Completed;Phase 3
718;Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.;Progression-free Survival (PFS) as Assessed by the Independent Review Committee (Data Cut-off Date 14 July 2019);"From randomization until the data cut-off date of 14 July 2019; as of the data cut-off date, a median of 40.29 weeks of treatment (any study drug) in the Kd group and 70.14 weeks of treatment (any study drug) in the KdD group.";Quality of Life Core Module (QLQ-C30) Global Health Status/Quality of Life Scores For Baseline Up to the First Follow-Up Visit After the Last Dose (Data Cut-off Date 14 July 2019);Completed;Phase 3
719;Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma;Maximum Tolerated Dose (MTD) and Recommended MTD of Dasatinib in Combination With Bortezomib and Dexamethasone;Days 1 to 21;Best Overall Tumor Response Rate (RR) As Assessed Using International Uniform Response Criteria for Multiple Myeloma and Criteria of the European Bone Marrow Transplant Registry;Terminated;Phase 1
719;Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma;MTD and Recommended MTD of Bortezomib in Combination With Dasatinib and Dexamethasone;Days 1 to 21;Duration of Response;Terminated;Phase 1
720;A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants With Dose Limiting Toxicities (DLT);Day 1 up to Day 36;Percentage of Participants With Overall Response;Completed;Phase 1
720;A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants affected by Adverse Events;Baseline up to 4 Weeks after the last dose of study drug administration;Time to Response;Completed;Phase 1
721;Panobinostat/Velcade in Multiple Myeloma;Toxicity of bortezomib combined with one of 3 doses of panobinostat IV as measured by the occurrence of dose-limiting toxicity (DLT);up to 42 days (two 21-day cycles),;Terminated;Phase 1
722;Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0;28 days post infusion;Concentration of Anti-BCMA CAR T Cells in blood;Recruiting;Phase 1
722;Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0;28 days post infusion;Concentration of Anti-BCMA CAR T Cells in bone marrow;Recruiting;Phase 1
722;Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0;28 days post infusion;Pharmacodynamics (Levels of Cytokines in Serum);Recruiting;Phase 1
722;Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0;28 days post infusion;Pharmacodynamics (Content of clonal plasma cells in bone marrow);Recruiting;Phase 1
722;Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0;28 days post infusion;Overall response rate (ORR) after administration;Recruiting;Phase 1
722;Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0;28 days post infusion;Negative proportion of minimal residual disease (MRD);Recruiting;Phase 1
722;Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0;28 days post infusion;Duration of remission (DOR) after administration;Recruiting;Phase 1
722;Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0;28 days post infusion;Progress Free Survival (PFS) after administration;Recruiting;Phase 1
722;Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0;28 days post infusion;Overall Survival (OS)after administration;Recruiting;Phase 1
722;Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma;Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0;28 days post infusion;Positive incidence of anti-drug antibody;Recruiting;Phase 1
723;Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients;Percentage of Participants With Overall Response Rate of Partial Response or Better;Approximately 40 months;Number of Participants with Adverse Events;Terminated;Phase 2
724;Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma;Patient responses (CR, PR, MR, and overall response) are assessed using EBMT criteria, which primarily involve assessments of monoclonal paraprotein in the serum and urine and assessment of changes in soft tissue plasmacytomas and bone lesions.;Day 73;Time to first response, time to best response, and percentage of patients with disease progression were assessed.;Completed;Phase 2
724;Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma;Patient responses (CR, PR, MR, and overall response) are assessed using EBMT criteria, which primarily involve assessments of monoclonal paraprotein in the serum and urine and assessment of changes in soft tissue plasmacytomas and bone lesions.;Day 73;Size and number of lytic bone lesions were summarized.;Completed;Phase 2
724;Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma;Patient responses (CR, PR, MR, and overall response) are assessed using EBMT criteria, which primarily involve assessments of monoclonal paraprotein in the serum and urine and assessment of changes in soft tissue plasmacytomas and bone lesions.;Day 73;Quality of life and pain was assessed.;Completed;Phase 2
724;Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma;Patient responses (CR, PR, MR, and overall response) are assessed using EBMT criteria, which primarily involve assessments of monoclonal paraprotein in the serum and urine and assessment of changes in soft tissue plasmacytomas and bone lesions.;Day 73;Performance status was evaluated.;Completed;Phase 2
724;Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma;Patient responses (CR, PR, MR, and overall response) are assessed using EBMT criteria, which primarily involve assessments of monoclonal paraprotein in the serum and urine and assessment of changes in soft tissue plasmacytomas and bone lesions.;Day 73;Bone disease was monitored by assessing various markers.;Completed;Phase 2
725;Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma;Evaluate efficacy in terms of Measurable Residual Disease (MRD) negative Complete Remission rate by Next Generation Flow Cytometry after Teclistamab plus Daratumumab intensification.;22 months approximately;To evaluate MRD negative CR rate after Daratumumab plus bortezomib, lenalidomide and dexamethasone (D-VRD) induction.;Not yet recruiting;Phase 2
725;Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma;Evaluate efficacy in terms of Measurable Residual Disease (MRD) negative Complete Remission rate by Fluorodeoxyglucose Positron Emission Tomography-Computerized Tomography (FDG PET-CT) scan using the Deauville score, after Tec-Dara intensification.;22 months approximately;To evaluate MRD negativity after Teclistamab plus Daratumumab (Tec-Dara) intensification using alternative methods;Not yet recruiting;Phase 2
726;Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to either progressive disease or death, whichever occurs first (approximately 3 years);Time to Disease Progression (TTP);Active, not recruiting;Phase 3
726;Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to either progressive disease or death, whichever occurs first (approximately 3 years);Percentage of Participants With a Very Good Partial Response (VGPR) or Better;Active, not recruiting;Phase 3
726;Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to either progressive disease or death, whichever occurs first (approximately 3 years);Overall Response Rate (ORR);Active, not recruiting;Phase 3
726;Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to either progressive disease or death, whichever occurs first (approximately 3 years);Percentage of Participants With Negative Minimal Residual Disease (MRD);Active, not recruiting;Phase 3
726;Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to either progressive disease or death, whichever occurs first (approximately 3 years);Overall Survival (OS);Active, not recruiting;Phase 3
727;Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma;Number of Participants With Treatment Emergent Adverse Events (TEAE);From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.;Overall Response;Completed;Phase 3
727;Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma;Number of Participants With Treatment Emergent Adverse Events (TEAE);From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.;Time to Response;Completed;Phase 3
727;Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma;Number of Participants With Treatment Emergent Adverse Events (TEAE);From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.;Kaplan Meier Estimate of Duration of Response;Completed;Phase 3
727;Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma;Number of Participants With Treatment Emergent Adverse Events (TEAE);From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.;Kaplan Meier Estimate of Progression Free Survival (PFS) According to the European Medicines Agency Guidelines;Completed;Phase 3
727;Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma;Number of Participants With Treatment Emergent Adverse Events (TEAE);From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.;Kaplan Meier Estimate of Time to Progression;Completed;Phase 3
727;Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma;Number of Participants With Treatment Emergent Adverse Events (TEAE);From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.;Kaplan Meier Estimate of Overall Survival (OS);Completed;Phase 3
727;Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma;Number of Participants With Treatment Emergent Adverse Events (TEAE);From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.;Pomalidomide Exposure - Apparent (Oral) Clearance (CL/F);Completed;Phase 3
727;Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma;Number of Participants With Treatment Emergent Adverse Events (TEAE);From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.;Pomalidomide Exposure - Apparent Volume of Distribution (V/F);Completed;Phase 3
727;Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma;Number of Participants With Treatment Emergent Adverse Events (TEAE);From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.;Cytogenetic Analysis;Completed;Phase 3
728;Short Course Daratumumab in Patients With Multiple Myeloma;Rate of MRD negativity by the completion of 6 months of daratumumab therapy;6 months,;Completed;Phase 2
729;Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma;Incidence of completion of treatment;up to 24 months;IFE level;Completed;Phase 1
729;Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma;Incidence of completion of treatment;up to 24 months;sFLC level;Completed;Phase 1
729;Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma;Incidence of completion of treatment;up to 24 months;Bone marrow MRD analysis;Completed;Phase 1
729;Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma;Incidence of completion of treatment;up to 24 months;Progression-Free Survival;Completed;Phase 1
729;Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma;Incidence of completion of treatment;up to 24 months;CyTOF mass cytometry;Completed;Phase 1
729;Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma;Incidence of completion of treatment;up to 24 months;SPEP level;Completed;Phase 1
730;CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma;At least very good partial response rate (according to the criteria IMWG) after four cycles of induction therapy;date from randomization to 1 month after completion of 4 cycles of induction therapy (up to 6 months);complete response rate(according to the criteria IMWG) after four cycles of induction therapy;Unknown status;Phase 3
730;CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma;At least very good partial response rate (according to the criteria IMWG) after four cycles of induction therapy;date from randomization to 1 month after completion of 4 cycles of induction therapy (up to 6 months);At least partial response rate (according to the criteria IMWG) after four cycles of induction therapy;Unknown status;Phase 3
731;Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma;Number of participants with adverse events (AEs);Up to 30 days after last dose;Overall Survival (OS);Unknown status;Phase 1
731;Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma;Type of adverse events(AEs);Up to 30 days after last dose;Progression-free survival(PFS);Unknown status;Phase 2
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Carfilzomib starting dose;18 months;International Staging System (ISS) score and revised ISS stage at diagnosis and carfilzomib regimen initation;Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Carfilzomib dose;18 months;Eastern Cooperative Oncology Group (ECOG) performance status;Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Carfilzomib dose modification;18 months;Cytogenetic risk profile at diagnosis;Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Time to carfilzomib dose modification;18 months;Presence of CRAB features (i.e. hypercalcemia, renal insufficiency, anemia and/or bone pain);Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Reason for dose modification;18 months;Presence of comorbidities;Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Number of cycles started;18 months;Previously received anti-myeloma treatment;Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Carfilzomib regimen;18 months;Response to prior treatment;Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Carfilzomib dosing frequency;18 months;Number of prior relapses;Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Carfilzomib dosing schedule;18 months;Adverse event;Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Carfilzomib duration of treatment;18 months;Time to adverse event;Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Starting dose of concomitant anti-myeloma agents;18 months;Electrocardiogram (ECG) changes;Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Dose modification for concomitant anti-myeloma agents;18 months;Decrease in left ventricular ejection fraction (LVEF);Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Reason for frequency modification;18 months;Initiation or dose increase of antihypertensive treatment;Completed,
732;Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe;Reason for change in frequency of concomitant multiple myeloma therapies;18 months;Initiation or dose increase of existing heart failure treatment;Completed,
733;Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma;Objective response rate;2 Years;Progression Free Survival;Active, not recruiting;Phase 2
734;Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial;safety and efficacy of Daratumumab assessed by free survival;1-year progression free survival in such patients;Disease response rate;Withdrawn;Phase 2
734;Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial;safety and efficacy of Daratumumab assessed by free survival;1-year progression free survival in such patients;Overall survival;Withdrawn;Phase 2
734;Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial;safety and efficacy of Daratumumab assessed by free survival;1-year progression free survival in such patients;GVHD-free;Withdrawn;Phase 2
734;Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial;safety and efficacy of Daratumumab assessed by free survival;1-year progression free survival in such patients;Relapse-free survival;Withdrawn;Phase 2
734;Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial;safety and efficacy of Daratumumab assessed by free survival;1-year progression free survival in such patients;Cumulative incidence of relapse, death from disease, and non-relapse mortality;Withdrawn;Phase 2
734;Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial;safety and efficacy of Daratumumab assessed by free survival;1-year progression free survival in such patients;Cumulative incidence of chronic GVHD as assessed by NIH Consensus Criteria;Withdrawn;Phase 2
734;Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial;safety and efficacy of Daratumumab assessed by free survival;1-year progression free survival in such patients;Serious adverse events of Daratumumab and number of infusion per patient;Withdrawn;Phase 2
734;Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial;safety and efficacy of Daratumumab assessed by free survival;1-year progression free survival in such patients;Serious adverse events of prophylactic donor lymphocytes infusion (pDLI) and number of infusion per patient;Withdrawn;Phase 2
734;Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial;safety and efficacy of Daratumumab assessed by free survival;1-year progression free survival in such patients;Quality of Life;Withdrawn;Phase 2
734;Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 Trial;safety and efficacy of Daratumumab assessed by free survival;1-year progression free survival in such patients;immune response analysis;Withdrawn;Phase 2
735;"A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy";Percentage of Participates Who Achieve CR;From baseline up to approximately 24 months;Percent of Participants Who Achieve MRD Negativity;Withdrawn;Phase 2
735;"A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy";Percentage of Participates Who Achieve CR;From baseline up to approximately 24 months;Percent of Participants Who Achieve VGPR or Better;Withdrawn;Phase 2
735;"A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy";Percentage of Participates Who Achieve CR;From baseline up to approximately 24 months;Overall Response Rate (ORR);Withdrawn;Phase 2
735;"A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy";Percentage of Participates Who Achieve CR;From baseline up to approximately 24 months;Time to Response (TTR);Withdrawn;Phase 2
735;"A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy";Percentage of Participates Who Achieve CR;From baseline up to approximately 24 months;Duration of response (DOR);Withdrawn;Phase 2
735;"A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy";Percentage of Participates Who Achieve CR;From baseline up to approximately 24 months;Progression-free Survival (PFS);Withdrawn;Phase 2
735;"A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy";Percentage of Participates Who Achieve CR;From baseline up to approximately 24 months;Minimal Residual Disease (MRD) Negativity Rate at 12 Months;Withdrawn;Phase 2
735;"A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy";Percentage of Participates Who Achieve CR;From baseline up to approximately 24 months;Time to Disease Progression (TTP);Withdrawn;Phase 2
735;"A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy";Percentage of Participates Who Achieve CR;From baseline up to approximately 24 months;Time to Next Treatment (TTNT);Withdrawn;Phase 2
735;"A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy";Percentage of Participates Who Achieve CR;From baseline up to approximately 24 months;Overall Survival (OS) Rate;Withdrawn;Phase 2
736;Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma;Joint positive adjudication of safety summary in Phase 1b by steering committee, investigator and sponsor (Yes/No);At 13 months;Objective response rate (ORR) in Phase 1b, in the proportion of subjects in the analysis population who have complete response (CR), stringent complete response (sCR), very good partial response (VGPR), partial response (PR), or stable disease (SD);Withdrawn;Phase 1
736;Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma;Progression-free survival (PFS) in Phase 2, defined as the time (in days) from date of randomization to disease progression;Up to 25 months;Duration of response in Phase 1b, defined as the time (in days) from the date of first response to treatment (CR, sCR, VGPR, PR) to the date of disease progression or death;Withdrawn;Phase 2
737;Trial of Romidepsin and Bortezomib for Multiple Myeloma;Count of Participant Best Overall Response As Assessed by the Investigator;up to 8 months;Participants With Treatment-emergent Adverse Events (TEAEs);Terminated;Phase 2
737;Trial of Romidepsin and Bortezomib for Multiple Myeloma;Count of Participant Best Overall Response As Assessed by the Investigator;up to 8 months;Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞);Terminated;Phase 2
737;Trial of Romidepsin and Bortezomib for Multiple Myeloma;Count of Participant Best Overall Response As Assessed by the Investigator;up to 8 months;Maximum Observed Concentration (Cmax);Terminated;Phase 2
737;Trial of Romidepsin and Bortezomib for Multiple Myeloma;Count of Participant Best Overall Response As Assessed by the Investigator;up to 8 months;Time to Maximum Observed Concentration (Tmax);Terminated;Phase 2
737;Trial of Romidepsin and Bortezomib for Multiple Myeloma;Count of Participant Best Overall Response As Assessed by the Investigator;up to 8 months;Terminal Half-life (t1/2);Terminated;Phase 2
737;Trial of Romidepsin and Bortezomib for Multiple Myeloma;Count of Participant Best Overall Response As Assessed by the Investigator;up to 8 months;Total Clearance (CL);Terminated;Phase 2
737;Trial of Romidepsin and Bortezomib for Multiple Myeloma;Count of Participant Best Overall Response As Assessed by the Investigator;up to 8 months;Total Volume of Distribution (Vz);Terminated;Phase 2
737;Trial of Romidepsin and Bortezomib for Multiple Myeloma;Count of Participant Best Overall Response As Assessed by the Investigator;up to 8 months;Kaplan Meier Estimate for Time to Progression Assessed by the Investigator;Terminated;Phase 2
737;Trial of Romidepsin and Bortezomib for Multiple Myeloma;Count of Participant Best Overall Response As Assessed by the Investigator;up to 8 months;Kaplan Meier Estimate for Time to Response Assessed by the Investigator;Terminated;Phase 2
737;Trial of Romidepsin and Bortezomib for Multiple Myeloma;Count of Participant Best Overall Response As Assessed by the Investigator;up to 8 months;Kaplan Meier Estimate for Duration of Response Assessed by the Investigator;Terminated;Phase 2
737;Trial of Romidepsin and Bortezomib for Multiple Myeloma;Count of Participant Best Overall Response As Assessed by the Investigator;up to 8 months;Kaplan Meier Estimates for Progression-free Survival Assessed by the Investigator;Terminated;Phase 2
737;Trial of Romidepsin and Bortezomib for Multiple Myeloma;Count of Participant Best Overall Response As Assessed by the Investigator;up to 8 months;Kaplan Meier Estimates for Overall Survival;Terminated;Phase 2
738;A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma;Percentage of Participants With Complete Response (CR), Partial Response (PR) and Minimal Response (MR) or Minor Response (MinR): (Response Rate);Baseline to measured progressive disease up to 40.51 months;Duration of Response (DOR);Completed;Phase 2
738;A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma;Percentage of Participants With Complete Response (CR), Partial Response (PR) and Minimal Response (MR) or Minor Response (MinR): (Response Rate);Baseline to measured progressive disease up to 40.51 months;Time to Progressive Disease;Completed;Phase 2
738;A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma;Percentage of Participants With Complete Response (CR), Partial Response (PR) and Minimal Response (MR) or Minor Response (MinR): (Response Rate);Baseline to measured progressive disease up to 40.51 months;Number of Participants With Adverse Events (Safety and Adverse Events);Completed;Phase 2
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Post induction MRD negativity rate by NGS;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Progression-free survival (PFS) in the 2 arms;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Post light-consolidation MRD negativity rate by NGS;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Overall Response Rate (ORR) post-induction;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Overall Response Rate (ORR) post-transplant;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Overall Response Rate (ORR) post-consolidation;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Overall Response Rate (ORR) post light-consolidation;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Post ASCT MRD negativity rate by NGS;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;MRD negativity rate by NGF post induction;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;MRD negativity rate by NGF post induction;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;MRD negativity rate by NGF post consolidation;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;MRD negativity rate by NGF post light consolidation;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Duration of response;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Duration of MRD negativity (by NGS and NGF);Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Determine the rate of sustained for 1-year MRD negativity (by NGF and NGS) from post ASCT consolidation to post light consolidation;Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Determine the time to progression (TTP);Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Overall Survival (OS);Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Time to next therapy (TNT);Active, not recruiting;Phase 3
739;Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL);Rate of MRD negativity after ASCT consolidation treatment by NGS;The end of consolidation, average of 12 months;Progression-free survival on the next line of therapy (PFS2);Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Time to Biochemical or Diagnostic (SLiM-CRAB) Progression;Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Overall Response Rate (ORR);Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Complete Response (CR) Rate;Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Time to First-Line Treatment for Multiple Myeloma (MM);Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Progression-Free Survival on First-Line Treatment for MM (PFS2);Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Overall Survival (OS);Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Percentage of Participants who Progress to MM With Adverse Prognostic Features;Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Serum Daratumumab Pharmacokinetic (PK) Concentration;Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Maximum Observed Concentration (Cmax) of Daratumumab;Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Minimum Observed Concentration (Cmin) of Daratumumab;Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Number of Participants With Anti-daratumumab Antibodies;Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Number of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies;Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score;Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale;Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Change From Baseline in European Quality (EuroQoL) 5-Dimension 5-Level Health Status (EQ-5D-5L) Questionnaire;Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Duration of Response;Active, not recruiting;Phase 3
740;A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma;Progression-free Survival (PFS);From the date of randomization to active multiple myeloma (MM) or the date of death, whichever occurs first (up to approximately 8 years);Time to Response;Active, not recruiting;Phase 3
741;Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma;The overall response rate of PAD and TAD in patients with MM assessed by International Myeloma Working Group(IMWG) criteria;every treatment cycle;The concentrations of bone metabolites;Unknown status;Phase 4
741;Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma;The overall response rate of PAD and TAD in patients with MM assessed by International Myeloma Working Group(IMWG) criteria;every treatment cycle;chromosome examination by cytogenetic and interphase Fluorescence in situ hybridization(FISH) method;Unknown status;Phase 4
741;Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma;The overall response rate of PAD and TAD in patients with MM assessed by International Myeloma Working Group(IMWG) criteria;every treatment cycle;Overall survival(OS) and progression-free survival(FPS);Unknown status;Phase 4
741;Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma;The overall response rate of PAD and TAD in patients with MM assessed by International Myeloma Working Group(IMWG) criteria;every treatment cycle;European Organisation for Research and Treatment of Cancer Quality Of life-Questionnaires-C30 (EORTC QLQ-C30);Unknown status;Phase 4
742;A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma;Progression-free Survival (PFS);From randomization to either disease progression or death whichever occurs first until 21 months;Time to Disease Progression (TTP);Active, not recruiting;Phase 3
742;A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma;Progression-free Survival (PFS);From randomization to either disease progression or death whichever occurs first until 21 months;Percentage of Participants Who Achieved Very Good Partial Response (VGPR) or Better;Active, not recruiting;Phase 3
742;A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma;Progression-free Survival (PFS);From randomization to either disease progression or death whichever occurs first until 21 months;Percentage of Participants With Negative Minimal Residual Disease (MRD);Active, not recruiting;Phase 3
742;A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma;Progression-free Survival (PFS);From randomization to either disease progression or death whichever occurs first until 21 months;Overall Response Rate;Active, not recruiting;Phase 3
742;A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma;Progression-free Survival (PFS);From randomization to either disease progression or death whichever occurs first until 21 months;Overall Survival (OS);Active, not recruiting;Phase 3
742;A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma;Progression-free Survival (PFS);From randomization to either disease progression or death whichever occurs first until 21 months;Time to Response;Active, not recruiting;Phase 3
742;A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma;Progression-free Survival (PFS);From randomization to either disease progression or death whichever occurs first until 21 months;Duration of Response (DOR);Active, not recruiting;Phase 3
743;Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients;Assessment of success rate expressed as % of patients mobilizing ≥2x106 CD34+ cells/kg in maximum 3 apheresis and patient who achieves the optimal target of 4x106 CD34+ cells/kg up to 5 apheresis.;3 years;% of patients having received plerixafor in the study population;Active, not recruiting,
743;Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients;Assessment of success rate expressed as % of patients mobilizing ≥2x106 CD34+ cells/kg in maximum 3 apheresis and patient who achieves the optimal target of 4x106 CD34+ cells/kg up to 5 apheresis.;3 years;Evaluate in patients failing mobilisation how many of them received plerixafor and how many did not;Active, not recruiting,
743;Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients;Assessment of success rate expressed as % of patients mobilizing ≥2x106 CD34+ cells/kg in maximum 3 apheresis and patient who achieves the optimal target of 4x106 CD34+ cells/kg up to 5 apheresis.;3 years;Evaluation of speed of mobilization using plerixafor, in terms of increase in number of circulating CD34+ cells from time 0 to 6-11 hours after the first dose of plerixafor.;Active, not recruiting,
743;Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients;Assessment of success rate expressed as % of patients mobilizing ≥2x106 CD34+ cells/kg in maximum 3 apheresis and patient who achieves the optimal target of 4x106 CD34+ cells/kg up to 5 apheresis.;3 years;Total number of CD34+ cells collected per apheresis day;Active, not recruiting,
743;Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients;Assessment of success rate expressed as % of patients mobilizing ≥2x106 CD34+ cells/kg in maximum 3 apheresis and patient who achieves the optimal target of 4x106 CD34+ cells/kg up to 5 apheresis.;3 years;Confirmation of factors predicting a poor mobilization: patients who experienced grade 3-4 haematological toxicity during induction, used lenalidomide as induction treatment, aged > 60 years old and experienced cytopenia at diagnosis.;Active, not recruiting,
744;Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma;Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bortezomib, Dexamethasone, Doxorubicin, and ALCAR;Every 21 days, up to 24 weeks;Overall Survival;Completed;Phase 2
744;Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma;Confirmed Anti-tumor Response Rate (Complete Response and Partial Response) to the Combination of Bortezomib, Dexamethasone, Doxorubicin, and ALCAR;Every 21 days, up to 24 weeks;Progression-free Survival;Completed;Phase 2
745;Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102);Progression-Free Survival (PFS);Year 3;Overall Survival (OS) for Standard Risk;Completed;Phase 3
745;Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102);Progression-Free Survival (PFS);Year 3;Overall Survival (OS) for High Risk;Completed;Phase 3
745;Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102);Progression-Free Survival (PFS);Year 3;Cumulative Incidence of Progression/Relapse;Completed;Phase 3
745;Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102);Progression-Free Survival (PFS);Year 3;Cumulative Incidence of Treatment Related Mortality (TRM);Completed;Phase 3
745;Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102);Progression-Free Survival (PFS);Year 3;Interval From First to Second Transplantation;Completed;Phase 3
745;Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102);Progression-Free Survival (PFS);Year 3;Incidences of Graft Versus Host Disease (GVHD);Completed;Phase 3
745;Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102);Progression-Free Survival (PFS);Year 3;Incidences of Chronic GVHD;Completed;Phase 3
746;A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to approximately 3.5 years after the last participant is enrolled;Minimal Residual Disease (MRD);Active, not recruiting;Phase 2
746;A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma;Very Good Partial Response or Better Response Rate (VGPR);Up to approximately 3.5 years after the last participant is enrolled;Cmax of Venetoclax;Active, not recruiting;Phase 2
746;A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma;Complete Response (CR) or Better Rate;Up to approximately 3.5 years after the last participant is enrolled;Tmax of Venetoclax;Active, not recruiting;Phase 2
746;A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma;Time to Response (TTR);Up to approximately 3.5 years after the last participant is enrolled;AUC0-24 of Venetoclax;Active, not recruiting;Phase 2
747;Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma;Number of participants with dose-limiting toxicities (DLTs) in each of the cohorts 1-3;Five (5) years after last participant randomization;Recruiting;Phase 1
747;Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma;Overall Response rate as per IMWG by Investigator Assessment, defined as the percentage of participants with a confirmed PR, VGPR, CR or sCR;Five (5) years after last participant randomization;Recruiting;Phase 2
748;Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients;Maximum tolerated dose (MTD) for selected regimens;Cycles 1-2 for selected regimens (up to 2 months);Time to Progression;Unknown status;Phase 1
748;Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients;Number of subjects with adverse events;up to 48 months;Progression-free survival (PFS);Unknown status;Phase 2
749;STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS;Event-free survival;3 years;Progression-free survival (PFS);Active, not recruiting;Phase 3
749;STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS;Event-free survival;3 years;Overall survival (OS);Active, not recruiting;Phase 3
749;STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS;Event-free survival;3 years;Time to progression (TTP);Active, not recruiting;Phase 3
749;STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS;Event-free survival;3 years;Overall response rate (ORR);Active, not recruiting;Phase 3
749;STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS;Event-free survival;3 years;Time to response (TTR);Active, not recruiting;Phase 3
749;STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS;Event-free survival;3 years;Duration of response (DOR);Active, not recruiting;Phase 3
749;STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS;Event-free survival;3 years;Time to the next therapy (TNT);Active, not recruiting;Phase 3
749;STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS;Event-free survival;3 years;Incidence of dose reduction and drug discontinuation;Active, not recruiting;Phase 3
749;STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS;Event-free survival;3 years;Health care cost;Active, not recruiting;Phase 3
749;STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS;Event-free survival;3 years;Correlation between tumor response and outcome with baseline prognostic factors;Active, not recruiting;Phase 3
749;STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS;Event-free survival;3 years;Quality of life assessment (HRQOL);Active, not recruiting;Phase 3
750;Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma;Overall Survival;12.9 Median Years;Number of Patients <56 Years Old Experiencing Grade 3-4 Regimen Related Toxicity;Completed;Phase 2
750;Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma;Initial Response to Therapy;Evaluated at Day +84-90 Post-Transplant;Number of Patients ≥56 Years Old Experiencing Grade 3-4 Regimen Related Toxicity;Completed;Phase 2
751;Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma;Maximum tolerated dose of vorinostat;4 years;Overall response rate;Terminated;Phase 1
751;Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma;Maximum tolerated dose of vorinostat;4 years;Duration of response;Terminated;Phase 1
752;A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Number of participants who experience dose-limiting toxicities (DLTs);28 days;Maximum serum concentration (Cmax) of AMG 701;Withdrawn;Phase 1
752;A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Number of participants who experience one or more treatment-emergent adverse events (TEAEs);up to approximately 9 months;Time to maximum concentration (Tmax) of AMG 701;Withdrawn;Phase 1
752;A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Number of participants who experience one or more treatment-related TEAEs;up to approximately 9 months;Area under the concentration-time curve (AUC) of AMG 701;Withdrawn;Phase 1
752;A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Number of participants with abnormal changes in vital signs;up to approximately 9 months;Minimum concentration over the dosing interval (Ctrough) of AMG 701;Withdrawn;Phase 1
752;A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Number of participants with abnormal changes in electrocardiograms (ECGs) findings;up to approximately 9 months;Incidence of anti-AMG 701 antibody formation;Withdrawn;Phase 1
752;A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Number of participants with abnormal changes in clinical laboratory tests;up to approximately 9 months;Overall response (OR);Withdrawn;Phase 1
753;The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma;To assess the toxicity associated with vaccination of patients multiple myeloma with dendritic cell(DC)/tumor cell fusions co-administered with GM-CSF.;5 years;To determine whether evidence of tumor specific cellular and humoral immunity can be induced by serial vaccination with DC/tumor cell fusion cells co-administered with GMCSF;Completed;Phase 1
753;The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma;To assess the toxicity associated with vaccination of patients multiple myeloma with dendritic cell(DC)/tumor cell fusions co-administered with GM-CSF.;5 years;to determine if vaccination with DC/tumor cell fusions co-administered with GM-CSF results in clinical disease response.;Completed;Phase 1
754;A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib;The primary endpoint is the overall response rate defined as the partial or complete response to treatment according to EBMT criteria. Overall response will be assessed at each treatment cycle up to 8 cycles.;Assessed at each 21-day treatment cycle up to 8 cycles and over 6 months following discontinuation of all study drugs.;"Secondary endpoints include time to disease progression (treatment start to disease progression or death due to progression); best response assessed by the investigator; duration of response; and overall survival (treatment start to death by any cause).";Withdrawn;Phase 2
755;A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);From first dose to up to approximately 66 months;Time-To-Response (TTR);Terminated;Phase 2
755;A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma;Number of Participants With Adverse Events (AEs);From first dose to 90 days after last dose (up to approximately 58 months);Kaplan-Meier Estimate of Duration of Response (DOR) - Simon Stage 1: D2 Arm;Terminated;Phase 2
755;A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma;Number of Participants With Serious Adverse Events (SAEs);From first dose to 90 days after last dose (up to approximately 58 months);Kaplan-Meier Estimate of Duration of Response (DOR) - PD3 Arm;Terminated;Phase 2
756;Combination Chemotherapy in Treating Patients With Multiple Myeloma,,,;Completed;Phase 2
757;Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma;The Proportion Of Patients In Deep Response;2 years;Objective Response Rate;Active, not recruiting;Phase 2
757;Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma;The Proportion Of Patients In Deep Response;2 years;Duration of Response;Active, not recruiting;Phase 2
757;Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma;The Proportion Of Patients In Deep Response;2 years;Complete Response Rate;Active, not recruiting;Phase 2
757;Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma;The Proportion Of Patients In Deep Response;2 years;Overall Response Rate;Active, not recruiting;Phase 2
757;Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma;The Proportion Of Patients In Deep Response;2 years;Progression Free Survival;Active, not recruiting;Phase 2
757;Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma;The Proportion Of Patients In Deep Response;2 years;Incidence of Treatment Emergent Adverse Events (Safety and Tolerability);Active, not recruiting;Phase 2
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Objective Response (OR) greater or equal to Partial Response (PR) per IMWG response criteria as determined by the IRC;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Objective Response Rate (ORR) greater or equal to Very Good Partial Response (VGPR) per IMWG response criteria as determined by IRC;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Objective Response Rate (ORR) greater or equal to Complete Response (CR) per IMWG response criteria as determined by IRC;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Incidence of minimal residual disease (MRD) negative status;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Overall Survival (OS);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Mean change from baseline in the worst pain score measured by Brief Pain Inventory-Short Form (BPI-SF) Item 3;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Progression-free Survival (PFS) per IMWG response criteria as determined by the investigator;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Incidence of treatment emergent adverse events (TEAEs);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Severity of treatment emergent adverse events (TEAEs);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Incidence of adverse events of special interest (AESI);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Severity of adverse events of special interest (AESI);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Incidence of Serious Adverse Events (SAE);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Severity of Serious Adverse Events (SAE);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;ORR greater or equal to PR per IMWG response criteria as determined by the investigator;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;ORR greater or equal to VGPR per IMWG response criteria as determined by the investigator;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;ORR greater or equal to CR per IMWG response criteria as determined by the investigator;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Duration of Response (DoR) as per IMWG response criteria as determined by the investigator;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;DoR as per IMWG response criteria as determined by the IRC;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Duration of MRD negative status in the bone marrow;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Time from randomization to objective response (≥PR) as per IMWG response criteria as determined by the IRC;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Time from randomization to objective response (≥PR) as per IMWG response criteria as determined by the investigator;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Concentration of linvoseltamab in the serum over time;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Incidence of antidrug antibodies (ADAs);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Titer of antidrug antibodies (ADAs);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Incidence of neutralizing antibodies (Nabs) to linvoseltamab over time;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Proportion of Pain Responders;Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Change from baseline in patient-reported global health status/quality of life (QoL), per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Change from baseline in patient reported disease symptoms per EORTC Quality of Life Questionnaire-Multiple Myeloma (MM) module 20 [QLQ-MY20]);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Patient-Reported Outcomes in Patient Global Impression of Symptom Severity (PGIS);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Patient-Reported Outcomes in Patient Global Impression of Change (PGIC);Not yet recruiting;Phase 3
758;A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Participants With Relapsed/Refractory Multiple Myeloma;Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC);Up to approximatively 5 years;Change from baseline in patient-reported general health status per EuroQoL-5 Dimension-5 Level Scale [EQ-5D-5L]);Not yet recruiting;Phase 3
759;Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma;Identification of dose-limiting toxicity (DLT);1 year;Determine the rate of very good partial response (VGPR) or more with the CBd association:;Active, not recruiting;Phase 1
759;Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma;Identification of dose-limiting toxicity (DLT);1 year;Determine the rate of very good partial response (VGPR) or more with the CBd association:;Active, not recruiting;Phase 2
760;Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.;Sensitivity;6 months;Specificity, positive predictive value (PPV) and negative predictive value (NPV) of [68Ga]Ga-PentixaFor-PET.;Not yet recruiting;Phase 2
760;Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.;Sensitivity;6 months;Prognostic impact of FDG-PET and of [68Ga]Ga-PentixaFor-PET depending on the uptake detected by each imaging technique.;Not yet recruiting;Phase 2
760;Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.;Sensitivity;6 months;Discrepancies rate between FDG-PET and [68Ga]Ga-PentixaFor-PET and factors associated with.;Not yet recruiting;Phase 2
760;Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.;Sensitivity;6 months;Correlation between FDG-PET and [68Ga]Ga-PentixaFor-PET uptakes evaluated by SUV.;Not yet recruiting;Phase 2
760;Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.;Sensitivity;6 months;Correlation between FDG-PET and [68Ga]Ga-PentixaFor-PET uptakes evaluated by the RNAseq data evaluated on the myelogram.;Not yet recruiting;Phase 2
760;Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.;Sensitivity;6 months;Prognostic impact of FDG-PET and [68Ga]Ga-PentixaFor-PET depending on the positivity, number and intensity of uptake detected by each imaging technique.;Not yet recruiting;Phase 2
760;Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.;Sensitivity;6 months;Link between FDG-PET, [68Ga]Ga-PentixaFor-PET results and minimal residual disease evaluated by NGS.;Not yet recruiting;Phase 2
760;Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.;Sensitivity;6 months;Tolerance of [68Ga]Ga-PentixaFor-PET.;Not yet recruiting;Phase 2
761;Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma;Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (Safety Run-in Cohorts);First dose date up to the end of the first dosing cycle (Cycle 1=35 days);Percentage of Participants Experiencing TEAE's According to the NCI CTCAE Version 5.0 (Dose Expansion Cohorts);Recruiting;Phase 2
761;Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma;Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE's) According to the NCI CTCAE Version 5.0 (Safety Run-in Cohorts);From date of first dose of any study drug up to the date of last dose of any study drug plus 30 days (Up to 2.5 years);Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0 (Dose Expansion Cohorts);Recruiting;Phase 2
761;Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma;Percentage of Participants Experiencing Treatment-emergent Laboratory Abnormalities According to the NCI CTCAE Version 5.0 (Safety Run-in Cohorts);From baseline to the date of last dose of any study drug plus 30 days (Up to 2.5 years);Duration of Response (Dose Expansion Cohorts);Recruiting;Phase 2
761;Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma;Objective Response Rate (ORR) (Dose Expansion Cohorts);Up to 2.5 years;Progression-free Survival (Dose Expansion Cohorts);Recruiting;Phase 2
762;A Study to Learn About the Study Medicine (Elranatamab) Either Alone or in Combination With Dexamethasone in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment;Proportion of participants with Grade 2 or higher Cytokine Release Syndrome (CRS) (Part 1 and 2);Cycle 1 (28 days);Incidence of Dose Limiting Toxicities (Part 2A and 2C);Recruiting;Phase 2
762;A Study to Learn About the Study Medicine (Elranatamab) Either Alone or in Combination With Dexamethasone in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment;Number of participants with overall response rate (ORR) per International Myeloma Working Group (IMWG) criteria (Part 3).;From the date of first dose until the first documentation of progressive disease (PD), death or start of new anticancer therapy, whichever occurs first (timeframe: approximately 2 years).;Frequency of Adverse Events;Recruiting;Phase 2
763;High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy;Time to disease progression,;Response rate to bortezomib, doxorubicin hydrochloride, and dexamethasone (PAD);Unknown status;Phase 3
763;High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy;Time to disease progression,;Overall response rate following randomized treatments;Unknown status;Phase 3
763;High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy;Time to disease progression,;Overall survival;Unknown status;Phase 3
763;High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy;Time to disease progression,;Progression-free survival;Unknown status;Phase 3
763;High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy;Time to disease progression,;Toxicity and safety of autologous stem cell transplantation;Unknown status;Phase 3
763;High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy;Time to disease progression,;Toxicity and safety of weekly cyclophosphamide;Unknown status;Phase 3
763;High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy;Time to disease progression,;Toxicity and safety of PAD therapy;Unknown status;Phase 3
763;High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy;Time to disease progression,;Feasibility of stem cell collection;Unknown status;Phase 3
763;High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy;Time to disease progression,;Pain;Unknown status;Phase 3
763;High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy;Time to disease progression,;Quality of life;Unknown status;Phase 3
764;Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma;Adverse Events (AEs);Up to 60 months;Overall Response Rate (ORR);Recruiting;Phase 1
764;Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma;Dose Limiting Toxicity (DLT);Up to 60 months;Time to Response;Recruiting;Phase 1
764;Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma;Non-Tolerated Dose (NTD);Up to 60 months;Duration of Response;Recruiting;Phase 1
764;Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma;Maximum Tolerated Dose (MTD);Up to 60 months;Progression Free Survival;Recruiting;Phase 1
765;UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib;The response rate of Trametinib when administered orally to patients with relapsed multiple myeloma;28 day,;Withdrawn;Phase 2
766;The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics;The long axial strain of echocardiography;From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 mouths,;Enrolling by invitation,
767;Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma;Not applicable for this trial.;Not applicable for this trial.,;Completed;Phase 1
768;A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma;Complete Response Rate: Number of Participants Who Achieved a Complete Response;From Cycle 2 until 28 days following completion of treatment;Overall Response: Number of Participants Who Achieved a Complete Response (CR) or Partial Response (PR);Completed;Phase 3
768;A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma;Complete Response Rate: Number of Participants Who Achieved a Complete Response;From Cycle 2 until 28 days following completion of treatment;Time to 1st Response;Completed;Phase 3
768;A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma;Complete Response Rate: Number of Participants Who Achieved a Complete Response;From Cycle 2 until 28 days following completion of treatment;Time to Progression;Completed;Phase 3
768;A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma;Complete Response Rate: Number of Participants Who Achieved a Complete Response;From Cycle 2 until 28 days following completion of treatment;Overall Survival: Number of Participants Died Due to Any Cause;Completed;Phase 3
768;A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma;Complete Response Rate: Number of Participants Who Achieved a Complete Response;From Cycle 2 until 28 days following completion of treatment;Transplantation: Number of Participants Who Underwent Transplantation (Peripheral Stem Cell / Bone Marrow);Completed;Phase 3
768;A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma;Complete Response Rate: Number of Participants Who Achieved a Complete Response;From Cycle 2 until 28 days following completion of treatment;Engraftment: Number of Participants Who Underwent Engraftment;Completed;Phase 3
769;A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma;Median Number of Cycles to Tumor Progression (TTP);18 months;Terminated;Phase 2
769;A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma;Overall Survival (OS) - Number of Participants Alive at Study Completion;18 months,;Terminated;Phase 2
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Complete response rate (CRR);Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Overall response rate (ORR);Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Duration of response (DoR) after administration of study treatment;Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Time to response (TTR) after administration of study treatment;Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Time to Progression (TTP) after administration of study treatment;Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Overall survival (OS);Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Progression-free survival on subsequent line of therapy (PFS2);Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Minimal Residual Disease (MRD) negativity rate after administration of study treatment;Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Number of participants with adverse events (AEs);Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Number of participants with serious adverse events (SAEs);Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Number of participants with abnormal ocular findings on ophthalmic examination;Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Plasma concentrations of belantamab mafodotin at indicated time points;Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Plasma concentrations of total monoclonal antibody (mAb) at indicated time points;Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Plasma concentrations of monomethyl auristatin-F with a cysteine linker (cys-mcMMAF) at indicated time points;Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin;Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Titers of ADAs against belantamab mafodotin;Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Change from Baseline in symptoms as measured by Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE);Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Change from Baseline in impacts as measured by PRO-CTCAE;Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Change from Baseline in health related quality of life (HRQoL) as measured by European Organization for Research and Treatment of Cancer Quality of life Questionnaire 30-item core module (EORTC QLQ-C30);Active, not recruiting;Phase 3
770;Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma;Progression-free survival;Up to an average of 34 months;Change from Baseline in HRQoL as measured by EORTC, 20-Item Multiple Myeloma Module (QLQ-MY20);Active, not recruiting;Phase 3
771;A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant;Part 1 Dose Limiting Toxicity;From the first dose of elranatamab until 28 days (+/- visit window) from the first administration of the EDR combination;Overall minimal residual disease negativity rate;Recruiting;Phase 3
771;A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant;Part 2: Progression free survival by blinded independent central review;From randomization up to 73 months.;Duration of minimal residual disease negativity (Part 2);Recruiting;Phase 3
771;A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant;Part 2: Sustained minimal residual disease negativity rate;For at least 12 months after randomization;PFS by investigator;Recruiting;Phase 3
772;Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma,,,;Completed;Phase 2
773;Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma;Number of patients reporting dose limiting toxicities;2 months;Immunogenicity of PDR001 and CJM112;Completed;Phase 1
773;Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma;The number of patients who experience a treatment-related adverse event after being treated with a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161;24 months;Overall Response Rate (ORR);Completed;Phase 1
773;Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma;The number of patients requiring interruptions after a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161;24 months;Best Overall Response (BOR);Completed;Phase 1
773;Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma;The number of patients treated with single agent CJM112, or PDR001 in combination with either CJM112 or LCL161, who discontinued treatment;24 months;Progression Free Survival (PFS);Completed;Phase 1
773;Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma;The number of patients requiring a dose reduction after a single dose of single agent CJM112, or two doses of PDR001 in combination with CJM112 or LCL161;24 months;Disease Control Rate (DCR);Completed;Phase 1
774;Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma;Part A (phase I);Secondary objectives of the study are:;Completed;Phase 1
774;Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma;To determine the safety and maximum tolerated dose (MTD) of;Part A plus Part B;Completed;Phase 2
775;Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma;Number of participants with adverse events;15 months,;Completed;Phase 1
775;Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma;Number of participants with adverse events;15 months,;Completed;Phase 2
776;Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma;Overall Response Rate (ORR) According to the IMWG Response Criteria Per Investigator Assessment;14 Months;Clinical Benefit Response (CBR);Terminated;Phase 1
776;Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma;Overall Response Rate (ORR) According to the IMWG Response Criteria Per Investigator Assessment;14 Months;Duration of Response (DOR);Terminated;Phase 2
777;Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma;Safety of patients receiving SAHA and lenalidomide following autologous PBSCT;up to 3 years;Duration of response;Completed;Phase 1
777;Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma;Safety of patients receiving SAHA and lenalidomide following autologous PBSCT;up to 3 years;Time to progression (TTP);Completed;Phase 1
777;Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma;Safety of patients receiving SAHA and lenalidomide following autologous PBSCT;up to 3 years;Progression-free survival (PFS);Completed;Phase 1
777;Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma;Safety of patients receiving SAHA and lenalidomide following autologous PBSCT;up to 3 years;Time to response;Completed;Phase 1
777;Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma;Safety of patients receiving SAHA and lenalidomide following autologous PBSCT;up to 3 years;Duration of overall response;Completed;Phase 1
777;Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma;Safety of patients receiving SAHA and lenalidomide following autologous PBSCT;up to 3 years;Overall survival;Completed;Phase 1
777;Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma;Safety of patients receiving SAHA and lenalidomide following autologous PBSCT;up to 3 years;Response rate;Completed;Phase 1
778;CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma;Time to Tumor Progression (TTP);60 weeks (median Time To Progression of CC-5013/Dex treatment group);Overall Survival;Completed;Phase 3
778;CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma;Time to Tumor Progression (TTP);60 weeks (median Time To Progression of CC-5013/Dex treatment group);Myeloma Response;Completed;Phase 3
778;CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma;Time to Tumor Progression (TTP);60 weeks (median Time To Progression of CC-5013/Dex treatment group);"Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)";Completed;Phase 3
779;FT576 in Subjects With Multiple Myeloma;Incidence and nature of DLTs within each dose-escalation cohort to determine the MTD or MAD;"Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1";Objective response rate (ORR);Recruiting;Phase 1
779;FT576 in Subjects With Multiple Myeloma;Determine the RP2D which will be based on the overall safety and anti-tumor activity among the dose escalation and dose expansion cohorts;From FPI to LPI's end of Cycle 1 study treatment (End of cycle is Day 29 from Day 1 FT576 infusion);Duration of response (DOR);Recruiting;Phase 1
779;FT576 in Subjects With Multiple Myeloma;Incidence, nature, and severity of adverse events;"Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1";Progression-free survival (PFS);Recruiting;Phase 1
780;Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients;Determine maximum tolerated dose (MTD);12 months;Withdrawn;Phase 1
780;Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients;Overall response rate (ORR);12 months,;Withdrawn;Phase 2
781;Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma;Percentage of Patients With an Objective Response;3 months;Number of Participants With Complete Response (CR);Active, not recruiting;Phase 2
781;Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma;Percentage of Patients With an Objective Response;3 months;Duration of Response;Active, not recruiting;Phase 2
781;Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma;Percentage of Patients With an Objective Response;3 months;Progression Free Survival Time;Active, not recruiting;Phase 2
781;Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma;Percentage of Patients With an Objective Response;3 months;Time to Treatment Failure;Active, not recruiting;Phase 2
782;Descartes-11 in Multiple Myeloma;Incidence (number) of Treatment-Emergent Adverse Events;14 Days;Treatment Response;Active, not recruiting;Phase 1
782;Descartes-11 in Multiple Myeloma;Incidence (number) of Treatment-Emergent Adverse Events;14 Days;Treatment Response;Active, not recruiting;Phase 2
783;A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma;Phase I: Determine a safe dose of ATN-224 and bortezomib to be used in the phase II portion of the study;Ongoing;Phase I: Preliminary evidence of efficacy;Terminated;Phase 1
783;A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma;Phase II: Efficacy;End of Study;Phase II: progression-free survival and duration of response;Terminated;Phase 2
784;A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Approximately 2 years;Minimum Observed Serum Concentration (Cmin) of JNJ-54767414 (Daratumumab);Completed;Phase 1
784;A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Approximately 2 years;Maximum Observed Serum Concentration (Cmax) of JNJ-54767414 (Daratumumab);Completed;Phase 1
784;A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Approximately 2 years;Serum Concentration of JNJ-54767414 (Daratumumab) Antibodies;Completed;Phase 1
784;A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Approximately 2 years;Percentage of Participants With Overall Response Rate (ORR);Completed;Phase 1
784;A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Approximately 2 years;Percentage of Participants with Complete Response (CR) or better;Completed;Phase 1
784;A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Approximately 2 years;Percentage of Participants with a Very Good Partial Response (VGPR) or better;Completed;Phase 1
784;A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Approximately 2 years;Time to Response;Completed;Phase 1
785;Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma;Quality of life;30 days;Time to engraftment;Completed;Not Applicable
785;Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma;Quality of life;30 days;Rate of febrile neutropenia;Completed;Not Applicable
786;MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb;objective response rate;assessed approximately every 4 weeks [up to approximately 2 years];objective response rate by baseline extramedullary disease status;Active, not recruiting;Phase 2
786;MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb;objective response rate;assessed approximately every 4 weeks [up to approximately 2 years];duration of response;Active, not recruiting;Phase 2
786;MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb;objective response rate;assessed approximately every 4 weeks [up to approximately 2 years];complete response rate;Active, not recruiting;Phase 2
786;MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb;objective response rate;assessed approximately every 4 weeks [up to approximately 2 years];duration of complete response;Active, not recruiting;Phase 2
786;MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb;objective response rate;assessed approximately every 4 weeks [up to approximately 2 years];progression free survival;Active, not recruiting;Phase 2
786;MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb;objective response rate;assessed approximately every 4 weeks [up to approximately 2 years];time to response;Active, not recruiting;Phase 2
786;MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb;objective response rate;assessed approximately every 4 weeks [up to approximately 2 years];minimal residual disease negativity rate;Active, not recruiting;Phase 2
786;MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb;objective response rate;assessed approximately every 4 weeks [up to approximately 2 years];frequency of treatment-emergent adverse events;Active, not recruiting;Phase 2
786;MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb;objective response rate;assessed approximately every 4 weeks [up to approximately 2 years];frequency of laboratory abnormalities;Active, not recruiting;Phase 2
786;MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb;objective response rate;assessed approximately every 4 weeks [up to approximately 2 years];concentrations of elranatamab (PF-06863135);Active, not recruiting;Phase 2
786;MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb;objective response rate;assessed approximately every 4 weeks [up to approximately 2 years];immunogenicity of elranatamab (PF-06863135);Active, not recruiting;Phase 2
786;MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb;objective response rate;assessed approximately every 4 weeks [up to approximately 2 years];overall survival;Active, not recruiting;Phase 2
787;Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185);Progression Free Survival (PFS) Evaluated According to the International Myeloma Working Group (IMWG) Response Criteria 2011 by Clinical Adjudication Committee (CAC) Blinded Central Review;Up to approximately 30 months;Overall Survival (OS);Terminated;Phase 3
787;Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185);Progression Free Survival (PFS) Evaluated According to the International Myeloma Working Group (IMWG) Response Criteria 2011 by Clinical Adjudication Committee (CAC) Blinded Central Review;Up to approximately 30 months;Overall Response Rate (ORR) Evaluated According to the IMWG Response Criteria by CAC Blinded Central Review;Terminated;Phase 3
787;Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185);Progression Free Survival (PFS) Evaluated According to the International Myeloma Working Group (IMWG) Response Criteria 2011 by Clinical Adjudication Committee (CAC) Blinded Central Review;Up to approximately 30 months;Duration of Response (DOR) Evaluated According to IMWG Response Criteria by CAC Blinded Central Review;Terminated;Phase 3
787;Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185);Progression Free Survival (PFS) Evaluated According to the International Myeloma Working Group (IMWG) Response Criteria 2011 by Clinical Adjudication Committee (CAC) Blinded Central Review;Up to approximately 30 months;Disease Control Rate (DCR) Evaluated According to the IMWG Response Criteria by CAC Blinded Central Review;Terminated;Phase 3
787;Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185);Progression Free Survival (PFS) Evaluated According to the International Myeloma Working Group (IMWG) Response Criteria 2011 by Clinical Adjudication Committee (CAC) Blinded Central Review;Up to approximately 30 months;Second Progression Free Survival (PFS2);Terminated;Phase 3
787;Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185);Progression Free Survival (PFS) Evaluated According to the International Myeloma Working Group (IMWG) Response Criteria 2011 by Clinical Adjudication Committee (CAC) Blinded Central Review;Up to approximately 30 months;Number of Participants Who Experienced One or More Adverse Events (AEs);Terminated;Phase 3
787;Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185);Progression Free Survival (PFS) Evaluated According to the International Myeloma Working Group (IMWG) Response Criteria 2011 by Clinical Adjudication Committee (CAC) Blinded Central Review;Up to approximately 30 months;Number of Participants Discontinuing Study Treatment Due to an AE;Terminated;Phase 3
788;Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma;Establish Maximum Tolerated Dose (MTD);time to complete Cycle 1 (28 days);Complete Response (CR);Recruiting;Phase 1
788;Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma;Evaluate Complete Response (CR);up to 5 years;Best Response;Recruiting;Phase 2
789;Thalidomide-Dexamethasone for Multiple Myeloma;Response Rate;Baseline, with each course and monthly tests,;Completed;Phase 2
789;Thalidomide-Dexamethasone for Multiple Myeloma;Response Rate;Baseline, with each course and monthly tests,;Completed;Phase 3
790;Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma,,,;Completed;Phase 2
791;Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma;Hematological Response Rate Defined as the Number of Participants Who Achieve a Confirmed Response;4 months;Overall Survival (OS);Terminated;Phase 2
791;Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma;Hematological Response Rate Defined as the Number of Participants Who Achieve a Confirmed Response;4 months;Progression-free Survival (PFS);Terminated;Phase 2
791;Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma;Hematological Response Rate Defined as the Number of Participants Who Achieve a Confirmed Response;4 months;Duration of Response (DOR);Terminated;Phase 2
791;Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma;Hematological Response Rate Defined as the Number of Participants Who Achieve a Confirmed Response;4 months;Number of Participants With Severe Non-hematological Adverse Events;Terminated;Phase 2
792;Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma;Determination of maximum tolerated dose;42 days in Arm A;Safety and tolerability will be analyzed for all patients. Safety endpoints will be based on adverse event reports, and include frequent adverse event (AE)s, serious adverse event (SAE)s and lab abnormalities;Completed;Phase 1
792;Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma;Determination of maximum tolerated dose;35 days in Arm B;Pharmacokinetic (PK) measures will be collected for all patients who received study medication. The pharmacokinetic parameters will be maximum observed concentration (Cmax);Completed;Phase 1
793;Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM);Part 1 - Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Up to approximately 31 months;Part 1 - Percentage of Participants With ORR;Active, not recruiting;Phase 1
793;Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM);Part 1 - Number of Participants With Dose Limiting Toxicities (DLTs);Up to 21 days;Part 2 - Number of Participants With AEs and SAEs;Active, not recruiting;Phase 2
794;Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma;Assess the ability of DVd plus arsenic trioxide to achieve an overall response (complete and partial) rate in patients with untreated Multiple myeloma(MM);2004-2008,;Completed;Phase 2
795;Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma;Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.;45 months;Overall Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone;Completed;Phase 3
795;Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma;Progression Free Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.;45 months;Overall Survival in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone;Completed;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Achieving minimal residual disease (MRD) negativity in participants with complete response (CR) or better at 12 (± 3) months of maintenance treatment;Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Overall Survival;Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Recommended iberdomide dose for Stage 2;Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Area under the iberdomide plasma concentration-time curve from time zero to tau;Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Area under the iberdomide plasma concentration-time curve within a dosing interval AUC (TAU);Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Maximum iberdomide concentration (Cmax);Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Time to maximum iberdomide plasma concentration (Tmax);Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Number of participants with adverse events (AEs);Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Progression-free survival on next line of treatment (PFS2);Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Achieving MRD negativity in participants with CR or better at any time after the date of randomization;Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Conversion from MRD positive to MRD negative in participants with CR or better;Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Achievement of CR or better and maintaining MRD-negative status in 2 bone marrow aspirate assessments that are a minimum of 6 months or 1 year apart, without any examination showing MRD positive status in between assessments;Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Time to progression (TTP);Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Time to next treatment (TTNT);Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Best response achieved prior to progressive disease (PD);Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Patient-reported health-related quality of life (HRQoL) outcomes and multiple myeloma-related symptoms as measured by the European Organization for Research and Treatment of Cancer [EORTC] Quality of Life C30 questionnaire (QLQ-C30);Not yet recruiting;Phase 3
796;A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma;Progression-free survival (PFS);Up to 6 years;Patient-reported HRQoL outcomes and multiple myeloma-related symptoms as measured by the EORTC Quality of Life Multiple Myeloma Module (QLQ-MY20);Not yet recruiting;Phase 3
797;Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma;Maximum tolerated dose of elotuzumab in combination with belantamab mafodotin in subjects;28 days;Preliminary evaluation of clinical efficacy/response rate;Recruiting;Phase 1
797;Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma;Number of Participants who Experienced Dose-Limiting Toxicities (DLTs);28 days;To evaluate progression free survival (PFS);Recruiting;Phase 2
798;PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma;Detectable Paraprotein Level (IgG or IgA)at ≤5 g/dL Who Show a 50% Reduction (Complete Response + Partial Response) in Their Paraprotein After Starting Treatment With the Study Drug;Day 90;Time to Progression;Terminated;Phase 2
798;PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma;Detectable Paraprotein Level (IgG or IgA)at ≤5 g/dL Who Show a 50% Reduction (Complete Response + Partial Response) in Their Paraprotein After Starting Treatment With the Study Drug;Day 90;Safety and Tolerability of PTK787/ZK 222584;Terminated;Phase 2
798;PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma;Detectable Paraprotein Level (IgG or IgA)at ≤5 g/dL Who Show a 50% Reduction (Complete Response + Partial Response) in Their Paraprotein After Starting Treatment With the Study Drug;Day 90;Disease Free Survival;Terminated;Phase 2
799;Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma;comparison progression-free survival (PFS) in patients with newly diagnosed myeloma treated with lenalidomide plus low dose dexamethasone versus bortezomib plus lenalidomide and low dose dexamethasone;Four years,;Completed;Phase 3
800;Pethema Multiple Myeloma 2000,,,;Completed;Phase 3
801;Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma;Overall Response Rate (ORR);From date of registration until 28 days after last dose of trial medication with longest treatment time of approximately 36 months;Overall Survival (OS);Terminated;Phase 2
801;Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma;Overall Response Rate (ORR);From date of registration until 28 days after last dose of trial medication with longest treatment time of approximately 36 months;Overall Survival (OS) at 12 months;Terminated;Phase 2
801;Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma;Overall Response Rate (ORR);From date of registration until 28 days after last dose of trial medication with longest treatment time of approximately 36 months;Progression-free survival (PFS);Terminated;Phase 2
802;Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma;Determine Maximum Tolerated Dose (MTD) if any, and recommended dose schedule;Every 56 days on treatment, estimated average of 4 months.;Safety;Completed;Phase 1
802;Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma;Determine Maximum Tolerated Dose (MTD) if any, and recommended dose schedule;Every 56 days on treatment, estimated average of 4 months.;Anti-Tumor Activity;Completed;Phase 1
802;Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma;Determine Maximum Tolerated Dose (MTD) if any, and recommended dose schedule;Every 56 days on treatment, estimated average of 4 months.;Pharmacokinetics;Completed;Phase 1
802;Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma;Determine Maximum Tolerated Dose (MTD) if any, and recommended dose schedule;Every 56 days on treatment, estimated average of 4 months.;Pharmacodynamics;Completed;Phase 1
803;Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma;Rate of grade 3 or 4 treatment related adverse effect;24 weeks after last dose of CAR-T treatment;Pharmacokinetics of CAR-T cells (implantation endpoint);Recruiting;Phase 1
803;Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma;Overall response rate (ORR) after treated by CAR-T treatment;up to 2 years after CAR-T treatment;Overall survival;Recruiting;Phase 1
804;Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma;Improvement in functional status, as measured by the Oswestry Disability Index (ODI);1 month;Change in Quality of Life (SF-35 Health Survey);Withdrawn;Phase 4
804;Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma;Improvement in functional status, as measured by the Oswestry Disability Index (ODI);1 month;Change in Back Pain (VAS);Withdrawn;Phase 4
804;Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma;Improvement in functional status, as measured by the Oswestry Disability Index (ODI);1 month;Change in Physical Disability associated with back pain (Roland-Morris Disability Questionnaire);Withdrawn;Phase 4
805;A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma;Number of patients with adverse events as a measure of safety and tolerability;Up to 14 months;Serum siltuximab concentration;Terminated;Phase 1
805;A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma;Number of patients with adverse events as a measure of safety and tolerability;Up to 14 months;Number of patients with a positive immune response to siltuximab;Terminated;Phase 1
805;A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma;Number of patients with adverse events as a measure of safety and tolerability;Up to 14 months;Number of patients with an overall response (complete response and partial response);Terminated;Phase 1
806;Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma;Overall Response Rate;Up to 24 months;Adverse Events;Completed;Phase 2
806;Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma;Overall Response Rate;Up to 24 months;Progression Free Survival (PFS);Completed;Phase 2
806;Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma;Overall Response Rate;Up to 24 months;Overall Survival;Completed;Phase 2
806;Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma;Overall Response Rate;Up to 24 months;Response duration;Completed;Phase 2
806;Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma;Overall Response Rate;Up to 24 months;Maximum observed concentration in plasma;Completed;Phase 2
806;Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma;Overall Response Rate;Up to 24 months;Area under the plasma concentration-time curve;Completed;Phase 2
806;Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma;Overall Response Rate;Up to 24 months;Time to maximum concentration;Completed;Phase 2
806;Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma;Overall Response Rate;Up to 24 months;Terminal half-life;Completed;Phase 2
806;Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma;Overall Response Rate;Up to 24 months;Apparent total body clearance;Completed;Phase 2
806;Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma;Overall Response Rate;Up to 24 months;Apparent volume of distribution;Completed;Phase 2
807;Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma;Response rate, as measured by International Bone Marrow Transplant Registry (IBMTR)/European Group for Blood and Marrow Transplantation (EBMT) Response Criteria, at 4 weeks,;Toxicity as assessed by NCI CTC v2.0;Completed;Phase 2
807;Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma;Response rate, as measured by International Bone Marrow Transplant Registry (IBMTR)/European Group for Blood and Marrow Transplantation (EBMT) Response Criteria, at 4 weeks,;Formation of antirabbit antibodies;Completed;Phase 2
808;Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,,,;Unknown status;Phase 2
809;Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma;Incidence and severity of AEs and SAEs, incl. changes in laboratory parameters, vital signs and ECGs.;2 years;"Best Overall response (BOR) per International Myeloma Working Group (IMWG) criteria for Myeloma; and per revised criteria for staging of the International Working Group (IWG) guidelines for Lymphoma";Completed;Phase 1
809;Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma;Incidence of DLTs during the first cycle of treatment with single agent MIK665 during the dose escalation phase only;2 years;Area Under Curve (AUC);Completed;Phase 1
809;Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma;Tolerability: Dose interruptions;2 years;Maximum Plasma Concentration (Cmax);Completed;Phase 1
809;Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma;Tolerability: Dose reductions;2 years;Terminal elimination half-life (T1/2);Completed;Phase 1
809;Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma;Tolerability: Dose intensity;2 years;Apparent volume of distribution (Vz);Completed;Phase 1
810;VitD3 Supplementation in Patients With Multiple Myeloma;To describe the lymphocyte subset analysis for the two treatment arms at 120 days post autologous stem cell transplant [120 days];120 days;To report the 3-year progression-free survival for both treatment arms - intensified vs. therapeutic Vitamin D supplementation;Not yet recruiting;Early Phase 1
810;VitD3 Supplementation in Patients With Multiple Myeloma;To describe the lymphocyte subset analysis for the two treatment arms at 120 days post autologous stem cell transplant [120 days];120 days;To report the overall response rate for both treatment arms 120 days after ASCT for adult patients with multiple myeloma.;Not yet recruiting;Early Phase 1
810;VitD3 Supplementation in Patients With Multiple Myeloma;To describe the lymphocyte subset analysis for the two treatment arms at 120 days post autologous stem cell transplant [120 days];120 days;To report the overall response rate for both treatment arms 2 years after transplantation;Not yet recruiting;Early Phase 1
810;VitD3 Supplementation in Patients With Multiple Myeloma;To describe the lymphocyte subset analysis for the two treatment arms at 120 days post autologous stem cell transplant [120 days];120 days;To report the 3-year overall survival for the two treatment arms after transplantation.;Not yet recruiting;Early Phase 1
810;VitD3 Supplementation in Patients With Multiple Myeloma;To describe the lymphocyte subset analysis for the two treatment arms at 120 days post autologous stem cell transplant [120 days];120 days;To report the minimal residual disease status for the two treatment arms at randomization, and within 120 days after transplantation and 2 years after transplantation.;Not yet recruiting;Early Phase 1
810;VitD3 Supplementation in Patients With Multiple Myeloma;To describe the lymphocyte subset analysis for the two treatment arms at 120 days post autologous stem cell transplant [120 days];120 days;To report the vitamin D levels between the two treatments arms before autologous stem cell transplant, within 120 days, and 3-years post-transplantation;Not yet recruiting;Early Phase 1
810;VitD3 Supplementation in Patients With Multiple Myeloma;To describe the lymphocyte subset analysis for the two treatment arms at 120 days post autologous stem cell transplant [120 days];120 days;To describe the adverse events for the two treatment arms;Not yet recruiting;Early Phase 1
810;VitD3 Supplementation in Patients With Multiple Myeloma;To describe the lymphocyte subset analysis for the two treatment arms at 120 days post autologous stem cell transplant [120 days];120 days;To report time to neutrophil and platelet engraftment as well as transfusion independence after transplantation in both treatment arms;Not yet recruiting;Early Phase 1
811;Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma;The difference in event-free survival time will be compared between both arms;Every 35 days during treatment phase, after 4, 8, 12, 18, 24 months during follow-up;"Best response to chemotherapy, response rate to chemotherapy , duration of response, toxicities and quality of life; timepoints for assessments will be at end of study, at 1,5 + 4 + 8 +12 + 18 + 24 + 30 months and thereafter 6 monthly";Completed;Phase 3
812;Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab;Change in Patient's Qualitative Assessment of Treatment Real World version (PQAT-RW);Change in baseline perception of treatment experience at 3 months;Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30);Recruiting;Not Applicable
812;Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab;Qualitative Interview;Within the last month of study participation;Change in Quality of Life Questionnaire Multiple Myeloma (QLQ-MY20);Recruiting;Not Applicable
813;Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma;Maximum tolerated dose and dose-limiting toxicity,;Response rate (complete, partial, and minimal response);Completed;Phase 1
813;Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma;Maximum tolerated dose and dose-limiting toxicity,;Time to disease progression and time to response;Completed;Phase 1
813;Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma;Maximum tolerated dose and dose-limiting toxicity,;Progression-free and overall survival;Completed;Phase 1
813;Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma;Maximum tolerated dose and dose-limiting toxicity,;Antitumor effects;Completed;Phase 1
814;A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.;The safe dose of AUY922 when administered once a week.;54 weeks (Maximum Tolerated Dose (MTD));The safe dose of AUY922 when administered once a week in combination with bortezomib and dexamethasone.;Completed;Phase 1
814;A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.;The safe dose of AUY922 when administered once a week.;54 weeks (Maximum Tolerated Dose (MTD));Efficacy of AUY922 administered once a week alone and in combination;Completed;Phase 2
815;Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma;Number of Participants With Adverse Events (AEs);"From the first dose of any study drug up to 30 days after the last dose of any study drug; median (range) duration of treatment with carfilzomib was 32 (1.1, 76.7) weeks in RRMM participants and 26 (1.0, 94.4) weeks in NDMM participants.";Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group;Completed;Phase 1
815;Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma;Change From Baseline in Hemoglobin Levels;Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15;Time to Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group;Completed;Phase 1
815;Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma;Change From Baseline in Platelet Count;Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15;Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group;Completed;Phase 1
815;Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma;Change From Baseline in Neutrophil Count;Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15;Overall Response Rate (ORR);Completed;Phase 1
815;Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma;Change From Baseline in Bilirubin;Baseline and Cycle 2 day 1;Complete Response Rate (CRR);Completed;Phase 1
815;Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma;Change From Baseline in Creatinine;Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15;Progression-free Survival (PFS);Completed;Phase 1
816;A Phase II Study of BI-505 in Smoldering Multiple Myeloma;To assess the change in disease activity measured as M-protein levels in serum/urine following BI-505 treatment compared to base line according to the International Myeloma Working Group (IMWG) uniform response criteria;M-protein will be measured at screening, prior to each dose and at end of study visit, for up to 19 weeks.;The clinical safety of BI-505 will be assessed by reporting the numbers of AEs, the severity and the relationship to IMP.;Terminated;Phase 2
816;A Phase II Study of BI-505 in Smoldering Multiple Myeloma;To assess the change in disease activity measured as M-protein levels in serum/urine following BI-505 treatment compared to base line according to the International Myeloma Working Group (IMWG) uniform response criteria;M-protein will be measured at screening, prior to each dose and at end of study visit, for up to 19 weeks.;The pharmacokinetic profile of BI-505 will be determined by calculating the following pharmacokinetic parameters: AUC, % AUCex, Cmax, Tmax, CL, Vss and T1/2.;Terminated;Phase 2
816;A Phase II Study of BI-505 in Smoldering Multiple Myeloma;To assess the change in disease activity measured as M-protein levels in serum/urine following BI-505 treatment compared to base line according to the International Myeloma Working Group (IMWG) uniform response criteria;M-protein will be measured at screening, prior to each dose and at end of study visit, for up to 19 weeks.;The pharmacodynamics of BI-505 will be assessed by measuring soluble biomarkers and ICAM-1 saturation on bone marrow plasma cells.;Terminated;Phase 2
816;A Phase II Study of BI-505 in Smoldering Multiple Myeloma;To assess the change in disease activity measured as M-protein levels in serum/urine following BI-505 treatment compared to base line according to the International Myeloma Working Group (IMWG) uniform response criteria;M-protein will be measured at screening, prior to each dose and at end of study visit, for up to 19 weeks.;The immunogenicity profile of BI-505 will be assessed by measuring antibodies towards BI-505.;Terminated;Phase 2
817;A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria;From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.;Time-to-Response (TTR);Completed;Phase 2
817;A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria;From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.;Duration of Response (DOR);Completed;Phase 2
817;A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria;From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.;Progression Free Survival;Completed;Phase 2
817;A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria;From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.;Overall Survival;Completed;Phase 2
817;A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria;From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.;Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration Of Durvalumab;Completed;Phase 2
817;A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria;From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.;Area Under the Plasma Concentration-time Curve From Time 0 to Extrapolated to Infinity (AUC-inf) of Durvalumab;Completed;Phase 2
817;A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria;From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.;Maximum Observed Concentration (Cmax) Of Durvalumab;Completed;Phase 2
817;A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria;From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.;Time to Reach Maximum Concentration (Tmax) of Durvalumab;Completed;Phase 2
817;A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria;From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.;Terminal Half-Life (T1/2) of of Durvalumab;Completed;Phase 2
817;A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria;From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.;Apparent Total Clearance (CL/F) of of Durvalumab;Completed;Phase 2
817;A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria;From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.;Apparent Volume of Distribution (Vz/F) of Durvalumab;Completed;Phase 2
817;A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria;From randomization until the data cut-off date of 17 April 2018. The median duration of treatment for durvalumab and daratumumab was 7.9 weeks and 8.0 weeks respectively.;Participants With Treatment-Emergent Adverse Events (TEAEs);Completed;Phase 2
818;UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment;Change in Serum Osteocalcin From Baseline to End of Study in Patients With Relapsed/Refractory Multiple Myeloma.;Baseline, Treatment (28-day cycles for 6 cycles),;Completed;Phase 2
819;Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma;Objective response rate (ORR);Up to 90 days after T cell infusion;Incidence and Severity of Adverse Events as a Measure of Safety;Withdrawn;Not Applicable
819;Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma;Objective response rate (ORR);Up to 90 days after T cell infusion;Duration of persistence of BCMA-CART;Withdrawn;Not Applicable
820;Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma;Overall response rate,;time to progression;Terminated;Phase 2
820;Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma;Overall response rate,;duration of response;Terminated;Phase 2
820;Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma;Overall response rate,;number of cycles of azacitidine required to first achieve a response;Terminated;Phase 2
820;Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma;Overall response rate,;progression free survival;Terminated;Phase 2
820;Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma;Overall response rate,;safety;Terminated;Phase 2
820;Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma;Overall response rate,;tolerability;Terminated;Phase 2
821;Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma;Number of participants with adverse events;1 years;Clinical response after completion of Vax-DC/MM injection;Unknown status;Phase 1
821;Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma;Number of participants with adverse events;1 years;Progression free survival;Unknown status;Phase 2
822;Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma;Overall Response Rate (ORR);up to end of study, an average of 11 months;Fraction of Participants Who Experience a Complete Response (CR) or Stringent Complete Response (sCR) Using the Study Treatment;Terminated;Phase 2
822;Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma;Overall Response Rate (ORR);up to end of study, an average of 11 months;Fraction of Participants Who Experience a Minimal Residual Disease Negative (MRDneg)Complete Response (CR) Using the Study Treatment;Terminated;Phase 2
822;Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma;Overall Response Rate (ORR);up to end of study, an average of 11 months;Percent Change in Aberrant Circulating Plasma Cells in the Peripheral Blood (PB) and Bone Marrow (BM) From Baseline;Terminated;Phase 2
822;Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma;Overall Response Rate (ORR);up to end of study, an average of 11 months;Percent Reduction in Size of On-irradiated Extramedullary Lesions;Terminated;Phase 2
822;Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma;Overall Response Rate (ORR);up to end of study, an average of 11 months;Fluorodeoxyglucose (FDG) Avidity Positron-Emission Tomography/Computed Tomography (PET/CT) of Non-irradiated Extramedullary Lesions (Abscopal Effect) Compared to Baseline;Terminated;Phase 2
822;Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma;Overall Response Rate (ORR);up to end of study, an average of 11 months;Progression-free Survival (PFS);Terminated;Phase 2
822;Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma;Overall Response Rate (ORR);up to end of study, an average of 11 months;Percentage of Participants With Overall Survival (OS);Terminated;Phase 2
822;Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma;Overall Response Rate (ORR);up to end of study, an average of 11 months;Number of Participants With Grade ≥1 Non-serious Adverse Events;Terminated;Phase 2
822;Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma;Overall Response Rate (ORR);up to end of study, an average of 11 months;Number of Participants Overall Best Response;Terminated;Phase 2
823;Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,,,;Completed;Phase 1
823;Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,,,;Completed;Phase 2
824;Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma;Confirmed response (i.e., clinical or immunological),,;Completed;Phase 2
825;A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma;Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs);28 days;Clinical Benefit Response Rate;Completed;Phase 1
825;A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma;Overall Response Rate (ORR);"Disease response was assessed once every treatment cycle (28 days) and 30 days after last dose; the median overall treatment duration was 33.6 weeks.";Progression-free Survival;Completed;Phase 2
826;Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma;Change in Quality of life using questionnaires EORTC QLQ-30;At baseline, at the 6th month and the 12th month;Survival;Recruiting,
826;Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma;Change in Quality of life using questionnaires EORTC QLQ-MY20;At baseline, at the 6th month and the 12th month;Multidimensional evaluation of home care;Recruiting,
827;Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 30 days;Time to Next Treatment (TTNT);Completed;Phase 2
827;Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma;Toxicities of Single Agent Tivantinib: Grade 3 Nonhematologic or Grade 4 Hematologic Toxicities According to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4;Up to 30 days;Time to Next Treatment (TTNT);Completed;Phase 2
828;A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma;Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087;First cycle of treatment;Overall Response Rate;Completed;Phase 1
828;A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma;Number of Participants Who Develop Anti-MOR03087 Antibodies;during treatment period, maximum 3 years after 1st dose;Time to Progression;Completed;Phase 2
829;P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM);Phase 1: Assess the Safety of P-BCMA-101;Baseline through Day 28;Phase 1:Assess the safety of P-BCMA-101;Terminated;Phase 1
829;P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM);Phase 1: Maximum tolerated dose of P-BCMA-101;Baseline through Day 28;Phase 1:Assess the feasibility P-BCMA-101;Terminated;Phase 2
830;Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma;Progression free survival (scale);1 year;Response rate (scale);Unknown status;Phase 1
830;Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma;Progression free survival (scale);1 year;Incidence of graft failure, engraftment and time to neutrophil and platelet recovery (hematology);Unknown status;Phase 2
831;High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma;Overall Response Rate After 4 Cycles;4 months;Progression-free Survival;Completed;Phase 2
831;High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma;Overall Response Rate After 4 Cycles;4 months;Overall Survival;Completed;Phase 2
832;Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma;Dose-Limiting Toxicities (DLTs);Up to 28 days after the first dose;Preliminary Efficacy - Overall Response Rate (ORR);Recruiting;Phase 1
832;Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma;Maximum Tolerated Dose (MTD);Up to 12 weeks after the last dose;Preliminary Efficacy - Time to response;Recruiting;Phase 1
832;Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma;Incidence of Adverse Events (AEs);Up to 12 weeks after the last dose;Preliminary Efficacy - Duration of response;Recruiting;Phase 1
833;Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma;Progression Free Survival (PFS);From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months;Overall Response Rate (ORR);Withdrawn;Phase 2
834;A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma;Overall Response Rate (ORR);From the date of randomization up to death (approximately 14 months);Duration of Response (DOR);Recruiting;Phase 2
834;A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma;Overall Response Rate (ORR);From the date of randomization up to death (approximately 14 months);Clinical Benefit Rate (CBR);Recruiting;Phase 2
834;A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma;Overall Response Rate (ORR);From the date of randomization up to death (approximately 14 months);Disease control rate (DCR);Recruiting;Phase 2
834;A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma;Overall Response Rate (ORR);From the date of randomization up to death (approximately 14 months);Progression-Free Survival (PFS);Recruiting;Phase 2
834;A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma;Overall Response Rate (ORR);From the date of randomization up to death (approximately 14 months);Overall Survival (OS);Recruiting;Phase 2
834;A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma;Overall Response Rate (ORR);From the date of randomization up to death (approximately 14 months);Time to Next Treatment (TTNT);Recruiting;Phase 2
834;A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma;Overall Response Rate (ORR);From the date of randomization up to death (approximately 14 months);Number of Participants with Adverse Events (AE);Recruiting;Phase 2
835;Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma,,,;Completed;Phase 2
836;Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region Living With a Myeloma in West-Occitanie;Treatment lines and procedures followed by the patients;5 to 10 years;Best response (BR);Recruiting,
836;Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region Living With a Myeloma in West-Occitanie;Transplants;5 to 10 years;Progression-free Survival (PFS);Recruiting,
836;Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region Living With a Myeloma in West-Occitanie;Treatments discontinuation;5 to 10 years;PFS after the second therapeutic line;Recruiting,
836;Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region Living With a Myeloma in West-Occitanie;Therapeutic medical care description;5 to 10 years;"Overall Survival (OS);";Recruiting,
836;Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region Living With a Myeloma in West-Occitanie;Unconventional alternative medicine;5 to 10 years;Quality of life (QOL) during the treatment course;Recruiting,
836;Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region Living With a Myeloma in West-Occitanie;Outpatient support structure;5 to 10 years;Second primary cancers (SPC) and grade 3 and higher neuropathies;Recruiting,
837;Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR);From Day 1 of study treatment up to 60 months;Treatment failure-free survival (TFFS) Time;Recruiting;Phase 2
837;Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR);From Day 1 of study treatment up to 60 months;Progression-Free Survival (PFS);Recruiting;Phase 2
837;Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR);From Day 1 of study treatment up to 60 months;Maximum Depth of Response;Recruiting;Phase 2
837;Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR);From Day 1 of study treatment up to 60 months;Rate of achievement of bone marrow minimal residual disease (MRD) negativity;Recruiting;Phase 2
837;Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR);From Day 1 of study treatment up to 60 months;Clinical Benefit Rate (minimal response (MR) + ORR);Recruiting;Phase 2
837;Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR);From Day 1 of study treatment up to 60 months;Time to Response;Recruiting;Phase 2
837;Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR);From Day 1 of study treatment up to 60 months;Duration of Response;Recruiting;Phase 2
837;Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR);From Day 1 of study treatment up to 60 months;Time to Next Treatment;Recruiting;Phase 2
837;Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR);From Day 1 of study treatment up to 60 months;Overall Survival;Recruiting;Phase 2
837;Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR);From Day 1 of study treatment up to 60 months;Toxicity Rate;Recruiting;Phase 2
838;Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial;response rate;2012;Time to progression;Unknown status;Phase 1
838;Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial;response rate;2012;Time to progression;Unknown status;Phase 2
839;Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR) During Induction Therapy;Up to 8 months;Severe Adverse Event Rate;Terminated;Phase 2
839;Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR) During Induction Therapy;Up to 8 months;Maximum Depth of Response During Induction Therapy;Terminated;Phase 2
839;Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR) During Induction Therapy;Up to 8 months;Maximum Depth of Response During Maintenance Therapy;Terminated;Phase 2
839;Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR) During Induction Therapy;Up to 8 months;Median Time to Response;Terminated;Phase 2
839;Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR) During Induction Therapy;Up to 8 months;Median Duration of Response;Terminated;Phase 2
839;Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR) During Induction Therapy;Up to 8 months;Median Progression-free Survival;Terminated;Phase 2
839;Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR) During Induction Therapy;Up to 8 months;Median Overall Survival;Terminated;Phase 2
839;Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR) During Induction Therapy;Up to 8 months;QLQ-C30 Question 29;Terminated;Phase 2
839;Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR) During Induction Therapy;Up to 8 months;QLQ-C30 Question 30;Terminated;Phase 2
839;Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR) During Induction Therapy;Up to 8 months;Functionality as Assessed Using the Cancer and Leukemia Group B (CALGB) Geriatric Assessment Tool;Terminated;Phase 2
839;Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma;Overall Response Rate (ORR) During Induction Therapy;Up to 8 months;Risk Score as Assessed Using the Cancer and Leukemia Group B (CALGB) Geriatric Assessment Tool;Terminated;Phase 2
840;Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,,,;Completed;Phase 2
841;Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM);Maximal Tolerated Dose (MTD);28 days (within first treatment cycle);Response;Completed;Phase 1
841;Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM);Maximal Tolerated Dose (MTD);28 days (within first treatment cycle);Rates of Adverse Events (AE),Serious Adverse Events and AEs leading to permanent treatment discontinuation;Completed;Phase 2
842;Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant;Maximum tolerated dose;At course 8;Overall response rate by Southwest Oncology Group (SWOG) criteria;Completed;Phase 1
842;Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant;Safety and tolerability;At course 8;Complete response rate by SWOG criteria;Completed;Phase 1
843;A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039,,,;Completed;Phase 3
844;Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma;Toxicity (Phase I);Immunoglobulin free light chain response;Completed;Phase 1
844;Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma;Confirmed clinical response (complete response, very good partial response, partial response, or minimal response) (Phase II),;Changes in complete blood cell count and micronucleated reticulocyte count;Completed;Phase 2
845;Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma;Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria;up to around 44 weeks;Response Rate (sCR+CR) Based on IMWG Criteria;Completed;Phase 2
845;Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma;Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria;up to around 44 weeks;Complete Response (CR) Based on the Blade Criteria;Completed;Phase 2
845;Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma;Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria;up to around 44 weeks;Response Rate (CR+PR) Based on the Blade Criteria;Completed;Phase 2
845;Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma;Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria;up to around 44 weeks;Progression-Free Survival (PFS);Completed;Phase 2
845;Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma;Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria;up to around 44 weeks;Time to Treatment Failure (TTF);Completed;Phase 2
845;Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma;Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria;up to around 44 weeks;Duration of Response (DOR);Completed;Phase 2
845;Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma;Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria;up to around 44 weeks;Overall Survival (OS);Completed;Phase 2
845;Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma;Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria;up to around 44 weeks;Adverse Events;Completed;Phase 2
845;Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma;Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria;up to around 44 weeks;Number of Subjects With Abnormality (Grade ≥3) in Laboratory Test Values;Completed;Phase 2
845;Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma;Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria;up to around 44 weeks;Number of Abnormalities (Grade ≥3) in Laboratory Test Values;Completed;Phase 2
846;"Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)";Time to disease progression (from the date of the first dose to the date of the first observation of disease progression);The final analysis of disease progression will be run when at least 29 events will occur (expected average of 32months ).;Safety of pomalidomide and dexamethasone;Completed;Phase 2
846;"Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)";Time to disease progression (from the date of the first dose to the date of the first observation of disease progression);The final analysis of disease progression will be run when at least 29 events will occur (expected average of 32months ).;Overall Response rate (Partial Response and better), Very Good Partial Response (VGPR) + Complete Response (CR) rate and stringent Complete Response (sCR) rate to pomalidomide and dexamethasone in MM patients;Completed;Phase 2
846;"Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)";Time to disease progression (from the date of the first dose to the date of the first observation of disease progression);The final analysis of disease progression will be run when at least 29 events will occur (expected average of 32months ).;Time to response and Response duration of pomalidomide and dexamethasone.;Completed;Phase 2
846;"Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)";Time to disease progression (from the date of the first dose to the date of the first observation of disease progression);The final analysis of disease progression will be run when at least 29 events will occur (expected average of 32months ).;Overall Survival of pomalidomide and dexamethasone and event free survival;Completed;Phase 2
846;"Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)";Time to disease progression (from the date of the first dose to the date of the first observation of disease progression);The final analysis of disease progression will be run when at least 29 events will occur (expected average of 32months ).;Response and Time to disease progression with regards to cytogenetic abnormalities in the bone marrow tumor plasma cells;Completed;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Duration of Response (DOR);Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Very Good Partial Response (VGPR) or Better Rate;Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Complete Response (CR) or Better Rate;Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Stringent Complete Response (sCR) Rate;Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Time to Response (TTR);Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Progression-Free Survival (PFS);Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Overall Survival (OS);Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Minimal Residual Disease (MRD) Negative Rate;Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability;Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Number of Participants with Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability;Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Number of Participants with AEs by Severity;Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Number of Participants with Abnormalities in Clinical Laboratory Values;Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Serum Concentration of Talquetamab;Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Number of Participants with Talquetamab Antibodies;Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Change from Baseline in Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC QLQ-C30);Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Change from Baseline in HRQoL as Assessed by EuroQol Five Dimension Five Level Questionnaire (EQ-5D-5L);Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Change from Baseline in HRQoL as Assessed by Patient Global Impression of Severity (PGIS);Recruiting;Phase 2
847;A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 2 years and 10 months;Overall Response Rate (ORR) in Participants with High-risk Molecular Features;Recruiting;Phase 2
848;Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma,,,;Completed;Phase 2
849;Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma;response rate;12 months;time to relapse;Completed;Phase 3
849;Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma;response rate;12 months;overall survival;Completed;Phase 3
850;A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma.;Frailty status defined according to Geriatric assessment;18 months from Recruitment End;Active, not recruiting,
850;A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma.;Frailty status defined according to biomarkers of frailty: Teleomere Length;18 months from Recruitment End;Active, not recruiting,
850;A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma.;Frailty status defined according to biomarkers of frailty: miRNAs;18 months from Recruitment End;Active, not recruiting,
850;A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma.;Frailty status defined according to biomarkers of frailty: CDKN2A;18 months from Recruitment End;Active, not recruiting,
850;A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma.;Frailty status defined according to Geriatric assessment;18 months from Recruitment End;Active, not recruiting,
850;A Single-centre Prospective Study to Explore the Role of Frailty in Patients With Multiple Myeloma.;Frailty status defined according to Geriatric assessment;18 months from Recruitment End,;Active, not recruiting,
851;Frontline Therapy in de Novo Multiple Myeloma Patients Under 65;Evaluation of the best response after consolidation;6 to 8 months after start of induction for each patient = after consolidation therapy for all patients;Response Evaluation after 3 cycles;Completed;Phase 2
851;Frontline Therapy in de Novo Multiple Myeloma Patients Under 65;Evaluation of the best response after consolidation;6 to 8 months after start of induction for each patient = after consolidation therapy for all patients;Safety and tolerability : number and nature of Adverse Events;Completed;Phase 2
851;Frontline Therapy in de Novo Multiple Myeloma Patients Under 65;Evaluation of the best response after consolidation;6 to 8 months after start of induction for each patient = after consolidation therapy for all patients;Stem Cells Collection;Completed;Phase 2
851;Frontline Therapy in de Novo Multiple Myeloma Patients Under 65;Evaluation of the best response after consolidation;6 to 8 months after start of induction for each patient = after consolidation therapy for all patients;Response After HDT-ASCT and 2 cycles;Completed;Phase 2
851;Frontline Therapy in de Novo Multiple Myeloma Patients Under 65;Evaluation of the best response after consolidation;6 to 8 months after start of induction for each patient = after consolidation therapy for all patients;Progression Free Survival;Completed;Phase 2
852;Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib;The change in the quality of life as measured by EORTC QLQ-C30 and EQ-5D before and after the administration of bortezomib;On day 1 at the first cycle, 12 weeks, 24 weeks;Relationship between the primary outcome and the complete remission (CR) rate;Completed,
852;Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib;The change in the quality of life as measured by EORTC QLQ-C30 and EQ-5D before and after the administration of bortezomib;On day 1 at the first cycle, 12 weeks, 24 weeks;Relationship between the primary outcome and overall response;Completed,
852;Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib;The change in the quality of life as measured by EORTC QLQ-C30 and EQ-5D before and after the administration of bortezomib;On day 1 at the first cycle, 12 weeks, 24 weeks;Relationship between the primary outcome and the time to response;Completed,
852;Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib;The change in the quality of life as measured by EORTC QLQ-C30 and EQ-5D before and after the administration of bortezomib;On day 1 at the first cycle, 12 weeks, 24 weeks;Relationship between the primary outcome and the survival;Completed,
852;Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib;The change in the quality of life as measured by EORTC QLQ-C30 and EQ-5D before and after the administration of bortezomib;On day 1 at the first cycle, 12 weeks, 24 weeks;Adverse events;Completed,
853;Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) using investigator's response assessment;All patients treated for 6 cycles (cycle=28 days);Very Good Partial Response (VGPR) or better as best response using investigator response assessment based on International Myeloma Working Group (IMWG) criteria;Withdrawn;Phase 2
853;Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) using investigator's response assessment;All patients treated for 6 cycles (cycle=28 days);Progression-free survival (PFS) using investigator's response assessment based on IMWG criteria;Withdrawn;Phase 2
853;Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) using investigator's response assessment;All patients treated for 6 cycles (cycle=28 days);Overall survival (OS);Withdrawn;Phase 2
853;Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) using investigator's response assessment;All patients treated for 6 cycles (cycle=28 days);Time to response (TTR) using investigator's response assessment based on IMWG criteria;Withdrawn;Phase 2
853;Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) using investigator's response assessment;All patients treated for 6 cycles (cycle=28 days);Duration of Response (DOR) using investigator's response assessment based on IMWG criteria;Withdrawn;Phase 2
853;Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) using investigator's response assessment;All patients treated for 6 cycles (cycle=28 days);Time to progression (TTP) using investigator's response assessment based on IMWG criteria;Withdrawn;Phase 2
853;Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) using investigator's response assessment;All patients treated for 6 cycles (cycle=28 days);Time to reach Cmax for panobinostat (PAN) and carfilzomib (CFZ);Withdrawn;Phase 2
853;Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) using investigator's response assessment;All patients treated for 6 cycles (cycle=28 days);Minimum observed plasma concentration (Cmin) for carfilzomib;Withdrawn;Phase 2
853;Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) using investigator's response assessment;All patients treated for 6 cycles (cycle=28 days);Concentration of panobinostat in blood plasma in 48 hrs after the dose.;Withdrawn;Phase 2
853;Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) using investigator's response assessment;All patients treated for 6 cycles (cycle=28 days);Total carfilzomib exposure over time in blood plasma .;Withdrawn;Phase 2
853;Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;Overall response rate (ORR) using investigator's response assessment;All patients treated for 6 cycles (cycle=28 days);Health related quality of life (HRQoL) change over time measured by EORTC questionnaire QLQ-C30 and QLQ-MY20 for disease symptoms;Withdrawn;Phase 2
854;A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma;Presence of biochemical bone turnover;Average of 3 months;Number of Adverse Events related to sotatercept;Withdrawn;Phase 2
854;A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma;Presence of biochemical bone turnover;Average of 3 months;Bone marrow density;Withdrawn;Phase 2
854;A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma;Presence of biochemical bone turnover;Average of 3 months;Change in biochemical myeloma markers;Withdrawn;Phase 2
854;A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma;Presence of biochemical bone turnover;Average of 3 months;Size of target bone lesions;Withdrawn;Phase 2
855;A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma;Incidence of dose-limiting toxicities;28-day observation period following C1D1 of therapy;Overall response of TTI-621;Recruiting;Phase 1
855;A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma;Incidence of dose-limiting toxicities;28-day observation period following C1D1 of therapy;Overall response of TTI-622;Recruiting;Phase 1
856;Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma;Overall Remission Rate (ORR);2 monthes after infusion;Progression-free survival (PFS);Recruiting;Early Phase 1
856;Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma;Incidence of dose limiting toxicity (DLTs);within 2 monthes after infusion;Duration of Response (DOR);Recruiting;Early Phase 1
857;Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma;Maximum Tolerated Dose (MTD) of Carfilzomib in combination with bendamustine and dexamethasone;6 months;Overall response rate (ORR);Completed;Phase 1
857;Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma;Maximum Tolerated Dose (MTD) of Carfilzomib in combination with bendamustine and dexamethasone;6 months;Duration of response (DOR);Completed;Phase 2
858;Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma;Proportion of patients experiencing treatment-related ≥ grade 3 hematologic or nonhematologic toxicity or treatment-related death (phase I),;Time to response (phase II);Unknown status;Phase 1
858;Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma;Proportion of patients experiencing treatment-related ≥ grade 3 hematologic or nonhematologic toxicity or treatment-related death (phase I),;Progression-free survival (phase II);Unknown status;Phase 2
859;Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,,,;Completed;Phase 1
859;Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,,,;Completed;Phase 2
860;A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma;Progression Free Survival;Analysis to be conducted after a minimum of 201 events;Overall Time to Progression;Terminated;Phase 3
860;A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma;Progression Free Survival;Analysis to be conducted after a minimum of 201 events;Overall Survival;Terminated;Phase 3
861;P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma;Part 1: Assess the maximum tolerated dose (MTD) of P-BCMA-ALLO1 based on dose limiting toxicities (DLT);Baseline through Day 28;The safety of P-BCMA-ALLO1;Recruiting;Phase 1
861;P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma;Part 2: Assess the safety and tolerability of P-BCMA-ALLO1 when administered as a fixed dose of cells.;Baseline through 36 months;The anti-myeloma effect of P-BCMA-ALLO1 (ORR);Recruiting;Phase 1
862;Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5);DE Phase: Number of participants achieving dose limiting toxicities (DLT);Up to 12 months;DE Phase: Number of participants achieving ORR;Recruiting;Phase 1
862;Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5);DE Phase: Number of participants with adverse events (AEs) and serious adverse events (SAEs);Up to 12 months;CE Phase: Number of participants achieving Clinical Benefit Rate (CBR);Recruiting;Phase 2
863;UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma;To evaluate whether high-dose density treatment during the initial seven months, including tandem transplants within six months after starting therapy, results in superior event-free and overall survival rates as compared to historical controls.;seven months;To evaluate the ability of pegfilgrastim to mobilize stem cells when administered following DTPACE in MM patients with active disease, compared to historical controls mobilized with DTPACE and either GM-CSF or G-CSF.;Completed;Phase 2
864;A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma;Determine the maximum tolerated dose of SGN-40 when combined with bortezomib;Length of study;Determine safety, pharmacokinetics, and clinical response rate for combination therapy with SGN-40 and bortezomib;Completed;Phase 1
865;Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT);Relative Dose Intensity (RDI) Per Cohort;Up to 2 years;Complete Response Rate;Completed;Phase 2
865;Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT);Relative Dose Intensity (RDI) Per Cohort;Up to 2 years;Progression Free Survival (PFS);Completed;Phase 2
865;Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT);Relative Dose Intensity (RDI) Per Cohort;Up to 2 years;Overall Survival (OS);Completed;Phase 2
866;Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma;Response Rate (CR + PR After 2 Cycles);Up to 2 years;Number of Participants With Adverse Events of Grade 3 or Higher;Terminated;Phase 2
866;Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma;Response Rate (CR + PR After 2 Cycles);Up to 2 years;Percentage of Subjects Who Have Complete Response or Partial Response and Have 2+ or Higher Autophagy;Terminated;Phase 2
866;Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma;Response Rate (CR + PR After 2 Cycles);Up to 2 years;Median Duration of Response of This Regimen;Terminated;Phase 2
867;UARK 89-001 Phase II Study of Intensive TOTAL THERAPY For Untreated or Minimally Treated Patients With Multiple Myeloma;Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy;5 years,;Completed;Phase 2
868;Autologous Transplantation for Multiple Myeloma;Complete or near Complete Response Rate,;Relapse-free Survival;Completed;Phase 3
868;Autologous Transplantation for Multiple Myeloma;Complete or near Complete Response Rate,;Event-free Survival;Completed;Phase 3
868;Autologous Transplantation for Multiple Myeloma;Complete or near Complete Response Rate,;Overall Survival;Completed;Phase 3
869;Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance;Overall Response Rate (ORR);6 months;Number of Participants Evaluated for Toxicity;Completed;Phase 2
870;A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure;Description of current treatment regimens for MMY.;Every 3 months from baseline to 3 years after last patient recruited;Utilisation of current treatment regimens for MMY;Completed,
870;A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure;Description of current treatment regimens for MMY.;Every 3 months from baseline to 3 years after last patient recruited;Quality of life and health economic parameters associated with MMY treatment regimens;Completed,
870;A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure;Description of current treatment regimens for MMY.;Every 3 months from baseline to 3 years after last patient recruited;Safety profile of current treatment regimens for MMY;Completed,
870;A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure;Description of current treatment regimens for MMY.;Every 3 months from baseline to 3 years after last patient recruited;The effectiveness of current treatment regimens for MMY;Completed,
871;Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma;Phase 1: Incidence of dose-limiting toxicities (DLTs);21 days;Phase 1 and Phase 2: Maximum concentration (Cmax) of JCARH125 in the blood;Active, not recruiting;Phase 1
871;Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma;Phase 1: Incidence and severity of adverse events;2 years;Phase 1 and Phase 2: Time to maximum concentration (Tmax) of JCARH125 in the blood;Active, not recruiting;Phase 2
872;Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant;Number of toxicity incidents (Phase I);Number of responses (Phase I);Completed;Phase 1
872;Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant;Proportion of successes (Phase II),;Overall survival (Phase II);Completed;Phase 2
873;Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma;Does Limiting Toxicity (DLT) rates _Phase 1;Up to 28 days from start of the combination therapy;Incidence of Adverse Event (AEs);Recruiting;Phase 1
873;Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma;Complete Response Rate (CRR)_ Phase 2;Up to 24 months;Overall Response Rate (ORR);Recruiting;Phase 2
874;Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction;Number of Participants in Phase I Component With Dose Limiting Toxicities During the First Cycle of Therapy;First cycle of therapy (28 days);Overall Survival Time;Terminated;Phase 1
874;Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction;Percentage of Participants Who Experience a Response [sCR, CR, VGPR, PR];56 months;Duration of Response;Terminated;Phase 2
875;Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients;Evaluate the change of neuropathy in actively treated multiple myeloma subjects diagnosed with CIPN who received acupuncture vs standard of care management.;approx. 10 weeks;Assess Specific features of CIPN - Nausea;Recruiting;Not Applicable
875;Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients;Evaluate the change of neuropathy in actively treated multiple myeloma subjects diagnosed with CIPN who received acupuncture vs standard of care management.;approx. 10 weeks;Assess Specific features of CIPN - Sadness;Recruiting;Not Applicable
875;Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients;Evaluate the change of neuropathy in actively treated multiple myeloma subjects diagnosed with CIPN who received acupuncture vs standard of care management.;approx. 10 weeks;Assess Specific features of CIPN - Nervousness;Recruiting;Not Applicable
875;Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients;Evaluate the change of neuropathy in actively treated multiple myeloma subjects diagnosed with CIPN who received acupuncture vs standard of care management.;approx. 10 weeks;Assess Specific features of CIPN - Sleep quality;Recruiting;Not Applicable
875;Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients;Evaluate the change of neuropathy in actively treated multiple myeloma subjects diagnosed with CIPN who received acupuncture vs standard of care management.;approx. 10 weeks;Assess Specific features of CIPN - Lack of energy;Recruiting;Not Applicable
875;Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients;Evaluate the change of neuropathy in actively treated multiple myeloma subjects diagnosed with CIPN who received acupuncture vs standard of care management.;approx. 10 weeks;Assess Specific features of CIPN - Pain;Recruiting;Not Applicable
875;Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients;Evaluate the change of neuropathy in actively treated multiple myeloma subjects diagnosed with CIPN who received acupuncture vs standard of care management.;approx. 10 weeks;Assess Specific features of CIPN - Constipation;Recruiting;Not Applicable
875;Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients;Evaluate the change of neuropathy in actively treated multiple myeloma subjects diagnosed with CIPN who received acupuncture vs standard of care management.;approx. 10 weeks;Assess Specific features of CIPN - Dizziness;Recruiting;Not Applicable
875;Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients;Evaluate the change of neuropathy in actively treated multiple myeloma subjects diagnosed with CIPN who received acupuncture vs standard of care management.;approx. 10 weeks;Assess Specific features of CIPN - Dry Mouth;Recruiting;Not Applicable
875;Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients;Evaluate the change of neuropathy in actively treated multiple myeloma subjects diagnosed with CIPN who received acupuncture vs standard of care management.;approx. 10 weeks;Assess Quality of Life;Recruiting;Not Applicable
876;Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment;Overall response rate,;Toxicity;Unknown status;Phase 2
876;Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment;Overall response rate,;Tolerability;Unknown status;Phase 2
876;Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment;Overall response rate,;Duration of response after completion of treatment;Unknown status;Phase 2
876;Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment;Overall response rate,;Time to progression;Unknown status;Phase 2
876;Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment;Overall response rate,;Overall and progression-free survival;Unknown status;Phase 2
877;Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma;Daratumumab Related Infusion Reactions;28 days;Determination of Response Rates;Recruiting;Phase 2
878;A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients;Minimal residual disease (MRD);5 years;Progression-free survival (PFS);Active, not recruiting;Phase 2
878;A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients;Minimal residual disease (MRD);5 years;Overall response rate (ORR);Active, not recruiting;Phase 2
878;A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients;Minimal residual disease (MRD);5 years;Progression-free survival 2 (PFS2);Active, not recruiting;Phase 2
878;A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients;Minimal residual disease (MRD);5 years;Duration of response (DOR);Active, not recruiting;Phase 2
878;A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients;Minimal residual disease (MRD);5 years;Overall survival (OS);Active, not recruiting;Phase 2
878;A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients;Minimal residual disease (MRD);5 years;Safety as incidence of toxicities;Active, not recruiting;Phase 2
878;A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients;Minimal residual disease (MRD);5 years;Time to next therapy (TNT);Active, not recruiting;Phase 2
878;A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients;Minimal residual disease (MRD);5 years;Percentage of patients with negative MRD and survival indices;Active, not recruiting;Phase 2
879;A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function;Part 1 and Part 2: Maximum observed plasma concentration (Cmax) of GSK2857916;Up to 48 months;Part 1 and Part 2: Change from Baseline in Vital Signs- Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) (millimeters of mercury [mmHg]);Recruiting;Phase 1
879;A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function;Part 1 and Part 2: Time to Cmax (Tmax) of GSK2857916;Up to 48 months;Part 1 and Part 2: Change from Baseline in Vital Sign- Heart rate (beats per minute);Recruiting;Phase 1
879;A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function;Part 1 and Part 2: Concentration at the end of infusion (C-EOI);Up to 48 months;Part 1 and Part 2: Number of participants with adverse events (AEs) and serious adverse events (SAEs);Recruiting;Phase 1
879;A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function;Part 1 and Part 2: Predose plasma concentration (Ctrough) of GSK2857916;Up to 48 months;Part 1 and Part 2: Number of participants with toxicity grading for hematology parameters;Recruiting;Phase 1
879;A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function;Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval);Up to 48 months;Part 1 and Part 2: Number of participants with toxicity grading for clinical chemistry parameters;Recruiting;Phase 1
879;A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function;Part 1 and Part 2 : AUC over the dosing interval (AUC[0-tau]) of GSK2857916;Up to 48 months;Part 1 and Part 2: Number of participants with toxicity grading for urine parameters;Recruiting;Phase 1
879;A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function;Part 1 and Part 2: Last time point where the concentration is above the limit of quantification (Tlast) of GSK2857916;Up to 48 months;Part 1 and Part 2: Number of participants with abnormal physical examination parameters;Recruiting;Phase 1
880;A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers;Number of Participants Who Completed 12 Cycles of Treatment;12 cycles (each cycle is 28 days);Percentage of Expected Dose of Carfilzomib Received in Cycles 1 to 6 and 7 to 12;Terminated;Phase 2
880;A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers;Percentage of Expected Dose of Carfilzomib Received in Cycles 1 to 12;Up to 12 cycles (each cycle is 28 days);Relative Dose Intensity of Carfilzomib in Cycles 1 to 6 and 7 to 12;Terminated;Phase 2
880;A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers;Relative Dose Intensity of Carfilzomib in Cycles 1 to 12;Up to 12 Cycles (each cycle is 28 days);Number of Participants With Carfilzomib Dose Modifications During Cycles 1 to 6;Terminated;Phase 2
880;A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers;Number of Participants With Carfilzomib Dose Modifications During Cycles 1 to 12;Cycles 1 - 12 (each cycle is 28 days);Number of Participants With Carfilzomib Dose Modifications During Cycles 7 to 12;Terminated;Phase 2
880;A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers;Number of Participants With Treatment-emergent Adverse Events;From the first dose of study drug until 30 days after the last dose (12 months);Number of Participants Who Discontinued Carfilzomib in Cycles 1 to 6 and 7 to 12;Terminated;Phase 2
881;Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma;Plerixafor Maximum Tolerated Dose (MTD) [Phase I];"Participants were assessed every 3 weeks while on study; The observation period for MTD evaluation was the first 21 days of treatment.";Time to Progression (TTP) [Phase II];Completed;Phase 1
881;Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma;Bortezomib Maximum Tolerated Dose (MTD) [Phase I];"Participants were assessed every 3 weeks while on study; The observation period for MTD evaluation was the first 21 days of treatment.";Duration of Response (DOR) [Phase II];Completed;Phase 2
882;A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma;Number of Participants with Dose Limiting Toxicities (DLT) of ABBV-383;Up to approximately 28 Days;Overall Response Rate (ORR);Recruiting;Phase 1
882;A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma;Number of Participants with Adverse Events (AEs);Up to Approximately 3 Years;Progression-Free Survival (PFS);Recruiting;Phase 1
883;Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma;Randomisation 1: Number of participants with early treatment cessation;Within 60 days of Randomisation 1;Progression-free survival (PFS-R1);Recruiting;Phase 3
883;Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma;Randomisation 2: Progression-free survival (PFS-R2);The time from the date of Randomisation 2 to the date of first documented evidence of disease progression or death from any cause, up to 120 months;Time to disease progression;Recruiting;Phase 3
884;Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma;Transplant-related mortality at 180 days,;Disease response (complete response);Completed;Phase 2
884;Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma;Transplant-related mortality at 180 days,;Progression-free survival;Completed;Phase 2
884;Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma;Transplant-related mortality at 180 days,;Overall survival at 1 year;Completed;Phase 2
885;CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma;(Part A) Number of patients with dose limiting toxicities (DLT);28 days;Recruiting;Phase 1
885;CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma;(Part B) Overall Response Rate (ORR);12 Months,;Recruiting;Phase 1
886;Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma;Evaluate the safety and dose-limiting toxicity of treatment with dovitinib in combination with bortezomib/ dexamethasone.;Treatment Cycle 1 (three weeks) for each participant.;To assess the overall response rate for the combination dovitinib/bortezomib/ dexamethasone in patients receiving at least 4 cycles of therapy.;Withdrawn;Phase 1
887;Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma;Progression to multiple myeloma;Up to 2 years;Overall response rate (ORR);Withdrawn;Phase 2
887;Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma;Overall survival;Up to 2 years;Incidence of adverse events (AEs);Withdrawn;Phase 2
888;Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);up to 4 years;Duration of Response (DOR);Completed;Phase 1
888;Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma;Overall Response Rate (ORR);up to 4 years;Overall Survival;Completed;Phase 2
889;UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients;Maximal Dose of Busulfex® Given in a 2, 3, or 4 Day Period With Acceptable Toxicity to Myeloma Patients;three years,;Terminated;Phase 1
889;UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients;Maximal Dose of Busulfex® Given in a 2, 3, or 4 Day Period With Acceptable Toxicity to Myeloma Patients;three years,;Terminated;Phase 2
890;A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants with Dose-limiting toxicities (DLT);Day 21;Objective Response Rate (ORR);Active, not recruiting;Phase 1
890;A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs);Up to 3 Years;Percentage of Participants with Overall Survival (OS);Active, not recruiting;Phase 2
891;Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma;Maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of regimen (Phase I only);Completion of first cycle of treatment for all participants enrolled in Phase I portion (estimated to be 9 months);Number of adverse events experienced by participants (Phase I and Phase II);Active, not recruiting;Phase 1
891;Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma;Overall response rate (ORR) (Phase II only);6 months;Progression-free survival (PFS) (Phase II only);Active, not recruiting;Phase 1
892;A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma;90% confidence interval of the relative mean Cmax, AUC0-t, AUC0-∞, of the test and reference;2 cycles;Treatment Emergent Adverse Events;Completed;Phase 1
893;A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients;To determine whether the orthostatic hypotension reported among subjects during bortezomib-containing regimen is caused by a dysfunction of the autonomic nervous system (ANS).;1 year;To gather pilot data on the incidence of autonomic dysfunction in patients with Multiple Myeloma prior to treatment with Bortezomib.;Unknown status,
893;A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients;To determine whether the orthostatic hypotension reported among subjects during bortezomib-containing regimen is caused by a dysfunction of the autonomic nervous system (ANS).;1 year;To characterize the changes in the ANS including the fluctuations in blood pressure (hypotension /hypertension) associated with bortezomib.;Unknown status,
894;Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients;Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment;24 months,;Completed;Phase 1
894;Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients;Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment;24 months,;Completed;Phase 2
895;Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP;Maximum Tolerated Dosage;1 Year;Percentage (%) of patients with drug-related adverse events (adverse reactions);Terminated;Phase 1
895;Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP;Recommended Dosage;1 Year;The pharmacokinetic profile (AUC INF) for APO010 at doses above 60 µg/m2;Terminated;Phase 2
896;Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients;progression-free survival;2 years;rate of complete remission;Unknown status;Not Applicable
896;Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients;overall survival;2 years;minimal residual disease;Unknown status;Not Applicable
897;A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients;The primary endpoint was complete response (CR) and near complete response rate (nCR) post induction therapy (i.e. 4 cycles of therapy). Each cycle consisted of 21 days.,;The secondary endpoints included time to best response, assessment of peripheral blood stem cells harvesting ( 3 weeks post cycle 4 day 21) and engraftment (within 4 weeks of mobilization), CR post-engraftment, QoL and safety (every cycle).;Completed;Phase 2
898;Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.;The proportion of patients with stem cell yield at least 5 × 10^6 CD34+ cells/kg in each treatment arm.;After up to three leukaphereses (7-20 days after starting mobilization regimen).;Peak level of CD34+ cells in peripheral blood (/μl).;Completed;Phase 3
898;Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.;The proportion of patients with stem cell yield at least 5 × 10^6 CD34+ cells/kg in each treatment arm.;After up to three leukaphereses (7-20 days after starting mobilization regimen).;Total number of harvested CD34+cells/kg.;Completed;Phase 3
898;Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.;The proportion of patients with stem cell yield at least 5 × 10^6 CD34+ cells/kg in each treatment arm.;After up to three leukaphereses (7-20 days after starting mobilization regimen).;Number of leukaphereses needed to harvest target amount of stem cells.;Completed;Phase 3
898;Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.;The proportion of patients with stem cell yield at least 5 × 10^6 CD34+ cells/kg in each treatment arm.;After up to three leukaphereses (7-20 days after starting mobilization regimen).;The proportion of hematologic and non-hematologic complications.;Completed;Phase 3
898;Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.;The proportion of patients with stem cell yield at least 5 × 10^6 CD34+ cells/kg in each treatment arm.;After up to three leukaphereses (7-20 days after starting mobilization regimen).;Duration of neutropenia < 0.5 x10^9/L and thrombocytopenia <50 x10^9/L.;Completed;Phase 3
898;Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.;The proportion of patients with stem cell yield at least 5 × 10^6 CD34+ cells/kg in each treatment arm.;After up to three leukaphereses (7-20 days after starting mobilization regimen).;Number of blood transfusions needed and number of days of antibiotics therapy.;Completed;Phase 3
898;Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.;The proportion of patients with stem cell yield at least 5 × 10^6 CD34+ cells/kg in each treatment arm.;After up to three leukaphereses (7-20 days after starting mobilization regimen).;Duration of hospital stay.;Completed;Phase 3
898;Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.;The proportion of patients with stem cell yield at least 5 × 10^6 CD34+ cells/kg in each treatment arm.;After up to three leukaphereses (7-20 days after starting mobilization regimen).;Time of neutrophil and platelet engraftment after autologous stem cel transplantation.;Completed;Phase 3
899;PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma;Overall response rate;Planned analysis cut-off per patient: two weeks after last vaccination.;Immunogenicity of the PD-L1 vaccine;Terminated;Phase 2
899;PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma;Overall response rate;Planned analysis cut-off per patient: two weeks after last vaccination.;Incidence of Treatment Emergent Adverse Events;Terminated;Phase 2
899;PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma;Overall response rate;Planned analysis cut-off per patient: two weeks after last vaccination.;Progression-free survival (PFS);Terminated;Phase 2
899;PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma;Overall response rate;Planned analysis cut-off per patient: two weeks after last vaccination.;Time to progression (TTP);Terminated;Phase 2
899;PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma;Overall response rate;Planned analysis cut-off per patient: two weeks after last vaccination.;Overall survival (OS);Terminated;Phase 2
900;LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma;4-Month Progression Free Survival;4 months;Objective Response Rate (ORR);Active, not recruiting;Phase 1
900;LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma;Dose Limiting Toxicity (DLT);28 days;Clinical Benefit Rate;Active, not recruiting;Phase 2
901;Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma;3-Year Progression-free survival (PFS);3-years after randomization;Assessment of response;Active, not recruiting;Phase 2
902;Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma;Complete remission after 4 cycles:;Terminated;Phase 2
902;Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma;disappearance of serum and/or urine M-component (confirmed by immunofixation);Terminated;Phase 2
902;Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma;< 5% plasma cells in the bone marrow resolution of all extra-osseous plasmacytomas;Terminated;Phase 2
902;Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma;no evidence of bone progression,,;Terminated;Phase 2
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Recommended CC- 92480 dose;Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Plasma concentrations of CC-92480;Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Overall Survival (OS);Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Overall Response Rate (ORR);Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Percentage of participants with Complete Response Rate (CRR) or better as assessed by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma;Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Percentage of participants with Very Good Partial Response Rate (VGPRR) or better as assessed by the IMWG Uniform Response Criteria for Multiple Myeloma;Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Time to Response (TTR);Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Duration of Response (DOR);Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Time to Progression (TTP);Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Time to Next Treatment (TTNT);Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Progression-free Survival 2 (PFS-2);Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Minimal Residual Disease (MRD) negativity rate;Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Number of participants with Adverse Events (AEs);Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life C30 questionnaire (EORTC QLQ-C30) scores;Recruiting;Phase 3
903;A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM);Progression-free Survival (PFS);From date of randomization to date of disease progression or death due to any cause (Up to approximately 5 years);Change from baseline in European Organization for Research and Treatment of Cancer - Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20) score;Recruiting;Phase 3
904;Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple Myeloma;Personal Patient Preference Towards Using the MOATT Intervention assessed by a 5 point Likert scale.;18 months from study recruitment date.;Objective adherence rate of medication assessed by number of cap openings.;Unknown status;Not Applicable
904;Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple Myeloma;Personal Patient Preference Towards Using the MOATT Intervention assessed by a 5 point Likert scale.;18 months from study recruitment date.;Self Reported Adherence Rate assessed by Brief Adherence Rating Scale (BARS).;Unknown status;Not Applicable
904;Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple Myeloma;Personal Patient Preference Towards Using the MOATT Intervention assessed by a 5 point Likert scale.;18 months from study recruitment date.;Toxicities of Oral Myeloma Treatment assessed by the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE tool).;Unknown status;Not Applicable
905;An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD;Percentage of Participants With Overall Response;Up to 14.4 Months;Duration of Response;Completed;Phase 2
905;An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD;Percentage of Participants With Overall Response;Up to 14.4 Months;Overall Survival;Completed;Phase 2
905;An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD;Percentage of Participants With Overall Response;Up to 14.4 Months;Percentage of Participants With Clinical Benefit;Completed;Phase 2
905;An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD;Percentage of Participants With Overall Response;Up to 14.4 Months;Time to Response;Completed;Phase 2
905;An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD;Percentage of Participants With Overall Response;Up to 14.4 Months;Progression Free Survival;Completed;Phase 2
905;An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD;Percentage of Participants With Overall Response;Up to 14.4 Months;Time to Disease Progression;Completed;Phase 2
906;Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia;To determine if arsenic trioxide and ascorbic acid at doses up to 0.25 mg/mg/dose can be given in combination with reduced-dose dexamethasone, bortezomib and thalidomide without dose limiting toxicity, especially sensory neuropathies.;Days 1, 4, 8 & 11 of each 21 day cycle;Estimate the Overall Response Rate (ORR), Complete Response Rate (CRR), and Response Duration (RD) in patients treated with the Maximally Tolerated Dose (MTD) of this regimen.;Completed;Phase 1
906;Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia;To determine if arsenic trioxide and ascorbic acid at doses up to 0.25 mg/mg/dose can be given in combination with reduced-dose dexamethasone, bortezomib and thalidomide without dose limiting toxicity, especially sensory neuropathies.;Days 1, 4, 8 & 11 of each 21 day cycle;Determine if addition of Arsenic Trioxide[AT]/Ascorbic Acid (Vit C)[AA] starting in cycle 2 of treatment increases NF-kappa-B [NFKB] inhibition in cycles 2 and 3 compared to cycle 1.;Completed;Phase 1
907;Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM);Phase I: Number of Participants With Dose Limiting Toxicity;28 days;Phase II - Percent of Patients With Acute Graft Versus Host Disease (GvHD);Terminated;Phase 1
907;Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM);Phase II: Percent of Patients Alive and Free of Progression at 12 Months Following Transplant;Transplant (Day 0) through 1 year post-transplant;Phase II - Percent of Patients With Chronic Graft Versus Host Disease (GvHD);Terminated;Phase 2
908;Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma;The Number of Patients That Achieve Complete Response;180 days post-transplant;The Estimated Percentage of Patients Alive Without Relapse or Progression at 2 Years;Completed;Phase 2
908;Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma;The Number of Patients That Achieve Complete Response;180 days post-transplant;The Estimated Percentage of Patients Alive at 2 Years;Completed;Phase 2
909;Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.;To determine the highest and safest dose of LBH589 when it is administered in combination with lenalidomide & dexamethasone;24 weeks;Safety and tolerability assessed by monitoring of adverse events, serious adverse events and laboratory parameters To characterize the pharmacokinetic profile of the study treatment To characterize the pharmacodynamic profile of the study treatment;Completed;Phase 1
910;Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma,,,;Terminated;Phase 3
911;A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients;Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria;Up to disease progression, approximately 3 years;Percentage of Participants Who Achieved Overall Response ie, Complete Response (CR) or Partial Response (PR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria;Completed;Phase 2
911;A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients;Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria;Up to disease progression, approximately 3 years;Percentage of Participants Who Achieved Stringent Complete Response (sCR) - International Myeloma Working Group (IMWG) Criteria;Completed;Phase 2
911;A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients;Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria;Up to disease progression, approximately 3 years;Progression-Free Survival (PFS);Completed;Phase 2
911;A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients;Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria;Up to disease progression, approximately 3 years;1-year Progression-Free Survival (PFS) Rate;Completed;Phase 2
911;A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients;Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria;Up to disease progression, approximately 3 years;Duration of Response (DOR);Completed;Phase 2
911;A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients;Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria;Up to disease progression, approximately 3 years;1-year Survival Rate;Completed;Phase 2
911;A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients;Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria;Up to disease progression, approximately 3 years;Overall Survival;Completed;Phase 2
911;A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients;Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria;Up to disease progression, approximately 3 years;Change From Baseline to Cycle 9 in Global Health Status/Quality of Life Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30);Completed;Phase 2
912;Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma;To assess of the overall response rate (complete response (CR) + partial response (PR));After four 28-day consecutives cycles;Time to best response;Completed;Phase 2
912;Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma;To assess of the overall response rate (complete response (CR) + partial response (PR));After four 28-day consecutives cycles;Progression-free survival;Completed;Phase 2
912;Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma;To assess of the overall response rate (complete response (CR) + partial response (PR));After four 28-day consecutives cycles;Time to progression;Completed;Phase 2
912;Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma;To assess of the overall response rate (complete response (CR) + partial response (PR));After four 28-day consecutives cycles;Overall survival;Completed;Phase 2
912;Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma;To assess of the overall response rate (complete response (CR) + partial response (PR));After four 28-day consecutives cycles;Rate of additional response;Completed;Phase 2
912;Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma;To assess of the overall response rate (complete response (CR) + partial response (PR));After four 28-day consecutives cycles;Toxicity/Adverse events;Completed;Phase 2
913;Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma;Adverse events and lab abnormalities.;Within 3 weeks of final infusion of SGN-40;Best clinical response, progression-free survival, and overall survival.;Completed;Phase 1
913;Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma;Adverse events and lab abnormalities.;Within 3 weeks of final infusion of SGN-40;PK profile.;Completed;Phase 1
913;Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma;Adverse events and lab abnormalities.;Within 3 weeks of final infusion of SGN-40;Anti-drug antibody immune responses.;Completed;Phase 1
914;Quality of Life in Patients With Multiple Myeloma,,,;Completed,
915;Multiparametric Imaging in Multiple Myeloma;Quantitative measure of C11 Methionine uptake;12 months,;Completed;Phase 1
916;Linvolseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM2);Incidence of pre-defined safety criteria or dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period;Up to 28 Days;Objective response rate (ORR) as measured by International Myeloma Working Group (IMWG) criteria;Recruiting;Phase 1
916;Linvolseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM2);Incidence of treatment-emergent adverse events (TEAEs);Up to 5 Years;Duration of response (DOR) by IMWG criteria;Recruiting;Phase 1
916;Linvolseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM2);Severity of TEAEs;Up to 5 Years;Progression-free survival (PFS) as measured by IMWG criteria;Recruiting;Phase 1
916;Linvolseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM2);Incidence of serious adverse events (SAEs);Up to 5 Years;Rate of minimal residual disease (MRD) negative status by IMWG criteria;Recruiting;Phase 1
916;Linvolseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM2);Severity of SAEs;Up to 5 Years;Concentrations of total REGN5458 in serum over time;Recruiting;Phase 1
916;Linvolseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM2);Incidence of adverse events of special interest (AESIs);Up to 5 Years;Incidence over time of anti-drug antibodies (ADAs) to REGN5458;Recruiting;Phase 1
916;Linvolseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma (LINKER-MM2);Severity of AESIs;Up to 5 Years;Overall Survival (OS);Recruiting;Phase 1
917;Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission;2-year progression free survival;2 years;Response Conversion Rate;Active, not recruiting;Phase 2
917;Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission;2-year progression free survival;2 years;MRD Conversion Rate;Active, not recruiting;Phase 2
917;Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission;2-year progression free survival;2 years;Time to Response;Active, not recruiting;Phase 2
917;Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission;2-year progression free survival;2 years;Progression Free Survival (PFS);Active, not recruiting;Phase 2
917;Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission;2-year progression free survival;2 years;Evaluate toxicity of allogenic myeloma vaccine;Active, not recruiting;Phase 2
917;Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission;2-year progression free survival;2 years;Measure tumor specific immunity and correlate with systemic immunity;Active, not recruiting;Phase 2
918;A Safety Study of SEA-BCMA in Patients With Multiple Myeloma;Incidence of adverse events (AEs);Through 30-37 days following last dose, up to approximately 3 years;Pharmacokinetic (PK) outcome: Cmax (maximum serum concentration);Active, not recruiting;Phase 1
918;A Safety Study of SEA-BCMA in Patients With Multiple Myeloma;Number of participants with laboratory abnormalities by grade;Through 30-37 days following last dose, up to approximately 3 years;PK outcome: AUC (area under the serum concentration-time curve);Active, not recruiting;Phase 1
918;A Safety Study of SEA-BCMA in Patients With Multiple Myeloma;Incidence of dose-limiting toxicities (DLTs);Through up to 28 days following first dose;Incidence of SEA-BCMA antitherapeutic antibodies (ATA);Active, not recruiting;Phase 1
919;Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma;COmprehensive Score for Financial Toxicity (COST);4 months;Functional Assessment of Cancer Therapy (FACT-G);Active, not recruiting;Not Applicable
919;Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma;COmprehensive Score for Financial Toxicity (COST);4 months;Patient Satisfaction Questionnaire Short-Form [PSQ-18];Active, not recruiting;Not Applicable
920;Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone;Comparison of Progression Free Survival Between Treatment Arms;Assessed monthly from randomization until disease progression (PD) or death whichever occurs first (approximately up to 3 years)];Overall Response Rate;Active, not recruiting;Phase 3
920;Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone;Comparison of Progression Free Survival Between Treatment Arms;Assessed monthly from randomization until disease progression (PD) or death whichever occurs first (approximately up to 3 years)];Depth of Response;Active, not recruiting;Phase 3
920;Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone;Comparison of Progression Free Survival Between Treatment Arms;Assessed monthly from randomization until disease progression (PD) or death whichever occurs first (approximately up to 3 years)];Duration of Response;Active, not recruiting;Phase 3
920;Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone;Comparison of Progression Free Survival Between Treatment Arms;Assessed monthly from randomization until disease progression (PD) or death whichever occurs first (approximately up to 3 years)];Time to Next Therapy;Active, not recruiting;Phase 3
920;Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone;Comparison of Progression Free Survival Between Treatment Arms;Assessed monthly from randomization until disease progression (PD) or death whichever occurs first (approximately up to 3 years)];Overall Survival;Active, not recruiting;Phase 3
920;Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone;Comparison of Progression Free Survival Between Treatment Arms;Assessed monthly from randomization until disease progression (PD) or death whichever occurs first (approximately up to 3 years)];Health-related Quality of Life-Time to Worsening in EORTC QLQ-C30 Scale Scores;Active, not recruiting;Phase 3
920;Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone;Comparison of Progression Free Survival Between Treatment Arms;Assessed monthly from randomization until disease progression (PD) or death whichever occurs first (approximately up to 3 years)];Health-related Quality of Life-Time to Worsening in EQ-5D-5L Utility Score;Active, not recruiting;Phase 3
920;Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone;Comparison of Progression Free Survival Between Treatment Arms;Assessed monthly from randomization until disease progression (PD) or death whichever occurs first (approximately up to 3 years)];Health-related Quality of Life-Time to Worsening in EQ-5D-5L Visual Analogue Scale;Active, not recruiting;Phase 3
921;S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis;Overall Survival;5 years from initial registration, or until death, whichever occurred earlier, on average, about 4.5 years;Hematologic Response;Completed;Phase 2
922;Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma;Safety and efficacy of a conditioning regimen with Fludarabine, Melphalan and ATG prior allogeneic SCT after high dose chemotheraoie and autologous SCT. Evaluation of underlying disease and donor-recipient-chimerism.,;Evaluation of engraftment of leucocytes and platelets;Completed;Phase 2
922;Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma;Safety and efficacy of a conditioning regimen with Fludarabine, Melphalan and ATG prior allogeneic SCT after high dose chemotheraoie and autologous SCT. Evaluation of underlying disease and donor-recipient-chimerism.,;Evaluation of incidence of acute and chronic GvHD;Completed;Phase 2
922;Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma;Safety and efficacy of a conditioning regimen with Fludarabine, Melphalan and ATG prior allogeneic SCT after high dose chemotheraoie and autologous SCT. Evaluation of underlying disease and donor-recipient-chimerism.,;Evaluation of infectious complications;Completed;Phase 2
922;Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma;Safety and efficacy of a conditioning regimen with Fludarabine, Melphalan and ATG prior allogeneic SCT after high dose chemotheraoie and autologous SCT. Evaluation of underlying disease and donor-recipient-chimerism.,;Evaluation of the effects of DLI in case of no CR;Completed;Phase 2
922;Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma;Safety and efficacy of a conditioning regimen with Fludarabine, Melphalan and ATG prior allogeneic SCT after high dose chemotheraoie and autologous SCT. Evaluation of underlying disease and donor-recipient-chimerism.,;Evaluation of disease-free and overall survival;Completed;Phase 2
923;SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;The percentage of patients with treatment-related and treatment-emergent adverse events;Up to 12 months;SL-401 plasma concentration at multiple time points;Terminated;Phase 1
923;SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma;The percentage of patients with treatment-related and treatment-emergent adverse events;Up to 12 months;SL-401 maximum plasma concentration;Terminated;Phase 2
924;Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma;Dose Limiting Toxicity;Assessed daily (while inpatient) through clinical and laboratory examinations up to 90 days.;Engraftment;Completed;Phase 1
925;Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients;White blood cell (WBC) count;24 hour;CD34+ cells;Completed;Phase 1
925;Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients;White blood cell (WBC) count;24 hour;CD34+ cells;Completed;Phase 2
926;A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma;Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR);After 4 cycles of Induction (Approximately 4 months);Overall Response Rate (ORR);Completed;Phase 2
926;A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma;Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR);After 4 cycles of Induction (Approximately 4 months);Time to Very Good Partial Response (VGPR) or Better;Completed;Phase 2
926;A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma;Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR);After 4 cycles of Induction (Approximately 4 months);Time to Partial Response (PR) or Better;Completed;Phase 2
926;A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma;Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR);After 4 cycles of Induction (Approximately 4 months);Duration of Response (DOR);Completed;Phase 2
926;A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma;Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR);After 4 cycles of Induction (Approximately 4 months);Progression Free Survival (PFS);Completed;Phase 2
926;A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma;Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR);After 4 cycles of Induction (Approximately 4 months);Time to Disease Progression (TTP);Completed;Phase 2
926;A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma;Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR);After 4 cycles of Induction (Approximately 4 months);Overall Survival (OS);Completed;Phase 2
926;A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma;Percentage of Participants Who Achieved Complete Response (CR) or Very Good Partial Response (VGPR);After 4 cycles of Induction (Approximately 4 months);Percentage of Participants With Treatment Emergent-Adverse Event;Completed;Phase 2
927;Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma;maximum tolerated dose (MTD) in subjects with relapsed and relapsed/refractory Multiple Myeloma (MM);1year;clinical response of P276-00 in subjects with relapsed and relapsed/refractory MM 2. Exploratory pharmacogenomic analysis of serum and molecular markers associated with P276-00 use in the study population;Withdrawn;Phase 1
928;Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab ;Response by IMWG criteria;4 weeks;T cell subset numbers;Completed;Phase 2
928;Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab ;Response by IMWG criteria;4 weeks;T cell subset numbers;Completed;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Overall Response Rate (ORR);Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Percentage of Participants With Very Good Partial Response (VGPR) or Better;Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Percentage of Participants With Complete Response (CR) or Better;Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Percentage of Participants With Negative Minimal Residual Disease (MRD);Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Overall Survival (OS);Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Progression Free Survival on Next Line of Therapy (PFS2);Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Percentage of Participants With Stringent Complete Response (sCR);Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Time to Disease Progression (TTP);Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Time to Response;Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Duration of Response (DOR);Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Time to Next Treatment (TNT);Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Percentage of Participants With Best M-protein Response;Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30: Emotional Functioning Score;Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L): Visual Analogue Scale (VAS);Active, not recruiting;Phase 3
929;A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma;Progression Free Survival (PFS);From randomization to either disease progression or death whichever occurs first (up to 2.4 years);Change From Baseline in EuroQol 5 Dimensions-5 Level (EQ-5D-5L) Utility Score;Active, not recruiting;Phase 3
930;Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression;To strengthen preliminary data;2 years;Recruiting,
930;Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression;Potential marker of PD;2 years;Recruiting,
930;Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression;Analysis both MM cells and MM-BMSC compartment.;2 years;Recruiting,
930;Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression;To investigate eNAMPT role;2 years;Recruiting,
930;Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression;To determine the effects;2 years,;Recruiting,
931;A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma;Incidence of dose-limiting toxicity (DLTs);Cycle 1 (28 days);Maximum plasma concentration (Cmax) of KTX-1001;Recruiting;Phase 1
931;A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma;Incidence of dose-limiting toxicity (DLTs);Cycle 1 (28 days);Time to achieve Cmax (tmax) for KTX-1001;Recruiting;Phase 1
931;A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma;Incidence of dose-limiting toxicity (DLTs);Cycle 1 (28 days);Area under the plasma concentration-time curve (AUC) for KTX-1001;Recruiting;Phase 1
931;A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma;Incidence of dose-limiting toxicity (DLTs);Cycle 1 (28 days);Objective response rate (ORR) for KTX-1001;Recruiting;Phase 1
931;A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma;Incidence of dose-limiting toxicity (DLTs);Cycle 1 (28 days);Duration of response (DOR) for KTX-1001;Recruiting;Phase 1
931;A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma;Incidence of dose-limiting toxicity (DLTs);Cycle 1 (28 days);Progression-free survival (PFS) for KTX-1001;Recruiting;Phase 1
931;A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma;Incidence of dose-limiting toxicity (DLTs);Cycle 1 (28 days);Overall survival (OS) for KTX-1001;Recruiting;Phase 1
932;Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma;To determine the safety and maximum tolerated dose of IPI-504;Following 1 cycle of treatment;To examine the pharmacokinetic parameters of IPI-504;Completed;Phase 1
932;Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma;Recommend a dose for subsequent studies of IPI-504;Once MTD is reached;To evaluate the potential anti-tumor activity with standard markers of disease progression;Completed;Phase 1
933;Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma;Determine if there is grade 3 to 5 cytokine release syndrome;2 weeks-12 months after initial dose;Investigators try to assess major reaction rate (MRR, PR+VGPR+CR) at the end of the research.;Recruiting;Phase 1
933;Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma;Determine if there is grade 3 to 5 cytokine release syndrome;2 weeks-12 months after initial dose;Investigators try to assess major reaction rate (MRR, PR+VGPR+CR) at the end of the research.;Recruiting;Phase 2
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Participants With Adverse Events of Special Interest: Peripheral Neuropathy;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Time to First Peripheral Neuropathy Treatment-Emergent Adverse Event (TEAE);Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Participants With Adverse Events of Special Interest: Venous Thromboembolic Events;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Time to First Venous Thromboembolic Treatment-Emergent Adverse Event (TEAE);Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Physical Functioning Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Role Functioning Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Emotional Functioning Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Cognitive Functioning Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Social Functioning Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Fatigue Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Pain Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Nausea/Vomiting Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Constipation Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Diarrhea Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Insomnia Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Dyspnoea Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Appetite Loss Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Financial Problems Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Cancer (EORTC QLQ-C30) Global Quality of Life Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Disease Symptoms Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Side Effects Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Future Perspective Scale;Completed;Phase 3
934;A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Treatment-emergent Adverse Events (TEAEs), by Severity, Seriousness, and Relationship to Treatment;up to 123 weeks;Change From Baseline to Week 24 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients With Multiple Myeloma (EORTC QLQ-MY20) Body Image Scale;Completed;Phase 3
935;Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);30 months;Progression Free Survival (PFS);Withdrawn;Phase 2
935;Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);30 months;Overall survival (OS);Withdrawn;Phase 2
935;Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);30 months;Safety of combination therapy assessed using the National Cancer institute-Common Toxicology Criteria (NCI-CTC) grade scale for AEs and Lab assessments;Withdrawn;Phase 2
936;Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma;Incidence of mucositis;5 years,;Completed;Phase 1
937;A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma;Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) standard uptake value (SUV);Pre-study to after 6 months of therapy;Overall response rate (ORR);Completed;Phase 1
937;A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma;Fluorine F18 sodium fluoride positron emission tomography (NaF-PET/CT) influx constant (Ki);Pre-study to after 6 months of therapy;Progression free survival (PFS);Completed;Phase 1
937;A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma;F18 fluorodeoxyglucose positron emission tomography (FDG-PET/CT) standard uptake value (SUV);Pre-study to after 6 months of therapy;Duration of response;Completed;Phase 1
937;A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma;Number of patients with treatment emergent adverse events;Baseline to study completion (approximately 7 months);Overall survival;Completed;Phase 1
938;Role of the Host Microbiota and Il-17 in Favoring Multiple Myeloma Progression;the role of microbiota and IL17 in MM;5YRS,;Recruiting,
939;Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma;Number of Patients Experiencing a Toxicity;21 days,;Terminated;Phase 1
939;Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma;Number of Patients Experiencing a Toxicity;21 days,;Terminated;Phase 2
940;Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma;To determine the maximum tolerated dose of TMI when followed by aHSCT in patients with relapsed or refractory multiple myeloma;30 days from the time of aSCT;The frequency and timing of engraftment following TMI and aHSCT;Recruiting;Phase 1
940;Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma;To determine the maximum tolerated dose of TMI when followed by aHSCT in patients with relapsed or refractory multiple myeloma;30 days from the time of aSCT;The early morbidity and mortality associated with TMI and aHSCT;Recruiting;Phase 2
941;MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma;Response rate;3 years;Progression-free survival;Withdrawn;Phase 2
941;MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma;Response rate;3 years;Duration of response;Withdrawn;Phase 2
942;Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01);Safety of UCARTCS1A;24 months.;Response Assessment;Recruiting;Phase 1
942;Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01);Safety of UCARTCS1A;24 months.;Duration of Response;Recruiting;Phase 1
942;Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01);Safety of UCARTCS1A;24 months.;Progression Free Survival;Recruiting;Phase 1
942;Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01);Safety of UCARTCS1A;24 months.;Overall Survival;Recruiting;Phase 1
943;Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma;Proportion of participants with treatment-emergent adverse events (AE) (Dose Escalation);From initiation of study treatment (day 1) to 29 days following CAR-T infusion;Duration of response;Recruiting;Phase 1
943;Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma;Proportion of participants who experience a dose-limiting toxicity (DLT) (Dose Escalation);From initiation of study treatment (day 1) to 29 days following CAR-T infusion;Progression-free Survival (PFS);Recruiting;Phase 1
943;Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma;Overall Response Rate (ORR);Up to 12 months following CAR- T infusion;Overall Survival;Recruiting;Phase 1
944;Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma;Assessing Patient Response to Bendamustine - Phase I by assessing patient adverse events;6 months;Toxicity of Treatment Regimen - Phase I and II by assessing patient adverse events;Terminated;Phase 1
944;Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma;Overall Response Rate of Treatment Regimen - Phase II by assessing patient response rates;8 months;Evaluation of Survival - Phase II by assessing patient survival times;Terminated;Phase 2
945;Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma,,,;Available,
946;Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma,,,;Unknown status;Phase 3
947;An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments;Part 1: Number of participants with dose limiting toxicities (DLTs);Day 1 to 21 of Cycle 1 (each cycle of 21 days);Part 1: Area under the plasma concentration time curve from time 0 to the time of the last quantifiable concentration (AUC [0 to t]) for GSK2857916 following single dose administration;Active, not recruiting;Phase 1
947;An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments;Part 2: Arm A: Number of participants with DLTs;Day 1 to 21 of Cycle 1 (each cycle of 21 days);Part 2: Arm A: AUC (0 to t) for GSK2857916 following single dose administration;Active, not recruiting;Phase 1
947;An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments;Part 2: Arm B: Number of participants with DLTs;Day 1 to 28 of Cycle 1 (each cycle of 28 days);Part 2: Arm B: AUC (0 to t) for GSK2857916 following single dose administration;Active, not recruiting;Phase 1
947;An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments;Part 1 and Part 2: Number of participants with adverse events (AEs) and serious adverse events (SAEs);Up to approximately 2.2 years;Part 1: Area under the plasma concentration-time curve from time 0 to the end of dosing (AUC [0 to tau]) for GSK2857916 following single dose administration;Active, not recruiting;Phase 1
947;An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments;Part 1 and Part 2: Number of participants with abnormal hematology, clinical chemistry, urinalysis parameters;Up to approximately 2.2 years;Part 2: Arm A: AUC (0 to tau) for GSK2857916 following single dose administration;Active, not recruiting;Phase 1
947;An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments;Part 1 and Part 2: Number of participants with abnormal vital signs;Up to approximately 2.2 years;Part 2: Arm B: AUC (0 to tau) for GSK2857916 following single dose administration;Active, not recruiting;Phase 1
947;An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments;Part 1 and Part 2: Number of participants with abnormal electrocardiogram (ECG) findings;Up to approximately 2.2 years;Part 1: Area under the plasma concentration-time curve from time 0 to infinite time (AUC [0 to inf]) for GSK2857916 following single dose administration;Active, not recruiting;Phase 1
947;An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments;Part 1 and Part 2: Number of participants with abnormal physical examination findings;Up to approximately 2.2 years;Part 2: Arm A: AUC (0 to inf) for GSK2857916 following single dose administration;Active, not recruiting;Phase 1
947;An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments;Part 1 and Part 2: Number of participants with abnormal ocular examination findings;Up to approximately 2.2 years;Part 2: Arm B: AUC (0 to inf) for GSK2857916 following single dose administration;Active, not recruiting;Phase 1
947;An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments;Part 1 and Part 2: Mean Eastern Cooperative Oncology Group (ECOG) scores;Up to approximately 2.2 years;Part 1: Maximum observed plasma concentration (Cmax) for GSK2857916 following single dose administration;Active, not recruiting;Phase 1
948;Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma;Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs);From KITE-585 infusion until 28 days after KITE-585 infusion;Objective Response Rate (ORR) as Determined by Study Investigators According to the International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria;Terminated;Phase 1
948;Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma;Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs);From KITE-585 infusion until 28 days after KITE-585 infusion;Progression Free Survival (PFS) as Determined by Study Investigators According to the IMWG Consensus Panel 1;Terminated;Phase 1
948;Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma;Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs);From KITE-585 infusion until 28 days after KITE-585 infusion;Overall Survival (OS);Terminated;Phase 1
948;Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma;Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs);From KITE-585 infusion until 28 days after KITE-585 infusion;Percentage of Participants Experiencing Treatment-Emergent Adverse Events;Terminated;Phase 1
948;Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma;Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs);From KITE-585 infusion until 28 days after KITE-585 infusion;Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities;Terminated;Phase 1
948;Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma;Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs);From KITE-585 infusion until 28 days after KITE-585 infusion;Duration of Response (DOR) as Determined by Study Investigators According to the IMWG Consensus Panel 1;Terminated;Phase 1
948;Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma;Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs);From KITE-585 infusion until 28 days after KITE-585 infusion;Time to Next Treatment (TTNT);Terminated;Phase 1
949;The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma;Assess baseline anxiety levels in MM patients undergoing therapy using the PROMIS assessment tool for anxiety;Baseline;Assess baseline depression levels in MM patients using the PROMIS assessment tool for depression;Active, not recruiting;Not Applicable
949;The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma;Assess anxiety levels 12 weeks after educational program (MPI) in MM patients undergoing therapy using the PROMIS assessment tool for anxiety;12 weeks post intervention;Assess depression levels 12 weeks after education intervention (MPI) in MM patients using the PROMIS assessment tool for depression;Active, not recruiting;Not Applicable
949;The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma;Assess anxiety levels 24 weeks after educational program (MPI) in MM patients undergoing therapy using the PROMIS assessment tool for anxiety;24 weeks post intervention;Assess depression levels 24 weeks after education intervention (MPI) in MM patients using the PROMIS assessment tool for depression;Active, not recruiting;Not Applicable
950;A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma;Adverse Events (AEs);From the time of informed consent and follow up to 2 years after infusion of CC-98633:;Overall Response Rate (ORR);Active, not recruiting;Phase 1
950;A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma;Adverse Events (AEs);From the time of informed consent and follow up to 2 years after infusion of CC-98633:;Complete Response (CR) Rate;Active, not recruiting;Phase 1
950;A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma;Adverse Events (AEs);From the time of informed consent and follow up to 2 years after infusion of CC-98633:;Duration of response (DOR);Active, not recruiting;Phase 1
950;A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma;Adverse Events (AEs);From the time of informed consent and follow up to 2 years after infusion of CC-98633:;Time to response (TTR);Active, not recruiting;Phase 1
950;A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma;Adverse Events (AEs);From the time of informed consent and follow up to 2 years after infusion of CC-98633:;Time to complete response (TTCR);Active, not recruiting;Phase 1
950;A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma;Adverse Events (AEs);From the time of informed consent and follow up to 2 years after infusion of CC-98633:;Progression free survival (PFS);Active, not recruiting;Phase 1
950;A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma;Adverse Events (AEs);From the time of informed consent and follow up to 2 years after infusion of CC-98633:;Overall survival (OS);Active, not recruiting;Phase 1
950;A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma;Adverse Events (AEs);From the time of informed consent and follow up to 2 years after infusion of CC-98633:;Pharmacokinetics - maximum serum concentration (Cmax);Active, not recruiting;Phase 1
950;A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma;Adverse Events (AEs);From the time of informed consent and follow up to 2 years after infusion of CC-98633:;Pharmacokinetics -time to peak serum concentration (tmax);Active, not recruiting;Phase 1
950;A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma;Adverse Events (AEs);From the time of informed consent and follow up to 2 years after infusion of CC-98633:;Pharmacokinetics - Area under curve (AUC);Active, not recruiting;Phase 1
950;A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma;Adverse Events (AEs);From the time of informed consent and follow up to 2 years after infusion of CC-98633:;Very good partial response (VGPR) or better;Active, not recruiting;Phase 1
951;Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma;Incidence of Adverse Events Summarized by System Organ Class, Preferred Term, Severity, Seriousness, and Relationship to Treatment.;Median time-on-study=18.3 weeks;Completed;Phase 3
951;Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma;Overall Incidence of Adverse Events;Median time-on-study=18.3 weeks,;Completed;Phase 3
952;Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma;minimal residual disease-negativity rate;22 months;Adverse events;Recruiting;Phase 2
952;Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma;minimal residual disease-negativity rate;22 months;Response rates;Recruiting;Phase 2
952;Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma;minimal residual disease-negativity rate;22 months;Progression free survival;Recruiting;Phase 2
952;Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma;minimal residual disease-negativity rate;22 months;Overall survival;Recruiting;Phase 2
953;A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma;Percentage of Participants With Adverse Events (AEs);Randomization up to end of study (up to approximately 3 years, 7 months);Percentage of Participants With Clinical Benefit as Determined by the Investigator Using IMWG Response Criteria;Completed;Phase 1
953;A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma;Percentage of Participants With Overall Response Rate (ORR) as Determined by the Investigator Using International Myeloma Working Group (IMWG) Response Criteria;From randomization to the first occurrence of a response as defined above (up to approximately 3 years, 7 months);Progression-Free Survival (PFS) as Determined by the Investigator Using IMWG Response Criteria;Completed;Phase 2
954;MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma;Phase 1: Participants With Dose-Limiting Toxicities (DLT) in Cycle 1;Up to Day 28 (Cycle 1);Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) While on Single-Agent Pomalidomide as of the 01 April 2011 Cut-off;Completed;Phase 1
954;MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma;Phase 2: Kaplan-Meier Estimates of Progression-free Survival (PFS) as of the 01 April 2011 Cut-off;up to 67 weeks;Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) While on Both Pomalidomide and Dexamethasone as of the 01 April 2011 Cut-off;Completed;Phase 2
955;Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma;Dose limiting toxicities (DLTs);From cycle 1 day 1 up to the administration of cycle 2 day 1 (up to 22 days);Safety and toxicity;Unknown status;Phase 1
955;Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma;Proportion o f participants achieving at least partial response;within 16 cycles of therapy (an expected average of 48 weeks);Proportion of patients with each maximum response category;Unknown status;Phase 2
956;KRDI in Transplant-Eligible MM;Complete Response (CR + stringent CR) rate;112 Days;Overall Response Rate;Recruiting;Phase 2
956;KRDI in Transplant-Eligible MM;Complete Response (CR + stringent CR) rate;112 Days;Minimal residual disease (MRD) Rate;Recruiting;Phase 2
956;KRDI in Transplant-Eligible MM;Complete Response (CR + stringent CR) rate;112 Days;Minimal residual disease (MRD) Rate;Recruiting;Phase 2
956;KRDI in Transplant-Eligible MM;Complete Response (CR + stringent CR) rate;112 Days;Minimal residual disease (MRD) Rate;Recruiting;Phase 2
956;KRDI in Transplant-Eligible MM;Complete Response (CR + stringent CR) rate;112 Days;Minimal residual disease (MRD) Rate;Recruiting;Phase 2
956;KRDI in Transplant-Eligible MM;Complete Response (CR + stringent CR) rate;112 Days;Progression Free Survival;Recruiting;Phase 2
956;KRDI in Transplant-Eligible MM;Complete Response (CR + stringent CR) rate;112 Days;Overall Survival;Recruiting;Phase 2
956;KRDI in Transplant-Eligible MM;Complete Response (CR + stringent CR) rate;112 Days;Number of Participants with Treatment-Related Adverse Events as NCI CTCAE Version 5.0 severity grades.;Recruiting;Phase 2
956;KRDI in Transplant-Eligible MM;Complete Response (CR + stringent CR) rate;112 Days;Complete Response rate (Transplant);Recruiting;Phase 2
956;KRDI in Transplant-Eligible MM;Complete Response (CR + stringent CR) rate;112 Days;Complete Response rate (Transplant Deferred);Recruiting;Phase 2
956;KRDI in Transplant-Eligible MM;Complete Response (CR + stringent CR) rate;112 Days;Complete Response rate (All );Recruiting;Phase 2
957;Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone;Detection rate of residual/refractory;4 months;Myeloma lesion response rate;Completed;Not Applicable
957;Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone;Detection rate of residual/refractory;4 months;Overall clinical response rate;Completed;Not Applicable
958;Vaccination With PD-L1 Peptide Against Multiple Myeloma;Incidence of toxicity;12 months;Evaluation of immunological responses;Completed;Phase 1
959;Study of DNA Samples From Patients With Multiple Myeloma;Increased frequency of ≥1 polymorphic alleles associated with clinical endpoints using custom myeloma SNP chip analysis of banked DNA samples from patients with multiple myeloma;1 month;Completed,
959;Study of DNA Samples From Patients With Multiple Myeloma;SNPs associated with toxicities caused by individual genetic variations affecting drug activation, distribution, metabolism, and export (ADME);1 month;Completed,
959;Study of DNA Samples From Patients With Multiple Myeloma;SNPs associated with response;1 month;Completed,
959;Study of DNA Samples From Patients With Multiple Myeloma;SNPs associated with bone disease;1 month;Completed,
959;Study of DNA Samples From Patients With Multiple Myeloma;SNPs associated with epidemiology (i.e., risk factors for the development of multiple myeloma);1 month,;Completed,
960;Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma;Efficacy of trial treatment;Up to 5 years;Safety of trial treatment;Active, not recruiting;Phase 2
960;Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma;Efficacy of trial treatment;Up to 5 years;Depth of response to the trial treatment;Active, not recruiting;Phase 2
960;Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma;Efficacy of trial treatment;Up to 5 years;Progression Free survival;Active, not recruiting;Phase 2
961;Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma;Objective response rate (ORR);Every 2 months until disease progression or study completion，an average of 2 year;Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v4.03;Unknown status;Phase 2
961;Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma;Objective response rate (ORR);Every 2 months until disease progression or study completion，an average of 2 year;Progression-Free Survival (PFS);Unknown status;Phase 2
961;Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma;Objective response rate (ORR);Every 2 months until disease progression or study completion，an average of 2 year;Overall Survival (OS);Unknown status;Phase 2
961;Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma;Objective response rate (ORR);Every 2 months until disease progression or study completion，an average of 2 year;Duration of Response (DOR);Unknown status;Phase 2
962;A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma;Objective Response Rate;approximately 3 months;Response rate between treatment arms and time-to-event endpoints.;Completed;Phase 2
962;A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma;Objective Response Rate;approximately 3 months;Response rate between treatment arms and time-to-event endpoints.;Completed;Phase 3
963;Study of XL999 in Patients With Multiple Myeloma;Response rate;Inclusion of subject until disease progression;Duration of response;Terminated;Phase 2
963;Study of XL999 in Patients With Multiple Myeloma;Safety and tolerability;Inclusion until 30 days post last treatment;Progression-free survival;Terminated;Phase 2
964;A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal);Number of MM Participants Categorized by Sociodemographic Variables;Day 1;Number of Participants Categorized by Sociodemographic Characteristics at the Latest Symptomatic R/R Episode per Type of Treatment;Completed,
964;A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal);Number of MM Participants Categorized by Clinical Variables on Diagnosis and During Previous Relapses;Day 1;Number of MM Participants Categorized by Clinical Variables at Latest Symptomatic R/R Episode per Type of MM;Completed,
964;A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal);Number of MM Participants Categorized by Clinical Variables at Last R/R Episode;Day 1;Number of Participants Categorized by Relevant Variables that are not Currently Collected in Clinical Record and Could Influence in the Disease Management at Relapse;Completed,
965;Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma;Incidence of all adverse events(AE) to elotuzumab in real-world practice in Japan;Up to 72 weeks;Completed,
965;Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma;Incidence of immune-related (IR) adverse events to elotuzumab in real-world practice in Japan;Up to 72 weeks;Completed,
965;Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma;Number of patients who achieve a Stringent complete response (sCR) as measured by International Myeloma Working Group (IMWG) criteria;Up to 72 weeks;Completed,
965;Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma;Number of patients who achieve a Complete response (CR) as measured by International Myeloma Working Group (IMWG) criteria;Up to 72 weeks;Completed,
965;Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma;Number of patients who achieve a Very good partial response (VGPR) as measured by International Myeloma Working Group (IMWG) criteria;Up to 72 weeks;Completed,
965;Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma;Number of patients who achieve a Partial response (PR) as measured by International Myeloma Working Group (IMWG) criteria;Up to 72 weeks;Completed,
965;Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma;Number of patients who achieve a Progressive Disease (PD) as measured by International Myeloma Working Group (IMWG) criteria;Up to 72 weeks;Completed,
965;Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma;Number of patients who achieve a Relapse from complete response as measured by International Myeloma Working Group (IMWG) criteria;Up to 72 weeks,;Completed,
966;TCD Followed by autoSCT for Newly Diagnosed MM Patients;Response rate of TCD induction Therapy,;Progression free survival and Overall survival of TCD, followed by high dose chemotherapy and autoPBSCT and TD maintenance;Unknown status;Phase 2
966;TCD Followed by autoSCT for Newly Diagnosed MM Patients;Response rate of TCD induction Therapy,;To evaluate toxicities of TCD, followed by high dose chemotherapy and autoPBSCT and TD maintenance.;Unknown status;Phase 2
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Overall survival (OS);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Overall response rate (ORR);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Clinical benefit rate (CBR);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Duration of response (DoR);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Time to response (TTR);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Time to progression (TTP);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Number of participants with adverse events (AEs);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in hematology parameters: absolute white blood cell count (WBC), basophils,eosinophils, lymphocytes, monocytes, platelet count, and neutrophils (Giga cells per liter);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in hematology parameters: Red Blood Cell (RBC) count and reticulocyte count (Trillion cells per liter);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in hematology parameters: Mean Corpuscular Hemoglobin concentration (MCHC) and hemoglobin (Grams per Liter);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in hematology parameters: Hematocrit (Proportion of red blood cells in blood);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in hematology parameters: Mean Corpuscular Volume (MCV) [Femtoliter];Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in hematology parameters: Mean Corpuscular Hemoglobin (MCH) [Picograms];Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in clinical chemistry parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine kinase (CK), Gamma Glutamyl Transferase (GGT), and lactate dehydrogenase (LDH);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in clinical chemistry parameters: Calcium, chloride, glucose, potassium, sodium, magnesium, blood urea nitrogen (BUN), and phosphorous (Millimoles per Liter);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in clinical chemistry parameters: Creatinine, direct bilirubin, total bilirubin, uric acid (Micromoles per liter);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in clinical chemistry parameters: Albumin and total protein (Grams per Liter);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in Urinalysis Parameter: Specific Gravity (Ratio);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in Urinalysis Parameters- Urine potential of hydrogen (pH) (Points on a scale);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in urinalysis parameter: Glucose (Millimole per liter);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in urinalysis parameter: Protein (Grams per liter);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in urinalysis parameter: Ketones (Millimoles per liter);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in urinalysis parameter: blood (10^9 cells per liter);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Change from Baseline in urinalysis parameter: creatinine/albumin ratio (ratio);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Number of participants with abnormal ocular findings;Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Plasma concentrations of belantamab mafodotin;Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Plasma concentrations of total monoclonal antibody (mAb);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Plasma concentrations of cys-mc Microtubular inhibitor monomethyl auristatin-F (MMAF);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Number of participants with Anti-drug antibody (ADAs) against belantamab mafodotin;Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Titer of ADAs against belantamab mafodotin;Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Number of participants with symptomatic adverse effects measured by Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Number of participants with symptomatic adverse effects measured by Ocular Surface Disease Index (OSDI);Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core module (EORTC QLQC30) score;Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;European Organization for Research and Treatment of Cancer IL52 (EORTC IL52) score;Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) Score;Active, not recruiting;Phase 3
967;Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM);Progression-free survival (PFS);Up to 25 months;Rate of Minimal Residual Disease (MRD);Active, not recruiting;Phase 3
968;Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma;Best Confirmed Disease Response;every 28 days during treatment period for up to 6 to 8 cycles;Duration of Response (DOR);Terminated;Phase 2
968;Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma;Best Reported Disease Response;every 28 days during treatment period for up to 6 to 8 cycles;Duration of Response (DOR);Terminated;Phase 2
969;Stem Cell Translpantation in Multiple Myeloma;Progression free survival;5 years;Transplant related mortality;Completed;Phase 2
969;Stem Cell Translpantation in Multiple Myeloma;Progression free survival;5 years;Complete hematological and molecular remission rate;Completed;Phase 2
969;Stem Cell Translpantation in Multiple Myeloma;Progression free survival;5 years;Relapse rate;Completed;Phase 2
969;Stem Cell Translpantation in Multiple Myeloma;Progression free survival;5 years;Survival;Completed;Phase 2
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Overall Survival;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Minimal Residual Disease negativity rate;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Sustained MRD negativity rate;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Progression Free Survival;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Overall minimal residual disease negativity rate;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Duration of minimal residual disease negativity;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Sustained minimal residual disease negativity rate;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Complete response rate;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Duration of complete response;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Frequency of adverse events;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Frequency of laboratory abnormalities;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Pre-dose concentrations of elranatamab;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Post-dose concentrations of elranatamab;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Incidence and titers of Anti-Drug Antibody and Neutralizing Antibody against elranatamab;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20;Recruiting;Phase 3
970;Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant;Progression Free Survival;Assessed for up to approximately 5 years;Progression Free Survival 2;Recruiting;Phase 3
971;Comparing Treatments for Multiple Myeloma,,,;Completed;Phase 2
972;Prevalence of Asymptomatic Thrombosis in Multiple Myeloma;Analysis of the occurrence of venous thromboembolic events via transverse Doppler echo;1 day,;Withdrawn;Not Applicable
973;Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma;Progression-Free Survival (PFS);"From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.";Overall Survival (OS);Completed;Phase 3
973;Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma;Progression-Free Survival (PFS);"From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.";Overall Response Rate;Completed;Phase 3
973;Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma;Progression-Free Survival (PFS);"From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.";Complete Response Rate;Completed;Phase 3
973;Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma;Progression-Free Survival (PFS);"From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.";Percentage of Participants With ≥ Grade 2 Peripheral Neuropathy;Completed;Phase 3
973;Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma;Progression-Free Survival (PFS);"From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.";European Organisation for Research and Treatment of Cancer Quality of Life Core Module (EORTC QLQ-C30) Global Health Status/Quality of Life (QOL) Scores;Completed;Phase 3
973;Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma;Progression-Free Survival (PFS);"From randomization until the data cut-off date of 15 July 2016; median follow-up time for PFS was 21.6.and 22.2 months in the bortezomib and carfilzomib arms respectively.";Number of Participants With Adverse Events;Completed;Phase 3
974;A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens;D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR);Up to 2 years 3 months;Maximum Observed Serum Concentration (Cmax) of Daratumumab;Active, not recruiting;Phase 2
974;A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens;D-VRd Cohort: Percentage of Participants With Very Good Partial Response (VGPR) or Better Response;Up to 2 years and 3 months;Percentage of Participants With Infusion-Related Reactions (IRRs);Active, not recruiting;Phase 2
975;Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma;MTD of Pomalidomide;12 months;Number of Patients with Adverse Events;Unknown status;Phase 1
975;Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma;Overall Response Rate;24 months;Time to Progression;Unknown status;Phase 2
976;A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment.;Incidence of dose-limiting toxicities (DLTs);"End of the Observation period; up to day 28";Concentrations of Linvoseltamab in serum;Not yet recruiting;Phase 1
976;A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment.;Incidence of treatment-emergent adverse events (TEAEs);Post-Last Linvoseltamab Dose, up to 90 days;Concentrations of total soluble B-cell maturation antigen (BCMA);Not yet recruiting;Phase 2
977;Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour);Overall response rate to vorinostat, bortezomib and dexamethasone.;up to 24 weeks;Number of dose reductions during treatment with vorinostat, bortezomib and dexamethasone.;Completed;Phase 2
977;Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour);Overall response rate to vorinostat, bortezomib and dexamethasone.;up to 24 weeks;Overall numbers and rates of adverse events;Completed;Phase 2
977;Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour);Overall response rate to vorinostat, bortezomib and dexamethasone.;up to 24 weeks;Progression free survival;Completed;Phase 2
977;Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour);Overall response rate to vorinostat, bortezomib and dexamethasone.;up to 24 weeks;Maximum response to treatment;Completed;Phase 2
977;Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour);Overall response rate to vorinostat, bortezomib and dexamethasone.;up to 24 weeks;Time to maximum response;Completed;Phase 2
978;Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse;Overall Response Rate, defined as the best response on treatment assessed using the EBMT criteria;2 years;Time To Progression, defined as the time from commencement of treatment to the date of first evidence of progressive disease.;Completed;Phase 2
978;Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse;Overall Response Rate, defined as the best response on treatment assessed using the EBMT criteria;2 years;Overall survival, defined as the time from commencement of treatment to the date of death from any cause.;Completed;Phase 2
979;Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668);Objective Response Rate (ORR);Up to approximately 2 years;Disease Control Rate (DCR);Withdrawn;Phase 2
979;Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668);Objective Response Rate (ORR);Up to approximately 2 years;Duration of Response (DOR);Withdrawn;Phase 2
979;Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668);Objective Response Rate (ORR);Up to approximately 2 years;Adverse Events (AEs);Withdrawn;Phase 2
979;Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668);Objective Response Rate (ORR);Up to approximately 2 years;Study Treatment Discontinuations Due to AEs;Withdrawn;Phase 2
980;Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy;Response Rates;36 weeks after start of induction treatment (9 cycles, each cycle is 28 days);Feasibility of a carfilzomib monotherapy maintenance;Active, not recruiting;Phase 2
980;Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy;Response Rates;36 weeks after start of induction treatment (9 cycles, each cycle is 28 days);Safety (adverse events) of a carfilzomib monotherapy maintenance;Active, not recruiting;Phase 2
980;Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy;Response Rates;36 weeks after start of induction treatment (9 cycles, each cycle is 28 days);Overall response rate (efficacy) of a carfilzomib monotherapy maintenance;Active, not recruiting;Phase 2
980;Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy;Response Rates;36 weeks after start of induction treatment (9 cycles, each cycle is 28 days);Response;Active, not recruiting;Phase 2
980;Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy;Response Rates;36 weeks after start of induction treatment (9 cycles, each cycle is 28 days);Overall survival (OS);Active, not recruiting;Phase 2
980;Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy;Response Rates;36 weeks after start of induction treatment (9 cycles, each cycle is 28 days);Progression free survival (PFS);Active, not recruiting;Phase 2
980;Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy;Response Rates;36 weeks after start of induction treatment (9 cycles, each cycle is 28 days);Safety and tolerability (adverse events) of induction and maintenance treatment;Active, not recruiting;Phase 2
980;Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy;Response Rates;36 weeks after start of induction treatment (9 cycles, each cycle is 28 days);Changes in quality of life (QoL);Active, not recruiting;Phase 2
980;Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy;Response Rates;36 weeks after start of induction treatment (9 cycles, each cycle is 28 days);Changes in quality of life (QoL) using multiple myeloma specific questionnaire;Active, not recruiting;Phase 2
980;Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy;Response Rates;36 weeks after start of induction treatment (9 cycles, each cycle is 28 days);Changes of general health status;Active, not recruiting;Phase 2
981;A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma;Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT);Up to 30 days after the last dose of study medication;Maximum observed concentration of daratumumab;Active, not recruiting;Phase 1
981;A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma;Number of participants affected by dose-limiting toxicities;Up to 30 days after the last dose of study medication;Number of participants with generation of antibodies to daratumumab;Active, not recruiting;Phase 1
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);Overall Survival;Completed;Phase 2
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);Time to First Skeletal-Related Event (SRE);Completed;Phase 2
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);Number of Participants With >30% Reduction in Brief Pain Inventory (BPI) - Worst Pain Score;Completed;Phase 2
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);Time to Progression (TTP);Completed;Phase 2
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);Duration of Response (DoR);Completed;Phase 2
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);Time to Next Treatment (TNT);Completed;Phase 2
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tabalumab;Completed;Phase 2
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);PK: Time to Maximum Plasma Concentration (Tmax) of Tabalumab;Completed;Phase 2
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);PK: Area Under the Curve Over the Dosing Interval (AUC-T) for Tabalumab;Completed;Phase 2
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);Number of Participants Developing Anti-tabalumab Antibodies;Completed;Phase 2
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);Participants With Best Overall Response (BOR) in Each Category;Completed;Phase 2
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);Number of Participants With a Given Best Objective Myeloma Response (Quality of Response [QoR]);Completed;Phase 2
982;A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM);Progression Free Survival (PFS);Baseline up to Objective Disease Progression or Death From Any Cause (assessed up to 9 months);Overall Response Rate (ORR);Completed;Phase 2
983;Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma;ARM I: Incidence of Dose-Limiting Toxicities (DLT);Up to 60 days of the last dose of study drug;ARM I: Pharmacokinetic (PK) profile of isatuximab;Recruiting;Phase 1
983;Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma;ARM I: Maximum tolerated dose (MTD) of isatuximab;At the end of Cycle 1 (each cycle is 28 days);ARM I: Overall Response Rate (ORR);Recruiting;Phase 1
983;Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma;ARM II: Overall Response Rate (ORR);Up to 60 days of the last dose of study drug;ARM I: Clinical benefit response (CBR);Recruiting;Phase 1
984;Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma;Progression Free Survival;"From randomization until the data cut-off date of 15 June 2017; median (minimum, maximum) follow-up time for PFS was 12.0 (0, 20) and 12.6 (0, 19) months in each treatment group respectively.";Overall Response Rate;Completed;Phase 3
984;Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma;Progression Free Survival;"From randomization until the data cut-off date of 15 June 2017; median (minimum, maximum) follow-up time for PFS was 12.0 (0, 20) and 12.6 (0, 19) months in each treatment group respectively.";Overall Survival;Completed;Phase 3
984;Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma;Progression Free Survival;"From randomization until the data cut-off date of 15 June 2017; median (minimum, maximum) follow-up time for PFS was 12.0 (0, 20) and 12.6 (0, 19) months in each treatment group respectively.";Number of Participants With Adverse Events (AEs);Completed;Phase 3
984;Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma;Progression Free Survival;"From randomization until the data cut-off date of 15 June 2017; median (minimum, maximum) follow-up time for PFS was 12.0 (0, 20) and 12.6 (0, 19) months in each treatment group respectively.";Plasma Carfilzomib Concentration During Cycle 2;Completed;Phase 3
985;Selinexor and Backbone Treatments of Multiple Myeloma Patients;Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD);12 months;Active, not recruiting;Phase 1
985;Selinexor and Backbone Treatments of Multiple Myeloma Patients;Phase 1 (Dose-escalation): Recommended Phase-2 dose (RP2D);12 months;Active, not recruiting;Phase 2
986;Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients;Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE);Day 1 to approximately Day 38 (before start of chemotherapy);Fold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL After First Dose of Plerixafor;Completed;Phase 2
986;Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients;Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE);Day 1 to approximately Day 38 (before start of chemotherapy);Number of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant;Completed;Phase 2
986;Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients;Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE);Day 1 to approximately Day 38 (before start of chemotherapy);Increase in Peripheral Blood (PB) CD34+ Cells From Steady-state Hematopoiesis to Pre-leukapheresis in G-CSF+Plerixafor Treated Participants Compared to Historical Controls Treated With G-CSF Alone or Chemotherapy and G-CSF;Completed;Phase 2
987;Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma,,,;Completed;Phase 3
988;Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma;Phase 1: MTD / RP2D of AO-176 assessed by incidence of dose-limiting toxicities and incidence of treatment-related adverse events (TEAEs) as assessed by CTCAE v5.0;12 months;Phase 1: ORR of single agent AO-176;Active, not recruiting;Phase 1
988;Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma;Phase 2: Objective response rate (ORR) of AO-176 + DEX + BORT;12 months;Phase 1: Duration of response (DOR) of single agent AO-176;Active, not recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Cumulative event rate of corneal events to Week 16 (KVA scale);Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Incidence rate of corneal events by grade (KVA scale);Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Exposure adjusted incidence rate of corneal events by grade (KVA scale);Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Median duration of dose delay;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Percentage of participants requiring dose reductions, dose delays, and study treatment discontinuation due to corneal events;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Cumulative incidence of corneal events by grade;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Toxicity Index score by assessment/visit;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Duration of corneal events;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Percentage of time on study with corneal events;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Change in best corrected visual acuity (BCVA);Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Overall response rate (ORR);Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Percentage of participants with very good partial response (VGPR) or better;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Time to response (TTR);Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Duration of response (DoR);Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Time to progression (TTP);Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Progression-free survival (PFS);Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Overall survival (OS);Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Number of participants with AEs and serious AEs (SAEs);Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis laboratory parameters;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Percentage of participants requiring dose reductions, dose delays, and study treatment discontinuation due to any AEs;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Maximum concentration (Cmax) of belantamab mafodotin;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Time taken to reach Cmax (Tmax) of belantamab mafodotin;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Area under the concentration time-curve (AUC) of belantamab mafodotin;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin;Recruiting;Phase 2
989;Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma;Incidence rate of Grade ≥2 Corneal events according to the keratopathy visual acuity (KVA) scale;Up to 12 months;Titers of ADAs against belantamab mafodotin;Recruiting;Phase 2
990;Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients;Evaluate Rate of Stringent Complete Response (sCR) transplant ineligible multiple myeloma patients.;After 4 cycles of therapy (each cycle is 28 days);Evaluate Objective Response;Not yet recruiting;Phase 2
991;Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy;Response rate of abatacept + ixazomib citrate + dexamethasone in multiple myeloma patients;Up to 1.5 years;Incidence of adverse events assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;Active, not recruiting;Phase 2
991;Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy;Response rate of abatacept + ixazomib citrate + dexamethasone in multiple myeloma patients;Up to 1.5 years;Overall survival;Active, not recruiting;Phase 2
991;Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy;Response rate of abatacept + ixazomib citrate + dexamethasone in multiple myeloma patients;Up to 1.5 years;Progression-free survival;Active, not recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Overall Response Rate (ORR);Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;VGPR or Better Rate;Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Clinical Benefit Rate (CBR);Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Duration of Response (DOR);Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Time to Response (TTR);Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;MRD Negative Rate at 12 Months for Participants who Achieve a Complete Response (CR);Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Time to MRD Negativity;Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Duration of MRD Negativity;Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;MRD Negative Rate Across Clinical Response;Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Number of Participants with Adverse Events by Severity;Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability;Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Number of Participants with Laboratory Abnormalities;Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Number of Participants with Vital Sign Abnormalities;Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Levels of B-Cell Maturation Antigen (BCMA) Expressing Cells and Soluble BCMA;Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Systemic Inflammatory Cytokine Concentrations;Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Levels of JNJ-68284528 T Cell Expansion (proliferation), and Persistence;Recruiting;Phase 2
992;A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma;Percentage of Participants with Negative Minimal Residual Disease (MRD);At least 1 year after JNJ-68284528 infusion on Day 1;Number of Participants with Anti-JNJ-68284528 Antibodies;Recruiting;Phase 2
993;Geriatric Assessments in Senior Adults With Multiple Myeloma;The relationship between initial treatment recommendation and baseline questionnaires assessment;At baseline visit;Changes in questionnaires from baseline to 6 months;Completed,
993;Geriatric Assessments in Senior Adults With Multiple Myeloma;The relationship between initial treatment recommendation and baseline questionnaires assessment;At baseline visit;Completion of the questionnaires at baseline, 3 months and 6 months.;Completed,
994;A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma;To assess the efficacy;from 8 to 12 months;To evaluate the Overall Survival (OS) in the 2 arms of treatment;Completed;Phase 2
994;A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma;To assess the toxicity;From 1 to 12 months;To evaluate the Duration of Remission (DR) in the 2 arms of treatment;Completed;Phase 2
995;Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma;Dose Limiting Toxicities (DLT) in dose finding phase;End of cycle 1 of treatment, 4 weeks;Safety of trial treatment;Withdrawn;Phase 1
995;Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma;Response rate;From registration until disease progression, 2 years;Progression free survival (PFS);Withdrawn;Phase 2
996;Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma;Number of Participants With Dose Limitations Toxicities of the Combination of Lenalidomide and Thalidomide and Dexamethasone (LTD) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM);After one 28-day cycle;Time to Progression;Completed;Phase 1
996;Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma;Complete Response(CR) and Very Good Partial Response(VGPR);Evaluated each 28-day cycle and nadir of criteria is considered best overall response (median time to best response for this study was 2 cycles (range for best overall response was 1-21 cycles).;Progression Free Survival;Completed;Phase 2
997;Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy;Overall Response Rate (ORR) After 8 Courses of Treatment;At 32 weeks;Overall Response Rate (ORR) After 4 Courses of Treatment;Terminated;Phase 2
997;Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy;Overall Response Rate (ORR) After 8 Courses of Treatment;At 32 weeks;Progression-free Survival (PFS);Terminated;Phase 2
997;Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy;Overall Response Rate (ORR) After 8 Courses of Treatment;At 32 weeks;Time to Progression (TTP);Terminated;Phase 2
997;Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy;Overall Response Rate (ORR) After 8 Courses of Treatment;At 32 weeks;Duration of Response (DOR);Terminated;Phase 2
997;Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy;Overall Response Rate (ORR) After 8 Courses of Treatment;At 32 weeks;Treatment Related Adverse Events Grade 3 or Higher;Terminated;Phase 2
998;Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma;Dose Maximum Tolerate of Carfilzomib Weekly;35 days;number of patients who reach Very Good Partial Response and Complete;Unknown status;Phase 2
999;A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Adverse Events (AEs);From enrollment until at least 28 days after completion of study treatment;Overall response rate (ORR);Recruiting;Phase 1
999;A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM);Pharmacokinetics- AUC;Up to approximately 28 days;Time to response (TTR);Recruiting;Phase 2

